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Abstract 
Background:  Chronic Kidney Disease (CKD) is often progressive leading to End Stage Renal 
Disease (ESRD). Early detection of progressive CKD would almost certainly improve long term 
outcome. Current kidney function tests have serious limitations as they only can detect 
dysfunction after significant damage has occurred, provide limited help with diagnosis and are 
unhelpful in assessing early response to therapy or long term prognosis. Therefore there is a 
requirement for identification of early and reliable non invasive biomarkers of kidney disease 
and its progression. Regardless of the underlying disease, fibrosis drives movement to ESRD. 
Fibrosis is characterised by excessive accumulation of Extracellular Matrix (ECM). This thesis 
tests the hypothesis that mediators of the kidney fibrotic process are present in urine and would 
make good biomarkers of CKD and its progression.   
Aims: To assess  urine samples from three animal models of kidney fibrosis (5/6th 
Subtotalnephrectomy (SNx), Diabetic Nephropathy (DN) and Chronic Allograph Nephropathy 
(CAN) as well as 325 human urine samples (292 CKD and 33 controls) to determine if urinary 
ECM molecules, Transglutaminase 2 (TG2), ε (γ-glutamyl) lysine, Hydroxyproline, 
Metalloproteinases 1, 2 and 9, TIMPs 1, 2 and 3, TIMP-1/MMP-1 complex, PAI-1 and MMP 
activity have potential to act as an early biomarker of kidney scarring and if any of them could 
predict the rate of progression better than Albuminuria. 
Experimental methods: Cation exchange chromatography was used to evaluate urine levels 
of ε (γ-glutamyl) lysine and Hydroxyproline. An in-house developed sandwich ELISA was used 
to analyse urine and blood levels of TG2 and commercially available immunoassays were used 
for determination of urine concentration of MMPs 1, 2 and 9, TIMPs 1, 2 and 3, TIMP-1/MMP-
1 complex and PAI-1. MMP activity was measured by the EnzCheck Collagenase assay.  One 
way ANOVA with Bonferroni correction was applied to estimate differences between groups.  
Area under the curve for Receiver Operating Characteristic (ROC) analysis was used to 
determine prediction accuracy.  p < 0.05 was considered statistically significant. 
Results: TG2 and ε (γ-glutamyl) lysine excretion were significantly increased as renal scarring 
developed in SNx and CAN models. However, in DN, increased levels were only observed as 
a 24 hour excretion at 8 months of study only due to the increased proteinuric state. TG inhibitor 
treated animals had a reduction in the measured levels of both TG2 and of ε (γ-glutamyl) lysine 
in the SNx study.  Urine Hydroxyproline had increased levels as renal disease scarring 
progressed. MMP-1 was significantly increased in SNx and DN animals, with MMP-9 excretion 
undetectable in all control samples. Amongst the TIMPs, TIMP-1 gave the most promising 
response in the early stages of SNx and DN with a 6.4 fold increase at 7 days post SNx, p-
0.0025 and 25 fold increase at 4 months post STZ injection, p=0.0006. Whereas in CAN, the 
TIMP2: CR ratio was double that in F-L Allografts than in L-L Isografts (p=0.0095) as early as 
8 weeks post-transplant and remained elevated up to 33 weeks. Urine PAI-1 excretion was 
within the lower limits of detection and therefore was not used in human samples.  In the human 
study, ROC curve analysis demonstrated that the TG2/CR ratio (86.4%) and TIMP1/CR ratio 
(75.7%) are better predictors of patients with progressive CKD than ACR (73.5%) indicating 
their potential as non-invasive biomarkers of progressive kidney scarring. The ROC curve 
analysis of ε (γ-glutamyl) lysine / CR ratio (73.3%) and TIMP2/ CR ratio (71.2%) presented 
similar levels of accuracy of prediction as ACR, whereas all other candidates were inferior to 
ACR.  Measurement of MMP-1 activity had a remarkable predictive value in detecting rapid 
progressive patients, as very low levels were found in this subgroup of patients. A combo ROC 
III 
 
curve analysis using TG2CR, XLCR, TIMP1CR and ACR as prognostic tools of CKD 
progression generated a remarkable 87.7% risk prediction. 
Conclusions:  The data presented in this thesis demonstrates a potential benefit of using 
ECM molecules (especially TG2, TIMP-1 and ε (γ-glutamyl) lysine) detected in urine as 
biomarkers of CKD progression.  Using a combined biomarker panel containing ACR, TG2/CR, 
TIMP/CR and XL/CR ratios may allow the earlier and more reliable detection of patients with 
more aggressive CKD that requires stronger treatment strategies to give better long term 
outcomes and facilitate shorter clinical trials in CKD. 
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Chapter 1 
Introduction 
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1.1. Chronic Kidney Disease 
 
Chronic Kidney Disease (CKD) represents a major healthcare problem. It is defined by the 
persistence of kidney damage or reduced glomerular filtration rate (GFR) < 60ml/min/1.73m2 
for 3 months or longer regardless of its cause.  In most cases, this damage is progressive and 
irreversible, leading to a reduction in kidney function (glomerular, tubular and endocrine) and 
later development of End Stage Kidney Disease (ESKD) and requirement for renal 
replacement therapy (RRT) (Floege 2013).  According to the Kidney/Dialysis Outcome Quality 
Initiative (K/DOQI) guidelines, CKD can be subdivided into 5 stages (guidelines 2002) based 
on function, evidence of kidney damage (albuminuria or haematuria) and histology (table 1.1). 
 
This classification from K/DOQI guidelines has evolved with time. In 2008, the U.K. National 
Institute of Health and Clinical Excellence (NICE) developed a guideline that recommended 
splitting  the CKD stage 3 from the K/DOQI classification into 3a (estimated GFR between 45 
and 59ml/min/1.73m2) and 3b (between 30 and 44ml/min/1.73m2). This subdivision is 
understood to improve clinical knowledge of prognosis and therefore enhance treatment 
(2008).  The NICE guidelines also suggested the adoption of the suffix ‘(p)’ for patients with 
significant proteinuria (>0.5g/24h) as this represents a major risk factor for disease 
progression. 
 
In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) group suggested a new 
classification in which the prognosis of CKD is given by the association of six categories of 
GFR (G1 to G5, with G3 subdivided into G3a and G3b) and three levels of albuminuria; A1 
(normal to mildly increased albuminuria <30mg/g or albumin to creatinine ratio <3mg/mmol), 
A2 (moderately increased albuminuria 30-300mg/g or albumin to creatinine ratio 3-
30mg/mmol) and A3 (severely increased albuminuria >300mg/g or albumin to creatinine ratio 
>30mg/mmol) (table 1.2) (KDIGO 2012). 
 
CKD is associated with increased risk of development of Cardiovascular Diseases (CVD) (Ito 
2012), Cerebrovascular Diseases (Bao et al. 2013), depression (Palmer et al. 2013), 
premature death (Tonelli et al. 2006), decreased quality of life (Cruz et al. 2011), reduced 
cognitive function (Davey et al. 2013), metabolic and nutritional disorders as well as increased 
health-care expenditures (Jha et al. 2012).  Early detection is a key step to effective therapy, 
however, current kidney function and damage tests have several limitations as they can only 
detect dysfunction after significant damage had occurred, provide limited help with the disease 
stage and are also unhelpful in assessing early response to therapy. Hence, there is a 
requirement for identification of early and reliable biomarkers of kidney disease. 
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Table 1.1: CKD classification by the K/DOQI guidelines  
 
CKD 
Stage 
GFR 
(ml/min/1.73m2) 
 
Description 
 >90 (with CKD risk 
factors) 
At increased risk 
1 >90 Normal renal function, but with other evidence of kidney  
damage, such as microalbuminuria, haematuria or 
 histological changes 
2 60-89 Mild reduction in GFR 
3 30-59 Moderate reduction in GFR 
4 15-29 Severe reduction in GFR 
5 <15 ESKD, RRT needs to be considered 
 
 Table 1.1: Classification of CKD stages as defined in the K/DOQI guidelines. Data obtained from the 
National Kidney Foundation (NKF). Am J Kidney Disease 1, S1-S266 
 
 Table 1.2: Current CKD classification used by KDIGO 
 
Table 1.2: Classification and prognosis of CKD according to the KDIGO guidelines 2012. Data obtained 
from the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic kidney 
Disease. http://kdigo.org/home/guidelines/ckd-evaluation-management/ 
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1.2. Causes of CKD 
 
Numerous conditions can cause CKD.  However, there is a distinct difference between the 
causes of CKD detected in the general population (Community CKD; cCKD) and those who 
are referred to nephrology centres (Referred CKD; rCKD).  Community CKD is most common 
in the elderly population and is associated with an age-related decline in GFR. The majority of 
individuals that present cCKD die before reaching ESRD.  On the other hand, rCKD mostly 
affects individuals that present acquired or inherited nephropathies.  Referred CKD patients 
frequently present early kidney dysfunction and often progress to ESRD with time. 
 
Community CKD is a condition mainly originated by the long lasting exposition suffered by the 
elderly individual to cardiovascular risk factors.  This includes hypertension, diabetes, 
cardiovascular and atherosclerotic lesions which occur as a result of vascular aging.  In 
developing countries, cCKD is also associated with socio-economic causes such as poverty, 
malnutrition, infectious diseases and exposition to environmental toxic factors (Floege 2013). 
 
 The commonest identifiable causes of rCKD are: diabetic nephropathy (Fox et al. 2005, 
Middleton et al. 2006, Whaley-Connell et al. 2008), hypertension (Andersen and Agarwal 
2005, Barri 2008), glomerulonephritis (Kawasaki 2011), vascular diseases (Piecha et al. 
2012), tubulointerstitial diseases (Hodgkins and Schnaper 2012), toxic nephropathy (De Broe 
2012), cystic kidney disease (Grantham 1996), neoplasms and hereditary / congenital 
diseases and obstructive uropathy.  In developed countries there is a bigger incidence of 
Glomerulonephritis (most common is IgA nephropathy) and diabetes whereas in the 
developing countries it is common to find causes of CKD such as hypertension, 
glomerulonephritis and interstitial nephritis due to infectious diseases as malaria, filariasis, 
schistosomiasis, tuberculosis, hepatitis C and others, all aggravated by undiagnosed 
conditions and social problems  (El Nahas 2005, Weiner 2007).  Less common causes of CKD 
include: vasculitis, dysproteinaemias and metabolic causes including cystinosis, cystinuria, 
hyperuricemia, oxalosis and nephrocalcinosis (Nestor Schor 2004). 
 
Overall, diabetic kidney disease remains one of the most common causes of kidney failure 
worldwide, accounting for 24% of cases in the UK (table 1.3) although this number varies 
between countries (figure 1.1).  Data is subdivided into age groups and shows that the incident 
rates of ESKD due to Diabetes increases with age, being significantly higher in individuals 
aged over 65 years old. 
  
5 
 
Comparative percentage distribution of primary renal diagnosis on patients starting RRT on 
two different developed countries (UK and USA) against two developing countries (Brazil and 
Singapore) - (SRR 2009) shows glomerulonephritis, hypertension and diabetes amongst the 
leading causes of CKD (figure 1.2). 
 
Table 1.3: Common causes of ESKD in the UK 
 
Causes Percentage 
Diabetes 24.2 
Glomerulonephritis 11.6 
Renal vascular disease 7.5 
Pyelonephritis 7.4 
Hypertension 6.7 
Polycystic kidney disease 6.6 
Other 16.2 
Unknown aetiology 19.8 
 
Table 1.3: Registry data of primary common causes of ESKD in the UK. Total Glomerulonephritis 
include presumed GN not biopsy proven. Data from UK Renal Registry 2011.       
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Figure 1.1: Percentage of incident patients with ESRD due to Diabetes, 2010 
 
 
Figure 1.1: Incidence of patients with ESKD due to Diabetes in different countries in 2010.  Data 
represents unadjusted rates of Diabetes divided by age groups from countries which relevant 
information was available.  UK data includes England, Wales and Northern Ireland only.  Adapted 
from U.S. Renal Data System, USRDS 2012 
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 Figure 1.2: Percentage distribution of primary renal diagnosis of ESKD 
   
                   
 
 
               
Figure 1.2: CKD aetiology of patients starting RTT in different countries.  Data from local renal 
registries in 2009 (Singapore) and 2011 (UK, USA and Brazil).  Total Glomerulonephritis include 
presumed GN not biopsy proven. 
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1.3. Epidemiology of CKD 
 
It is difficult to assess the exact incidence and prevalence of CKD in the general population.  
According to a wide range of adult population screening studies, overall CKD prevalence is 
estimated to be >10% in the general population, with community prevalence screening ranging 
from 0.8% to 42.6% depending of the country of data collection (systematic review from 
(McCullough et al. 2012)).  However, little data is available at the earlier stages of CKD when 
symptoms are mild, ignored or poor diagnosed.  It is considered that the majority of patients 
at early and asymptomatic stages of CKD are undiagnosed and consequently untreated 
(Schieppati et al, 2005; Levin et al, 2001).  This decreases the possibility of applying therapy 
to retard the progression of the disease early.  
 
In the United States of America, according to the Third National Health and Nutritional Survey 
(NHANES III, 1988-1994), a report which analysed a sample of 15625 adults over 20 years 
old showed that the prevalence of CKD in adult Americans was estimated to be 10.8% (or 
approximately 19.2 million people) (Coresh et al. 2003).  From this, 3.3% were estimated to 
be on stage 1 (or 5.9 million people), 3.0% on stage 2 (5.3 million), 4.3% on stage 3 (7.6 
million), 0.2% on stage 4 (400 000 people) and less than 0.2% on stage 5 (300 000 people).  
This study also demonstrated that CKD prevalence increases with age as 11% of population 
aged above 65 years old were diagnosed with CKD 3, 4 or 5, even in the absence of Diabetes 
Mellitus (DM) or Hypertension (HTN) (table 1.4).  The United States Renal Data System 
projects an increase of nearly 50% of the incidence and prevalence of ESKD in the American 
population by 2020 (System 2012). 
 
Data from the Japanese annual health check program from 2000-2004 analysed 574,024 
individuals over 20 years old and predicted a prevalence of around 13% (or 13.3 million) of 
the Japanese adult population had CKD in 2005 (Imai et al. 2009).  The prevalence of CKD 
stages 1, 2, 3, and 4 plus 5 were estimated on 0.6, 1.7, 10.4 and 0.2% respectively. 
 
A Southern Chinese study with 6101 subjects aged 20 years or older detected an overall 5.8% 
prevalence of low albuminuria with a general 12.1% prevalence of CKD (Chen et al. 2009), 
whereas some other studies have showed even higher CKD prevalence, such as 18.9% in 
Iran (Hosseinpanah et al. 2009).  However, these high prevalence rates of CKD could be due 
either to an elevated ingress of older people in the study, or to the different type of equation 
applied to estimate GFR and also to the incorporation of low level albuminuria in the inclusion 
criteria despite the fact that this is not a specific marker of CKD.  
9 
 
1.4. Epidemiology of ESRD 
 
Despite the rareness of accurate data on the epidemiology of CKD at early stages, there are 
numerous studies presenting information on moderate to advanced CKD as well as reports 
from renal registries in which focuses on ESRD.  Overall, the incidence and prevalence of 
ESRD has increased globally over the past two decades leading to high health care 
expenditures (1999). 
 
In Europe, the ERA – EDTA (European Renal Association – European Dialysis and Transplant 
Association) in 2010 took the data collected from 52 national or regional registries from 29 
countries.  The average incidence of ESKD on Europe was about 130 pmp and prevalence of 
939 pmp (Registry 2012).  
 
According to the United Kingdom (UK) Renal registry report from 2012, the incidence rate of 
ESKD in the UK in 2011 was stable at 108 pmp, with 25% of cases due to diabetic kidney 
disease (DKD).  The overall prevalence of patients undergoing RTT was 842 pmp (Registry 
2012).  The prevalence rate was greater in males than females at all age groups, peaking in 
men aged between 75-79 years at 2918 pmp and for women aging between 65-69 years at 
1460 pmp. 
 
In 2011, the prevalence and the incidence of patients on RTT in Brazil corresponded to 475 
pmp and 149 pmp respectively.  57.3% of individuals on RTT were male and 84.9% funded 
by the Brazilian Public Health System (SUS) (Nefrologia 2011, Sesso Rde et al. 2012). This 
represented less than half of the prevalence found on developed countries such as USA, 
which supports the presupposition that ESKD is underdiagnosed and/or undertreated in 
developing countries (Oliveira et al. 2005, Lugon 2009). 
 
As well as the above renal registries, there is also diverse information on epidemiology of RTT 
in several worldwide registries.  For instance, the Australia and New Zealand Dialysis and 
Transplantation Registry (ANZDATA), described an incidence of 110 pmp in Australia and 108 
pmp in New Zealand, with a prevalence of 885 pmp in Australia and 877 pmp in New Zealand 
on 2011 (Report 2012).  The Sociedad Latino-Americana de Nefrologia e Hipertension 
(SLANH), which aggregates data from twenty Latin American countries, showed an average 
of 604 pmp of prevalence and 198 pmp incidence in 2009. ((SLANH) 2012).  A recent cross-
sectional study in India analysed a cohort of 5588 people and reported a CKD prevalence of 
17.2%.  From this, 7%, 4.3%, 4.3%, 0.8% and 0.8% were estimated to be on CKD stages 1, 
2, 3, 4 and 5 respectively (Singh et al. 2013). 
10 
 
In general we can observe an enormous increasing in the numbers related to CKD with an 
overall estimated increase of 6% per year.  Differences on the incidence and prevalence data 
between countries may be related to the prevalence of the primary disease causes of the 
kidney injury as well as to ethnic and environmental reasons.  Low rates displayed by 
developing countries could also be explained by an inadequate coverage by the registries, 
underdiagnosis and scant resources to detect and treat patients with CKD (figure 1.3). 
 
Table 1.4: Prevalence (%) of CKD in the NHANES population within age, gender, 
race/ethnicity, & risk-factor categories 
 
 All CKD eGFR <60 
ml/min/1.73m2 
ACR >=30 mg/g 
  1988-
1994 
2005-
2010 
1988-
1994 
2005-
2010 
1988-
1994 
2005-
2010 
20-39 5.1 5.7 0.1 0.2 5.0 5.7 
40-59 8.4 9.1 1.3 2.2 7.7 7.6 
60+ 32.2 35.0 19.5 24.1 18.3 18.4 
Male 10.2 12.1 4.1 5.6 7.4 8.6 
Female 14.2 15.8 5.6 7.7 10.2 10.2 
Non-Hispanic White 12.3 14.3 5.5 7.9 8.2 8.6 
Non-Hispanic Black 
Afro  American 
14.5 16.0 4.1 6.2 12.7 12.6 
Other 10.5 11.9 2.2 2.6 9.2 10.6 
Diabetes 43.1 40.1 15.6 19.3 36.3 29.9 
Self-reported diabetes 42.7 41.6 16.4 20.4 35.9 30.8 
Hypertension 22.2 23.2 10.4 12.9 15.4 14.8 
Self-reported 
hypertension 
25.3 26.8 12.9 15.6 17.1 16.7 
Cardiovascular 
disease 
25.4 40.8 14.5 27.9 16.6 24.3 
Obesity (BMI >=30) 16.6 16.8 6.2 7.4 12.3 11.7 
All 12.3 14.0 4.9 6.7 8.8 9.4 
 
 
Table 1.4: Percentage of CKD prevalence from 1988 to 2010 in the United States of America 
population. Data from the United States Renal Data System 
http://www.usrds.org/2012/view/v1_01.aspx 
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                                          Figure 1.3: Geographic variations on the incidence and prevalence of ESRD 
 
 
 
 
 
Figure 1.3: Worldwide ESRD epidemiology.  A – Comparison of unadjusted ESRD incidence worldwide 
in 2010. Japan AND Taiwan are dialysis only.  B – Prevalence rate of RRT per million population in 
different parts of the world. Adapted from U.S. Renal Data System, USRDS 2012  
Comparison of ESKD incidence worldwide - 2010
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1.5. Progression of CKD 
 
After the initial process of renal injury and irrespective of the cause, a progressive deterioration 
in renal function occurs that can lead to irreversible renal failure.  Most cases of rCKD stages 
G3 to G5 progresses to ESKD with an estimated rate of decline in GFR that varies from -1 to 
-2 ml/min/year in patients with controlled blood pressure and glycaemia, to -10 ml/min/year in 
patients with Diabetic Nephropathy (DN) (Floege 2013).  However, a portion of these patients 
can remain with stable CKD function and not develop ESKD or have a premature death 
caused by CVD or other causes (Floege 2013).  The rate of progression to ESRD can vary 
spontaneously or according to internal and external factors such as uncontrolled blood 
pressure or glycaemia, infections, presence of proteinuria, haemodynamic status and others 
(reviewed by (Nahas 2000)). 
 
Several experimental models and human trials have demonstrated that proteinuria is 
associated with tubulointerstitial damage and subsequent progression of kidney disease 
(McClellan and Flanders 2003, Remuzzi et al. 2006).  Another pathway related to the 
progression of the initial kidney injury is the hyperfiltration that occurs in remaining nephrons 
after loss of renal mass; initially it is an adaptative effect to maintain GFR but subsequently 
would cause glomerular damage (Hostetter et al. 2001). 
 
Interventions to prevent or slow CKD progression include control of blood pressure and 
cardiovascular risk factors as well as of the secondary hemodynamic and metabolic factors 
involved in the process of advancement of kidney disease.  The eradication of all associated 
modifiable risk factors is a vital part of the treatment strategy for preventing the development 
and progression of CKD. 
 
1.5.1 Risk Factors for progressive CKD 
 
There is a considerable person-to-person variability on the rate of progression and loss of 
renal function.  Such variation occurs not only between different diseases, but also in different 
individuals that share similar pathological processes (Schrier 2003).  This can be consequence 
of the multifactorial nature of the biological mechanisms that are involved (Adler 2006).  The 
factors that can influence the progression of CKD are as follow: non-modifiable - age, gender, 
race and genetics and modifiable risk factors, such as smoking, alcohol consumption, illicit 
drug use, use of nephrotoxic agents, presence of proteinuria, hyperphosphatemia, 
hypertension, uncontrolled blood glucose, dyslipidaemia, obesity, underlying disease activity, 
anaemia and others. 
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1.5.1.1. Non-modifiable risk factors 
 
Age 
Increased age is associated with increased risk for decline in renal function, although normally 
there is a loss of renal mass and function with aging.  This normal alteration of kidney structure 
and function that occurs with aging has several reasons including the loss of self-renewing 
stem-cells (Lasagni and Romagnani 2010), decreased proximal tubular cell proliferation 
caused by an over expression of zinc-alpha-2 glycoprotein (Zag) (Schmitt et al. 2008), 
abnormal DNA methylation and modification of histones damaging the structure of renal cells 
(Dressler 2008) and the effects of telomere shortening and oxidative stress on cell senescence 
(Yang and Fogo 2010). 
The incidence of CKD progression is higher in older people, especially those above 75 years 
old (Anderson et al. 2009).  Aged-related glomerulosclerosis can be linked to atherosclerotic 
vascular disease as the arterial lumen narrowing could cause ischemia and/or thrombosis 
leading to subsequent glomerular damage (Schrier 2005, Abdelhafiz et al. 2008).  Ageing is 
also associated with reduction in effective renal plasma flow with a preserved GFR.  Systemic 
hypertension or intrinsic renal disease could contribute to the progression of the existent 
glomerulosclerosis on this group as there is an increased filtration fraction in those diseases.  
Another cause for CKD progression in elderly patients (above 65 years old) is linked to the 
occurrence of episodes of Acute Kidney Injury (AKI) which leads to a lower recovery of kidney 
function within this group when compared to younger patients (Schmitt et al. 2008). 
 
Gender 
Gender is also an additional risk factor for the progression of some renal disease (Carrero 
2010).  It is reported that males have a greater risk than females in certain types of 
nephropathies and this could be linked to the modulation of genes involved in ECM 
metabolism by Estrogen (Neugarten and Golestaneh 2013).  Additional studies show slower 
progression rates of renal failure in females patients with hypertension, polycystic kidney 
disease, membranous glomerulopathy, IgA nephropathy, diabetes type I and some hereditary 
kidney diseases present a faster rate of decline in males that could be explained by differences 
in kidney sizes and in glomerular hemodynamics, different diet composition and by the effects 
of sex hormones in genetic pathways (Eriksen and Ingebretsen 2006, Silbiger and Neugarten 
2008, Silbiger 2011). 
 
Race 
Race, ethnicity and genetics are correlated as factors associated with progression of kidney 
disease.  There are numerous hypotheses to support this association.  Examples include 
studies of familial aggregation of risk (Freedman et al. 1997), mutations in mitochondrial genes 
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(Watson et al. 2001), the reduced foetal growth theory which is associated with low nephrons 
mass and glomerular hypertrophy (Huxley et al. 2002) and polymorphisms of the gene UMOD 
which encodes the protein Uromodulin and in the gene encoding TGFβ1 (Tampe and Zeisberg 
2013). 
 
Overall, there is a higher predisposition to progressive kidney damage in blacks and in ethnic 
minority populations compared to Caucasians (Byrne et al. 1994, Tarver-Carr et al. 2002), 
especially those with increased proteinuria (Erickson et al. 2013).  It has been demonstrated 
a higher prevalence and greater severity of diabetes and hypertension among black people 
than in white and that the response to some drugs such as the Angiotensin Converting 
Enzyme (ACE) inhibitors is lower in Blacks (Brenner et al. 2001, Lewis et al. 2001, Norris and 
Agodoa 2005).  
1.4.1.2. Modifiable risk factors 
 
Modifiable risk factors include: hypertension, presence of proteinuria, smoking, alcohol 
consumption, illicit drug use, chronic use of anti-inflammatory agents, unbalanced nutritional 
status, dyslipidaemia, anaemia, metabolic and mineral disturbances such as 
hyperparathyroidism and hyperuricemia, late referral to the nephrologist and socio-economic 
factors (Remuzzi et al. 2006, J Feehaly 2007, Turgut et al. 2007, Yamagata et al. 2007, Bello 
et al. 2008, Muntner et al. 2013). 
 
Hypertension 
Hypertension can act not only as the cause, but also in accelerating CKD.  It is involved in the 
pathophysiology of CKD progression though the event of arteriolar nephrosclerosis and by its 
role on the divalent cation regulation system, which includes phosphate metabolism managed 
by the fibroblast growth factor 23 (FGF-23)/klotho system (John et al. 2011, Cozzolino et al. 
2013).  Poor blood pressure control can induce a faster GFR decline by increasing the 
glomerular filtration pressure and subsequently proteinuria levels that leads to higher degree 
of kidney injury.  Furthermore, hypertension also accounts for increased cardiovascular risk.  
The Multiple Risk Factor Intervention Trial (MRFIT) studied 332 544 middle-aged men and 
revealed an elevated risk of progression to ESRD beginning at the third quintile of systolic and 
diastolic blood pressure (127/82 mm Hg)(Klag et al. 1996).  Later on, similar findings were 
observed in the Okinawa mass screening program (n = 98 759) (Tozawa et al. 2003). 
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Proteinuria 
Although the presence of proteinuria/albuminuria has been shown to be an independent risk 
factor for increased CVD events and progression of CKD in several studies (Martins et al. 
2006, Foster et al. 2007, Ruggenenti et al. 2012), it has been also suggested that it acts more 
as a marker of CKD progression rather than its cause (Yusuf et al. 2008, Parving et al. 2012).  
In a meta-analysis of 10 cohorts involving 266 975 patients at increased risk of CKD, high 
albuminuria and low GFR predicted CVD and all-cause mortality independently of each other 
(van der Velde et al. 2011).  Several other clinical studies correlate proteinuria and renal 
function decline in diabetic and nondiabetic kidney disease.  It can accelerate kidney disease 
progression by multiple pathways such as complement activation, induction of tubular 
chemokine expression, inflammatory cell infiltration and subsequent glomerulosclerosis 
(Cravedi and Remuzzi 2013).  The REIN (Ramipril Efficacy in Nephropathy) study showed 
that individuals in the highest tertile of baseline proteinuria (protein excretion ≥3.8 g/d) 
presented the highest rate of GFR decline (Ruggenenti et al. 1998).  Likewise, the RENAAL 
(Reduction of Endpoints in NIDDM [Non–Insulin-Dependent Diabetes Mellitus] with the 
Angiotensin II Antagonist Losartan study reported that 85% of patients with proteinuria with 
protein excretion ≥3 g/d also were at higher risk of having increased serum creatinine levels 
and developing ESRD (de Zeeuw et al. 2004).  Another study showing the association 
between higher baseline proteinuria and decreased GFR was the African-American study of 
kidney disease and hypertension (AASK) (Wright et al. 2002).  Thereby proteinuria reduction 
by the use of ACE inhibitors/ARB and dietary protein restriction was considered to achieve 
renoprotective effects and improvement in renal function (Peterson et al. 1995, de Zeeuw 
2004, Perico et al. 2005).  However, new evidence shows that discontinuation of ACE 
inhibitors/ARB slows progression to RRT in advanced CKD patients (Ahmed et al. 2010).  In 
addition, the ONTARGET study showed that a combination of an ACE inhibitor (Ramipril) and 
an ARB (Telmisartan) caused a reduction in albuminuria levels and worsening of kidney 
function (Yusuf et al. 2008).  Comparable results were found in the ALTITUDE study where 
the addition of an ACE inhibitor (Aliskiren) did not improve kidney disease despite causing a 
reduction in the urinary albumin-to-creatinine ratio (Parving et al. 2012).  Therefore, further 
studies are needed to prove or not the complete benefits of proteinuria reduction and better 
renal outcomes. 
 
Smoking and alcohol consumption 
Tobacco and alcohol consumption are associated with increased CV risk and with GFR 
decrease.  Smoking-induced renal function impairment is stimulated by sympathetic 
activation, increased endothelin production and impaired endothelial cell-dependent 
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vasodilatation (Orth et al. 1997, Orth 2000, Ritz and Orth 2000, Orth 2004, Orth and Hallan 
2008).  In the United States, a prospective observational study of 20 years of duration 
analysed data from 23 534 people and identified a significantly high risk of CKD in individuals 
that smoked cigarettes with a hazard ratio of 2.9 in women and of 2.4 in men (Haroun et al. 
2003). Cigarette smoking was also identified as an independent risk factor for diabetic 
nephropathy due to increased inflammation and microvascular dysfunction (Cignarelli et al. 
2008). Therefore, CKD patients are strongly encouraged to quit this habit.  
 
Nephrotoxicity 
Use of illicit drugs along with nephrotoxic drugs such as NSAIDS can cause papillary necrosis 
and therefore haematuria.  Intra-arterial infusion of radiocontrast agents causes initial 
vasodilation, followed by vasoconstriction resulting in medullary ischemia.  Direct cytotoxicity 
to the tubular epithelial cells has also been observed (Solomon et al. 2009, Traub et al. 2013). 
 
Obesity 
The increasing rate of obesity in the world is a major problem.  Overweight and obesity 
promote the development of insulin resistance, impaired glucose tolerance and consequent 
Diabetes Mellitus, metabolic syndrome, increased hypertension and cardiovascular risks.  
Histological changes comprise glomerulomegaly with or without focal segmental 
glomerulosclerosis (FSFS) (Kramer 2006, Hossain et al. 2007, Griffin et al. 2008, Goumenos 
et al. 2009, Kawar et al. 2009, Othman et al. 2009).  
 
Malnutrition 
Malnutrition is also a risk factor for the progression of CKD and it is associated with an 
increased risk of morbidity and mortality amongst those patients (Garg et al. 2001, Kuhlmann 
MK 2007).  It can also be a consequence of CKD, especially at stages 4 and 5 where it is 
reported to affect roughly 40-50% of patients undergoing RRT as there is a spontaneous 
reduction of protein intake, poor appetite and fatigue in these patients.  It can lead to the 
development of infections, MIA syndrome (Malnutrition Inflammation and Arteriosclerosis) and 
concomitant comorbidities that can worsen the prognosis of renal disease. 
 
Later referral to the nephrologist 
It was demonstrated that patients who are referred to a nephrologist at later stages of the 
disease are at an increased risk of CKD progression and premature death.  Timely referral to 
the specialist is associated with better CKD management including modification of risk factors, 
more controlled haemoglobin levels and minimization of metabolic disturbances such as 
hyperuricemia and hyperparathyroidism (Levin 2001, Avorn et al. 2002, Kazmi et al. 2004, 
Jones et al. 2006). 
17 
 
 
Poverty 
Several studies have revealed that a lower socioeconomic status is directly related to elevated 
incidence of ESRD (Young et al. 1994, Thamer et al. 1999, Cass et al. 2001, Fored et al. 2003, 
Maheswaran et al. 2003, Merkin 2008, Ward 2008).  Diverse reasons can justify this inverse 
correlation between income level and ESRD incidence.  These include: inequalities in the 
access of preventive health care and subsequently to dialysis treatment and renal 
transplantation, poor nutritional status, higher exposure to infectious diseases and to 
nephrotoxins and precarious urban environmental characteristics. 
1.6. Pathology of Kidney Fibrosis 
 
Despite this variety of factors that influence the progression of CKD to ESKD, its pathological 
mechanisms follows a final process characterised by the excessive accumulation of 
Extracellular Matrix (ECM) and consequent development of kidney fibrosis and scarring (el 
Nahas 1995, Liu 2006).  Renal fibrosis is often characterized by glomerulosclerosis, 
tubulointerstitial fibrosis, vascular sclerosis, interstitial leukocyte infiltration and a reduction in 
the number of functioning nephrons. A representative microscopic photographs of progressive 
glomerulosclerosis (A-D) and Tubulointerstitium scarring (E-H) is shown in figure 1.4. 
 
1.6.1. Glomerulosclerosis 
 
Glomerular damage  is usually initiated by localised loss of glomeruli, intracapillary 
hypertension, immunological injury, metabolic disorders and genetic defects (Schlondorff 
2008).  Subsequent expansion of the mesangial matrix and basement membrane is seen, often 
mediated by chemokines.  Podocytes become hypertrophic with eventual apoptosis and 
glomerulosclerosis.  Loss of podocytes leads to reduced vascular endothelial growth factor 
(VEGF) production and thereby glomerular endothelial apoptosis. Under these circumstances 
the glomeruli alter their permselectivity leading to proteinuria and the glomerular capillary flow 
is reduced causing tubular ischaemia and hypoxia.  
 
1.6.2. Tubulointerstitial Fibrosis 
 
The tubulointerstitial compartment plays a significant role in renal function and consequently 
the progression of renal disease as it accounts for over 90% of kidney cortical tissue (Nath 
1998).  Tubulointerstitial fibrosis can be initiated by an inflammatory process and is associated 
with tissue hypoxia resulting from reduced glomerular capillary flow and Angiotensin induced 
vasoconstriction, initiating the expression of cell adhesion molecules (ICAM-1 and VCAM-1) 
and upregulation of various chemokines, cytokines and growth factors such as Interleukins 1 
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and 8, Tumour Necrosis Factor α (TNF-α), Connective Tissue Growth Factor (CTGF), Bone 
Morphogenic protein 7, platelet-derived growth factor (PDGF) and Monocyte Chemoattractant 
protein-1 (MCP-1) (Boor and Floege 2011, Liu 2011).  In addition, intracellular signal 
transduction pathways including the TGFbeta/Smad, integrin-linked kinase (ILK) and Wnt/beta-
catenin signalling induce a concomitant epithelial mesenchymal transformation (EMT) which 
leads to the appearance of interstitial fibroblasts and de novo expression of α-smooth muscle 
actin (αSMA) with subsequent increased ECM deposition (Liu 2010).  
 
Figure 1.4: Development of kidney fibrosis 
 
                          
Figure 1.4: Histological development of glomerulosclerosis (A-D) and Tubulointerstitium scarring (E-
H): Normal Glomerulus by light microscopy (A) showing thin capillary loops and endothelial and 
mesangial cells. (B), Mesangial hypercellularity. (C) and (D) progressive stages of sclerotic glomerulus. 
(E), normal tubules, surrounded by Tubular Basement Membrane (TBM) with small interstitium space. 
(F) shows dilated tubules and interstitium oedema. (G), segmental interstitial fibrosis and (H) 
development of diffuse interstitial fibrosis with deposition of Extracellular Matrix (ECM).  
1.7. Mechanisms of Kidney Fibrosis 
 
 Kidney fibrosis is the common final outcome of most cases of progressive chronic kidney 
disease (Hewitson 2012).  Following kidney damage, independently of the original 
nephropathy, there is a complex cascade of multiple cellular and molecular events (table 1.5).  
A B C D 
E F G H 
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Briefly, this involves haemodynamic, immune and metabolic changes that injure endothelial 
cells, leading to the release of chemokines and cytokines initiating an inflammatory process 
(el Nahas and Coles 1997, Eddy 2000, Klahr and Morrissey 2003).  In this process, mesangial 
and endothelial cells start to proliferate and dedifferentiate.  This dedifferentiation is mediated 
by the action of several fibrogenic growth factors such as TGF-β1, which can dedifferentiate 
epithelial and endothelial cells into a myofibroblast  phenotype that produce ECM components, 
such as Types I and III Collagen (Boor and Floege 2011, Meran and Steadman 2011).  
Myofibroblasts can also result from activated residential fibroblasts, bone marrow fabrication, 
vascular pericytes, endothelial-to-mesenchymal transition (EndMT) or endothelial-fibroblast 
transition (He et al. 2013) via regulation of microRNAs (Srivastava et al. 2013). 
 
TGF-β1 can also promote podocyte apoptosis and consequential podocytopenia (Lopez-
Hernandez and Lopez-Novoa 2012) as well as induce CTGF and bFGF production which are 
capable of inducing fibroblast proliferation and matrix protein synthesis (Liu 2011).  Fibroblast 
activation and proliferation is mediated by numerous factors such as the hypermethylation of 
RASAL1 (RAS GTPase protein activator like 1) (Bechtel et al. 2010), hypoxia (Tanaka and 
Nangaku 2010), high glucose (Lam et al. 2004) and Angiotensin II (Faulkner et al. 2005).  As 
a result of this inflammatory process, the fibrotic matrix becomes filled with fibrilar material 
such as fibronectin, collagens types I, III, IV and V, integrins and various fibrillins such as 
TGFβ-binding proteins (LTBP) (Zeisberg and Neilson 2010) (figure 1.5).  The increased 
synthesis of ECM components by fibroblasts associated with elevated deposition by 
Transglutaminase 2 and/or decreased breakdown  by collagenolytic enzymes such as matrix 
metalloproteinases (MMPs) and Plasmin ultimately leads to ECM accumulation and 
subsequent formation of glomerulosclerosis, tubular atrophy and tubulointerstitial scarring 
(Johnson et al. 2007, Hewitson 2012). 
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Table 1.5: Phases of kidney fibrogenesis 
I – Induction phase 
 A sustained injury sets up haemodynamic, immune and metabolic changes 
 Tubular epithelial cells release a wide range of chemokines and  profibrogenic cytokines 
 Inflammatory response with infiltration of damaged kidneys by mononuclear cells 
 Mesangial cells proliferation and dedifferentiation 
 Activation and proliferation of interstitial fibroblasts and pericytes 
 Epithelial-mesenchymal transformation 
 
II – Inflammatory phase 
 Increased synthesis and deposition of ECM  
 Continuous inflammatory response; release of neutrophils, T lymphocytes,  macrophages, 
hematopoietic stem cells and other inflammatory cells  
 
III – Fibrosis phase 
 Release of profibrogenic cytokines 
 Excessive ECM formation 
 Glomerular damage, tubular atrophy and microvascular rarefaction 
 Loss of podocytes, tissue hypoxia, apoptosis 
 Scar formation, progression to ESKD 
 
Table 1.5: Irrespective of the initial causes, kidney fibrogenesis is a dynamic and complex process that 
consists of at least three overlapping phases: Induction, Inflammation and post-inflammation.  
 
 
Figure 1.5: The involvement of cytokines in kidney fibrogenesis 
 
 
Figure 1.5: NF-Κb activators and inhibitors modulate Tubular epithelial cells which release chemokines 
and proinflammatory cytokines.  T and B lymphocytes and macrophages are recruited to the 
tubulointerstitium.  Fibroblasts are modulated by EMT/EndMT factors. A wide range of cytokines such 
as IL-1, IL-6, TNFα and TGFβ are released. The final end point is the accumulation of ECM and 
subsequent scar formation. Copied with permission from (Zeisberg and Neilson 2010). 
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1.8. Models of Experimental renal scarring 
 
Some of the best tools available to help understand the process of CKD and identify potential 
intervention sites are in vivo animal models.  These allow us to follow the disease process 
from inception to ESKD with complete access to tissue and biofluids in a condensed 
timeframe.  Several experimental models are commonly used such as the 5/6th Subtotal 
nephrectomy (SNx), the diabetic nephropathy (DN) and the chronic allograft nephropathy 
(CAN) models. 
 
1.8.1. 5/6th Subtotal Nephrectomy (SNx) 
 
This experimental model of renal scarring, also known as the remnant kidney model, consists 
of the development of chronic renal failure caused by a reduction in renal mass (Platt et al. 
1952). The procedure involves the surgical removal of two-thirds of a kidney by either pole 
resection or selective ligation of renal arteries. This is followed by an unilateral 
Uninephrectomy which can occur at the same time or sometime later the partial resection 
(Gretz N 1993). This model has been used in a wide variety of animals including rats (Joo et 
al, 2013), mice (Kren et al, 1999), cats (Adams et al, 1994), dogs (Brown et al, 2013), rabbits 
and monkeys (Bourgoignie et al, 1994)  (Adams et al. 1994, Bourgoignie et al. 1994, Kren and 
Hostetter 1999, Brown 2013, Joo et al. 2013). 
 
The most common species to perform SNx in is rat.  Typically rats are subjected to a one step 
five-sixths nephrectomy procedure where the left kidney is removed and two-thirds of the right 
ligated and removed (Johnson et al. 2007).  Following this reduction in the number of 
functioning nephrons, glomerular hemodynamic adaptive changes take place and leads to the 
development of hyperfiltration, proteinuria and systemic hypertension.  Progressive increases 
in serum urea and creatinine concentration as well as reduced creatinine clearance are 
observed.  Such metabolic changes produces a decrease in 5' adenosine monophosphate-
activated protein kinase (AMPK) activity and subsequent  hypercholesterolemia (Satriano et 
al. 2013). 
 
These hemodynamic adaptations are associated with significant structural changes such as: 
glomerular and proximal tubular hypertrophy and at a late stage with progressive 
glomerulosclerosis and tubulointerstitial scarring. This experimental model of renal scarring 
typically evolves in three phases: the acute phase that develops after nephrectomy which is 
characterised by inflammation and hypertrophy of the remnant kidney, a stable renal function 
phase although there is increasing proteinuria and hypertension and a final stage where the 
animal develops end-stage renal failure due to focal segmental glomerular sclerosis (Kim et 
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al. 2003).  This progress to end-stage renal failure generally occurs within 60 to 180 days. 
Although this experimental model resembles several aspects of the development of human 
CKD, it lacks the association with further risk factors for CKD progression such as vascular 
damage.  However, in a recent study, the use of a Nitric Oxide synthase inhibitor combined to 
a high salt diet after SNx improved this aspect as it promoted endothelial dysfunction (van 
Koppen et al. 2013). 
 
1.8.2. Diabetic Nephropathy 
 
A large number of animal models of Diabetic Nephropathy (DN) have been used to resemble 
either type I or type II human diabetes. Experimental Diabetic Nephropathy is most often 
induced in rodents (Brosius et al. 2009, Kong et al. 2013), but can also be done in monkeys 
(Liu et al. 2013), hamsters (Inenaga et al. 2002) and other animals.  Type I diabetes is usually 
induced by the performance of pancreatectomy or administration of either alloxan or 
streptozotocin; agents that cause pancreatic β cell failure (Lenzen 2008).  On the other hand, 
type II diabetes can be generated by mutations in the gene that encodes the leptin receptor, 
agouti mutations or a high-fat diet to induce obesity and insulin resistance (Soler et al. 2012).  
However, although these animal models exhibit many features in common with the 
development of diabetic nephropathy in humans, they also show some morphological and 
functional differences. 
 
In humans with type I or II diabetes, the development of nephropathy can be subdivided into 
four categories (Class I - IV) according to the degree of severity of the glomerular lesions.  
Class I is observed at onset of diabetes and is characterised by glomerular hypertrophy and 
hyperfunction.  Class II is characterised by glomerular alterations such as mild mesangial 
expansion, thickening of the capillary basement membranes and ECM expansion.  This stage 
generally occurs 10-15 years after the disease is diagnosed and is characterised by the 
presence of microalbuminuria.  In the Class III, patients develop clinical nephropathy which is 
marked by persistent proteinuria, Kimmelstiel-Wilson lesions, arteriolar hyalinosis and 
progressive decline of kidney function. As disease progresses, global glomerulosclerosis 
takes place (Class IV) and patients will develop end-stage renal failure  (Tervaert et al. 2010). 
 
Diabetic rats express similar early morphological alterations as well as increased glomerular 
filtration and proteinuria in the same way as diabetic patients in the first stage of nephropathy.  
They also produce comparable characteristics as in Class II.  But, diabetic rats do not mimic 
late morphological features such as nodular Kimmelstiel-Wilson lesions, capillary occlusion 
and progressive decline in kidney function in the same extent as observed in advanced human 
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DN.  Therefore, novel models of DN were developed to overcome this issue of inconsistent 
expression of late histopathological changes in diabetic rats.  These include the knockout of 
endothelial nitric oxide synthase (eNOS3) model (Zhao et al. 2006), the development of a new 
inbred transgenic strain of mice (BTBR; black and tan, brachyuric) with the ob/ob leptin-
deficiency mutation (Hudkins et al. 2010) and the GIPR(dn) transgenic mice model which 
express the mutated human glucose-dependent insulinotropic polypeptide receptor (GIPR) 
(Herbach et al. 2009).  
 
The Animal Models of Diabetic Complications Consortium (AMDCC) established validation 
criteria for murine models of diabetic nephropathy so that these could try to replicate features 
of human nephropathy.  These include: decline in GFR greater than 50% over the lifetime of 
the animal, increase in albuminuria greater than 10 fold compared with controls for that strain 
at the same gender and age, and renal pathology with advanced mesangial matrix expansion, 
nodular sclerosis, mesangiolysis, any degree of arteriolar hyalinosis, tubulointerstitial fibrosis 
and thickening of GBM by over 50% of baseline (Brosius et al. 2009).   
 
One model of DN that is in accordance with the AMDCC criteria is based on the development 
of diabetes by the administration of streptozotocin but after an uninephrectomy.  Following the 
induction of diabetes, renal vasodilation and glomerular hypertrophy occur as well as 
increased GFR and intraglomerular hypertension (Huang et al. 2009).  These changes occur 
early in the disease before nephrons loss has occurred. Progressive mesangial expansion 
and subsequent proteinuria are observed within 1 to 3 months after streptozotocin 
administration.  The development of glomerulosclerosis can take up to 18 months to develop 
without uninephrectomy as this causes systemic hypertension and thus reduces the 
development of glomerulosclerosis to 8 months. 
 
1.8.3. Chronic Allograft Nephropathy 
 
Chronic allograft nephropathy (CAN) is the major cause of kidney transplant failure.  It is 
associated with the development of glomerulosclerosis, progressive interstitial fibrosis, tubular 
atrophy and obliterative arteriolopathy.  CAN is characterised by progressive loss of renal 
tissue and ECM deposition, culminating in kidney fibrosis and failure (Nankivell et al. 2001, 
Morales 2005).  The pathogenesis of CAN is due to the interaction of both immune (acute 
rejection, alloantibody, allorecognition and viral infections) and non-immune risk factors 
(reduced renal mass, ischaemia-reperfusion injury, old donor age and calcineurin toxicity) 
leading to renal scarring (Joosten et al. 2004, Lutz et al. 2006, Akalin et al. 2007).  
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A typical experimental model of CAN is performed on male Fisher (F344) and Lewis (LEW) 
rats (Shrestha et al, 2014). In this model, donor kidneys obtained from Fisher rats (allograft) 
or Lewis rats (isograft) were transplanted into Lewis rats. Both isografts and allografts are 
given Cyclosporine for 10 days to prevent acute rejection.  As the development of 
glomerulosclerosis is considerably prolonged, a nephrectomy of the right native kidney is 
carried out 10 days after transplantation to accelerate the kidney scarring process. CAN 
develops over a 12 month period. 
1.9. Extracellular Matrix turnover 
 
1.9.1. ECM deposition 
 
All ECM is in a continuous state of turnover including that forming the interstitial matrix and 
basement membranes.  The ECM acts to provide a complex three-dimensional structural 
support to the cells and regulates intercellular communication amongst many other vital 
cellular functions such as  migration, polarity, adhesion, proliferation, differentiation and 
survival (Jarvelainen et al. 2009, Frantz et al. 2010).  These ECM-cell interactions are 
modulated by a group of molecules named “matricellular proteins” which include 
thrombospondin-1 and -2, SPARC (secreted protein, acidic and rich in cysteine), tenascin-C, 
fibulin, CCN proteins (CYR61/CTGF/NOV), and osteopontin (Bornstein 2009).  These 
signalling events are dependent on the interactions of such proteins with ECM adhesion 
receptors such as Integrins, growth factor receptors and proteoglycans (Kim et al. 2011).  In 
the kidneys, the ECM forms the structural basis of the glomerular mesangium and the 
interstitium.  Continuous turnover of ECM proteins is fundamental for tissue homeostasis and 
is kept by a balance between the deposition and degradation of its components (figure 1.7).  
Excessive ECM accumulation leads to scar formation and consequent distortion of the fine 
renal architecture, resulting in the collapse of its parenchyma and loss of kidney function. 
 
ECM deposition is driven by intracellulary synthesis of ECM proteins (as discussed above). 
These proteins include various Collagens types, Elastin, Non collagenous glycoproteins (such 
as Fibronectin, Tenascin, Osteonectin, Laminin and Thrombospondins) and Proteoglycans 
including hyaluronan (Jarvelainen et al. 2009). Numerous chemokines and profibrogenic 
cytokines (e.g. Fibroblast growth factor 23 (FGF23), Platelet-derived growth factor (PDGF), 
Epidermal growth factor (EGF), Connective tissue growth factor (CTGF), basic fibroblast 
growth factor (bFGF), IL-1, IL-6, IL-7, TNFα and TGFβ1) stimulate a myriad of intracellular 
signalling cascades that will lead to the transcription of matrix proteins (Boor and Floege 2011, 
Hsieh et al. 2012, Yang et al. 2012, Kovesdy and Quarles 2013, Staruschenko et al. 2013).  
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Fibronectin is one of the first proteins to be up regulated and is thought to form a scaffold for 
the deposition of other proteins in scarred tissue.  Increased synthesis of Collagens type IV, 
V and VI in addition to Laminin has been observed in normal ECM homeostasis (figure 1.6).  
Furthermore, an additional synthesis of ECM components that are not normally found in the 
glomeruli under physiological conditions, such as Collagen type I and III, has also been 
demonstrated (Miyazaki et al. 2003). 
 
Once secreted, ECM proteins need to be deposited by specific enzymes such as Tissue 
Transglutaminase and Lysyl Oxidase (Miyazaki et al. 2003, Eikmans et al. 2004). Tissue 
Transglutaminase has a decreased role in normal deposition pathways than that seen after 
insult, when it is linked to rapid ECM deposition (discussed in section 1.9.1).  Lysyl Oxidase is 
involved in collagen biosynthesis and in the conversion of lysine and Hydroxyproline residues 
unto stable crosslinks between collagen fibrils (Kagan 2000).  Different cell types have 
different capacities to synthesise and deposit ECM.  Fibroblasts are the greatest producers of 
interstitial collagens for example, while tubular epithelial cells can synthesise considerable 
amounts of basement membrane proteins such as Collagen IV. 
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Figure 1.6: Schematic structure of the ECM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.6: The ECM provides mechanical and structural support to cells and tissues as well as 
modulates major cell signalling processes. It is formed by numerous proteins including diverse 
Collagens types, Elastin, non-collagenous glycoproteins such as Fibronectin, Tenascin and Laminin, and 
Proteoglycans. 
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Figure 1.7: The main molecular components of normal and fibrotic ECM 
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1.9.2. ECM breakdown 
 
ECM levels are also regulated through the degradation of its components.  The degradation 
of the ECM is mediated by the activity of two collagenolytic systems, the Matrix 
Metalloproteinases (MMPs) (Page-McCaw et al. 2007) that can degrade most types of ECM 
proteins and the Plasminogen-Plasmin system (Eddy 2009), which also can degrade a variety 
of ECM substrates such as Proteoglycans, Laminin, Fibronectin, and Collagens III, IV and V.  
These enzymes are regulated by their inhibitors; Tissue Inhibitor of Metalloproteinases 
(TIMPs) and Plasminogen Activator Inhibitor (PAI) respectively.  A loss of equilibrium ECM 
metabolism, such as an increased synthesis or deposition of its components and/or decreased 
breakdown causes an accumulation of ECM and consequently scar formation and fibrosis.  
 
1.10. ECM related molecules involved in the scarring process 
 
1.10.1. Transglutaminase 2 
 
Transglutaminases (EC 2.3.2.13) are a family of proteins first described in 1957 by Clarke et 
al (Clarke et al. 1957).  So far there are nine characterised family members, one consists of a 
structural protein (protein 4.2) and eight encode active enzymes: Factor XIII (Fibrin Stabilizing 
factor), Keratinocyte transglutaminase, Transglutaminase 2, Epidermal Transglutaminase, 
Prostate Transglutaminase, TGM X, TGM Y and TGM Z (Lorand and Graham 2003, Iismaa et 
al. 2009).  These enzymes catalyse at least five types of post-translational modification of 
proteins that can be subdivided into three categories: transamidation through acyl-transfer 
reactions by the formation of proteinase resistant ε (ᵞ-glutamyl) lysine isopeptide bonds or 
through incorporation of primary amines at selected pepti-bound glutamine residues, 
esterification by the binding of an alcohol, and hydrolysis (Iismaa et al. 2009).   
 
All members of this family have four structurally distinct domains: an NH2-terminal β-sandwich, 
an α/β catalytic core containing a triad of Cys-His-Asp or Cys-His-Asn, and two COOH-
terminal β-barrel domains that undertake a compressed conformation in the absence of 
calcium.  They have been involved with a number of human disease states including celiac 
disease, cancer, abnormalities of coagulation, skin disorders, atherosclerosis and certain 
neurological diseases such as Huntington`s and Parkinson`s (Martin et al. 2006, Muma 2007, 
De Vivo and Gentile 2008).  They are also implicated on tissue fibrosis including lung fibrosis 
(Olsen et al. 2011), liver fibrosis (Grenard et al. 2001) and renal scarring (Johnson et al. 1997, 
Johnson et al. 2003).  The summary of their classification as well as their function can be seen 
on table 1.6. 
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Table 1.6: Physiological Transglutaminases and respective functions 
NAME GENE CROMOSSOME MW FUNCTION 
Factor XIII F13A1 6p25-p24 83 Coagulation and 
wound healing 
Keratinocyte 
transglutaminase 
(TG1) 
TGM1 14q11.2 90 Terminal 
differentiation of 
keratinocytes 
Transglutaminase 
2 (TG2) 
TGM2 20q11.2-q12 76 Ubiquitous, ECM 
stabilisation, 
Apoptosis 
Epidermal 
transglutaminase 
(TG3) 
TGM3 20q12 77 Terminal 
differentiation of 
keratinocytes 
Prostate 
transglutaminase 
(TG4) 
TGM4 3p22-p21.33 77 Semen 
coagulation 
TGM X (TG5) TGM5 15q15.2 81 Epidermal 
differentiation 
TGM Y (TG6) TGM6 20q11-15 Unknown Unclear 
TGM Z (TG7) TGM7 15q15.2 81 Lung, testis 
Erythrocyte 
protein band 4.2 
EPB42 15q15-q21 77 ATP-binding 
protein 
 
Transglutaminase 2 (tTG, TGase2; TG2) is a remarkably complex multifunctional protein 
associated with tissue stability and repair, ECM interactions, apoptosis, regulation of cell 
growth, differentiation, wound healing phases at multiple levels under normal and pathological 
situations and a wide range of biochemical functions (Verderio et al. 2004, Verderio et al. 
2005).  This includes the protein transamidation activity by incorporation of primary amines 
such as polyamines and histamine, the crosslinking of proteins via the formation of highly 
stable ε (ᵞ glutamyl) lysine bonds, deamidation of glutamines, structural adhesion activity, 
GTP-binding/hydrolysing function, Ca+2-dependent isopeptidase activity, and a recently found 
adenosine triphosphate (ATP) hydrolysis activity (Han et al. 2010, Gundemir et al. 2012).  
Outside the cells, TG2 promotes the interaction of integrins with fibronectin and also activates 
phospholipase C regulating transmembrane signalling through cell surface receptors (figure 
1.8). 
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Figure 1.8: Biochemical activities of Transglutaminase 2 
 
 
 
Figure 1.8: Biochemical functions of TG2.  Adapted from Fesus and Piacentini: TRENDS in Biochemical 
Sciences V27, No. 10: 534-539. (Fesus and Piacentini 2002). C; cytosol, N; nucleus, E; extracellular 
space and M; cell membrane. 
 
 
TG2 is the only member of the transglutaminase family which is ubiquitously expressed and it 
is notably released by epithelial cells, fibroblasts, endothelial cells, macrophages, osteoblasts 
and smooth muscle cells.  It can be found in intracellular compartments, such as the cytosol, 
nucleus, endolysosomes and mitochondria, and extracellularly on the plasma membrane and 
in the ECM (Nurminskaya and Belkin 2012).  Its extracellular release to the ECM increases in 
situations of tissue damage and cellular stress (Siegel et al. 2008). 
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1.10.1.1. TG2 structure 
 
Human TG2 is a 76Kd protein, composed of 687 amino acids. It has a four-sequential domain 
structure: an N-terminal β sandwich (contains fibronectin and integrin binding sites), a core 
domain containing both the catalytic and regulatory sites and two C-terminal β-barrel domains 
(binds phospholipase C) (figure 1.9). 
 
TG2 is characterised by a papain-like catalytic triad (Cys277, His335 and Asp358) on its 
transamidating active site (Kiraly et al. 2011).  In addition to the catalytic triad, TG2 
transamidating activity is also regulated by two conserved tryptophan residues (W241 and 
W332) which stabilize the enzyme-thiol intermediated formed during catalysis (Murthy et al. 
2002, Pinkas et al. 2007).  The catalytic activity of TG2 is positively regulated by calcium 
binding, which shifts TG2 to the “open” (extended) conformation by moving the β-barrel 
domains 3 and 4 apart from the catalytic domain 2, thus revealing the enzyme's active site 
(figure 1.9-B) (Pinkas et al. 2007).  On the other hand, TG2 is negatively regulated by GTP/ 
GDP, which inhibit it by converting it to the “closed” (compact) conformation (figure 1.9-C) 
(Han et al. 2010, Kiraly et al. 2011).  Furthermore, a mutation of the tryptophan residue W241 
to an alanine W241a knocks out TG2 transamidating activity without impacting on GTP/GDP 
binding (Pinkas et al. 2007).  TG2 is kept in a latent state as a transamidase with an 
intracellular average GTP/ Ca+2 ratio of ~ 150µM/~100nM (Gundemir et al. 2012) as well as in 
the absence of mechanical or chemical stress (Kiraly et al. 2011).  
 
TG2/GDP bound structure has a unique guanidine nucleotide binding site situated between 
the catalytic core and the β-barrel domain 1; this is coded by exon 10 of TGM2. (Liu et al. 
2002).  When TG2 is complexed with GDP there is a blockage to the transamidation active 
site along with an attachment of a Tyr residue to hydrogen on the active site cysteine. 
Defective forms of TG2 where there is a loss of the GTP-binding site are more prone to 
mediate apoptosis (Datta et al. 2007).  TG2/Ca+2 bound structure shows conformational 
changes including the displacement of the hydrogen-bonded Tyr which enables the active site 
to be accessible (Mariani et al. 2000).  It is believed that there are at least 5 (most probable 6) 
calcium binding sites and this confers different degrees of affinity of TG2 for calcium, however, 
the most important Ca2+ binding site is Cys277 located within the catalytic triad of the core 
domain (Kiraly et al. 2009, Gundemir et al. 2012). 
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 Figure 1.9: Transglutaminase 2 molecular structure 
   
     β-sandwich                          Catalytic core                              β-barrel1              β-barrel2   
 
 FN/Integrin                         *BH3     *NSL1                                  *Ca2+              GTP              *NSL2      PLCδ1 
 
 
 
Figure 1.9: Representation of Transglutaminase 2 structure. A) Genomic organization of the four-
sequential protein domains. Three-dimensional ribbon structure of TG2: B) compact, inactive GDP-
bound and C) extended, inhibitor-bound TG2 conformation. The four protein domains are colour-
coded:  the N-terminal β-sandwich is shown in blue (N), the catalytic domain (Core) in green, and the 
C-terminal β-barrels (β1 and β2) in yellow and red, respectively.  
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1.10.1.2 TG2 activity 
 
It is well established that Ca2+ in the range of 3–100μM is required for the activation of TG2 
transamidating activity, with maximum activity seen at 5mM (Kiraly et al. 2011).  However, the 
transglutaminase activity can be decreased by an interaction of TG2 with specific molecules 
such as sphingosylphosphocholine (Lai et al. 1997) and phosphoinositides (Zemskov et al. 
2011) and increased by direct binding of TG2 to heparan sulphate proteoglycans such as 
syndecan-4 (Scarpellini et al. 2009, Verderio and Scarpellini 2010). 
 
Transglutaminase activity is typically inhibited by GTP bounding, but can also be inhibited by 
nitrosylation of up to 15 of the 18 cysteine residues by nitric oxide (Telci et al. 2009, 
Santhanam et al. 2010).  Nitrolysed TG2, without the presence of Ca+2, was found to be 6-fold 
more susceptible to inhibition by Mg-GTP according to a study from Lai TS et al 2001. 
Otherwise, the presence of Ca+2  can trigger the release of nitric oxide groups as well as 
regulate the S-nitrosylation and therefore activate TG2 activity (Lai et al. 2001).  In addition, 
the formation of disulphide bonds between Cys370-Cys371 and Cys370-Cys230 can also 
result in the inactivation of the transglutaminase activity even in the presence of calcium 
(Stamnaes et al. 2010).  Likewise, the generation of alternative protein spliced isoforms 
(Antonyak et al. 2006, Lai et al. 2007, Tee et al. 2010), an  increased proteolytic cleavage of 
the molecule by trypsin (Fraij 2011), acetylation (Lai et al. 2010) and a highly oxidative state 
in the extracellular compartment in the absence of mechanical and/or chemical stresses 
(Siegel et al. 2008) were also reported to suppress the transamidating activity of TG2. On the 
other hand, the presence of Retinoic acid favours TG2 activity and this results in increased 
transamidation of RhoA and its binding to RhoA-associated kinase-2 (ROCK-2) with 
subsequent autophosphorylation of ROCK-2, increased kinase activity and phosphorylation of 
vimentin (Singh et al. 2001).  RhoA transamidation also leads to platelet aggregation, 
exocytosis, modification of cytoskeleton organization and activation of MAP kinase pathway 
(Schoenwaelder et al. 2002, Singh et al. 2003). 
1.10.1.3. TG2 transcription and externalization 
 
The human TG2 gene is located on the 20th chromosome (20q11.2-q12).  Multiple molecules 
can influence TG2 transcription, such as the retinoic acid (Chiocca et al. 1988, Nagy et al. 
1996), histone deacetylase inhibitors (Liu et al. 2007), TGFβ1, TGFβ2 (Telci and Griffin 2006), 
TNFα (Collighan and Griffin 2009), Interferon γ (IFNγ) (Esposito et al. 2003), epidermal growth 
factor, interleukins (Aeschlimann and Thomazy 2000), corticosteroids (Johnson et al. 1998), 
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Hypoxia inducer factor (HIF) (Jang et al. 2010) and also DNA methylation (Lu and Davies 
1997, Cacciamani et al. 2002).  
 
A small portion of TG2 is exported to cell surface despite the absence of an export leader 
sequence.  Recently, Chou et al have used mutation and deletion analysis in three different 
renal tubular cell lines and were able  to identify a vital sequence for TG2 externalization within 
the amino acids 88-106 in the N-terminal β-sandwich domain of TG2 (Chou et al. 2011). 
1.10.1.4. Major TG2 functions 
 
Transamidation function 
One of the most recognized enzymatic functions of TG2 is its characteristic 
transamidating/protein cross-linking activity by the establishment of covalent bonds between 
epsilon-amino groups of primary amines such as lysine and the gamma-carboxamine group 
of glutamine residues (Nurminskaya and Belkin 2012) (figure 1.8).  This reaction catalysed by 
TG2 leads to post-translational modifications of proteins such as fibrinogen/fibrin, fibronectin, 
collagens, dermatane sulphate proteoglycans, lipoprotein a, osteonectin, laminin, von 
Willebrand factor, Galectin-3, osteopontin, vitronectin and nidogen (Borth et al. 1991, 
Aeschlimann et al. 1992, Usui et al. 1993, Aeschlimann et al. 1995, van den Brule et al. 1998, 
Ritchie et al. 2000, Fisher et al. 2009).  TG2 can also crosslink itself through its reactive lysine 
residues to a number of glutamine-containing substrates such as fibronectin, fibrinogen 
(Barsigian et al. 1991) and gluten peptides (Fleckenstein et al. 2004).  The crosslinking of 
these proteins leads to the formation of highly stable ε (ᵞ glutamyl) lysine (XL) bonds and this 
not only affects these protein’s conformation, but also their molecular interactions, stability, 
and their capacity to undergo polymerization as such XL bonds are highly resistant to 
proteolytic degradation (Chen and Mehta 1999, Facchiano et al. 2006, Fisher et al. 2009). 
  
Due to its protein crosslinking function, TG2 has been implicated in ECM-cell interaction and 
stabilization (Aeschlimann and Thomazy 2000, Fisher et al. 2009).  Following tissue injury, 
accumulation of TG2 in the matrix leads to the intermolecular crosslinking of several ECM 
components, mainly collagens III and IV and fibronectin (Verderio et al, 2004).  This increased 
rate of deposition of ECM polymers leads to increased mechanical stability and stiffness with 
subsequent organ scarring and fibrosis, such as pulmonary (Olsen et al. 2011), liver (Grenard 
et al. 2001), and kidney fibrosis (Johnson et al, 1999) as well as atherosclerosis (Van Herck 
et al. 2010). Johnson et al (Johnson et al. 2007) studied the TG2 role in the rat SNx model of 
renal fibrosis and demonstrated that TG2 expression was increased in renal fibrotic cells and 
that pan transglutaminase inhibition could reduce the development of glomerulosclerosis and 
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tubulointerstitial fibrosis by diminishing the depositing of collagens I and III indicating its 
importance in the renal scarring process. 
 
Fibronectin is one of several proteins that can be crosslinked by TG2. However, further to its 
crosslinking activity, plasma membrane TG2 also interacts with the gelatin-binding domain of 
fibronectin mediated by alpha5beta 1 integrin and this contributes to fibrillogenesis (Akimov 
and Belkin 2001). 
 
TG2 is also able to interact with microtubule-binding proteins and Tubulin-β, being linked to 
increased apoptosis in human neuroblastoma cells (Piredda et al. 1999).  It  was reported that 
TG2 can be translocated to the nuclear compartment of  these cells through its interaction with 
the transport protein Importin α3 (Peng et al. 1999). Furthermore, it was shown that TG2 
ablation decreases neuronal death (Mastroberardino et al. 2002).  
 
Deamidation function 
TG2 can also modify the structure of proteins by its deamidation function.  TG-mediated 
deamidation is a variant of the transamidation reaction in which H2O is used as a nucleophile 
in the absence of amine co-substrates (Lorand and Graham 2003, Facchiano and Facchiano 
2009).  As a result of the deamidation reaction, glutamine residues are modified to glutamic 
acid residues (figure 1.8).  An example of TG2 deamidating function include the deamidation 
of peptides present in the wheat protein gliadin, causing them to become dominant epitopes 
for activating T cells in the pathogenesis of celiac disease (Shan et al. 2002, Sollid and Jabri 
2005).  Another example of TG2-induced protein deamidation is the deamidation of Gln15 in 
β-amyloid peptide what causes reduced solubility of this molecule and development of 
Amyloidosis (Schmid et al. 2011). 
 
Protein Disulphide Isomerase function 
In addition to the transamidation and deamidation functions, TG2 has also been implicated as 
a protein disulphide isomerase (PDI) and a regulator of mitochondrial function.  The PDI 
activity of TG2 was shown in a study where TG2 was able to convert completely denatured / 
inactive RNaseA molecule into an active enzyme by the formation of disulphide bonds 
(Hasegawa et al. 2003).  The same study showed that the PDI activity of TG2 is independent 
of calcium and not inhibited by nucleotides such as GTP.  In another studies, the PDI activity 
of TG2 was confirmed by the formation of disulphide bridges in mitochondrial respiratory 
complexes I, II and V and also by configuration of the prohibitin complexes (Mastroberardino 
et al. 2006, Malorni et al. 2009). 
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Protein Kinase function 
TG2 was also reported to have an intrinsic serine/threonine protein kinase activity as it was 
found that it can phosphorylate serine residues in a number of situations including; the insulin-
like growth factor-binding protein-3 (IGFBP-3) on the surface of cancer cells (Mishra and 
Murphy 2004), residue Ser15 and Ser20 in the p53 tumour suppressor protein (Mishra and 
Murphy 2006), histones H1 and H3 (Mishra et al. 2006-A) and  residue Ser780 in the 
retinoblastoma protein (Rb) in the nucleus (Mishra et al. 2007). Interestingly, TG2 can also 
phosphorylate itself by protein kinase A (PKA), and although this reaction decreases its 
transamidating activity, it increases the kinase activity of TG2 (Mishra and Murphy 2006-B). 
 
GTPase and Transmembrane signaling 
Another well established function of TG2 is linked to signal transduction across the plasma 
membrane (figure 1.8).  TG2 acts as a non-canonical G protein (guanidine nucleotide-binding 
protein; Gh) and therefore is able to bind and hydrolyse GTP (Nakaoka et al. 1994). Thus, it 
alters the signaling function of several molecules including CD38 (Umar et al. 1996) and 
insulin-like growth factor binding protein 1 (Sakai et al. 2001). 
 
TG2 also regulates other signaling pathways through its GTPase activity.  It was shown that 
TG2 can mediate the adrenergic activation of extracellular signal-regulated kinases (ERK) and 
their regulatory kinases (MEK) in cardiomyocytes (Lee et al. 2003).  Its GTPase activity was 
also found to promote cell proliferation induced by α1 adrenergic receptors in hepatocytes (Wu 
et al. 2000) and myometrial cells (Dupuis et al. 2004) as well as in its binding with α5 integrin 
subunit causing inhibition of vascular smooth muscle cell migration (Kang et al. 2004). 
 
Cytoskeleton organization 
A further TG2 function relates to its capacity of modifying the cytoskeleton organization by 
interaction with several cytoskeletal proteins such as Phospholipase C delta1 (PLCdelta1, 
PLCδ1) (Iismaa et al. 2000), Integrins (Akimov and Belkin 2001), Tubulin-β (Piredda et al. 
1999) and Importin α3 (Peng et al. 1999).  
 
 PLCδ1 is an enzyme that can accelerate TG2 binding to GTPγS following an increased 
release of GDP from TG2. It also can mediate alpha1B-adrenoreceptor (alpha (1B) AR) – TG2 
signalling (Baek et al. 2001).  Though its GTPase activity, TG2 can form non-covalent 
complexes between PLCδ1 and various transmembrane proteins such as  thromboxane A2 
(Vezza et al. 1999), oxytocin (Park et al. 1998), the α1D adrenergic (Im and Graham 1990) and 
follicle stimulating hormone receptors (Lorand and Graham 2003). 
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Apoptosis 
In vitro experiments have shown that TG2 is upregulated in several cell types undergoing 
apoptosis.  This could confer pro- or anti-apoptotic effects (Falasca et al. 2005, Fesus and 
Szondy 2005).  Initial experiments showed that TG2 can crosslink major modulators of cell 
survival and death, such as retinoblastoma protein (Oliverio et al. 1997) and the pro-apoptotic 
enzyme DAP-like kinase (DLK) (Robitaille et al. 2004).  One initial hypothesis was that the 
pro-apoptotic effect could be due to a TG2-dependent covalent polymerization of Bax 
throughnTG2 BH3 domain, which would induce a conformational change and translocation of 
Bax to the mitochondria, cytochrome-c releasing and subsequent cell death (Rodolfo et al. 
2004).  Some other studies have suggested that TG2 could exert an anti-apoptotic effect by 
binding to fibronectin and cell surface heparin sulphate chains (via α5β1 integrins) promoting 
the activation of Rho and the adhesion-dependent survival signalling of cells (Verderio et al. 
2003).  In another study, TG2 capability to prevent apoptosis was found to be independent to 
its binding to fibronectin.  Instead, TG2 could promote cell adhesion by regulation of PLCδ1 
(Baek et al. 2001). 
 
Tissue repair 
TG2 can potentially target the tissue repair process at multiple levels: incorporation of serum 
proteins such as Plasminogen activator inhibitor 2 (PAI-2), activation of TGFβ1 complex, post 
translational modification of sPLA2, phagocytic clearance, modulation of cell migration, RGD 
independent cell adhesion, fibril stabilisation, ECM homeostasis,  apoptosis and modulation 
of angiogenesis (Douthwaite et al. 1999, Jones et al. 2006, Harrison et al. 2007). 
 
Dermal wounding healing 
TG2 was associated with increased skin strength in rats by the crosslinking of fucoprotein in 
the ECM.  Its inhibition by the use of topical putrescine caused skin fragility and decreased 
wound firmness (Dolynchuk et al, 1994). 
Another biological function attributed to TG2 includes dermal wounding healing.   It may play 
a role in keratinocyte basement membrane crosslinking.  Pan Transglutaminase inhibitors, 
which also blocked TG1 and 3, were found to prevent keratinocyte terminal differentiation and 
consequently hyperproliferation, hyperproliferative epidermis with parakeratosis, loss of 
basement membrane collagen IV, enhanced expression of involucrin and cytokeratin 6 and 
16 and reduction of cytokeratin 10 (Harrison et al. 2007). 
1.10.1.5. The role of TG2 in human diseases 
 
TG2 has been linked to a number of human diseases including coeliac disease, neurological 
diseases, cancer, metabolic and endocrinologic diseases, renal disease, along with other 
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autoimmune, inflammatory and related diseases. It can target a broad spectrum of different 
substrates and therefore, act on several pathologies (table 1.7). 
 
Table 1.7:  TG2 Substrates in human diseases 
 
SUBSTRATE REGULATION 
PROCESS 
HUMAN DISEASE REFERENCES 
Amyloid beta A4 peptide ND Alzheimer (Rasmussen et 
al. 1994) 
Collagens I and III ECM-S, PS CKD (Johnson, 1999 
#765) 
Fibrinogen A alpha ECM-S, OTH Amyloidosis (Murthy et al. 
2000) 
Galectin 3 
 
ECM-S, CB Rheumatoid arthritis (Mehul et al. 
1995) 
Glucagon MED Hypoglycaemia (Molven et al. 
2002) 
Gluten ECM-S, OTH Coeliac disease (Esposito et al. 
2005) 
Huntingtin ND Huntington disease (Zainelli et al. 
2004) 
Insulin MED Diabetes Mellitus (Bungay et al. 
1984) 
Keratin, type II 
cytoskeletal 5 
DD, CR, MF Epidermolysis 
bullosa 
(Candi et al. 
1998) 
Myelin basic protein ND Multiple sclerosis (Selkoe et al. 
1982) 
Α-Synuclein ND Parkinson (Andringa et al. 
2004) 
Tau protein ND Alzheimer (Murthy et al. 
1998) 
 
Note: ND; neurological diseases, ECM-S; ECM interaction and stabilization, PS; protein stabilization, 
OTH; other autoimmune, inflammatory and related diseases, CB; cancer biology, MED; metabolic and 
endocrinology diseases, DD; dermatologic diseases, CR; cytoskeleton regulation, MF; membrane 
traffic and membrane structure/function. 
1.10.1.5.1. TG2 in Coeliac disease 
 
Coeliac disease (coeliac sprue, gluten-sensitive enteropathy) is an autoimmune disorder of 
the small intestine influenced by both environmental and genetic factors.  The inflammatory 
injury of the small intestine mucosa occurs after the ingestion of wheat, gluten or related rye 
and barley proteins.  It causes a malabsorption syndrome characterized by atrophy of villi in 
the jejunum.  Following specific recognition by T cells, there is a binding of gluten peptides to 
HLA molecules (HLA-DQ2 and HLA-DQ8) (Dieterich et al. 1997, Sollid 2002, Vader et al. 
2002).  TG2 causes crosslinking of these proteins and also deamidation of glutamine side 
chains, creating covalent complexes via a thioester bond to the active site cysteine of TG2 
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(Esposito et al. 2005).  Due to the TG2 modification on the gluten protein, the immune system 
cross-reacts with the small intestine causing inflammation and formation of autoantibodies 
anti-gliadin, anti-endomysial and IgA anti-TG2 (Vives-Pi et al. 2013).  Recently, it was found 
that a materno-fetal transfer of anti-transglutaminase antibodies could cause a passive 
transfer model for coeliac autoimmunity (Baldassarre et al. 2012). 
1.10.1.5.2. TG2 in Neurological diseases 
 
Neurodegenerative disorders such as Alzheimer, Parkinson and Huntington disease have in 
common an elevated deposition of multimeric structures in the degenerative region of the 
brain, increased TG2 activity and intracellular calcium concentration (Jeitner et al. 2009).  For 
instance, Alzheimer’s disease is characterised by increased deposition of amyloid β 
aggregates and intracellular neurofibrillary complexes of tau protein.  Parkinson’s disease 
shows an accumulation of alpha-synuclein protein in the brain in the form of lewy bodies.  
Finally, in Huntington’s disease there is a genetic mutation in which an expansion of CAG 
trinucleotide repeats in the gene encoding huntingtin.  As a consequence, insoluble 
aggregates of huntingtin protein presenting polyglutamine repeats in its N-terminal domain 
makes it a good TG2 substrate and as a consequence are deposited in the striatum and cortex 
of Huntington’s disease patients. 
 
TG2 can act on several substrates in the neuron cellular compartment, including the 
microtubule-associated tau protein (Murthy et al. 1998), amyloid beta-A4 peptide (Rasmussen 
et al. 1994), alpha-synuclein (Jensen et al. 1995) and Huntingtin (Kahlem et al. 1998, Zainelli 
et al. 2004).  It crosslinks these polypeptides resulting in the formation of ε (ᵞ glutamyl) lysine 
bonds and also bis-γ-glutamylpolyamine bridges (Jeitner et al. 2008). Hence, the increased 
crosslinking activity of TG2 on these substrates and subsequent formation of protein 
aggregates is recognized to be a determinant factor on the pathogenesis of these neurological 
diseases. 
1.10.1.5.3. TG2 in Cancer 
 
Cancer formation and progression is a complex mechanism which includes modulation of 
programmed cell death, cell adhesion and motility, cytoskeleton assembly, ECM homeostasis, 
angiogenesis and metastatic dissemination (Kotsakis and Griffin 2007). TG2 has been 
implicated in all these molecular processes and so, has been related to the modulation of 
tumour formation and secondary metastatic progression (Di Giacomo et al, 2009).  
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Several molecular targets associated with tumour development have been showed to be 
substrates for TG2.  In fact, TG2 can crosslink as well as act as a non-covalent interactor with 
a variety of ECM proteins, integrins, galectin-3, TGF-β and nuclear proteins such as E2F and 
retinoblastoma protein (van den Brule et al. 1998, Esposito and Caputo 2005).  However, TG2 
has a controversial involvement in carcinogenesis.  There is strong evidence that it can confer 
anti-apoptotic effects and subsequent chemotherapeutic resistance (Mehta 1994) as well as 
mediate metastasis and cancer cell progression (Mehta et al. 2004), but it was also described 
as a tumour suppressor (Mangala and Mehta 2005, Jones et al. 2006) and as critical for the 
execution of programmed cell death (Falasca et al, 2005). 
 
TG2 expression is up-regulated in a great variety of cancer types such as breast cancer 
(Mehta et al. 2004), ovarian (Satpathy et al. 2009, Cao et al. 2012), glioblastomas (Yuan et al. 
2007), melanomas (Di Giacomo et al. 2009) and pancreatic ductal adenocarcinomas (Verma 
et al. 2008). 
 
The involvement of TG2 in cancer development and progression could be due to a regulation 
at a transcriptional level of MMP-2 which is a major mediator of tissue invasiveness (Satpathy 
et al. 2009), integrin mediated signalling (Kotsakis et al. 2011), modulation of epithelial-to-
mesenchymal transition (EMT) induced by TGFβ, TNFα and NF-κB (Cao et al. 2012, Brown 
2013, Kumar and Mehta 2013), Akt phosphorylation (Verma et al. 2008), among other 
biological functions. 
 
On the other hand, injection of TG2 in CT26 colon carcinoma tumour has shown to decrease 
tumour growth and even cause tumour regression in few cases (Jones et al. 2006). This effect 
was related to the fact that TG2 increased ECM proteins deposition and consequently 
angiogenesis inhibition. Decreased colon carcinoma growth was also related to TG2 
interaction with integrin β3, activation of TGFβ1 and subsequent increased matrix-deposited 
fibronectin, which promotes elevated cell adhesion and less migratory cells (Kotsakis et al. 
2011). Notwithstanding, other different studies presented conflicting findings where TG2 could 
either inhibit or stimulate angiogenesis (Haroon et al. 1999, Haroon et al. 1999) and even 
inhibit metastasis (Mangala et al. 2005). Therefore, the role of TG2 in cancer biology 
represents a field that requires further investigation. 
1.10.1.5.4. TG2 in Metabolic and Endocrinologic diseases 
TG2 crosslinking and deamidation activities were observed in a number of hormones and 
hormone binding proteins including Insulin (Bungay et al. 1984, Lindsay et al. 1990), Glucagon 
(Molven et al. 2002), fatty acid synthase (Esposito and Caputo 2005), Glyceraldehyde 3-
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phosphate dehydrogenase (GAPDH) and alpha-ketoglutarate (Schmidt et al. 1998).  
Therefore, it is an important mediator in metabolic homeostasis.  
 
A TG2 knockout mice study showed impaired glucose-stimulated insulin secretion from 
pancreatic β cells (Bernassola et al. 2002).  In addition to its role in the membrane-mediated 
events required for insulin release, TG2 has also been implicated in crosslinking insulin 
receptors in the area of clathrin-coated pits (Baldwin et al. 1980).  It has also been 
demonstrated that TG2 is involved in the post-translational modification of Insulin-like growth 
factor-binding protein-1 (IGFBP-1) which binds and subsequently regulates cellular response 
to insulin-like growth factor-1 (IGF-1) (Sakai et al. 2001). 
1.10.1.5.5. TG2 in Kidney disease 
 
Regardless of the underlying disease, the final process of CKD is characterised by excessive 
accumulation of extracellular matrix what leads to fibrosis and scar formation (El Nahas 2005). 
TG2 has been strongly implicated in the kidney fibrotic process, being instrumental in scar 
tissue formation by catalysing the post-translational modification of ECM proteins by the 
formation of ε (γ-glutamyl) lysine bonds (Johnson et al. 1997).  
 
A study done by Johnson et al using the rat 5/6th Subtotalnephrectomy (SNx) model of renal 
scarring demonstrated that tissue levels of TG2 and ε (γ-glutamyl) lysine correlate well with 
histological renal scarring (Johnson et al. 1997).  Interestingly, in this study, the highest 
proportions of TG2 and ε (γ-glutamyl) lysine were found in the cytoplasm of renal tubular cells 
when compared to the extracellular renal interstitial space.  This increased expression of TG2 
is known to be modulated by many molecules, including TGFβ1 (Douthwaite et al. 1999).  
 
In addition to its crosslinking activity on large latent TGF β1 (Nunes et al, 1997), TG2 can 
favour renal fibrosis by activation of TGFβ1. Increased TGFβ1 activation stimulates ECM 
deposition through the elevated synthesis of several polypeptides such as Collagen I, III and 
IV by mesangial cells, fibronectin by epithelial cells and proteoglycans biglycan and decorin 
by glomerular mesangial cells (Okuda et al. 1990). Conversely, a study on TG2 knockout (KO) 
mice showed diminished renal interstitial fibrosis due to a reduction on TGFβ1 activation and 
subsequent decreased deposition of fibrilar collagen and inflammation, as described on an 
unilateral ureteral obstruction (UUO) model of renal scarring (Shweke et al. 2008).  Johnson 
et al demonstrated that administration of two irreversible inhibitors of TG2 (NTU281; acts 
mainly on the extracellular compartment, while NTU283; can also act on the intracellular 
compartment due to its high cell solubility) decreased the development of glomerulosclerosis 
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and tubulointerstitial fibrosis in rats submitted to SNx.  In this study, immunohistochemical 
analysis showed reduced levels of collagens I and III in the remnant kidney.  However, levels 
of active TGFβ1 were not reduced in rats treated with TG2 inhibitors in this study (Johnson et 
al. 2007). 
 
In the rat streptozotocin model of Diabetic Nephropathy (DN), increased levels of TG2 in the 
peritubular interstitial space with consequential accelerated ECM crosslinking was linked to 
the development of DN (Skill et al. 2001).  In a development of this model, treatment with TG2 
inhibitor NTU281 was associated with reduction of myofibroblasts and collagens I, III and IV, 
resulting in reduced ECM deposition with improvement of kidney function (Huang et al. 2009) 
which was partly through increased active TGFb1 levels.  TG2 inhibition with NTU283 in renal 
proximal tubular epithelial cells (OK cells) reduced ε (γ-glutamyl) lysine, hydroxyproline and 
fibronectin levels, thus reducing ECM accumulation (Skill et al. 2004).  
 
In human Diabetic Nephropathy, El Nahas et al confirmed the presence of increased levels of 
TG2 and ε (γ-glutamyl) lysine by immuno-localisation in DN type 2 renal biopsies (El Nahas et 
al. 2004).  Another study in human kidney disease showed a strong correlation between tissue 
levels of TG2 and its crosslink product and progressive renal scarring (Johnson et al. 2003).  
Thereby, TG2’s role in renal fibrosis is related to increased crosslinking of the ECM that leads 
to its accumulation and elevated resistance to degradation by MMPs (Fisher et al. 2009). 
 
1.10.2. Collagens 
 
Collagens are the most abundant protein in the body and the major component of the 
extracellular matrix.  They provide mechanical support in a variety of tissues including 
muscles, bone, cartilage, tendons, skin, heart valves, blood vessels and basement 
membranes (Pope and Nicholls 1987).  So far 28 types subdivided into subfamilies based on 
their structures had been found in humans; Fibrilar, Fibril Associated Collagens with 
Interrupted Triple helices (FACITs), Network-forming, Anchoring fibrils, Transmembranous, 
Endostatin precursor and other collagens with distinct molecular assembly (Ricard-Blum 
2011).  
 
The common structural feature of collagens consists of  three hydrogen bonded polypeptide 
 chains (662 up to 3152 amino acids) arranged in  super triple helix that can range from most 
of their structure (96% for collagen I) to less than 10% (collagen XII) (Gordon and Hahn 2010, 
Ricard-Blum 2011).  The most predominant are fibrilar collagens Type I (major component of 
tendon, ligament and, bones, corresponding to over 90% of the collagen in the body), Type II 
(cartilage), Type III (arteries, intestine, uterus and renal interstitium) and collagen IV (form 
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network-like structures including basal lamina of epithelia, glomerular and tubular basements 
membranes).  Type V is a less common component and is present mainly in the hair, cell 
surfaces and placenta (Gordon and Hahn 2010).  Collagen types I, II, III, V and XI self-
assemble into D-periodic cross-striated fibrils (Kadler et al. 2007).  The huge heterogeneity of 
the collagen family is a consequence of the existence of several different α chains, various 
distinct molecular isoforms and supramolecular structures for the same collagen type, and the 
use of alternative promoters and splicing variants.  Numerous collagens (IX, XII, XIV, XV, 
XVIII) bear glycosaminoglycan chains (chondroitin sulphate and/or heparan sulphate chains) 
and therefore are considered also as proteoglycans (Ricard-Blum 2011). 
 
Collagens are mainly synthesized by fibroblasts, osteoblasts, chondrocytes and mesangial 
cells, although epithelial cells can also synthesise them.  Collagen types and their respective 
domain structures can be summarised into distinct families (table 1.8).  
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Type XV 
Table 1.8: Structural characteristics of collagens 
Collagen subfamily Collagen types α chains assembly 
 
Fibrilar collagens 
 
 
I, II, III, V, XI, 
XXIV, XXVII 
 
 
 
 
Fibril associated 
collagens with 
interrupted triple 
helices (FACITs) 
 
IX, XII, XIV, XVI, 
XIX, XX, XXI, 
XXII, XXVI 
 
 
 
Network-forming 
collagens 
 
 
IV, VI, VIII, X 
 
 
 
 
Type VII collagen 
forming anchoring 
fibrils 
 
 
 
 
 
 
 
VII 
 
 
Transmembranous 
 
XIII, XVII, XXIII, 
XXV 
 
    
 
Endostatin precursor 
 
XV and XVIII 
 
 
 
Other collagens 
 
 
XXVII, XXVIII 
 
 
Table 1.8: Collagen types and their trimeric molecules.  The collagen family comprises 28 members 
subdivided in subfamilies according to their domain composition and supramolecular assembly of α 
chains. GAG; glycosamino glycan side chain, EBM; epithelial basement membrane, TSP; 
thrombospondin N terminal repeat, ; fibrils,          and      ; gly-X-Y domains,         ; 
noncollagenous domain,         ; hexagonal lattice,       ; fibronectin type III repeat,      ; transmembrane 
domain. 
 
Type IX 
EBM 
Type XIII 
TSP 
Type XXVII 
COL1 COL3 COL2 
GAG 
COL  
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1.10.2.1. Collagen biosynthesis 
 
Collagens are synthesised by a multistep process characterised by a large number of co and 
post-translational modifications mediated by highly specific enzymes (e.g. prolyl 3-
hydroxylase, prolyl 4-hydroxylase, Lysyl Hydroxylase, n terminal collagen protease and lysyl 
oxidase amongst others).  In a first step, a three dimensional stranded structure is assembled 
forming the precursor pre procollagen.  This structure presents the amino acids glycine and 
proline as its principal components.  Then, several molecules including vitamin C and 
Ascorbate modulate the conversion of pre procollagen to collagen (Myllyla et al. 1984, Boyera 
et al. 1998).  This conversion involves a hydroxylation reaction that substitutes a hydroxyl 
group for a hydrogen atom in the proline residues at certain points in the polypeptide chains, 
converting those residues to hydroxyproline (C5H9O3N).  This hydroxylation reaction is 
catalysed by two different enzymes: prolyl-4-hydroxylase and lysyl-hydroxylase (Gorres and 
Raines 2010).  In the folding step, the collagen’s structure will consist of three hydrogen 
bonded polypeptide α chains forming a super helix containing non-collagenous sequences 
(NC domains) at their termini.  In the final step, collagen fibers are formed by lysyl oxidase 
crosslinking.  The resultant super helix structure is composed of polypeptide chains containing 
at least one domain with Gly-X-Y sequences (X; Proline and Y; 4-Hydroxyproline) and formed 
by the amino acids glycine, proline, Hydroxyproline and Hydroxylysine (Prockop and Kivirikko 
1995, Shoulders and Raines 2009).  Hydroxyproline constitutes a major component of the 
collagens, around 1/6th of its total structure.  It is found in few proteins other than collagen 
(e.g.; elastin).  Therefore, the presence of Hydroxyproline is a strong indicator of the presence 
of collagen. 
1.10.2.2. Covalent crosslinking of Collagens 
 
Collagens can undergo crosslinking by a range of different pathways.  Transglutaminase 2 
catalyses the formation of stable and insoluble ε (ᵞ glutamyl) lysine isopeptide linkages in 
collagens I, III, IV, V, VI, VII, XI and XVI (Esposito and Caputo 2005, Collighan and Griffin 
2009, Wang and Griffin 2012). Likewise, mature crosslinks of lysine, hydroxylysine, and 
histidine residues present in collagens I, II, III, V, IX and XI can be produced by the enzyme 
lysyl oxidase (Eyre and Wu 2005, Wu et al. 2009, Wu et al. 2010).  Also, advanced glycation 
end-reaction products (AGEs) can form intermolecular crosslinking between two adjacent 
molecules such as lysine to lysine or lysine to arginine residues from collagen molecules within 
the fibre resulting in increased stiffness (Avery and Bailey 2006).  A good example of AGEs 
crosslinking is the action of Glucosepan on ECM collagens (Sjoberg and Bulterijs 2009).  
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Furthermore, it was recently identified a sulfilimine bond (-S=N-) crosslink between 
hydroxylysine-211 and methionine-93 in collagen IV (Vanacore et al. 2009).  
1.10.2.3. Collagen degradation 
 
Collagen degradation occurs through a two-step process that involves an extracellular and an 
intracellular pathway.  The extracellular pathway involves cleavage of collagen fibrils by 
proteolytic enzymes including the Matrix metalloproteinases (MMPs).  All collagens can be 
degraded by most MMPs, however, this degradation is mediated by recognition of specific 
cleavage sites.  Thus some MMPs had been shown to have preferential substrates for 
cleavage (Song et al. 2006).  For example, fibril-forming collagens I, II, and III are cleaved by 
MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase), MMP-13 (collagenase 3) 
and by membrane-anchored MMPs 14 and 16 (Ricard-Blum 2011).  Collagen I is also 
degraded by MMP-2, whilst collagen II is a preferential substrate of MMP-13 and collagen IV 
can be cleaved by MMPs 2  and 9 (Klein and Bischoff 2011).  Moreover, collagens can also 
be degraded by other membrane bound and soluble proteases such as subtilisin (Ran et al. 
2013) as well as by urokinase/tissue type plasminogen activator (uPA/tPA) and plasmin 
(Ghosh and Vaughan 2012).  The intracellular pathway involves binding and uptake of 
collagen fragments by fibroblasts and macrophages for lysosomal degradation by molecules 
such as cathepsins K and S which are two lysosomal cysteine proteases (Pietschmann et al. 
2013) .  
1.10.2.4. The role of Collagens in human diseases 
 
Collagen-related diseases are predominantly linked to genetic defects or mutations, nutritional 
deficiencies that alters their biosynthesis, unbalanced assembly into the matrix, changes in 
the posttranslational modification, secretion, or in other mechanisms implicated in collagen 
production (Gelse et al. 2003).  Mutations in the collagens structure have been linked to a 
diverse range of human diseases, such as Osteogenesis imperfecta and Marfan’s syndrome 
in collagen type I mutation (Gajko-Galicka 2002), Ehlers-Danlos Syndrome type IV in collagen 
type III mutation (Pope and Nicholls 1987, Kuivaniemi et al. 1991) and Leiomyomatosis in 
collagen type IV mutation (Hudson et al. 1993) ( table 1.9). 
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Table 1.9: Collagens types and their role in human diseases 
 
Collagen 
type 
Genes Human disease References 
I COL1A1, 
COL1A2 
Osteogenesis imperfecta, Marfan’s 
syndrome, Ehlers-Danlos Syndrome 
(Pope and Nicholls 1987, 
Gajko-Galicka 2002) 
II COL2A1 Chondrodysplasia (Horton et al. 1989) 
III COL3A1 Ehlers-Danlos Syndrome (Hamel et al. 1998) 
IV COL4A1, 
COL4A2, 
COL4A3, 
COL4A4, 
COL4A5, 
COL4A6 
Leiomyomatosis, Alport syndrome, 
Goodpasture's syndrome 
(Hudson et al. 1993, 
Kashtan 1993) 
V COL5A1, 
COL5A2, 
COL5A3 
Ehlers-Danlos syndrome (Kuivaniemi et al. 1991) 
VI COL6A1, 
COL6A2, 
COL6A3 
Ulrich myopathy and Bethlem 
myopathy 
(Bertini and Pepe 2002) 
VII COL7A1 Epidermolysis bullosa dystrophica (Almaani et al. 2011) 
VIII COL8A1, 
COL8A2 
Atherosclerosis (Lopes et al. 2013) 
IX COL9A1, 
COL9A2, 
COL9A3 
Multiple epiphyseal dysplasia  (Jackson et al. 2010) 
X COL10A1 Schmid-type metaphyseal dysplasia (Woelfle et al. 2011) 
 
1.10.2.4.1. Collagens in renal disease 
 
Collagens types I, III and IV are the most abundant in the kidneys, however, low levels are 
found until damage has been established.  Collagen type I is identified in smaller amounts in 
the interstitium and within the glomerular mesangium when compared to the collagen type III 
(Yoshioka et al. 1990).  Type III collagen is highly expressed in the mesangial matrix as well 
as in the vascular pole of sclerosed glomeruli (Yoshioka et al. 1989).  Collagen type IV is a 
major component of the GBM (Boutaud et al. 2000), being highly present in the mesangial and 
glomerular ECM. Interestingly, it was observed that whilst type I collagen promotes EMT, type 
IV renders protection to the epithelial phenotype in proximal tubular cells (Zeisberg et al. 
2001). 
 
Several studies have established that an increased synthesis and deposition of collagens on 
the ECM were directly involved with the development of renal fibrosis (Soylemezoglu et al. 
1997, Skill et al. 2004, Johnson et al. 2007, Fisher et al. 2009, Huang et al. 2009, Liu 2011). 
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An overproduction and increased ECM accumulation, genetic mutations of collagens can also 
contribute to renal dysfunction. 
 
Mutations of type I collagen are associated not only with Osteogenesis imperfecta and 
Marfan’s syndrome (Gajko-Galicka 2002), but also with glomerular collagen deposition in the 
mesangial matrix as well as between the fenestrated endothelial cells of COL1A2 deficient 
mice.  This fibrilar collagen deposition leads to the effacement of podocytes foot process and 
subsequent development of impaired kidney function (Brodeur et al. 2007).  Mutations in  
collagen type IV have been related to the pathogenesis of Goodpasture’s syndrome (carboxyl 
terminus of the NC1 domain of the α3 chain) and Alport syndrome (COL4A5 gene encoding 
the α5 chain) (Hudson et al. 1993). 
 
Urinary collagen levels have been used as markers of progressive kidney fibrosis. 
Measurements of urinary amino terminal peptide of procollagen III (PIIINP) demonstrated a 
high correlation with the severity of kidney fibrosis (Soylemezoglu et al. 1997).  Additionally, 
Hydroxyproline has been used to detect acute kidney injury in rats due to melamine and 
cyanuric acid nephrotoxicity (Schnackenberg et al. 2012). 
 
1.10.3. Matrix Metalloproteinases system 
 
1.10.3.1. MMPs 
 
Matrix Metalloproteinases (matrixins, MMPs) are a group of at least 25 multidomain zinc-
dependent endopeptidases (Iyer et al. 2012), secreted by a variety of cells such as 
macrophages (Hibbs et al. 1987), polymorphonuclear leukocytes (Murphy et al. 1982), 
fibroblasts (Wilhelm et al. 1989), osteoclasts (Reponen et al. 1994) and endothelial cells (Haas 
et al. 1998).  The MMP family has been categorised into five subgroups: matrilysins, 
collagenases, gelatinases,  stromelysins, and membrane-type MMPs (MT-MMPs) (Iyer et al. 
2012) (table 1.8). In order to be assigned as a member of the MMP family, there are five 
requirements that the enzyme should fulfil:  1) be able to cleave at least one ECM component, 
2) be inhibited by ethylenediaminetetraacetic acid, 1,10-phenanthroline, and one of the TIMPs, 
3) their catalysis function should be dependent on zinc at the active site, 4) activation by 
proteinases or organomercurials and 5) cDNA should have sequence homology to MMP-1 
(Iyer et al. 2012).  
 
Nearly all MMPs are capable of cleaving most components of the ECM and they can also 
process a number of bioactive molecules, like apoptotic ligands and growth factor receptors 
(Fingleton et al. 2001), pro-lysyl oxidase , IL-1β and α1-proteinase inhibitor (Chakraborti et al. 
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2003, Varghese 2006).  MMPs are also known to play a role on chemokine activation, cell  
localization, proliferation, differentiation, adhesion, apoptosis, angiogenesis and host defence 
(Clark et al. 2008, Manicone and McGuire 2008, Rydlova et al. 2008).  
1.10.3.1.1. MMPs transcription and activity 
 
A large number of molecules can regulate MMPs transcription such as cytokines, growth 
factors, activating protein 2 (AP-2), NF-kappaB, Specificity protein1 (Sp1), proto-oncogenes 
and hormones (Matrisian 1990, Mohan et al. 1998).  Their activity is strictly regulated at the 
level of transcription as well as by the activation of the precursor zymogens and through tight 
control from their endogenous inhibitors such as α2 macroglobulin, trombospondin-1, 
trombospondin-2, tissue factor pathway inhibitor, the membrane-anchored glycoprotein RECK 
and specifically by tissue inhibitors of metalloproteinases (TIMPs) (Oh et al. 2001, Baker et al. 
2002, Visse and Nagase 2003). 
1.10.3.1.2. MMPs biosynthesis 
 
Most MMPs are synthesized as prepro-enzymes and secreted in an inactive pro-form that 
requires zinc and proteolytic cleavage for activation (Nagase and Woessner 1999).  However, 
MMPs 11 and 28 are intracellulary activated by furin and are secreted in active forms and 
MMP-14 is not always secreted (Osenkowski et al. 2004, Iyer et al. 2012).  They share a 
primary three domain structure: the pro-peptide, the catalytic domain and the haemopexin-like 
C terminal domain (Bode et al. 1999, Nagase and Woessner 1999).  The pro-peptide domain 
contains around 80 amino acids.  It displays a cysteine switch motif PRCGXPD, where a 
cysteine residue inhibits binding and cleavage of substrates when interacting with zinc.  This 
keeps MMPs in their pro-form.  The catalytic domain has about 170 amino acids and contains 
the active site with a Zinc-binding motif HEXGHXXGXXH. This domain is composed of three 
α-helices, five-stranded β-sheet, and bridging loops (Dhanaraj et al. 1996).  The haemopexin-
like C terminal domain has around 210 amino acids and is connected to the catalytic domain 
by the Hinge region (around 75 amino acids).  It presents a structure which consists of four 
antiparallel β-strands and an α-helix (Gomis-Ruth et al. 1996).  Currently known MMPs, their 
correspondent domain composition and most common substrates are summarised in table 
1.10. 
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Table 1.10: MMPs types, substrates specificity and domain composition 
 
Subfamily MMP Protein name Main substrates Domain 
composition 
Collagenases MMP-1 Interstitial collagenase Col I, II, III, VII, VIII, 
X,XI, gelatin 
B 
Gelatinases MMP-2 Gelatinase-A Gelatin, Col I, II, III, 
IV, VII, X 
C 
Stromelysins MMP-3 Stromelysin 1 Col II, IV, IX, X, XI, 
gelatin 
B 
Matrilysins MMP-7 Matrilysin Fibronectin, laminin, 
Col IV, gelatin 
A 
Collagenases MMP-8 Neutrophil collagenase Col I, II, III, VII, VIII, X, 
aggrecan, gelatin 
B 
Gelatinases MMP-9 Gelatinase-B Gelatin, Col IV, V D 
Stromelysins MMP-10 Stromelysin 2 Col III,IV,V laminin, 
fibronectin, elastin 
B 
Stromelysins MMP-11 Stromelysin 3 Col IV, fibronectin, 
laminin, aggrecan 
E 
Metalloelastase MMP-12 Macrophage 
metalloelastase 
Elasin, fibronectin, 
Col IV 
B 
Collagenases MMP-13 Collagenase 3 Col I, II, III, IV, IX, X, 
XIV, gelatin 
B 
Membrane-type MMP-14 MT1-MMP gelatin, fibronectin, 
laminin,aggrecan 
F 
Membrane-type MMP-15 MT2-MMP gelatin, fibronectin, 
laminin, tenascin 
F 
Membrane-type MMP-16 MT3-MMP  gelatin, fibronectin, 
laminin 
F 
Membrane-type MMP-17 MT4-MMP fibrinogen, fibrin F 
Collagenases MMP-18 Collagenase 4 Unknown B 
Other MMP-19 RASI-1 Gelatin, tenascin B 
Enamelysin MMP-20 Enamelysin Amelogenin B 
Other MMP-21 X-MMP Unknown G 
Other MMP-23A CA-MMP Casein, gelatin B 
Other MMP-23B  Autoproteolysis H 
Membrane-type MMP24 MT5-MMP gelatin F 
Membrane-type MMP-25 MT6-MMP Pro-gelatinase A F 
Matrilysins MMP-26 Matrilysin-2 Gelatin 1α A 
Other MMP-27 MMP-22, C-MMP Unknown B 
Other MMP-28 Epilysin Unknown E 
 
A  
B  
C  
D  
E  
F  
G  
H  
    Signal peptide             Pro-peptide                    Catalytic domain         Hinge region 
                   Haemopexin-like domain        Fibronectin domain      furin cleavage site 
     Vitronectin-like domain        Hinge, transmembrane & cytoplasmatic domains 
           Cys-rich, Pro-rich and IgG-like domains 
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1.10.3.3. TIMPs 
 
Tissue inhibitors of metalloproteinases (TIMPs) are the main regulators of MMPs activities. 
They comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4 with 
molecular weights between 20-30 kDa (figure 1.11) and their expression is regulated during 
development and tissue remodelling (Clark et al. 2008).  TIMPs structure consists of an N-
terminal cysteine with an active site zinc dependent and has around 125 amino acids and a 
smaller C-terminal haemopexin domain, with around 65 amino acids. Each domain is 
characterized by parallel β strands (5 in the N-terminal and 2 in the C-terminal) and α helices 
secured by three disulfide loops (Brew and Nagase 2010) . 
 
Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a 184 amino acid residue glycoprotein that 
directly inhibits the action of most MMPs by binding to its catalytic site and consequently 
blocking the access of substrates.  TIMP-1 only has a relatively low affinity for membrane-type 
MMPs 14, 16, 19 and 24 (Murphy and Nagase 2008).  TIMP-1, on the other hand, is a potent 
inhibitor of MMPs 3 and 7 (Hamze et al. 2007) and ADAM10 (Amour et al. 2000) when 
compared to other TIMPs.  It is widely secreted by many cell types, including fibroblasts and 
macrophages amongst other connective tissue cells, but new evidence shows that it is 
preferentially secreted by T helper cells 1 and 17 (Adamson et al. 2013)  Besides its inhibitory 
action against MMPs, TIMP-1 also presents other distinct functions including an erythroid 
potentiating activity and inhibition of apoptosis in B cells (Stetler-Stevenson 2008). 
 
Tissue inhibitor of metalloproteinase 2 (TIMP-2) is a 194 amino acid glycoprotein, which 
comprises 12 cysteine residues that forms six disulfide bonds, three of which are in the N- and 
C-terminal domain, respectively (Brew and Nagase 2010).  It is secreted by Fibroblasts, 
macrophages, endothelial cells, VSMC and cardiomyocytes (Vanhoutte et al. 2006).  TIMP-2 
is a stoichiometric inhibitor of collagenases which alongside TIMP-1 acts by blocking the 
MMP’S catalytic core.  TIMP-2 has a distinct characteristic of promoting the binding of its C-
terminal domain to the haemopexin-like domain of pro-MMP-2 (Wang et al. 2000).  This 
interaction is essential in the cell-surface activation of pro-MMP-2 by active MMP-14 (Caterina 
et al. 2000).  Apart from MMPs inhibition and the cell-surface activation mechanism of latent 
MMP-2, it can also suppress EGF-mediated mitogenic signalling by short-circuiting the 
epidermal growth factor cognate receptor (EGFR) activation (Hoegy et al. 2001) as well as 
bind to the integrin α3β1 and inhibit cell migration (Stetler-Stevenson 2008).  High levels of 
TIMP-2 have been associated with several diseases, such as cancer (Kachra et al. 1999, 
Remacle et al. 2000), systemic sclerosis (Yazawa et al. 2000) and CKD (Ahmed et al. 2007). 
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Tissue inhibitor of metalloproteinase 3 (TIMP-3) is a glycoprotein with a molecular mass of 
30kDa produced by a wide variety of cells such as fibroblasts, macrophages, VSMC and 
cardiomyocytes (Vanhoutte et al. 2006).  TIMP-3 has a peculiar property of presenting a high 
affinity for binding to the extracellular matrix.  It forms a non-covalent binary complex with the 
MMP active site through its N-terminal; therefore it can protect the ECM from MMP attack 
Also, TIMP-3 has the broadest inhibition spectrum of all TIMPs; it is an effective inhibitor of 
ADAM 17, also known as tumour necrosis factor α converting enzyme or TASCE (Amour A et 
al, 1998 FEBS), ADAM 10 (Amour et al. 2000), ADAM 12 (Loechel et al. 2000, Mochizuki et 
al. 2004),  ADAM 28 (Mochizuki et al. 2004) and ADAM 33 (Zou et al. 2004) and as it is the 
only known member of the TIMP family that can inhibit members of ADAMs that have a 
trombospondin-1-like domain (ADAMTS) family such as ADAMTS 1, 2, 4 and 5 (Brew and 
Nagase 2010).  Mutations in the TIMP-3 gene have been reported to result in Sorsby’s fundus 
dystrophy (Li et al. 2005).  TIMP-3 has also been associated with accelerated apoptosis as 
well as decreased angiogenesis by blockage of VEGF binding to VEGF receptor-2 (Qi et al. 
2003, Handsley and Edwards 2005).  Amongst the TIMPs, TIMP3 possess a distinct role of 
binding to glycosaminoglycans (GAGs) such as heparin sulphate, heparin and chondroitin 
sulphate in the ECM (Yu et al. 2000).  
 
Tissue inhibitor of metalloproteinase 4 (TIMP-4) is a 26 kDa glycoprotein, composed of  194 
amino acids with a human gene located in the chromosome 3p25 (Olson et al. 1998). TIMP-4 
is able to inhibit most MMPs, having high affinity to pro-MMP-2 (Bigg et al. 1997) alongside 
ADAM 17, ADAM 28 and ADAM 33 (Brew and Nagase 2010).  TIMP-4 expression is greater 
in the brain, ovaries, skeletal muscles and heart (Lambert et al. 2004).  Low plasma TIMP-4 
levels has been associated with a higher cardiovascular risk due to an increased carotid artery 
intima-media (cIMT) thickness (Oikonen et al. 2012).  
 
All TIMPs can bind in a stoichiometric 1:1 molar ratio to all MMPs. Their inhibitory effect on 
the enzymatic activity of MMPs is an aftermath of their binding to the catalytic domain of MMPs 
(Massova et al. 1998, Brew and Nagase 2010).  However, they present varying affinity to 
specific MMPs.  For instance, TIMP-1 can form tight complexes with MMP3 through a residue 
located between Cys1 and Cys70 on the first disulfide bond (Meng et al. 1999). Howbeit, TIMP1 
has poor affinity to MMP-2, whereas TIMP-2 and TIMP-3 can form strong complexes with this 
MMP (Murphy et al. 1991, Will et al. 1996).  There is evidence that TIMPs present higher 
affinity to some pro-MMPs. For example, TIMP-1 form specific complexes with pro-MMP9 
(Vempati et al. 2007), whilst TIMP-2 (Morgunova et al. 2002) and TIMP-4 (Bigg et al. 1997) 
can bind to pro-MMP2. 
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In addition to being  inhibiting MMP activity, TIMPs present a wide range of biological activities, 
including: induction of apoptosis (Smith et al. 1997, Ahonen et al. 1998), inhibition (Gomez et 
al. 1997, Hoegy et al. 2001) or promotion of tumour growth (Bourboulia and Stetler-Stevenson 
2010) depending of the tumour model studied,  stimulation of erythroid activity (Gasson et al. 
1985, Stetler-Stevenson et al. 1992), stimulation of fibroblast proliferation along with the 
phenotypic differentiation into myofibroblasts (Lovelock et al. 2005), suppression of tyrosine 
kinase-type growth factor receptor activation (Hoegy et al. 2001) and modulation of myocardial 
remodelling (Vanhoutte and Heymans 2010). 
 
Table 1.11: General properties of human TIMPs 
 
Property TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Molecular weight 23 21 30 26 
Number of AA 184 194 188 194 
Chromosomal location X11p11.23-11.4 17q23-25 22q12.1-q13.2 3p25 
MMP inhibition Weak for MMPs 
14,16,19 and 24 
All All Most 
Pro-MMP interactions Pro-MMP-9 Pro-MMP-2 Pro-MMPs 9 & 2 Pro-MMP-2 
Other MP inhibition ADAM 10 ADAM 12 ADAM 10, 12, 
17, 28 and 33; 
ADAMTS 1, 4, 5 
and 2 (weak) 
ADAM 17 and 
28, ADAM 33 
(weak) 
Glycosilation Yes No Partial No 
Apoptotic effects Negative Positive/ 
Negative 
Positive Unknown 
Angiogenesis Negative Negative Negative Negative 
Genetic disorder   Sorsby’s  fundus 
dystrophy 
 
 
Table 1.11: A summary of the general properties of human TIMPs 1, 2, 3 and 4 including their 
molecular structure characteristics, activity as inhibitors of Matrix and other Metalloproteinases,  pro-
MMP interactions and main biological functions. 
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Figure 1.10: Binding of TIMPs to the active site of MMPs 
 
 
 
Figure 1.10: TIMPs bind to Pro-MMPs and to the active site of the MMPs in a stoichiometric 1:1 molar 
ratio, thereby blocking access to their extracellular substrates. A) Three-dimensional diagram of 
human TIMP-1 (in red) bound to the catalytic domain of MMP-3 (blue). B) Reactive centre residues of 
TIMP-1 in the active site of MMP-3. Disulfide bonds are shown in yellow, zinc ions in pink and calcium 
ions in blue. C) Three-dimensional diagram of human proMMP-2 and TIMP-2 complex. The catalytic 
domain is shown in red, fibronectin type II domains in blue, pro-domain in green, haemopexin domain 
in orange, and TIMP-2 in pink. Calcium ion is in blue sphere, Zinc ion in green sphere and disulfide 
bonds in yellow. Changed from (Murphy and Nagase 2008) 
 
1.10.3.4. The role of MMPs and their inhibitors in human diseases 
 
Degradation of ECM components is an important element of normal tissue remodelling, so 
reduced or inadequate ECM breakdown can result in a variety of pathologies.  In addition to 
the matrix remodelling function, MMPs are also key regulators of cell homeostasis and of 
diverse signaling pathways, therefore, an altered expression and/or an uncontrolled 
modulation of MMP activities together with an imbalanced MMP/TIMP ratio have been 
associated with the development of a wide range of diseases (Rodriguez et al. 2010, Moore 
and Crocker 2012).  Currently, there is ample evidence linking MMPs and their inhibitors to a 
wide range of pathological processes, amongst them arteriosclerosis (Galis and Khatri 2002), 
arthritis (Konttinen et al. 1999), aneurysms (Thompson and Parks 1996), cancer (Egeblad and 
Werb 2002, Ozden et al. 2013), systemic sclerosis (Young-Min et al. 2001), dermatitis 
herpertiformis (Zebrowska et al. 2005), pulmonary fibrosis (Nagase and Woessner 1999) 
TIMP-1 
c 
Catalytic domain 
pro-domain 
Hemopexin domain 
Fibronectin type II domains 
ProMMP-2 
TIMP-2 
MMP-3 
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kidney fibrosis (Ermolli et al, 2003; Tashiro et al, 2004; Catania et al, 2007) and liver fibrosis 
(Arthur 2000).   
1.10.3.4.1. MMPs and TIMPs in renal disease 
 
Several studies have described the role of the MMP system in renal disease development. 
MMPs 1, 2, 3, 8, 9, 13, 14, 24, 25, 27, 28 and TIMPs 1, 2 and 3 are all expressed in the kidneys 
(Catania et al. 2007), however, , MMPs 1, 2, 3, 8, 9, 13 are the ones with higher and significant 
renal expression (Lenz et al. 2000).  A variety of renal cells can express MMPs, including 
mesangial cells (Martin et al. 1994), glomerular epithelial cells (Knowlden et al. 1995), tubular 
epithelial cells and interstitial fibroblasts (Norman et al. 1995).  Mesangial and glomerular 
epithelial cells predominantly produce MMPs 2 and 9 alongside TIMPs 1 and 2 (Martin et al. 
1994, Knowlden et al. 1995), whereas tubular epithelial cells can produce MMPs 1, 2, 8, 9 and 
13 (Norman et al. 1995).  Interstitial fibroblasts have been shown to produce MMP2 as well as 
MMPs 1, 8 and 13 (Norman et al. 1995).  MMP 14 is expressed in distal tubules and TIMP 2 
in fibroblasts in a rat model of autosomal-dominant polycystic kidney disease (ADPKD) 
(Obermuller et al. 2001).  MMPs 24, 25, 27 and 28 are also expressed in tubular epithelial 
cells (Romanic et al. 2001, Lemaitre and D'Armiento 2006). 
 
Current evidence suggests that MMPs and their inhibitors are involved in a wide variety of 
acute and chronic renal pathologies including acute kidney injury (AKI) , CDK (Horstrup et al. 
2002), CAN (Ahmed et al. 2012) and diabetic nephropathy (Thrailkill et al. 2009, Altemtam et 
al. 2012).  
 
A recent study has shown a correlation between increased MMPs2 and 9 activities and the 
development of AKI (Kunugi et al. 2011).  It seems that both MMPs are involved in the process 
of regenerating tubular epithelial cells and so the use of a MMP2/MMP9 inhibitor impaired the 
repair process of ischemic AKI (Kaneko et al. 2012).  Interestingly, a previous study has also 
shown that MMP 9 levels were increased in an experimental model of acute kidney allograft 
rejection, however, MMP2 levels were decreased (Ermolli et al. 2003). Elevated pro-MMP 1 
levels (Rodrigo et al. 2000) and reduced TIMP 1 (Caron et al. 2005) were also observed in 
different stages of acute ischemic injury. 
 
The 5/6th subtotalnephrectomy model of renal scarring has provided some insightful 
information into the molecular mechanisms involving MMPs and their inhibitors in progressive 
kidney fibrosis.  Ahmed et al showed a reduction in MMP activity in the tubulointerstitium 
associated with increased glomerular expression of MMP1 and reduced TIMP3, with the 
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elevated levels of TIMP1 and TIMP2 with reduced tubular MMP3 was almost certainly being 
responsible for the lower MMP activity (Ahmed et al. 2007).  Further evidence that they play a 
central role in the development of renal scarring includes the significant elevation of  mRNA 
for MMPs 1 and 2 as well as TIMPs 1 and 2 mRNA in the remnant kidney (Johnson et al. 
2002). 
 
A number of studies have demonstrated a connection between altered MMP and TIMPs 
expression in CKD.  For instance, urine and serum levels of TIMP1 were increased in CKD 
patients (Horstrup et al. 2002).  TIMP1 in conjunction with MMPs 2, 3 and 9 were also 
overexpressed in patients with ANCA-associated Glomerulonephritis (Sanders et al. 2004). 
Downregulation of MMP activity has been linked to hypertensive glomerulosclerosis (Singhal 
et al. 1996) and cyclosporine nephrotoxicity (Duymelinck et al. 1998).  There is also evidence 
that reduced expression of MMPs 1, 2, 3 and 9 together with  an up regulation of TIMPs 2 and 
3 play a central role in the development of CAN (Ahmed et al. 2012, Yan et al. 2012).  
 
MMPs can also modulate ECM breakdown via the regulation of growth factors activity, such 
as the insulin-like growth factor-1 and therefore influence diabetes development (Fowlkes et 
al. 1995).  The majority of studies show increased serum and urinary MMPs 2, 8 and 9 in 
diabetic patients (Romanic et al. 2001, Tashiro et al. 2004, Lauhio et al. 2008, Gharagozlian 
et al. 2009, Thrailkill et al. 2009, van der Zijl et al. 2010).  Furthermore, in vitro studies reported 
decreased MMP activity in mesangial cells exposed to high glucose  (McLennan et al. 1998).  
However, a more recent study analysing urine from diabetic nephropathy patients described 
elevated MMP activity in such individuals (Altemtam et al. 2012). 
 
1.10.4. Plasminogen-Plasmin system 
 
The Plasminogen-plasmin system is the second major pathway involved in ECM catabolism.  
Plasminogen is a pro-serine protease released from the liver and activated by tissue 
Plasminogen activator (tPA) and urokinase Plasminogen activator (uPA) to plasmin.  The 
urokinase type can only cleave plasminogen to plasmin when it is bound to a urokinase type 
plasminogen activator receptor on the surface of the cells (Legrand et al. 2001).  Plasmin can 
degrade multiple components of the ECM including collagens III, IV, V, Fibronectin, Laminin 
and Proteoglycans (Baricos et al. 1995).  Plasmin also plays an important role in activating 
MMPs (Monea et al. 2002).  Plasminogen activators (tPA and uPA) are regulated by growth 
factors, TNF-α, IL-1, PDGF, TGF-β1 as well as some hormones and both are specifically 
inhibit by the Plasminogen Activator Inhibitor-1 (PAI-1) (Rerolle et al. 2000).  PAI-2 function is 
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expressed more during pregnancy, where decreased levels were associated with placental 
dysfunction and intrauterine growth retardation (Astedt et al. 1998). 
 
Alongside its role in ECM degradation, plasmin also plays a fundamental role in the clotting 
system.  The clotting system can be divided into two distinct cascades; the coagulation 
cascade and the fibrinolytic cascade.  Activation of the coagulation cascade results in the 
conversion of prothrombin to active thrombin, which in turn catalyses the conversion of soluble 
fibrinogen to fibrin (Nesheim 2003).  Conversely, the fibrinolytic cascade modulates the 
formation of plasmin from plasminogen, which catalyses the solubilisation of fibrin.   
1.11. Classical biomarkers of CKD progression 
 
1.11.1. GFR 
 
Among the functional biomarkers of CKD, the GFR is considered to be the gold standard 
method, with a prediction accuracy ranging from 65 to 74%.  Measurement of the true GFR 
by the clearance of exogenous markers such as Inulin or radioisotopes of 51Cr-EDTA 
(Delanaye et al. 2008) or 99mTc-DTPA (Frennby and Sterner 2002) provide sensitive tests for 
overall kidney function, however, as a consequence of adaptation to nephron loss, this test 
may not indicate loss of kidney function reduction until around 60% of damage has occurred. 
Furthermore, such measurements require intravenous application and equilibration time which 
is difficult to achieve routinely. 
 
The concentration of creatinine in the serum allows a mathematical estimate of the GFR, and 
provides the simplest and most common test used to measure kidney function in clinical 
practice.  However, it is inaccurate at detecting mild kidney impairment as it is insensitive to 
changes in GFR within the range of normal or slightly impaired function and so in patients at 
an early stage of kidney damage a decrease in the GFR would not be reflected in the 
measurement of serum creatinine.  Other limitations of creatinine-based equations to estimate 
the GFR are associated with non-GFR determinants such as muscle mass, age (especially 
among the elderly), gender and ethnicity (non-white populations). In addition, Creatinine 
clearance tends to overestimate the GFR by about 15% when the renal function is impaired 
as tubular secretion of creatinine accounts for a larger proportion of creatinine found in the 
urine.  This overestimation can be inhibited by the use of cimetidine, which competitively 
inhibits the tubular secretion of creatinine (Agarwal 1993, Hilbrands et al. 1993, Payne 1993, 
Ixkes et al. 1997). 
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1.11.2. Proteinuria 
 
The quantity of protein excreted in the urine is one of the strongest indicators of kidney disease 
progression and constitutes one of our “Classical” biomarkers of CKD progression (Lemley 
2007). Currently, proteinuria is considered one of the strongest markers of CKD severity and 
constitutes the most used predictor of eGFR decline in diabetic and nondiabetic kidney 
disease (Cravedi and Remuzzi 2013).  Moreover, proteinuria has been utilized as an useful 
surrogate end point in clinical trials with CKD patients and has been recognized as an 
important risk factor of cardiovascular disease.   
 
Normal individuals excrete between 40 and 80mg of protein per day, with the upper range of 
normal being 150mg per day (Schrier 2005, J Feehaly 2007).  Three main types of proteinuria 
can be seen: glomerular, due to an increased permeability of the glomerular capillary; tubular, 
due to an impairment in the tubular reabsorption; and overflow proteinuria, where an excessive 
production and filtration of low-molecular weight proteins such as monoclonal immunoglobulin 
light chains in Multiple Myeloma.  Depending on the pattern of the excreted proteins, we are 
able to classify its origin (glomerular or non-glomerular) and also in some cases the length of 
the injury, like the increased excretion of tubular proteins such as β-2-microglobulin or retinol-
binding protein reflects chronic damage characterized by interstitial fibrosis  (Remuzzi and 
Bertani 1998). Several different proteins can be excreted in the urine.  Tamm-Horsfall tubular 
mucoprotein or Uromodulin is the most common one and accounts for 30-50mg per day, 
whereas Albumin accounts for less than 20mg per day in normal subjects. 
 
Urine protein excretion used to be measured by a 24 hour collection. However, this is neither 
convenient nor an accurate method of detecting it. Using a spot urine sample to obtain the 
protein concentration followed by normalization to a creatinine ratio gives a more adequate 
measurement as it rectifies for variation in the urine volume.  
 
Studies have showed that elevated excretion of protein acts not only as an indicator of kidney 
damage, but it also plays a role in the progression of CKD.  The mechanisms of proteinuria 
driving CKD include the increased ultrafiltered protein load in the proximal renal tubular cells 
(PTECs) activating the NF-κB–dependent and NF-κB–independent pathways and 
upregulating adhesive molecules (Donadelli et al. 2003) and chemoattractants IL-8 (Tang et 
al. 2003), MCP-1 (Wang et al. 1997) and RANTES (Zoja et al. 1998) for inflammatory cells 
such as macrophages, neutrophils and T lymphocytes. 
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In glomerular disorders such as Focal Segmental Glomerulosclerosis (FSGS) or IgA 
Nephropathy (IgAN) for example, there is an abnormal glomerular permeability with 
consequence being the presence of proteinuria (Woo et al. 1991, Shiiki et al. 1996).  There is 
strong evidence that proteinuria is a factor inciting tubulointerstitial disease and this 
tubulointerstitial damage acts as a prime risk factor for subsequent kidney disease 
progression.  It has also been demonstrated that patients with Nephrotic Syndrome (syndrome 
characterized by presence of > 3.5g proteinuria / 1.73m2 / day with hypoalbuminaemia, 
oedema, hyperlipidaemia and lipiduria) have worse prognosis than the patients without 
Nephrotic Syndrome. 
 
Several experimental models and human trials show an association between the reduction of 
proteinuria and renoprotection (Kramer and Schweda 1997, Brenner et al. 2000, de Zeeuw et 
al. 2004).  The MDRD study, for example, showed that patients who already had a baseline 
proteinuria were more likely to have further decline in GFR (Kopple et al. 1989). Follow on 
studies confirmed this finding by analysing the effects of a low protein diet on the progression 
of kidney disease and the results demonstrated that reduction in proteinuria was significantly 
associated with better kidney outcome (Kopple et al. 1989, de Zeeuw et al. 2006). Several 
other experimental models and human trials showed an association between the reduction of 
proteinuria by lowering glomerular pressure and subsequent renoprotection (Kramer and 
Schweda 1997, Brenner et al. 2000, de Zeeuw et al. 2004). Better kidney survival was 
associated not only with the reduction of proteinuria by diet, but also by the use of Angiotensin 
Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blocker (ARB).  However, it 
seems that proteinuria acts more as a marker rather than the cause of CKD progression.   
Even the RIEN trial, showed that although a greater survival was reached within the Ramipril 
group, no benefits were seen when proteinuria was reduced to under 1.5g per day.  In addition, 
several recent large studies have shown that significant decreases in proteinuria did not reflect 
in slowing CKD progression.    In the ALTITUDE study, for instance, the use of the direct renin 
inhibitor Aliskiren combined to ACE inhibitors or Angiotensin Receptor blockers although 
promoting decrease in albuminuria levels, it failed to promote a significant impact in loss of 
renal function in Diabetic Nephropathy (Parving et al. 2012).  Similar results were also 
observed in the ONTARGET (Yusuf et al. 2008) and the ACCOMPLISH study (Jamerson et 
al. 2008). Interestingly, there is increasing evidence ACEi/ARB discontinuation on advanced 
CKD patients can slow down progression to RRT (Ahmed et al. 2010). 
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1.12. Experimental biomarkers of kidney disease 
 
Nowadays, the measurement of eGFR and proteinuria provides the most sensitive way for 
identifying progression of CKD to ESRD in clinical practice (Hallan et al. 2009).  However, 
these have limitations and as such early and more sensitive markers of CKD progression are 
required. There are several ongoing or recently completed studies on potential new 
biomarkers of kidney disease progression (Fassett et al, 2011).  Currently, none of these 
markers are ready for clinical use as large longitudinal, multicentre observational studies are 
necessary to investigate and validate them.  
Proteomic studies may be very useful to identify potential candidates, especially in settings in 
which significant posttranslational modification of proteins occurs (phosphorylation, 
ubiquitination, methylation, acetylation, glycosylation, etc.) (Vivekanandan-Giri et al. 2011).  
Also, the use of metabolomics (the study the profile of large number of small metabolites) in 
the future is likely to reveal a better understanding of physiology of the cells as it can 
simultaneously identify multiple metabolic changes caused by a pathological process (Lemley 
2007). 
Continually being developed are tests involving a multiplex panel of biomarkers which 
searches though a more comprehensive panel of potential biomarkers of CKD such as the β-
Trace protein, the connective tissue growth factor (CTGF), transforming growth factor β 1 
(TGFβ1), podocyturia or β-2-microglobulin/creatinine ratio for example.  This is a promising 
technique as it can give a multidimensional vision of the pathologic processes involved on 
CKD progression  (Lemley 2007) especially as multiple mechanisms involved in the CKD 
mechanism can be assessed (table 1.12). 
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Table 1.12: Experimental CKD biomarkers according to the pathophysiological process 
Main mechanism Biomarker 
Kidney function (GFR) Cystatin C 
β-Trace protein 
Tubulointerstitial injury NGAL 
KIM-1 
NAG 
Glomerular injury Nephrin 
Podoxin 
Podocalyxin 
Endothelial dysfunction ADMA 
Inflammation IL-18 
Tenascin,  
others 
Fibrosis TGFβ1 
Metabolic disorders FGF-23 
Adiponectin 
ApoA-IV 
Oxidative stress AGE 
Protein reduced thiols 
MDA 
TAS 
Urinary 8-hydroxydeoxy guanosine 
Superoxide dismutase, others 
 
Table 1.12:  Common experimental biomarkers in the kidney and their main mechanism of action. 
1.12.1. Cystatin C 
 
Cystatin C, a 13kDa serum protein encoded by the CST3 gene, is produced by all nucleated 
cells, freely filtered by the glomeruli and metabolized after tubular absorption (Madero et al. 
2006).  It has been shown as a better and more precise marker of kidney function than 
creatinine (Newman et al. 1994, Dharnidharka et al. 2002, Mussap et al. 2002), presenting a 
lower analytical and within-subject coefficient of variability (Delanaye et al. 2008).  Its serum 
concentration is directly correlated with GFR and its levels are less dependent of muscle mass 
and other variables such as sex and weight (Filler et al. 2005, Herget-Rosenthal et al. 2005).  
It has been reported in several studies that using cystatin C as a marker of kidney damage 
shows earlier responses to therapy than creatinine as well as more precise description of 
disease severity (He et al. 2013, Liu et al. 2013). ROC curve analysis of 592 adult CKD 
patients showed that cystatin C presented a better ability to predict to predict the correct GFR 
than creatinine (91.6 and 84.1%, respectively) (Hojs et al, 2008).  In addition, a combined 
creatinine-cystatin equation showed better GFR estimation than the calculations done by 
these individual markers by itself (Inker et al. 2012, Rule et al. 2013).  A large meta-analysis 
of 16 studies done by Shilipak et al including 90750 participants from the general population 
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and 2960 CKD patients, showed a correlation between creatinine-based and the combination-
based (creatinine and cystatin C) eGFR with a reverse J-shaped risk prediction of death from 
any cause and from cardiovascular causes as well as development of ESRD in the general 
population. Conversely, no reverse J-shaped association was found for the creatinine-based 
eGFR measurements in the CKD group. In this study, across all groups, reclassification to a 
decreased eGFR based on cystatin C measurement presented an improved risk prediction of 
CKD progression to ESRD when compared to creatinine. Nevertheless, this improvement was 
not statistically significant (Shlipak et al. 2013).  Furthermore, cystatin C concentration can be 
affected by different conditions such as use of ACE inhibitors (Filler et al. 2013), thyroid 
dysfunction (Ye et al. 2013), presence of asthma (Shigemura et al. 2012) and positivity for HIV 
(Inker et al. 2012).  
 
1.12.2. β-Trace protein 
  
β-Trace protein (BTP) is a 23-29kDa lipocalin glycoprotein, composed of 168 amino acids. 
BTP has shown to be a good predictor of CKD progression (Spanaus et al. 2010, Bhavsar et 
al. 2011) and it is a more sensitive marker of glomerular filtration rate than serum creatinine 
allowing earlier detection of loss of function (Donadio 2010).  However, it was demonstrated 
that it is inferior to Cystatin C as an indicator of GFR (Filler et al. 2013). 
 
1.12.3. Neutrophil gelatinase-associated lipocalin (NGAL) 
 
One of the most interesting novel biomarkers is the Neutrophil gelatinase-associated lipocalin 
(NGAL), also known as neutrophil lipocalin (NL or HNL for the human form) (Xu et al. 1994), 
lipocalin-2, siderocalin, uterocalin (Liu et al. 1997) and oncogene protein 24p3 (Flower et al. 
1991).  Human NGAL consists of a single disulfide-bridged polypeptide chain of 178 amino-
acid residues with molecular weight of 22kDa, but glycosylation raises its apparent molecular 
mass to 25kDa (Kjeldsen et al. 1993).  NGAL belongs to the lipocalin iron-carrying family of 
proteins (Fassett et al. 2011).  It was originally isolated from neutrophils (Xu et al. 1994), but 
it can be secreted by diverse tissues including the kidneys, prostate, liver, lungs, 
gastrointestinal tract, epithelial cells, vascular cells in the atherosclerotic plaques (Cowland 
and Borregaard 1997, Friedl et al. 1999, Hemdahl et al. 2006) and in carcinomas (Stoesz et 
al. 1998, Friedl et al. 1999, Lim et al. 2007, Chakraborty et al. 2012). Urine NGAL has been 
shown to be an useful  early marker of Acute Kidney Injury (AKI) as it is freely filtered by the 
glomeruli and levels rises within 2 hours of injury (Devarajan 2007).  In addition to AKI, kidney 
tissue expression of NGAL is also elevated in CKD patients where it directly increases the 
expression of epidermal growth factor receptor (EGFR), acting not only as a marker of kidney 
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fibrosis but also as an active cause for disease progression (Viau et al. 2010).  Furthermore, 
it benefits from having multiple molecular forms in urine; it occurs as a monomer when 
produced by neutrophils and as a dimer or trimer when originated from kidney tubular epithelial 
cells (Cai et al. 2010).  In kidneys, NGAL is secreted into urine by the thick ascending limb of 
loop of Henle and collecting ducts, with synthesis occurring in the distal nephrons (Bolignano 
et al. 2009).  There is evidence that NGAL is over expressed in cases of renal impairment 
after kidney transplantation (Malyszko et al. 2009), contrast nephropathy (Schilcher et al. 
2011), haemolytic uraemic syndrome (Lukasz et al. 2013) or in cases of CKD such as those 
caused by obstruction (Bolignano et al. 2008, Devarajan 2008), IgA nephropathy (Ding et al. 
2007), polycystic kidney disease (Bolignano et al. 2007) and lupus nephritis (Sharifipour et al. 
2013).  Urinary NGAL was measured in eighteen patients with HIV-associated nephropathy 
(HIVAN) and presented a 88% capacity of correctly diagnose the disease when calculated by 
ROC curve analysis, compared to 80% by urinary liver fatty acid-binding protein (uL-FABP) 
and 71% of total proteinuria (Sola-Del Valle et a., 2011). A prospective study with 96 CKD 
patients (stages 2 to 4) and 14 healthy subjects analysed the accuracy of prediction of CKD 
progression and showed a ROC AUC of 70% for serum NGAL, 78% for urine NGAL and 64% 
for eGFR (Bolignano et al. 2009).  However, a larger study from the Chronic Renal 
Insufficiency Cohort (CRIC) with 3386 CKD patients concluded that although urine NGAL 
concentration had a strong correlation with risk of CKD progression to ESRD, its levels were 
not better in correctly identifying it than current biomarkers (24 hours proteinuria and eGFR), 
with area under the ROC curve (C-statistic) of 84.7% with and without the addition of NGAL 
to the final model (Liu et al. 2013). 
 
1.12.4. Kidney Injury Molecule-1 (KIM-1) 
 
The Kidney injury molecule-1 (KIM-1), a 104kDa type 1 transmembrane protein, is a marker 
of proximal tubular injury.  KIM-1 has an ectodomain containing a six-cysteine immunoglobulin 
like domain, two N-glycosylation sites and a domain rich in threonine/serine and proline (Lim 
et al. 2013).  There are two human homologues of KIM-1; KIM-1a, which lacks the tyrosine 
kinase phosphorylation motif and is predominant in the liver and KIM-1b, which is predominant 
in the kidneys and contains a highly conserved tyrosine kinase phosphorylation motif at 
position 350.  KIM-1 is positively associated with kidney fibrosis and inflammation in many 
nephropathies (Bonventre 2008), progression to ESRD in IgA nephropathy patients (Peters et 
al. 2011) as well as with graft loss in kidney transplanted patients (van Timmeren et al. 2007) 
and nephrotoxicity (Vaidya et al. 2010).  This assessment of KIM-1 as a predictor of drug 
toxicity revealed a better performance when compared to blood urea nitrogen, serum 
creatinine and urinary N-acetyl-β-D-glucosaminidase (NAG) (Vaidya et al. 2010).  Although 
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KIM-1 expression and release are induced in proximal tubular epithelial cells (PTEC) upon 
injury (Lim et al. 2013), its expression is undetected in normal kidneys (van Timmeren et al. 
2007).  Despite having a potential great value in identifying kidney damage and repair process, 
urine levels of KIM-1 are currently used only as a specific indicator of tubular injury particularly 
in acute renal failure  (Han et al. 2002). 
 
1.12.5. Urinary Nephrin, Podoxin and Podocalyxin 
 
Urinary Nephrin, Podoxin and Podocalyxin are markers of glomerular damage.  Damaged 
podocytes detach from glomerular basement membrane, thus their presence in urine can be 
evaluated by the measurement of these three molecules.  This detection can be done by 
Immunoassays or mRNA in urine sediment (Wang et al. 2007, Wang et al. 2008, Zheng et al. 
2011, Hara et al. 2012).  The presence of Nephrinuria was shown to be elevated in Diabetic 
Nephropathy (Patari et al. 2003, Yu et al. 2005).  It has the advantage of being rapidly detected 
by Western Blot (185 kDa) using specific anti-nephrin antibodies. But, this detection has its 
limitations as just 1/3 of the patients with DN present damage to the filtration barrier of the 
glomerulus.  In addition to the detection in DN patients, urine podoxin and podocalyxin are 
also elevated in active lupus nephritis (Wang et al. 2007, Wang et al. 2008) and the later was 
also observed in post-streptococcal Glomerulonephritis (Kanno et al. 2003) and in patients 
with IgA nephropathy (Asao et al. 2012).  
 
1.12.6. Asymmetric dimethylarginine (ADMA)  
 
Asymmetric dimethylarginine or 2-Amino-5 [(amino-dimethylaminomethylene) amino] 
pentanoic acid (ADMA) is an amino acid, closely related to L-arginine. ADMA is created 
through protein methylation by a reaction catalysed by an enzyme called S-
adenosylmethionine protein N-methyltransferases (Rawal et al. 1995) and is measured using 
high-performance liquid chromatography.  ADMA mechanism of action involves inhibition of 
nitric oxide synthase, thus decreasing nitric oxide production (Vallance et al, 1992).  Raised 
levels of serum ADMA have been associated with development of nephropathy in patients 
with type 2 diabetes (Hanai et al. 2009), endothelial dysfunction and subsequent 
atherosclerosis (Ando et al. 2013, Eiselt et al. 2014), cardiorenal syndrome (Ueda et al. 2013) 
and  CKD progression to ESRD (Baylis 2012).  ROC curve analysis was used to evaluate the 
predictive potential of serum ADMA as a marker of inflammation in 142 CKD patients and 
compared to serum levels of symmetric dimethylarginine (SDMA), CRP, TNF-α and albumin, 
and as such was classified as an inferior biomarker giving only 66% prediction against 82% of 
CRP, 72% of albumin, 69% of SDMA and 57% of TNF-α (Schepers et al. 2011). 
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1.12.7. Interleukin 18  
 
Interleukin-18 (IL18, also known as interferon-gamma inducing factor) is a pro-inflammatory 
cytokine that belongs to the IL-1 superfamily and is expressed in the intercalated cell of the 
late distal convolute tubule, the connecting tubule and the collecting duct of healthy human 
kidneys (Urbschat et al. 2011).  It is a biomarker of proximal tubular injury in ischemic acute 
tubular necrosis (ATN) (Parikh et al. 2004) and has been shown to be a useful predictor of 
AKI (Nickolas et al. 2008, Liu et al. 2013) and of ESRD in patients with IgA nephropathy 
(Peters et al. 2011) and diabetic nephropathy (Miyauchi et al. 2009)).  Its plasma levels were 
also found elevated in cases of contrast-induced nephropathy (Ling et al. 2008, Duan et al. 
2013) and in various pathophysiological states; such as systemic lupus, inflammatory arthritis 
and hepatitis (Urbschat et al. 2011).  However, contrasting studies have showed low levels of 
prediction of tubule-interstitial damage in IgA nephropathy (64% by ROC-AUC analysis, n=76, 
(Shi et al. 2012), nephrotoxicity (65% by ROC-AUC analysis, n=85 children, (Zubowska et al. 
2013) and even in dialysis patients when used in combination with other cytokines (IL-1 β, IL-
6 and TNF-α, 59% by ROC-AUC analysis, n=217, (Zoccali et al. 2006).  It looks like although 
this cytokine seems to be a good predictor of AKI severity and mortality, its application as a 
biomarker of CKD progression may be limited by the fact that it is upregulated in diverse 
inflammatory diseases.  For instance, a study with 908 HIV-infected women showed that ACR 
was a better predictor of disease progression (based on eGFRcys decline) than IL-18, NGAL 
or KIM-1 (Shlipak et al. 2012), suggesting that it has no further beneficial value than the 
currently used standard biomarker. 
 
1.12.8. TGF-β1  
 
Transforming growth factor-beta1 (TGF-β1) is a 25kDa polypeptide member of the 
transforming growth factor beta superfamily of cytokines.  It is mainly secreted by T and B 
cells, myofibroblasts, macrophages and tubular cells, however, podocytes have also been 
implicated in the up-regulation of TGF-1 (Abbate et al. 2002).  TGF-β1 conducts a variety of 
cellular functions, including the control of cell growth, proliferation, differentiation and 
apoptosis. It is extensively known as a potent fibrogenic renal growth factor (Douthwaite et al. 
1999).  The pro-fibrogenic effects of TGF-1 are associated with the activation of pericyte-
myofibroblast transition induced by α smooth muscle actin (α-SMA) (Wu et al. 2013).  TGF-1 
has also been shown to modulate TG2 release and increase the synthesis of ECM 
polypeptides, such as fibronectin, heparan sulphate proteoglycan, laminin beta1 and collagen 
alpha1 (Douthwaite et al. 1999).  Such actions increase deposition of ECM components and 
thereby promote scar formation.  
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Increases in TGF-1 have been observed in a variety of kidney scarring models including 5/6th 
nephrectomy (Coimbra et al. 1996, Junaid et al. 1997), diabetic nephropathy (Chen et al. 2001, 
Huang et al. 2010) and unilateral ureteral obstruction (Wu et al. 2013).  In human kidney 
disease, there was an increase in urinary TGF-1 levels in DN (Fagerudd et al. 1997, Sato et 
al. 1998), chronic glomerulonephritis (Honkanen et al. 1997) and in CKD from different 
aetiologies  (De Muro et al. 2004).  Suthanthiran and colleagues were the first to report a 
positive association between TGF-1 and CKD progression in humans by activation of RAAS, 
affecting mostly African Americans (Suthanthiran et al. 2009).  In fact, several other cross-
sectional studies suggested a higher prevalence of CKD progression into ESRD in African 
Americans, but not in Caucasians, due to the effects of circulating TGF-1 (Lee et al. 2009; 
Suthanthiran et al. 1998).  Levels of circulating total and active TGF-1 and its natural 
antagonist Bone morphogenetic protein-7 (BMP-7) were measured in 102 patients with DM 
type 2, presenting a combined total TGF-1 plus BMP-7 ROC-AUC prediction of renal 
progression of 88%, compared to 94% in the combination of total and active TGF-1 plus 
BMP-7 and 73% for the combination of the conventional markers ACR and eGFR (Wong et 
al. 2013).  Howbeit, TGF-1 was added to a panel with other experimental biomarkers along 
with cystatin C, IL-6, high-sensitivity c-reactive protein (hsCRP) and fibroblast growth factor 
23 (FGF-23) and screened in 2544 patients recruited from the Canadian CKD cohort (stages 
4 and 3B) (Levin et al. 2014). In this large human study, TGF-1 failed to improve the 
prediction of progression to ESRD when compared to conventional markers such as ACR, 
phosphate and haemoglobin. 
 
1.12.9. FGF-23 and Klotho 
 
Fibroblast growth factor (FGF-23) is a 32kDa protein produced by osteoblasts and osteocytes 
which main function is the regulation of phosphate concentration in the plasma in response to 
elevated Calcitriol (1,25-dihydroxycholecalciferol or 1,25-dihydroxyvitamin D3) levels 
(Shimada et al. 2004, Juppner 2011, Kovesdy and Quarles 2013).  FGF-23 production is also 
upregulated by high phosphate intake as well as chronic hyperphosphatemia (Isakova et al. 
2011, Vervloet et al. 2011), whereas the use of phosphate binders such as sevelamer 
decreases the circulating levels of this hormone (Oliveira et al. 2010, Adema et al. 2013, Chue 
et al. 2013).  FGF23 acts on the kidneys, where it decreases the expression of NPT2a and 
NPT2c, two sodium-phosphate co-transporters in the proximal renal tubule (Juppner 2011).  
Thus, FGF23 reduces the reabsorption and increases urine excretion of phosphate (Olauson 
and Larsson 2013).  In addition, FGF-23 directly suppresses 1α-hydroxylase in the proximal 
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tubule leading to reduced conversion of 25-hydroxyvitamin D to its active metabolite (Liu et al. 
2006).  Further, FGF-23 can also regulate vitamin D metabolism through the stimulation of 24-
hydroxylase (Cyp24) which increases vitamin D degradation and also by inhibiting the 
transcription and secretion of PTH (Ben-Dov et al. 2007, Krajisnik et al. 2007). 
α-Klotho (Klotho) is a type-I membrane-bound protein that directly binds to FGF receptor 1c 
in a paracrine manner, converting it into a specific FGF-23 receptor (Olauson and Larsson 
2013).  Therefore, FGF-23 is dependent on Klotho to induce FGF-receptor signalling.  Klotho 
has a short transmembrane domain and two large extracellular domains (Shiraki-Iida et al. 
1998) and its expression in the kidneys is restricted to the distal tubules (Kovesdy and Quarles 
2013). This limited distribution of Klotho in the kidneys leads to a restriction in the physiologic 
actions of FGF-23 (Kovesdy and Quarles 2013). 
The phosphaturic action of FGF-23 increases dramatically as renal function declines (Pavik et 
al. 2013).  However, it is possible that the increase in FGF-23 levels in the initial stages of 
CKD is an adaptative response to the reduction in vitamin D rather than a consequence of 
reduced kidney mass per se (Quarles 2012, Kovesdy and Quarles 2013).  Blood concentration 
of FGF23 predicts adverse outcomes, particularly cardiovascular disease and CKD (Kendrick 
et al. 2011, Kovesdy and Quarles 2013, Zoccali et al. 2013).  In the study from Kendrick et al 
for example, plasma FGF-23 concentrations obtained from 1099 patients with advanced CKD 
were found to be strongly associated with progression to dialysis initiation, presenting a 
Hazard ratio of 1.68  (95% CI 1.38 to 2.05; P<0.0001) per standard deviation increase in log 
FGF-23 concentrations (Kendrick et al. 2011).  
 
Elevated circulating levels of FGF-23 had been associated with left ventricular hypertrophy 
(Gutierrez et al. 2009, Hsu and Wu 2009, Faul et al. 2011, Kirkpantur et al. 2011), bone-
mineral disorders (Weber et al. 2003, Komaba and Fukagawa 2009), vascular calcification 
(Jimbo et al. 2013, Liabeuf et al. 2013), arterial stiffness (Houston et al. 2013) and renal fibrosis 
(Olauson and Larsson 2013).  High serum FGF-23 levels were observed in 150 CKD patients 
at stages 3 to 5 and a ROC-AUC of 70.5% prediction for coronary calcification was found 
(Zhang et al. 2015). Conversely, tissue level of Klotho declines in early CKD and also 
contributes to an accelerated aging phenotype (Carracedo et al. 2012).  Several studies 
outline the importance of FGF-23/Klotho complex to the progression of CKD to ESRD (Fliser 
et al. 2007, Gutierrez et al. 2008, Isakova et al. 2011). For example, in a recent prospective 
study with 3879 CKD patients from stage 2 to 4 study (median follow-up of 3.5 years) showed 
that elevated FGF-23 was an independent risk factor for CKD progression and mortality 
(Isakova et al. 2011).  Also, in another study with 604 CKD patients, plasma FGF-23 was 
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positively correlated with proteinuria and smoking (Vervloet et al. 2012), major cardiorenal risk 
factors.  Likewise, FGF-23 plasma concentrations (c-terminal and intact FGF-23) were 
measured in 227 nondiabetic CKD patients from The Mild to Moderate Kidney Disease 
(MMKD) study (Fliser et al. 2007). Prediction of renal disease progression was evaluated by 
ROC-AUC of 81% and 72% for c-terminal and intact FGF-23 respectively. However, eGFR 
remained the best prognostic tool for evaluating progressive CKD as it presented the highest 
area under the curve, with a predictive value of 84%. 
 
1.12.10. Oxidative stress molecules  
 
Oxidative stress refers to the in vivo oxidation of macromolecules such as lipids, 
carbohydrates and DNA (Fassett et al. 2011).  It occurs as a result of an imbalance between 
the formation of reactive oxygen species (ROS) and anti-oxidant defence mechanisms. 
Formation of ROS such as hydrogen peroxide (H2O2) superoxide (O2-) and hydroxyl radicals 
(OH) is mediated by both the mitochondrial respiratory chain and the NADPH oxidase 
systems.  These are counteracted by the action of antioxidant enzyme systems such as 
superoxide dismutase, catalase and the oxidant scavenger glutathione peroxidase (Locatelli 
et al. 2003).  Examples of oxidative stress molecules include AGE (Witko-Sarsat et al. 1996), 
protein reduced thiols, MDA, TAS, Urinary 8-hydroxydeoxy guanosine, Superoxide dismutase, 
amongst many others (Fassett et al. 2011). 
 
Increased plasma levels of oxidative stress biomarkers (protein carbonyl group, free F2-
isoprostane and protein reduced thiol) have been observed in  60 CKD patients with stages 3 
to 5 (Oberg et al. 2004).  However, no significant relationship between those biomarkers and 
the MDRD eGFR was found.  Circulating levels of oxidative stress molecules have been 
particularly elevated in patients presenting chronic glomerulonephritis (Shah 2004), diabetic 
nephropathy (Ha and Lee 2003) and in ischaemia-reperfusion injury (Dobashi et al. 2000).  In 
addition, the predictive value of these markers has been studied in specific subsets of CKD 
patients, including 62 IgA nephropathy (ROC-AUC of 71% for predicting decline in renal 
function) (Camilla et al. 2011) and 626 Hypertensive individuals (ROC-AUC of 93.1% for 
plasma F2-isoprostane).  However, scant data on the predictive prognostic value is available 
in general CKD population and therefore, larger longitudinal studies are needed to investigate 
how well they can predict kidney disease progression.  
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1.12.11. Thesis rationale and hypothesis 
 
Chronic Kidney Disease (CKD) affects up to 16% of the global population and is associated 
with significant morbidity and mortality, consuming a large proportion of health care resources 
(Stringer et al. 2013).  It is often progressive leading to End Stage Renal Disease (ESRD) with 
the requirement for RRT (dialysis and transplantation).  With the above in mind, it is imperative 
to tackle this disease by establishing early detection and prevention. However, current kidney 
function and damage tests have known limitations as they do not fully indicate diagnosis and 
its outcomes, provide low accuracy in predicting disease progression and are inadequate in 
assessing early response to therapy.  Thus, there is a requirement for identification of early 
and reliable non-invasive biomarkers of progressive kidney disease.  This would allow us to 
individualize patient care, improve long term outcomes and potentially lead to the development 
of new therapies capable of retarding CKD progression. 
 
Current markers of kidney function include the estimation of GFR by measurement of urine 
creatinine, which does not provide an accurate evaluation, due to bias by race, sex, age, 
hydration status and muscle mass (Stevens et al. 2006; Wu et al. 2008).  Alternatively, β-
Trace protein or Cystatin C could be used for kidney function estimation.  Cystatin C has 
proven to be more effective than creatinine for GFR assessment.  However, results from a 
large meta-analysis conducted by Shlipak et al revealed that the improvement in risk prediction 
of CKD progression to ESRD was not statistically different from that observed with creatinine 
(Shlipak et al. 2013).  Furthermore, increase in cystatin C concentrations could also be 
affected by other inflammatory conditions such as thyroid dysfunction (Ye et al. 2013) and 
asthma  (Shigemura et al. 2012). As for β-Trace protein, although it is a more sensitive marker 
than serum creatinine, it is inferior to cystatin C (Filler et al. 2013). Amongst the novel 
experimental biomarkers of CKD progression, raised levels of NGAL, ADMA, TGF-1 and 
FGF-23 were shown to be elevated in overall CKD. Nonetheless, distinct ROC curve analysis 
from such individual markers was performed in several different studies and reported that such 
biomarkers presented no significant improvement in accurately predicting CKD progression to 
ESRD when compared to conventional markers. 
 
Regardless of the underlying disease, the final process of CKD is characterised by excessive 
accumulation of ECM what leads to fibrosis and scar formation. The pathology of this is well 
described and as such mediators of the process that are present in urine theoretically would 
make important biomarkers of CKD.  Transglutaminase 2 (TG2) is well described as one of 
the mediators of kidney fibrosis, being instrumental in scar tissue formation by catalysing the 
post-translational modification of ECM proteins by the formation of ε (γ-glutamyl) lysine bonds 
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(Fesus et al. 2002).  Previous studies demonstrated that tissue levels of TG2 and ε (γ-
glutamyl) lysine correlate well with histological renal scarring (Fisher et al. 2009; Johnson et 
al. 2003; Johnson et al. 1997; Skill et al. 2001).  Further studies have also established a good 
correlation between tissue levels of MMPs, TIMPs, PAI-1 and collagen with development of 
kidney fibrosis (Lauhio et al. 2008; Obermuller et al. 2001; Rodrigo et al. 2000; Tashiro et al. 
2004; van der Zijl et al. 2010; Yan et al. 2012; Eddy et al. 2009).  Hence, this study will evaluate 
if ECM related molecules in the urine could be used as potential non-invasive biomarkers of 
CKD progression and add prognostic value to current biomarkers. 
 
This study therefore aims to test the hypothesis that proteins known to be involved in fibrotic 
remodelling are present in the urine, can be measured and that the levels of these may predict 
the status of the fibrotic pathway and thus predict the rate of disease progression. 
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Chapter 2 
Aims 
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The main aims of this study are: 
 
1) To obtain sequential urine and serum from three animal models of CKD 
which have progressive disease.  These are the 5/6th SNx, DN and CAN 
models in the rat. 
2) In these animal models evaluate urine levels of ECM related molecules 
known to be linked to fibrotic remodelling including TG2 and its crosslink 
product ε (γ-glutamyl) lysine, MMPs, TIMPs, MMP activity, total collagen and 
PAI-1. 
3) To collect clinical samples (urine and blood) from >200 patients from all 
cause CKD at all stages of disease using the patient pool at the Sheffield 
Kidney Institute, NGH, UK. 
4) Measure the best biomarker candidates from the animal models in the human 
patient samples.  Determine their potential to predict progression by following 
these patients for 3 years post sampling.   
5) Correlate urine measurements to histological changes using a set of patients 
with matched biopsies available. 
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Chapter 3 
Materials and Methods 
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3.1. In Vivo Experimentation 
 
3.1.1. Experimental Animals 
  
Three animal studies were performed previously to the start of this study:  The 5/6th Subtotal 
Nephrectomy model of renal scarring (SNx) (Johnson et al. 2007), the UNx STZ model of 
Diabetic Nephropathy (DN) (Huang et al. 2010) and the Fisher to Lewis model of Chronic 
Allograft Nephropathy (CAN) (Shrestha et al. 2014).  Archival materials (kidney homogenate 
and urine samples) were available from these studies.  In brief, male Wistar harn rats weighing 
200-250g were used for the 5/6thSubtotal Nephrectomy model of renal fibrosis and for the UNx 
STZ model of Diabetic Nephropathy (University of Sheffield, UK).  In both models, animals 
were aged between 8-10 weeks, weighing 200 to 250 g at the beginning of the experiment.  
For the Fisher to Lewis transplant model of Chronic Allograft Nephropathy, male Fisher (F334, 
RT1v1) and male Lewis (Lew, RT1) rats (Harlan, UK), weighing 200-300g and aged 8-12 
weeks were used.   
In all models, rats were housed 2-4 animals per cage in an environment of 45% humidity on a 
12/12 hours light/dark cycle at 20-220C. Animals were allowed free access to rat chow 
(protein/casein content 18%; LabSure Ltd, Cambridge, UK) and water.  This represented a 
medium protein diet.  All experiments were performed under and complied with the Animal 
Scientific Procedures Act 1986. 
3.1.1.1. Anaesthesia 
 
In all three animal models, anaesthesia was induced with 5% Halothane (Animalcare Ltd, 
York), 4L/min O2 via inhalation in a sealed induction chamber and then maintained via nose 
cone at 3% Halothane, 1.5L/min O2.  The depth of anaesthesia was checked and confirmed 
by loss of both hind leg-withdrawal and corneal reflexes.  Body temperature was maintained 
using a heat mat.   
 
3.1.2. The 5/6th Subtotal Nephrectomy model of renal scarring 
 
Subtotal Nephrectomy was conducted as a one-step procedure through excision of 5/6 of the 
kidney mass (Johnson et al. 2007).  In this procedure, 2/3rds of the right kidney was resected 
following ligature (3/0 mersilk, Southern Syringe Services, London) of its lower and upper 
poles leaving the rat with only 1/3rd of the right kidney (figure 3.1).  The degree of resection 
was calculated from the weights of the removed kidney poles:  
% Nephrectomy = left kidney (g) + right kidney poles (g) +0.1g         x 100 
2 x left kidney (g) 
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This procedure leads to the development of CKD over 3 months by the development of 
progressive glomerulosclerosis and tubule-interstitial fibrosis.  Sham-operated rats (SNc) were 
used as controls.  These rats had retro-peritoneal incisions on both the left and right side 
without manipulation of either kidney.  Rats were sacrificed in groups at 7 (n=3-4), 28 (n=3-4) 
and 84 (n=3-11) days post surgery.  Biochemical measurements (Creatinine clearance, 
Proteinuria, Albuminuria) and histopathology were analysed at these time points to evaluate 
kidney function and scarring process. 
 
 
Figure 3.1: 5/6th Subtotal Nephrectomy procedure 
 
Figure 3.1: 5/6th Subtotal Nephrectomy was performed on male Wistar rats as a one-step procedure. 
Left Uninephrectomy was followed by decapsulation and resection of 2/3rds right kidney. Sham-
operated rats were used as controls. 
 
3.1.2.1. Pan Transglutaminase Inhibitors renal infusion in SNx 
 
Two different types of pan TG inhibitors were used for direct infusion into the rat kidneys.   Both 
compounds were site-directed and irreversible inhibitors of the enzyme, but with different 
properties.  N-benzyloxycarbonyl-L-phenylalanyl-6-dimethyl-sulfonium-5-oxo-L-norleucine 
(NTU 281) was chosen as it acts predominantly in the extracellular compartment due to its 
poor permeability across cell membranes, while 1,Dimethyl-2 [(oxopropyl)thio] imidazolium 
(NTU 283) has high cell solubility and consequently its action is both extra and intracellular.  
TG inhibitors were made up in PBS (pH7.4) at 50mMol/L, loaded into a 2ML4 Azlet® mini-
osmotic pump (Charles River, UK) which was inserted subcutaneously on the scruff and 
connected to a 9 cm long, 0.58 mm diameter polyethylene customised cannula placed into the 
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renal parenchyma,  The cannula was secured in the kidney using a silk tie and tissue glue.  
TG2 inhibitors were delivered at a flow rate of 0.5ul/hour for 28 days at which point pumps 
were replaced. 
 
3.1.3. The UNx STZ model of Diabetic Nephropathy 
 
A total of 25 male Wistar rats had a right Uninephrectomy (UNx) performed.  An infusion 
cannula was implanted in the lower pole of the left kidney and then connected to a mini-
osmotic pump.  7 days post-surgery, 35 mg/kg of Streptozotocin (STZ) was administrated in 
0.1 mol/L Sodium Citrate buffer (pH 4.0) by IV injection into the tail vein using a 23G Butterfly 
Cannula (Venisystems, UK).  After two days glycaemia was measured.  Animals above 
20mM/L glucose were considered diabetic.  Glycaemia was controlled to between 20 and 25 
mmol/L by titrating in quarters of a subcutaneous insulin implant (Linshin, Canada) to prevent 
animal wasting (figure 3.2).  Sham operated rats (n=10) were used as controls.  Control rats 
received 0.3ml of a 0.1mol/L sodium citrate (pH 4.0) solution.  Creatinine clearance, 
albuminuria, glycaemia and histopathology were analysed at 1 (n=3-4), 4 (n=3-7) and 8 (n=3-
5) months post Streptozotocin administration (Huang et al. 2009). 
 
 Figure 3.2: UNx STZ model of Diabetic Nephropathy 
 
 
Figure 3.2: Diabetic Nephropathy was induced in male Wistar rats by infusion of 35 mg/kg 
Streptozotocin into the tail vein.  Right Uninephrectomy was performed to accelerate the scarring 
process.  Subcutaneous insulin implant kept glycaemia between 20 and 25 mmol/L. 
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Figure 3.3: Renal Transplantation procedure 
 
  
 
Figure 3.3: A) Left native kidney removed from a Lewis rat showing hilar vessels and ureter. After 
retrieval, donor kidney was perfused with UW solution. The infrarenal aorta and Inferior Venacaval 
(IVC) were mobilised. B) Recipient end-to-side anastomosis and re-perfusion (n = 5 L-L Isografts, n= 7 
F-L Allografts). 
A B 
3.1.4. The Fisher to Lewis model of Chronic Allograft Nephropathy 
 
 
In this model, donor rats; Lewis (isograft) or Fisher (allograft) received 2ml of 0.9% saline 
solution in bolus followed by a 6ml/h intravenous infusion.  Testicular vessels, superior vesical 
artery, vessels supplying seminal vesicle, vas deferens and prostate, right ureter and urethra 
were ligated and divided.  300 units of Heparin were administrated intravenously, the supra- 
and infrarenal aorta and the infrarenal IVC were ligated with 6/0 Vicryl (Southern Syringe 
Services, London) and the donor kidney was perfused with 2ml/min solution of cold University 
of Wisconsin (UW) for 10 minutes through the infrarenal aorta.  The donor kidney was 
recovered and then stored in cold UW solution prior to transplantation.  Recipient Lewis  rats 
received an intravenous infusion of  2ml Succinylated fluid gelatine (Volplex, Maelor 
Pharmaceuticals Ltd, UK)  in bolus followed by an administration of 6ml/h of this plasma 
volume expander prior to left nephrectomy.  The donor kidney was transferred to the 
recipients.  Blood vessels were anastomised and the kidney reperfused.  A cystotomy was 
performed and the donor bladder cuff anastomised to the recipient bladder using continuous 
6/0 Vicryl suture.  The transplanted kidney was anchored to the retroperitoneum by suturing 
the perinephric fat to the psoas muscle.  5 rats were used on the Isograft group (Lewis to 
Lewis) and 7 on the Allograft group (Fisher to Lewis).  Both isografts and allografts were given 
5 mg/kg of Cyclosporine (Novartis, Basel, Switzerland) via intraperitoneal injection for 10 days 
to prevent acute rejection.  Biochemical measurements (Creatinine clearance, Proteinuria, 
Albuminuria) were analysed at 2, 8, 17, 24, 33 and 52 weeks post transplantation and 
histopathology at the final time point. 
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3.1.5. Clinical Chemistry 
 
Kidney function was assessed in order to monitor the progression of renal scarring in each 
animal model.  All rats were subjected to twenty four hour urine collections at specific time 
points to determine creatinine clearance, total protein excretion and albuminuria.  Blood 
samples were used to measure serum creatinine and glycaemia (UNx STZ model of Diabetic 
Nephropathy).  Body weight and blood pressure (using a Model 229 blood pressure 
Amplifier/Pump; IITC, USA) were also measured at each time point. 
3.1.5.1. Creatinine Clearance 
 
Rats were placed in metabolic cages (Techniplast, Italy) for 24 hours for kidney function 
assessment.  Urine was collect on chillers (Techniplast, Italy) to avoid protein denaturation 
and evaporation.  After this, the volume of urine was measured, aliquoted and stored at minus 
20°C.  Blood samples were collected by either cardiac puncture at termination (SNx and DN 
models) or taken from the tail vein using a 23g venisystems butterfly cannula (Hospira, Ireland) 
(CAN model) and were left 30 minutes at room temperature to clot before centrifugation at 
1500 X g, 4°C using a Sigma 3-18K centrifuge (SciQuip Ltd, UK) in order to collect serum.  
Urine and serum Creatinine were measured by the Clinical Chemistry Department at the 
Northern General Hospital (Sheffield, UK) using the Jaffe colorimetric method (figure 3.4).  
Creatinine Clearance was calculated using the equation below.  
 
Figure 3.4: Jaffe colorimetric method 
 
 
 
 
 
 
 
Figure 3.4: Urine or serum sample is placed in a reaction tube containing an alkaline picrate solution. 
The creatinine present in the sample reacts with picric acid to form a red-coloured product which is 
read by a Spectrophotometer at 520nm. The creatinine concentration will be directly proportional to 
the colour intensity.  
 
 
Creatinine Clearance = Urinary Creatinine (µmol/L) x Urine flow rate (ml/min)       
                   Serum Creatinine (µmol/L) 
+   1/35 serum 
          or 
     1/105 urine 
Alkaline 
picrate 
solution 
Red 
coloured 
product 
-OH 
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3.1.5.2. Proteinuria 
 
Estimation of protein concentration was done on 24 hour urines collected from rats placed in 
metabolic cages.  A modified Lowry protein assay (Lowry et al. 1951), the RC DC™ protein 
assay (Bio-Rad laboratories, UK), was used for this estimation, as described in section 3.2.2.1 
and expressed as mg/24hrs. 
3.1.5.3. Albuminuria 
 
Rat Albuminuria was determined by a commercial Albumin ELISA kit (Bethyl Laboratories, 
Texas, USA).  100ul of Monoclonal sheep anti-rat albumin affinity purified capture antibody 
diluted in 1:100 in coating buffer (0.05M Carbonate-Bicarbonate, pH 9.6)  was added to each 
well of a 96 well microplate (Costar 3590, Corning Incorporated, USA).  The microplate was 
incubated at room temperature (20-25°C) for 1 hour and then washed five times with a solution 
containing 50mM Tris (Fisher Scientific, UK), 0.14 M NaCl, 0.05% Tween 20 (Fisher Scientific, 
UK) at pH 8.0.  200μl of a blocking solution (50mM Tris, 0.14M NaCl, 1% BSA, pH 8.0) was 
added to each well after washing.  The microplate was incubated for 30 minutes at room 
temperature and then washed again for five times.  A standard curve of 1.95-10,000ng/ml 
albumin was generated in 50mMTris. Standards and urine samples were diluted in 50mM Tris, 
0.14M NaCl, 1% BSA, 0.05% Tween 20 solution in a range of 1:2, 1:5, 1:10 and 1:50, and 
were coated in duplicates (100ul each well) on the microplate . Rat serum was used as internal 
control.  After 1 hour incubation at room temperature, the microplate was washed a further 5 
times.  100ul of 1:100 diluted Polyclonal Sheep anti-rat albumin HRP conjugated detection 
antibody was added to each well and incubated for another 1 hour. After 5 final washes, 100ul 
of Tetramethylbenzidine (TMB) (Sigma-Aldrich, UK) substrate solution was applied to the 
microplate which was then left in the dark for 15 minutes for reaction development.  The 
reaction was stopped by addition of 0.18M Sulphuric Acid (H2SO4) (Analar Normarpur®, VWR 
International Ltd).  Absorbance was measured on Labsystems Multiskan Ascent plate reader 
(Bio-Rad Laboratories, Hertfordshire, UK) at a wavelength of 450nm.  Results were analysed 
by a Labsystems Genesis computer package (Bio-Rad Laboratories, Hertfordshire, UK).  A 
typical standard curve is shown in figure 3.5. 
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Figure 3.5: Rat Albumin ELISA standard curve generated with known concentrations of Albumin 
(1.95-10,000ng/ml). Data points are average of triplicates. Error bars showing standard error are 
smaller than symbols. 
 
 
 
 
 
 Figure 3.5: Rat Albuminuria Standard Curve 
 
 
 
 
 
 
 
 
 
 
3.1.5.4. Glycaemia 
 
Blood glucose was monitored in the morning using a One touch basic glucose monitor 
(Johnson & Johnson) and terminal glycaemia was determined by standard autoanalyser 
techniques by the Clinical Chemistry Department at the Northern General Hospital (Sheffield, 
UK) and expressed as mmol/L. 
 
 
3.1.6. Histopathology 
3.1.6.1. Procession and fixation of kidney tissue 
 
For estimation of the degree of kidney scarring, kidneys were harvested and placed in 10% 
neutral buffered formalin solution (Sigma-Aldrich, UK) for 24 hours at 4°C, then washed in 
autoclaved 1x Phosphate Buffered Saline (PBS) (8g Sodium Chloride (Fluka, Sigma-Aldrich, 
UK), 0.2g Potassium Chloride (Fisher Scientific, UK), 1.44g Disodium Hydrogen 
Orthophosphate (Fisher Scientific, UK), 0.24g Potassium Dihydrogen Orthophosphate (Analar 
Normarpur®, VWR International Ltd), dissolved in 1L H2O, pH 7.4) and stored in PBS until 
embedded in paraffin blocks.  
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3.1.6.2. Masson’s Trichrome staining 
 
4µm paraffin embedded sections were de-waxed in xylene (Fisher Scientific, UK) for 10 
minutes and rehydrated in a series of graded ethanol solutions (100%, 90%, 75%, 50%) 
(Analar Normarpur®, VWR International Ltd) for 5 minutes each and then washed with distilled 
H2O prior to Masson’s Trichrome staining which was performed by the Department of 
Histopathology, Northern General Hospital, Sheffield, UK.  Briefly, this is a three-colour 
staining protocol which involves the immersion of the fixed kidney sample into Weigert's iron 
haematoxylin, and then in three different solutions: A or plasma stain (acid fuchsin, Xylidine 
Ponceau, glacial acetic acid, and distilled water), B (phosphomolybdic acid in distilled water) 
and C, also called fibre stain (Light Green SF yellowish). 
 
Masson’s Trichrome stains Collagenous fibers and Extracellular Matrix blue or green, 
cytoplasm red or pink and cell nuclei in dark red or purple.  Glomerular and tubulointerstitial 
scarring levels were assessed by multiphase image analysis. 
3.1.6.3. Multiphase Image Analysis 
 
Multiphase image analysis of Masson’s Trichrome stained kidney sections was performed 
using the Analysis ™ 3.2 Software (Soft Imaging Systems, Germany) using an Olympus BX 
61 fluorescent microscope.  Sections were examined at 200 x magnification for 
tubulointerstitial fibrosis determination and at 400 x magnification for glomerulosclerosis.  A 
minimum of 10 random non-overlapping cortical fields per sample were analysed.  Three 
different phases were assigned to specific areas; Phase 1 (blue) covered all fibrotic areas, 
Phase 2 (pink) covered all stroma and cells, and Phase 3 (yellow) for blank areas (tubular 
lumen and vacuolation).  The area covered by each phase was quantified to give a percentage 
area value.  The combination off all 3 phases should show a minimum of 95% total phase 
coverage for accurate quantification.  Levels of scarring presented on kidney samples were 
obtained by dividing the area of phase 1 by phase 2.  Overall kidney scarring was determined 
by the average of the 10 scarring values (phase1/phase2) obtained from the 10 cortical fields 
selected. 
3.2. Human prospective study 
 
3.2.1. Study design 
 
The study was conducted at the Sheffield Kidney Institute (SKI) located on the Northern 
General Hospital site of Sheffield Teaching Hospitals NHS Foundation Trust, UK.  The SKI 
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covers a population in excess of 1.7 million in the North Trent region in England treating a 
large number of patients representing all different stages and forms of CKD.  Therefore, it 
provides a suitable environment for this study. 
 
This study consisted of a prospective observational cohort of adult CKD patients from stages 
1 to 5 over a period of 3 years.  Patients underwent a detailed bio-clinical assessment that 
included the measurement of blood pressure, pulse rate, BMI calculation, laboratory 
assessment (serum creatinine, blood urea nitrogen, eGFR, albuminuria, ACR, proteinuria, 
PCR, serum cholesterol, triglycerides, calcium, phosphorus and PTH), socio-economic status 
(employment type and household address), smoking habit, medications in use and collection 
of urine and blood samples for new biomarker analysis (figure 3.6).  The full bio-clinical 
assessment took place at baseline, whereas the laboratory assessment was collected at every 
outpatient’s clinical appointment for a period over 3 years in order to assess CKD progression 
and outcomes.   
 
This study aimed to recruit CKD patients above 18 years old and of any CKD ethiology 
attending the SKI outpatient clinic facilities to define the prognostic value of new urine CKD 
biomarkers with emphasis on ECM related molecules (TG2 and its crosslink product, total 
collagen, MMPs, TIMPs and PAI-1). This study also aimed to collect bio-samples (blood and 
urine) from healthy volunteers, diabetic controls and CKD patients undergoing renal biopsies 
to correlate these findings with histological changes as well as clinical parameters. 
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Figure 3.6: Overview of the Bio-Clinical assessment 
 
 
 
Figure 3.6: The structure of the Bio-Clinical assessment of patients recruited to the study  
3.2.2. Ethics and Research governance  
 
The study protocol has been approved by the South Humber Local Research Ethics 
Committee under the REC reference number 08/H1305/64 until October 2012 and 
12/YH/0297 after this date. It was registered with the STH NHS Foundation Trust Research 
Department under the ethics reference application number STH 15004 and was sponsored by 
Pfizer pharmaceuticals.  The research was conducted in accordance with the ethical principles 
set forth in the World Medical Association (WMA) Declaration of Helsinki and the International 
Conference on Harmonisation of Good Clinical Practice (ICH-GCP) guidelines in order to 
protect human subjects and to ensure collection of quality data.  The chief investigator as well 
as the principal investigator possessed GCP training and accreditation.  Patients received the 
Participants Information Sheet and Consent Forms before inclusion, having ample time before 
deciding whether or not they wished to take part in the study.  Quality assurance procedures 
and research office inspections were performed at a regular basis during these 5 years of 
research.  Copies of the Research Governance documents including the project registration 
forms, research department authorisation letter, the ethics committee approval letter, site 
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specific assessment, report of independent reviewers, letters of invitation to participants, 
Participants Information sheet and consent forms for healthy volunteers, CKD and kidney 
biopsy patients as well as the letter with information for GPs or consultants are attached in the 
thesis appendix. 
 
3.2.3. Patient recruitment 
3.2.3.1. Control group 
 
A total of 33 adult healthy volunteers were included as a control group.  This group consisted 
of subjects above 18 years old, without history of any type of kidney disease, hypertension, 
diabetes or any other chronic condition.  Healthy volunteers had urine tests to ensure they 
were fit to participate in the study. These included the collection of mid-stream urine for 
albuminuria and creatinine (Microalbustix, Siemens, UK) and for sediment test with a Multistix 
urine test strip (Multistix 8SG, Siemens, UK) to verify the presence of proteins, glucose, 
ketones, haemoglobin, bilirubin, urobilinogen, acetone, nitrite and leucocytes as well as to test 
the pH, specific gravity and infection by different pathogens.  Healthy volunteers’ height, 
weight, blood pressure and pulse were also measured. 
3.2.3.2. CKD patients 
 
A total of 292 CKD patients from stages 1 to 5 were recruited at the SKI Outpatients Clinic. 
Major CKD causes were: diabetic kidney disease, chronic glomerulonephritis, hypertensive 
nephrosclerosis, atherosclerotic renovascular disease, chronic interstitial nephritis and 
ADPKD.  From this total, 41 patients were recruited at the time of renal biopsy.  
 
The inclusion criteria for this study were: 
 Adult patients aged 18 or above 
 CKD stages 1 to 5 from any ethiology 
 
The exclusion criteria were: 
 Patients on any form of RRT (Dialysis or Transplantation) 
 Patients in a state of Acute Kidney Injury (AKI) at presentation 
 Presence of UTI at presentation 
 Mental incapacity 
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3.2.4. Protocol for Urine sample collection  
3.2.4.1. Urine processing 
 
220ml of fresh Mid-Stream Urine (MSU) were collected from every participant (CKD patients 
and Healthy volunteers) in the study.  Urine samples were collected into a sterile container not 
containing any protease inhibitor and placed immediately on ice.  110ml of urine was removed 
and placed into a 175ml conical tip centrifuge tube.  To ensure removal of cellular material, 
urines were centrifuged at 3000g for 10 minutes at 40C using a Sigma 3-18K centrifuge 
(SciQuip Ltd, UK).  The supernatant was removed and aliquoted into 5 x 20ml samples in 
universal tubes and 10 x 1ml in microfuge tubes to avoid protein degradation by 
freeze/thawing.  Vials were labelled and stored at -800C. These constituted the cell free urine 
(CFU) collection. The remaining 110ml of urine was aliquoted into 5 x 20ml samples in 
universal tubes and 10 x 1ml in microfuge tubes.  All vials were labelled with SKI numbers, 
urine type and date of collection and then stored at -800C. These constituted the complete 
urine collection (CU). 
3.2.4.2. Initial screening 
 
Initial screening of CKD patient’s urines included the testing albuminuria and creatinine with a 
Microalbustix urine test strip (Microalbustix, Siemens, UK) and for sediment test with the 
Multistix (Multistix 8SG, Siemens, UK) to verify the presence of proteins, glucose, ketones, 
haemoglobin, bilirubin, urobilinogen, acetone, nitrite and leucocytes as well as to test the pH, 
specific gravity and infection. One patient presenting results compatible with UTI was excluded 
from the study. 
3.2.4.3. Laboratory assessment 
 
Serum creatinine, blood urea nitrogen, albuminuria, serum cholesterol, triglycerides, calcium, 
phosphorus and PTH were analysed by standard autoanalyser techniques by the Clinical 
Chemistry Department at the Northern General Hospital (Sheffield, UK).  Total proteinuria was 
measured by the BCA assay (section 3.3.2.2).  Retrieval of laboratory data was from patients’ 
medical notes. 
 
3.2.5. Protocol for Blood collection 
 
10mls of blood were collected into 2 vacutainers; 1 containing EDTA for plasma and 1 
containing clotting agent for serum.  Both vacutainers were centrifuged at 400g for 10 minutes. 
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5ml of plasma and serum samples were aliquoted into 5x 1ml cryotubes, labelled and stored 
at -800C. 
 
3.2.6. Bio-repository database 
 
The Sheffield Kidney Institute (SKI) bio-repository database was specially designed to store 
data from this and future studies.  The database was constructed in Microsoft Access and was 
developed by the University of Sheffield Medical School Information technology support team.  
This electronic database enabled the automatic creation of a SKI patient (study) number which 
provided anonymity and therefore ensured the confidentiality of data collected from each 
subject.  After generation of a SKI number, demographic details including gender, age, 
ethnicity and employment status; anthropometric data (height, weight and BMI), smoking 
habit, CKD diagnosis and co-morbidities, list of current medications as well as full clinical and 
laboratory results were entered and stored in the SKI database (figure 3.7).  
Glomerulosclerosis, tubulointerstitial fibrosis and vascular sclerosis score from each kidney 
biopsy patient were also recorded.  In addition, 10 recordings of eGFR, serum creatinine and 
blood pressure collected during the follow-up period of 3 years were also recorded in the 
database (figure 3.8).  All collected urine (CFU and CU) and blood (plasma and serum) 
samples were labelled (Avery LaserJet mini labels, Avery®, UK) with SKI numbers, sample 
type and date of collection and then stored in a dedicated racked -800C upright Sanyo Freezer 
(MDF-U500VX, Sanyo-Biomedical, UK).  This freezer had a dual cooling compressor system, 
an inbuilt temperature display with 24 temperature monitoring and an extensive alarm system 
in order to guarantee continuous maintenance of a temperature of -800C.  The SKI Bio-
repository database is stored in a secure server designated by the University of Sheffield with 
exclusive access only by the investigators using onsite PCs only. 
3.2.7.1. Data protection and confidentiality 
 
All personal data collected in this study was processed in accordance with the rights of data 
subjects under the Data Protection Act 1998.  All personal information about any participant 
was kept securely, confidential and processed in a fairly and lawful manner.  Also, appropriate 
technical and organisational measures were taken to ensure the quality of the database and 
these included: undisclosed input of patients’ details, anonymous labelling of samples with 
automatically generated SKI (study) numbers and administration documents marked with 
unique identifiers without participants’ names recorded on them.  The information revealing 
and connecting the identifiers to patients’ names was kept separated from the rest of the data 
in a secure place where only authorised clinical investigators of this study had access.  Finally, 
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standard procedure checks were regularly taken to ensure accuracy of data and adequate 
level of protection. 
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Figure 3.7:  SKI Bio-repository database 
 
 
 
 
Figure 3.7: The SKI Bio-repository database stored patients demographic details, anthropometric data, 
smoking habit, CKD diagnosis, past medical history, a full list of current medications as well as all 
relevant clinical and laboratory reports from each patient included in the study. Urine, blood and 
kidney biopsy samples locations in the -800C freezer were also indicated in the files. Confidentiality 
was guaranteed by an anonymised input of data. 
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Figure 3.8:  SKI Bio-repository database: Follow-up data 
 
 
 
 
 
 
Figure 3.8:  Historic data recording comprised of 10 measurements of eGFR, serum creatinine and 
blood pressure collected during the follow-up period of 3 years. This allowed us to assess the CKD 
progression status of subjects participating in the study cohort. 
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3.3. Determination of Protein concentration 
 
3.3.1. Assays for estimation of protein concentration 
3.3.1.1. Reducing Compatible - Detergent Compatible (RC-DC) protein assay  
 
This commercial protein assay was undertaken as per manufacturer’s instructions (Bio-Rad 
Laboratories, UK).  This assay is based on a modification of the Lowry protocol (Lowry et al. 
1951).  Albumin stock of 100 mg/ml was prepared by the addition of 0.1g of Bovine Serum 
Albumin (BSA) (VWR International Ltd) to 10 ml of distilled water.  A standard curve of 0, 0.2, 
0.4, 0.6, 0.8, 1.0, 1.2 and 1.4mg/ml BSA stock in Phosphate Buffered Saline (PBS) was used.  
Samples were diluted 1:2, 1:5 and 1:10 with PBS to ensure 1 dilution was on the standard 
curve.  125ul of RC reagent 1 (35% Sodium chloride, 10% Trichloroacetic acid, 55% H2O) was 
added into each tube, vortexed and then incubated for 1 min at room temperature. 125ul of 
RC reagent 2 (3% acetone in H2O) was added into each tube, vortexed and then centrifuged 
at 15000xg for 5 mins.  Supernatant was discarded and again 125ul of RC reagent 1 was 
added into each tube, vortexed and then incubated for 1 min at room temperature and 125ul 
of RC reagent 2 was added into each tube, vortexed and then centrifuged at 15000xg for 5 
mins.  The supernatant was discarded. Reagent A1 was prepared by addition of 5ul of DC 
reagent S to each 250ul of reagent A (alkaline copper tartrate solution) that would be needed 
for use. 127ul of reagent A1 was added to each tube, vortexed and incubated at room 
temperature for 5 mins.  Tubes were vortexed again and then 1 ml of DC reagent B (Folin 
Ciocalteau reagent) was added to each tube. After vortexing, tubes were incubated at room 
temperature for 15 mins.  200ul of each standard and sample was pipette into a 96 well plate 
and read by photo spectrometry using absorbance with wavelength 750nm (Labsystems 
Multiskan Ascent, UK) with curve generation and analysis undertaken using genesis light 
software.  An example of a standard curve is shown in figure 3.9-A. 
3.3.1.2. Bicinchoninic Acid (BCA) protein assay 
 
A 100 mg/ml albumin stock was prepared by the addition of 0.1g of BSA (VWR International 
Ltd) to 10 ml of distilled water.  A standard curve of 0, 0.4, 0.8, 1.2, 1.6 and 2.0mg/ml BSA in 
distilled water was used.  100ul of each sample was added to 100ul of 0.1M sodium hydroxide 
(NaOH) (Analar Normarpur®, VWR International Ltd) 2% (w/v) sodium dodecyl sulphate 
(SDS) (Fisher Scientific, UK) and then boiled at 1000C for 5 mins to facilitate solubilisation of 
proteins.  Reagent A was prepared by addition of 1 g Bicinchoninic acid (Sigma-Aldrich, UK), 
2g sodium carbonate (Fisher Scientific, UK), 0.16 g sodium tartrate (Sigma-Aldrich, UK), 0.4 
g sodium hydroxide and 0.95 g sodium bicarbonate (Analar Normarpur®, VWR International 
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Ltd) brought to 100 ml with distilled water (the pH of the solution was adjusted to 11.25 with 
10M NaOH).  Reagent B was prepared by addition of 0.4 g cupric sulphate (5 x hydrated) 
(Analar Normarpur®, VWR International Ltd) to 10 ml of distilled water.  The BCA working 
solution was then prepared by addition of 25 mls of Reagent A to 1ml of Reagent B.  1 ml of 
BCA working solution was added to each standard and sample and all tubes were vortexed 
before incubation at 370C for 30 mins.  200ul of each standard and sample was pipette into a 
96 well plate and read by photo spectrometry using absorbance with wavelength 562 nm 
(Labsystems Multiskan Ascent, genesis light software, UK).  A typical standard curve is shown 
in figure 3.9-B. 
 
 
Figure 3.9: Protein Assay Standards Curves 
 
Figure 3.9: Examples of calibration Standard Curves generated with BSA stock to determine protein 
quantitation in urine samples. Data points are average of duplicates. Left (A), RC DC assay. Right (B), 
BCA assay.  O.D.; Optical Density. Protein concentration was expressed as mg/ml.  Error bars showing 
standard deviations are smaller than symbols. 
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3.4. Immunoassays 
 
3.4.1. Rationale and principals of the Immunoassays 
 
An Enzyme linked Immunosorbent Assay (ELISA) is a biochemical test that measures the 
concentration of an antigen in a sample through an immunological reaction with at least one 
antibody or immunoglobulin.  Urine Transglutaminase 2 as well as MMPs 1, 2, 9, MMP-1/ 
TIMP-1 complex, TIMPs 1, 2 and 3 were measured by this form of assay. 
 
This assay involves the binding of a polyclonal capture antibody into a 96 well polystyrene 
microtiter plate, followed by blocking of any non-specific binding sites on this plate with a 
neutral protein, such as bovine serum albumin (BSA).  Then, urine samples at determined 
dilutions were applied to the plate such that the desired antigen binds specifically to the 
primary antibody. The plate is washed with a mild detergent solution to remove unbound 
antigens. Then, a specific detection antibody from a different species to the capture antibody 
is applied so it can bind to the antigen forming a “sandwich” as the antigen is held between 
both antibodies.  An Enzyme-linked secondary monoclonal antibody is then applied and the 
plate washed to remove the unbound antibody-enzyme conjugates.  Following the use of the 
secondary antibody, Biotin conjugated to horse radish peroxidase (HRP) was applied.  The 
HRP targets the anti-species of the Secondary Antibody. Finally, a TMB substrate is added 
and this will lead to changes in the solution colour upon reaction with the HRP enzyme (figure 
3.10).  The subsequent chemical reaction produces a detectable signal, most commonly a 
color change in the substrate.  The color change can be read as a change in absorbance at a 
particular wavelength and is measured by a spectrophotometer.  The change in absorbance 
is proportional to the amount of antigen binding to the capture antibody bound by the 
secondary antibody within a defined range.  The optical density (OD) of the sample is 
compared to a standard curve, made by a serial dilution of a known-concentration solution of 
pure antigen. 
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Figure 3.10:  Schematic representation of a sandwich immunoassay 
 
 
Figure 3.10: Principles of Sandwich ELISA.  A microplate is coated with a capture antibody; then a 
sample containing the target protein is added, and any antigen present binds to the capture antibody.  
A detection antibody is added, and binds to antigen; an enzyme-linked tertiary antibody that 
recognises the species of the secondary antibody is added to that.  A substrate is then added, that 
changes colour upon reaction with the enzyme. The absorbance of the plate wells is measured by a 
spectrophotometer to determine the presence and quantity of antigen. 
 
3.4.2. Sample preparation 
 
Aliquoted rat and human urine samples that have been previously stored at -800C were thawed 
at 40C to avoid protein denaturation.  An appropriate assay dilution buffer was added to the 
samples according to the specific assay and the optimized dilution factor. 
 
3.4.3. Urine TG2 Enzyme-linked immunosorbent assay  
 
An in-house sandwich ELISA was developed for the quantification of TG2 in the urine. 
  3.4.3.1. Antibody selection 
 
A number of antibodies anti-transglutaminase 2 was tested in order to optimize this 
immunoassay.  Selected antibodies were also tested in several different concentrations to 
verify higher sensitivity and specificity against urine transglutaminase 2.  After analysis, the 
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Goat polyclonal anti TG2 and the mouse monoclonal CUB7402 (both from AbCam) were 
selected as the Capture and Detection Antibody respectively. The main properties of both 
antibodies are shown on table 3.1. 
 
Table 3.1: Anti-transglutaminase 2 antibodies 
 
 Goat polyclonal to 
Transglutaminase 2: Capture 
ATB 
Mouse monoclonal to 
Transglutaminase 2 
(CUB7402): Detection ATB 
Immunogen Synthetic peptide C-
ERDLYLENPEIKIR by a 
Cysteine residue linker 
Purified guinea pig liver 
Transglutaminase 2 
Epitope mapping amino acids 579-592 amino acids 447-478 
Species reactivity Mouse, Rat, Guinea pig, Cow, 
Pig, Human 
Mouse, Rat, Rabbit, Guinea pig, 
Dog, Human 
Purity IgG fraction IgG fraction 
Stock 
Concentration 
0.5mg/ml 0.1mg/ml 
 
3.4.3.3. Urine TG2 assay procedure 
 
96 well microplates (Costar 3590, Corning Incorporated, USA) were coated for 4h at room 
temperature or overnight at 40C with 100ul per well of goat anti-transglutaminase type II 
antibody (AbCam, UK) diluted 1/1000 in 50mM Carbonate Buffer (0.8g Sodium Carbonate 
anhydrous or 2.15g Sodium Carbonate Pentahydrated (Fisher Scientific, UK), 1.46g Sodium 
Hydrogen Carbonate (Analar GPR®, UK) 500 ml distilled water, pH 9.6). Plates were washed 
twice with PBS / 0.1% Tween 20 (8g Sodium Chloride (Fluka, Sigma-Aldrich, UK), 0.2g 
Potassium Chloride (Fisher Scientific, UK), 1.44g Disodium Hydrogen Orthophosphate (Fisher 
Scientific, UK), 0.24g Potassium Dihydrogen Orthophosphate (Analar Normarpur®, VWR 
International Ltd), 1L of distilled water, 1ml Tween 20 (Fisher Scientific, UK), pH to 7.4). Plates 
were then blocked for 1h at room temperature with 200ul of 5% (w/v) BSA in PBS and washed 
once with PBS / 0.1% Tween 20.  A standard curve was prepared with a 7 point serial dilution 
from a stock solution of either rat or human recombinant TG2 (Zedira, UK), both at a 
concentration of 10ng/µl.  Rat TG2 ELISA standard curve (SC) was made using a 2-fold 
dilution series: 31.25ng/ml, 62.5ng/ml, 125ng/ml, 250ng/ml, 500ng/ml, 1000ng/ml and 
2000ng/ml, whilst human SC ranged from 15.6ng/ml to 1000ng/ml.  Undiluted PBS served as 
the zero standard (0ng/ml).  100ul of Recombinant TG2 standards and of each urine sample 
(diluted in PBS) were added to each well of the microplate and incubated at room temperature 
for 2 hours.  Rat urine samples were diluted in a 1:10, 1:50 and 1:100 ratio and human samples 
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in 1:1, 1:2 and 1:5.  After this, plates were washed three times with PBS / 0.1% Tween 20.  
100ul of 1ug/ml mouse anti-transglutaminase type II antibody (AB-2 clone TG100; AbCam) 
diluted in PBS (1:1000) was added and plates were left for 1h at room temperature.  Plates 
were washed again three times with PBS / 0.1% Tween 20.  100ul of Biotinylated Goat anti 
Mouse IgG (H+L) (AbCam, UK) was added to each well and left for 1 hour at room 
temperature.  This was followed by three washes with PBS / 0.1% Tween 20.  100ul of 1 ug/ml 
Streptavidin poly-HRP (horseradish peroxidase conjugated secondary antibody, Thermo 
Scientific, UK) diluted in 1:2000 in PBS was added to each well and left for 1 hour at room 
temperature.  After final washes with PBS / 0.1% Tween 20, 100ul per well of the HRP 
substrate 1- Step Ultra TMB-ELISA (Pierce, USA) was added and left for 10 minutes.  The 
reaction was stopped by the addition of 100ul 1N H2SO4 (Analar Normarpur®, VWR 
International Ltd) and absorbance values were read at 450nm using a Labsystems Multiskan 
Ascent spectrophotometer with genesis light software (Bio-Rad Laboratories, Hertfordshire, 
UK).  
3.4.3.4. Determination of reproducibility and specificity 
 
The ability of the urine TG2 assay to reproduce accurate results in urine was tested by adding 
three different known amounts of recombinant human TG2 (rhTG2, Zedira, UK) to twenty 
human urine samples (ten controls and ten CKD) . Each urine sample was spiked with 0.25, 
0.5 and 1ug/ml of rhTG2, representing a low, medium and high TG2 concentration.  Ten un-
spiked control samples and ten un-spiked CKD samples were used to measure baseline 
values for TG2 concentration.  Then, the percentage of spiked TG2 was calculated by using 
the equation below. The results showed a % of spike measured and ranged from 82.6 to 
109.1% (table 3.2). 
 
The specificity of the assay was evaluated by testing other potential cross-reactive molecules 
such as Factor XIII, but no cross-reactivity was observed with this or other Transglutaminases. 
 
% measured =   Mean TG2 Spiked– un-spiked urine concentration (pg/ml) x 100 
                          Mean total value from TG2 Spiked urine concentration 
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Table 3.2: Urine TG2 Enzyme-linked immunosorbent assay reproducibility 
 
Tested 
Sample 
% measured 
(low) 
% measured 
(medium) 
% measured 
(high) 
% measured 
(average) 
Controls 82.6 89.8 102.4 91.6 
CKD 84.1 95.7 109.1 96.3 
 
Table 3.2:  The percent of spiked TG2 measured was calculated by dividing the average values of 
“spiked” samples with rhTG2 by “un-spiked” samples. The amount obtained was multiplied by 100 to 
express results in percentage. 
 
3.4.3.5. Determination of Inter and Intra assay Coefficients of Variability 
 
In order to obtain the precision, or repeatability, of our in-house TG2 immunoassay, two 
measures of the Coefficient of Variability (CV) were calculated: the inter- and the intra-assay 
CV.  The inter-assay CV is an expression of plate-to-plate consistency and was calculated by 
adding two samples with known TG2 concentration in every plate run.  The degree of precision 
was measured by the standard deviation of the two concentrations across all runs and 
converting it to the CV as below. 
 
Urine TG2 immunoassay coefficient of variability calculation 
Coefficients of Variability =   Standard Deviation       x 100%       
                          Mean concentration  
 
 
The intra-assay CV measures the precision of detection within the same plate.  It was analysed 
by calculating the standard deviation of ten samples in multiple assay plates. The Inter- and 
Intra-Coefficients of Variability were 1.2% and 3.9% respectively.  
 
A typical standard curve for the TG2 immunoassay is shown in figure 3.11. The lower limit of 
detection was 31.25pg/ml. 
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 Figure 3.11: Transglutaminase type 2 enzyme-linked immunosorbent assay standard 
curve 
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Figure 3.11: A TG2 standard curve generated using rrTG2 concentrations from 31.25 to 2000pg/ml.  
Colour development was allowed to proceed for 10 minutes and the plate read on a Labsystems 
Multiskan Ascent equipment using genesis light software to plot a curve using a cubic spline curve fit 
equation.  Data points are average of duplicates. 
 
 
3.4.4. Rat Immunoassays 
 
Rat urine samples were analysed by two different commercially available sandwich enzyme-
linked immunosorbent assay kits according to the availability and specificity of each assay in 
relation to the antigen to be measured.  MMP-1, TIMPs 2 and 3 and PAI-1 were assayed using 
Gentaur kits (Uscn Life Science Inc., USA) whilst MMP-9 and TIMP-1 were assayed using the 
Quantikine system (R&D Systems, UK) as they provided accurate and highly sensitive 
detection of these analytes with minimal assay development. 
3.4.4.1. Gentaur Enzyme-linked immunosorbent assay 
3.4.4.1.1. Reproducibility and specificity of assays in urine 
 
Four control samples and four SNx samples were spiked with either 250pg/ml of rat 
recombinant MMP-1 or 12.5ng/ml of TIMP-2 or 6.25ng/ml of TIMP-3 or 5ng/ml of rat 
recombinant PAI-1 and the spiked rates calculated by comparing the measured value to the 
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expected amount in samples (table 3.3).  No significant cross-reactivity or interference 
between MMP-1, TIMP-2, TIMP-3, PAI-1 and analogues was observed.  
 
Table 3.3:  Accuracy % of rat MMP-1, TIMP-2, TIMP-3 and PAI-1 immunoassays 
 
 Control (n=4) SNx (n=4) 
 Recovery range  
(%) 
Average  
(%) 
Recovery range 
(%) 
Average  
(%) 
MMP-1 92-102 99 84-103 98 
TIMP-2 83-104 93 87-101 94 
TIMP-3 89-108 98 81-102 92 
PAI-1 79-98 89 81-98 90 
  
 
The minimum detectable doses were: 0.115ng/ml for rat MMP-1, 0.61ng/ml of rat TIMP-2, 
0.094ng/ml for rat TIMP-3 and 0.18ng/ml for PAI-1. 
3.4.4.1.2. Inter and Intra assay Coefficients of Variability 
 
The Inter-assay CV (precision between assays) was tested by measuring two samples with 
low, middle and high levels of MMP-1, TIMPs 2 and 3 and PAI-1 on three different plates. The 
Intra-assay CV (precision within an assay) was calculated by assaying two samples, three 
times in duplicate on the same plate. 
 
The inter- and intra-coefficients of variability of MMP-1 were 7.8% and 9.2% respectively.  For 
TIMP-2 these values were 3.7% and 6.1%, TIMP-3, 5.4% and 7.2% and PAI-1 4.8% and 7.1% 
respectively. 
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3.4.4.1.3. Materials 
 
The following reagents were used for measurement of MMP-1, TIMP-2, TIMP-3 and PAI-1 in 
rat urine: 
 
Reagents MMP-1 TIMP-2 TIMP-3 PAI-1 
Capture 
Antibody 
(pre-coated) 
Monoclonal AB 
anti-rat MMP-1 
Monoclonal AB 
anti-rat TIMP-2 
Monoclonal AB 
anti-rat TIMP-3 
Monoclonal AB 
anti-rat PAI-1 
Detection 
Reagent A 
120µl Biotin-
conjugated 
polyclonal AB anti-
rat MMP-1 
120µl Biotin-
conjugated 
polyclonal AB anti-
rat TIMP-2 
120µl Biotin-
conjugated 
polyclonal AB anti-
rat TIMP-3 
120µl Biotin-
conjugated 
polyclonal AB anti-
rat TIMP-3 
Detection 
Reagent B 
120µl Avidin 
conjugated to 
Horseradish 
Peroxidase 
120µl Avidin 
conjugated to 
Horseradish 
Peroxidase 
120µl Avidin 
conjugated to 
Horseradish 
Peroxidase 
120µl Avidin 
conjugated to 
Horseradish 
Peroxidase 
Standard 20ng/ml of 
recombinant rat 
MMP-1 
100ng/ml of 
recombinant rat 
TIMP-2 
10ng/ml of 
recombinant rat 
TIMP-3 
80ng/ml of 
recombinant rat 
PAI-1 
Standard 
Diluent 
20ml of 
0.01mol/L PBS  
(Ph 7.2) 
20ml of 
0.01mol/L PBS  
(Ph 7.2) 
20ml of 
0.01mol/L PBS  
(Ph 7.2) 
20ml of 
0.01mol/L PBS  
(Ph 7.2) 
Wash Buffer  30 x concentrated 
Tween 20 in PBS, 
ph 7.4 
30 x concentrated 
Tween 20 in PBS, 
ph 7.4 
30 x concentrated 
Tween 20 in PBS, 
ph 7.4 
30 x concentrated 
Tween 20 in PBS, 
ph 7.4 
Substrate 9ml TMB solution 9ml TMB solution 9ml TMB solution 9ml TMB solution 
Stop 
solution 
6ml 2N H2SO4 6ml  2N H2SO4 6ml 2N H2SO4 6ml 2N H2SO4 
 
3.4.2.1.4. Reagents preparation 
 
 The standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate 
were stored at -20oC upon being received.  All the remaining reagents were stored at 
4OC. 
 All reagents were brought to room temperature and freshly reconstituted before use. 
 The unused strips were kept in a sealed bag with the desiccant to minimize exposure 
to damp air. 
 Rat MMP-1, TIMP-2, TIMP-3 and PAI-1 detection reagents A and B were diluted to a 
working concentration of 1:100 with their respective assay diluents.  
 Standards were prepared minutes before assay. 20ng/ml of recombinant rat MMP-1 
was reconstituted with 1ml of standard diluent to produce a stock solution of 20ng/ml.  
A seven point standard curve was prepared by a 2-fold serial dilution in standard 
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diluent: 20ng/ml, 10ng/ml, 5ng/ml, 2.5ng/ml, 1.25ng/ml, 0.625ng/ml and 0.312ng/ml 
(figure 3.12-A). 
 100ng/ml of Recombinant rat TIMP-2 was reconstituted with 1ml of standard diluent to 
produce a stock solution of 100ng/ml.  A seven point standard curve was prepared by 
a 2-fold serial dilution in standard diluent: 100ng/ml, 50ng/ml, 25ng/ml, 12.5ng/ml, 
6.25ng/ml, 3,12ng/ml and 1.56ng/ml (figure 3.12-B). 
 10ng/ml of Recombinant rat TIMP-3 was reconstituted with 1ml of standard diluent to 
produce a stock solution of 10ng/ml.  A seven point standard curve was prepared by a 
2-fold serial dilution in standard diluent: 10ng/ml, 5ng/ml, 2.5ng/ml, 1.25ng/ml, 
0.625ng/ml, 0.312ng/ml and 0.156ng/ml (figure 3.12-C). 
 80ng/ml of Recombinant rat PAI-1 was reconstituted with 2ml of standard diluent to 
produce a stock solution of 40ng/ml.  A seven point standard curve was prepared by a 
2-fold serial dilution in standard diluent: 40ng/ml, 20ng/ml, 10ng/ml, 5ng/ml, 2.5ng/ml, 
1.25ng/ml and 0.625ng/ml (figure 3.12-D). 
 20ml of wash solution concentrate (30x) was diluted with 580ml of deionized water to 
prepare 600ml of 1x wash solution. 
 The reconstituted standards, detection reagent A and detection reagent B could be 
used only once. 
3.4.4.1.5. Assay procedure 
 
Rat urine samples, standards and reagents were prepared as per manufacture instructions 
(Gentaur, Uscn Life Science Inc., USA).  A 96-well strip plate was pre-coated with a 
monoclonal capture antibody against either MMP-1, TIMP-2, TIMP-3 or PAI-1.  100µL of 
standards or rat urine sample (neat urine for MMP-1 and PAI-1 and 1:2, 1:5 and 1:10 dilution 
for TIMPs 2 and 3) was added to each well and incubated at 37oC for 2 hrs.  After incubation, 
plates were aspirated and washed in PBS. Then, 100µL of Detection Reagent A (a biotin-
conjugated antibody specific to each antigen) was added. Then, plates were incubated for one 
hour at 37oC after covering them with the plate sealer.  Plates were washed thrice with 
350µL/well of 1 X wash solution.  After the last wash, plates were inverted and blotted against 
an absorbent paper to remove any remaining wash buffer.  Next, 100µL of Detection Reagent 
B (Avidin conjugated to Horseradish Peroxidase (HRP) was added to each microplate well 
and incubated 30 minutes at 37oC.  Plates were washed for five times.  90µL of TMB Substrate 
solution was added to each well and plates were incubated for 15-25 minutes at 37oC in the 
dark for blue colour to develop.  The enzyme-substrate reaction is terminated by the addition 
of 50ul 2N sulphuric acid solution and the colour change was measured 
spectrophotometrically at a wavelength of 450nm using a Labsystems Multiskan Ascent 
spectrophotometer (Bio-Rad Laboratories, Hertfordshire, UK) using genesis light software.  
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The concentrations of MMP-1, TIMP-2, TIMP-3 and PAI-1 in the samples were then 
determined by comparing the O.D. of the samples to the standard curves (figure 3.12). 
 
Figure 3.12:  Gentaur Immunoassay Standard Curves 
 
      
 
 
 
Figure 3.11: Gentaur Rat MMP-1 (A), TIMP-2 (B), TIMP-3 (C) and PAI-1 (D) ELISA standard curves were 
created using a Labsystems Genesis computer package which generated a four parameter logistic (4-
pl) curve fit. Absorbance was measured on Labsystems Multiskan Ascent plate reader at a wavelength 
of 450nm. Optical density (O.D.) of each sample was plotted on the y-axis against the MMP-1 (pg/ml) 
or TIMP-2, TIMP-3, PAI-1 (ng/ml) on the x-axis.  Data points are average of duplicates.  Error bars 
showing standard deviations are smaller than symbols. 
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3.4.4.2. Quantikine Enzyme-linked immunosorbent assay 
 
Total rat MMP-9 (Pro-, active, and TIMP-complexed MMP-9) and rat TIMP-1 in urine were 
measured by the Quantikine immunoassay (R&D Systems, UK). 
3.4.4.2.1. Reproducibility and specificity of assays in urine 
 
Four control samples and four SNx samples were spiked with either 1.25ng/ml of recombinant 
rat MMP-9 or 300pg/ml of recombinant rat TIMP-1. The recovery/accuracy percentage rates 
of rat MMP-9 ranged between 80-107% (table 3.4) and between 82-115% for TIMP-1.  No 
significant cross-reactivity or interference between MMP-9 and related molecules was 
observed.  In addition, no significant cross-reactivity or interference was observed between 
TIMP-1 and 50 to 500ng/ml of the following molecules: TIMP-2, TIMP-3, MMP-1, MMP-2 and 
MMP-9. However, rat recombinant TIMP-1 showed 0.015% cross-reactivity with TIMP-1 
complexed with active MMP-9 at a 1:10 molar ratio. 
 
Table 3.4:  Accuracy % of rat MMP-9 and TIMP-1 immunoassays 
 
 Control (n=4) SNx (n=4) 
 Recovery range  
(%) 
Average  
(%) 
Recovery range 
(%) 
Average  
(%) 
MMP-9 87-107 94 80-103 92 
TIMP-1 82-109 95 84-115 99 
 
3.4.4.2.2. Inter and Intra assay Coefficients of Variability 
 
Two samples of known rat MMP-9 (1ng/ml) and two samples containing a rat TIMP-1 
concentration (450pg/ml) were tested on two plates to assess inter- and intra-assay precision 
and the coefficient of variability was 3.9% and 5.6% for MMP-9 and 3.2% and 6.0% for TIMP-
1, respectively. 
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3.4.4.2.3. Materials 
 
The following reagents were used for measurement of MMP-9 and TIMP-1 in rat urine: 
 
Reagents MMP-9 TIMP-1 
Capture Antibody 
(pre-coated) 
Monoclonal mouse 
anti-rat MMP-9 
Monoclonal mouse 
anti-rat TIMP-1 
Detection 
Antibody 
12ml of a Polyclonal anti-
rat MMP-9 conjugated to 
horseradish peroxidase 
0.65ml of a 23-fold solution 
containing a Polyclonal anti-
rat TIMP-1 conjugated to 
horseradish peroxidase 
Standard 50ng of recombinant rat 
MMP-9 in a buffered 
protein base 
12ng of recombinant rat 
TIMP-1 in a buffered protein 
base 
Control 5ng of recombinant rat 
MMP-9 in a buffered 
protein base 
600pg of recombinant rat 
TIMP-1 in a buffered protein 
base 
Assay diluent 11ml of a buffered 
protein base with blue 
dye 
12.5ml of a buffered protein 
base 
Calibrator diluent 2 vials (21ml/vial) of a 
buffered protein base 
2 vials (21ml/vial) of a 
buffered protein base 
Wash Buffer 50ml of a 25-fold 
concentrated solution of 
buffered surfactant 
50ml of a 25-fold 
concentrated solution of 
buffered surfactant 
Color reagent A 12ml of stabilised 
hydrogen peroxide 
12.5ml of stabilised hydrogen 
peroxide 
Color reagent B 12ml of stabilised 
chromogen (TMB) 
12.5ml of stabilised 
chromogen (TMB) 
Stop solution 23ml of diluted 
hydrochloric acid 
23ml of diluted hydrochloric 
acid 
 
3.4.4.2.4. Reagents preparation 
 
 All reagents were brought to room temperature and freshly reconstituted before use 
 Rat MMP-9 control and rat TIMP-1 control were reconstituted with 1ml of distilled water  
 0.5ml of rat TIMP-1 conjugate (detection antibody) was diluted in 11ml of conjugate 
diluent in a sterile container and protected from light. 
 25ml of wash buffer concentrate was added to 600ml of distilled water 
 Substrate solution: color reagents A and B were mixed together in equal volumes 
within 15 minutes of use in a place protected from light. 
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 Rat MMP-9 standard was reconstituted with 5ml of calibrator diluents to produce a 
stock solution of 10ng/ml. The standard curve was prepared by a 2-fold dilution series: 
10ng/ml, 5ng/ml, 2.5ng/ml, 1.25ng/ml, 0.625ng/ml, 0.313ng/ml and 0.156ng/ml (figure 
3.13-A). 
 Rat TIMP-1 standard was reconstituted with 5ml of calibrator diluents to produce a 
stock solution of 2400pg/ml. The standard curve was prepared by a 2-fold dilution 
series: 2400ng/ml, 1200ng/ml, 600ng/ml, 300ng/ml, 150ng/ml, 75ng/ml and 37.5pg/ml 
(figure 3.13-B). 
3.4.4.2.5. Assay procedure 
 
50µL of Assay Diluent was added to each well of the microplate pre-coated with a mouse 
monoclonal antibody specific for either rat MMP-9 or rat TIMP-1.  50µL/well of standards, 
control, and samples (all in duplicates) was added to each well to bind with the immobilized 
capture antibody. Rat urine samples were diluted 1:1, 1:2, 1:5 and 1:10 in both assays using 
the calibrator diluent.  50µL of standards, control, and samples (all in duplicate) was added to 
each well to bind with the immobilized capture antibody.  The plate was then covered with an 
adhesive sealer and incubated at room temperature for 2 hours with gentle rocking (Stuart 
Digital Rocker SRT6, Geneflow, UK).  Each well was aspirated and washed for a total of 5 
washes with a buffer surfactant available in the kit.  Complete removal of the wash buffer was 
achieved by inversion and blotting of the plate against clean paper towels.  After washing away 
any unbound antibody-enzyme reagent, 100µL of an enzyme-linked polyclonal antibody 
specific for either rat MMP-9 or rat TIMP-1 conjugated to HRP, was added to each well.  The 
plate was covered with a new sealer and incubated at room temperature for 2 hours.  After 
incubation, the plate was aspirated and washed for 5 times. Following the washing, 100µL of 
Substrate solution (1:1 stabilised hydrogen peroxide and the chromogen TMB) was added to 
each well and incubated at room temperature for 30 minutes in a place protected from light. 
The enzyme reaction yields a blue product that turned yellow when 100µL of stop solution 
(hydrochloric acid) was added to each well.  The samples values were then read at 450nm 
using a Labsystems Multiskan Ascent spectrophotometer (Bio-Rad Laboratories, 
Hertfordshire, UK) using genesis light software. 
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Figure 3.13:  Quantikine Immunoassay Standard Curves 
 
 
           
 
 
 
 
          
 
 
Figure 3.13: Quantikine Rat MMP-9 (A) and TIMP-1 (B) ELISA standard curves were obtained using 
either recombinant rat MMP-9 or TIMP-1 and calculated using a Labsystems Genesis computer 
package using a four parameter logistic (4-pl) curve fit.  Absorbance was measured on Labsystems 
Multiskan Ascent plate reader at a wavelength of 450nm.  Optical density (O.D.) of each sample was 
plotted on the y-axis against the MMP-9 or TIMP-1 concentration (ng/ml) on the x-axis.  Data points 
are average of duplicates. Error bars showing standard deviations are smaller than symbols. 
 
3.4.5. Human Immunoassays 
 
Human urine samples were analysed for total (active and pro-) MMP-1, 2 and 9 as well as 
TIMP-1, TIMP-3, TIMP-3 and MMP-1/TIMP-1 complex by using the DuoSet immunoassay 
(R&D Systems, UK) as per manufacturer’s instructions. 
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3.4.5.1.1. Reproducibility and specificity of assays in human urine 
 
The accuracy of the total human MMP-1 Duoset to quantify MMP-1 in urine was measured in 
four spiked samples with 625ng/ml recombinant human MMP-1 (R&D Systems, UK).  The 
average percentage accuracy of MMP-1 ranged between 85-112%.  No cross-reactivity was 
observed between MMP-1 and 100ng/ml of the following molecules: MMP-2, MMP-3, MMP-
9, TIMP-1, TIMP-2 and TIMP-3. 
 
Four spiked samples with 2.5ng/ml recombinant human MMP-2 (R&D Systems, UK) were 
used to calculate the recovery percentage of the assay.  The average % recovery of MMP-2 
ranged between 84-106%.  No cross-reactivity was observed between MMP-2 and 200ng/ml 
of the following recombinant human molecules: MMP-1, MMP-3, MMP-9, TIMP-1, TIMP-2, 
TIMP-3 and TIMP-2 complexed with MMP-2. 
 
The recovery of MMP-9 spiked with 250pg/ml recombinant human MMP-9 (R&D Systems, 
UK) was evaluated in four samples.  The average % recovery of MMP-2 ranged between 74-
108%.  No cross-reactivity was observed between MMP-9 and 50ng/ml of the following 
recombinant human molecules: MMP-1, MMP-2, MMP-3, TIMP-1, TIMP-2 and TIMP-3. 
 
The recovery of each human TIMP-1, TIMP-2 and TIMP-3 was measured in four different 
spiked samples (125pg/ml of recombinant human TIMPs 1 and 2 and 250pg/ml of TIMP-3) 
(R&D Systems, UK). The average % recovery of TIMP-1 ranged between 87-113, of TIMP-2; 
89-108 and of TIMP-3; 81-102. No cross-reactivity was observed within any TIMPs or when 
assayed against MMP-1, MMP-2 and MMP-9 when prepared at 100ng/ml.  
 
Human Samples 
(n=4) 
Amount spiked Recovery range  
(%) 
Average  
(%) 
MMP-1 625ng/ml 85-112 99 
MMP-2 2.5ng/ml 84-106 97 
MMP-9 250pg/ml 74-108 94 
TIMP-1 125pg/ml 87-113 99 
TIMP-2 125pg/ml 89-108 98 
TIMP-3 250pg/ml 81-102 96 
MMP-1/TIMP-1 
complex 
125pg/ml 83-109 97 
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3.4.5.1.2. Inter and Intra assay Coefficients of Variability 
 
Four different samples of known concentrations of MMPs 1, 2 and 9, TIMPs 1, 2 and 3, and 
MMP-1/TIMP-1 complex were tested in duplicates on every run plate. The Inter- and Intra-
Coefficients of Variability are as follows: 
 
Human Samples 
(n=4) 
Inter assay 
CV (%) 
Intra assay 
CV (%) 
MMP-1 3.9 6.2 
MMP-2 5.4 9.8 
MMP-9 2.9 6.9 
TIMP-1 3.9 4.9 
TIMP-2 4.4 7.3 
TIMP-3 5.6 7.8 
MMP-1/TIMP-1 
complex 
3.9 6.1 
 
3.4.5.1.3. Materials 
 
The following reagents were used for measurement of human MMPs 1, 2, 9, TIMPs 1, 2, 3 
and the MMP-1/TIMP-1 complex in urine: 
 
Reagents MMP-1 MMP-2 MMP-9 
Capture 
 Antibody 
360µg/ml of a goat 
monoclonal  
 anti-human MMP-1 
360µg/ml of a 
monoclonal mouse  
anti-human MMP-2 
  180µg/ml of a  
monoclonal mouse  
anti-human TIMP-3 
Detection  
Antibody 
18µg/ml of 
biotinylated goat anti-
human MMP-1 
90µg/ml of 
biotinylated mouse 
anti-human MMP-2 
18µg/ml of 
biotinylated goat anti-
human TIMP-3 
Standard 180ng/ml of 
recombinant human 
MMP-1 
1920ng/ml of 
recombinant human 
MMP-2 
95ng/ml of 
recombinant human 
TIMP-3 
Wash Buffer 0.05% Tween 20 in 
PBS, ph 7.4 
0.05% Tween 20 in 
PBS, ph 7.4 
0.05% Tween 20 in 
PBS, ph 7.4 
Reagent 
Diluent 
1% BSA in PBS,  
ph 7.4 
1% BSA in PBS,  
ph 7.4 
1% BSA in PBS, 
ph 7.4 
Streptavidin-
HRP 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
Substrate 
Solution 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
Stop solution 2N H2SO4 2N H2SO4 2N H2SO4 
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Reagents TIMP-1 TIMP-2 TIMP-3 
Capture 
 Antibody 
360µg/ml of a 
monoclonal mouse 
 anti-human TIMP-2 
360µg/ml of a 
monoclonal mouse  
anti-human TIMP-2 
360µg/ml of a 
monoclonal mouse 
anti-human TIMP-3 
Detection  
Antibody 
9µg/ml of biotinylated 
goat anti-human 
TIMP-1 
9µg/ml of biotinylated 
goat anti-human 
TIMP-2 
360µg/ml of 
biotinylated mouse 
anti-human TIMP-3 
Standard 80ng/ml of 
recombinant human 
TIMP-1 
95ng/ml of 
recombinant human 
TIMP-2 
90ng/ml of  
recombinant human 
TIMP-3 
Wash Buffer 0.05% Tween 20 in 
PBS, ph 7.4 
0.05% Tween 20 in 
PBS, ph 7.4 
0.05% Tween 20 in 
PBS, ph 7.4 
Reagent 
Diluent 
1% BSA in PBS,  
ph 7.4 
1% BSA in PBS,  
ph 7.4 
1% BSA in PBS, 
ph 7.4 
Streptavidin-
HRP 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
1ml of Streptavidin 
conjugated to 
horseradish-
peroxidase 
Substrate 
Solution 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
1:1 mixture of H2O2  
and 
Tetramethylbenzidine 
Stop solution 2N H2SO4 2N H2SO4 2N H2SO4 
 
3.4.5.1.4. Reagents preparation 
 
 All reagents were brought to room temperature and freshly reconstituted before use 
 Human MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3 capture antibodies were 
reconstituted with 1ml of sterile PBS without carrier protein, pH 7.4, 0.2µm filtered.  
After reconstitution, 55ul aliquots were stored at -80°C.  The capture antibody was 
further diluted with PBS to a working concentration of 2.0µg/ml prior to coating the 96-
well microplates. 
 Human MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3 detection antibodies 
were reconstituted with 1ml of reagent diluent.  After reconstitution, 55ul aliquots were 
stored at -80°C.  MMP-1 detection antibodies were further diluted with reagent diluent 
to a working concentration of 100µg/ml, whilst MMP-2 was diluted to 500ng/ml, TIMP-
1 and TIMP-2 to 50µg/m and TIMP-3 to 2.0µg/ml. MMP-9 detection antibody was 
diluted to a working concentration of 100ng.ml in reagent diluent with 2% heat 
inactivated normal goat serum (NGS) prepared 1-2 hours prior to use. 
 180ng/ml of Recombinant Human MMP-1 was reconstituted with 0.5ml of deionized 
water to produce a stock solution of 360ng/ml.  Reconstituted standard were aliquoted 
and stored at -80OC for up to 6 months.  A seven point standard curve was prepared 
by a 2-fold serial dilution in reagent diluent: 10000pg/ml, 5000pg/ml, 2500pg/ml, 
1250pg/ml, 626pg/ml, 312pg/ml and 156pg/ml (figure 3.14-A). 
 1920ng/ml of Recombinant Human MMP-2 was reconstituted with 0.5ml of deionized 
water to produce a stock solution of 3840ng/ml.  Reconstituted standard were aliquoted 
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and stored at -80OC for up to 6 months.  A seven point standard curve was prepared 
by a 2-fold serial dilution in reagent diluent: 20ng/ml, 10ng/ml, 5ng/ml, 2.5ng/ml, 
1.25ng/ml, 0.625ng/ml and 0.312ng/ml (figure 3.14-B). 
 95ng/ml of Recombinant Human MMP-9 was reconstituted with 0.5ml of deionized 
water to produce a stock solution of 190ng/ml.  Reconstituted standard were aliquoted 
and stored at -80OC for up to 6 months.  A seven point standard curve was prepared 
by a 2-fold serial dilution in reagent diluent: 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml, 62.5pg/ml and 31.25pg/ml (figure 3.14-C). 
 80ng/ml of Recombinant Human TIMP-1 was reconstituted with 0.5ml of reagent 
diluent to produce a stock solution of 160ng/ml.  Reconstituted standard were aliquoted 
and stored at -80OC for up to 6 months.  A seven point standard curve was prepared 
by a 2-fold serial dilution in reagent diluent: 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml, 62.5pg/ml and 31.25pg/ml (figure 3.15-A). 
 95ng/ml of Recombinant Human TIMP-2 was reconstituted with 0.5ml of reagent 
diluent to produce a stock solution of 190ng/ml.  Reconstituted standard were aliquoted 
and stored at -80OC for up to 6 months.  A seven point standard curve was prepared 
by a 2-fold serial dilution in reagent diluent: 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml, 62.5pg/ml and 31.25pg/ml (figure 3.15-B). 
 90g/ml of Recombinant Human TIMP-3 was reconstituted with 0.5ml of reagent diluent 
to produce a stock solution of 180ng/ml.  Reconstituted standard were aliquoted and 
stored at -80OC for up to 6 months.  A seven point standard curve was prepared by a 
2-fold serial dilution in reagent diluent: 4000pg/ml, 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml and 62.5pg/ml (figure 3.15-C). 
 For the MMP-1/TIMP-1 complex assay, 288µg/ml of goat anti-human MMP-1 was used 
as the capture antibody.  This was reconstituted in 1ml of PBS.  The capture antibody 
was further diluted with PBS without carrier protein to a working concentration of 
1.6µg/ml prior to coating the 96-well microplates.  For the detection antibody, 18µg/ml 
of biotinylated goat anti-human TIMP-1 was used.  This was reconstituted in 1ml of 
reagent diluent (50mM Tris, 10Mm CaCl2, 0.15M NaCl, 0.05% Brij® 35, Ph 7.45).  After 
reconstitution, 55ul aliquots of both capture and detection antibodies, were stored at -
80°C for up to 6 months.  Then, the detection antibody was further diluted to a working 
concentration of 100ng/ml in reagent diluent prior to coating the 96-well microplates. 
 80ng/ml of Recombinant Human MMP-1/TIMP-1 complex was reconstituted with 0.5ml 
of reagent diluent (50mM Tris, 10Mm CaCl2, 0.15M NaCl, 0.05% Brij® 35, Ph 7.45) to 
produce a stock solution of 160ng/ml.  Reconstituted standard were aliquoted and 
stored at -80OC for up to 2 months.  A seven point standard curve was prepared by a 
2-fold serial dilution in reagent diluent: 4000pg/ml, 2000pg/ml, 1000pg/ml, 500pg/ml, 
250pg/ml, 125pg/ml and 62.5pg/ml (figure 3.16). 
 40µl of Streptavidin-HRP was diluted in 9600µl of reagent diluent for every microplate 
used. 
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  The substrate solution was prepared by mixing equal volumes of H2O2 and 
Tetramethylbenzidine (e.g. 4800µl of each reagent for each microplate used) within 15 
minutes of use in a place protected from light. 
3.4.5.1.5. Assay procedure 
 
100µL per well of the diluted Capture Antibody (MMP-1 (for MMP-1 and MMP-1/TIMP-1 
complex assays), MMP-2, MMP-9, TIMP-1, TIMP-2 or TIMP-3) was coated in 96 wells 
microplates (Costar 3590, Corning Incorporated, USA).  Plates were sealed (Greiner multiwall 
plate sealer, Sigma-Aldrich, UK) and incubated overnight at room temperature with gentle 
rocking (Stuart Digital Rocker SRT6, Geneflow, UK).  After this first incubation, wells were 
aspirated and the plate was washed three times with 0.05% Tween 20 in PBS, ph 7.4.  
Complete removal of wash buffer was obtained by inverting the plates and blotting against 
clean absorbent paper towels.  300ul per well of reagent diluent was used to block the plates 
for one hour at room temperature.  Plates were again aspirated and washed three times with 
wash buffer.  100ul of standards or samples were added per well.  All standards and samples 
tested were coated in duplicates.  Plates were covered with a new adhesive strip and 
incubated two hours at room temperature with gentle rocking.  Aspiration and wash of the 
wells were repeated.  100µl per well of the diluted Detection Antibody (MMP-1,MMP-2, MMP-
9, TIMP-1 (for TIMP-1 and MMP-1/TIMP-1 complex assays), TIMP-2 or TIMP-3) was added 
to each well, plate was covered with a new adhesive strip and incubate two hours at room 
temperature at the rocker.  The aspiration/washing process was repeated for three times and 
100µl of Streptavidin-HRP 1:250 diluted in reagent diluent added to each well.  Plates were 
incubated for 20 minutes at room temperature avoiding direct contact with light.  The 
aspiration/washing process was repeated for a final time.  Next, 100ul of Substrate Solution 
(1:1 mixture of H2O2 and TMB, R&D Systems, UK) was added to each well.  Plates were 
incubated for another 20 minutes at room temperature, avoiding direct light.  After colour 
development, 50ul of 2N H2SO4 (Analar Normarpur®, VWR International Ltd) was added to 
each well.  Optical density was determined at 450nm using a Labsystems Multiskan Ascent 
spectrophotometer (Bio-Rad Laboratories, Hertfordshire, UK) using genesis light software.  
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Figure 3.14:  Human Matrix Metalloproteinases Immunoassay Standard Curves 
 
 
 
 
Figure 3.14: Human total MMP-1 (A), MMP-2 (B) and MMP-9 (C) immunoassay standard curves were 
obtained using recombinant human MMPS and calculated using a Labsystems Genesis computer 
package with a four parameter logistic (4-pl) curve fit.  Absorbance was measured on Labsystems 
Multiskan Ascent plate reader at a wavelength of 450nm. Optical density (O.D.) of each sample was 
plotted on the y-axis against the MMP concentration (pg/ml) on the x-axis.  Data points are average 
of duplicates.  
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Figure 3.15: Human Tissue Inhibitors of Metalloproteinases Immunoassay Standard 
Curves 
 
 
 
 
 
 
Figure 3.15: Human TIMP-1 (A), TIMP-2 (B) and TIMP-3 (C) immunoassay standard curves were 
obtained using recombinant human TIMPS and calculated using a Labsystems Genesis computer 
package using a four parameter logistic (4-pl) curve fit.  Absorbance was measured on Labsystems 
Multiskan Ascent plate reader at a wavelength of 450nm. Optical density (O.D.) of each sample was 
plotted on the y-axis against the TIMP concentration (pg/ml) on the x-axis. Data points are average of 
duplicates.  
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Figure 3.16: Human MMP-1/TIMP1 complex Standard Curve 
 
 
 
Figure 3.16: Human MMP-1/TIMP-1 complex immunoassay standard curve was obtained using a 
Labsystems Genesis computer package using a four parameter logistic (4-pl) curve fit.  Absorbance 
was measured on Labsystems Multiskan Ascent plate reader at a wavelength of 450nm. Optical 
density (O.D.) of each sample was plotted on the y-axis against the MMP-1/TIMP-1 complex 
concentration (pg/ml) on the x-axis. Data points are average of duplicates.  
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3.5. Amino acid analysis by cation exchange chromatography 
 
The analysis of amino acids and diamino acids in urine samples was performed on a Biochrom 
30 Amino Acid Analyser physiological system (Biochrom, UK) after preparation of the samples. 
 
3.5.1. Sample preparation  
3.5.1.1. TCA / Acetone precipitation 
 
5 mls of urine was added to 15 ml of 10% TCA / Acetone solution and left overnight at -200C 
to precipitate the proteins in the solution.  The precipitate was pelleted at 7000xg for 10 mins 
at 40C using a Sigma 3-18K centrifuge (SciQuip Ltd, UK).  The TCA / Acetone was poured off. 
The pellet was then washed with 15 ml of cold acetone and pelleted again at 7000xg for 10 
mins at 40C.  The final pellet was resuspended in 100ul H2O and 1900ul 0.1M NH4CO3 at room 
temperature. 50ul was taken off for protein measurement using BCA assay. 
3.5.1.2. TCA precipitation  with  Ether extraction for ε (γ-glutamyl) lysine analysis 
 
5 mls of urine was added to 1ml of 50% Trichloroacetic acid (TCA) (Sigma-Aldrich, UK) to 
make up a final concentration of 10% (w/v) TCA to precipitate the proteins in the solution. 
Precipitation occurred overnight at -200C.  Samples were centrifuged at 7000xg for 10 mins at 
40C using a Sigma 3-18K centrifuge (SciQuip Ltd, UK).  TCA was poured off and 5 mls of 10% 
TCA was added to the pellet and homogenised to resuspend the pellet.  Samples were 
centrifuged again at 7000xg for 10 mins at 40C.  TCA was poured off 5 mls of 1:1 diethylether: 
ethanol (Analar Normarpur®, VWR International Ltd), added to the pellet and then pelleted 
again at 7000xg for 15 mins at 40C. This step was repeated three times.  The diethylether: 
ethanol was poured off and 5 mls of diethylether was added to each sample.  After 
homogenising, samples were centrifuged again at 7000xg for 10 mins at 40C thrice.  The final 
pellet was resuspended in 100ul H2O and 1900ul 0.1M Ammonium carbonate (NH4CO3) (VWR 
International Ltd) at room temperature.  50ul was taken off for protein measurement using the 
RC-DC assay. 
 
3.5.2. Proteolytic digestion for ε (γ-glutamyl) lysine measurement 
 
A volume containing 10mg of protein from urine precipitate (TCA precipitation followed by 
ether extraction and resuspended in NH4CO3, section 3.5.1.2.) had a crystal of thymol (Fisher 
Scientific, UK) added to prevent bacterial decay.  2mg of Subtilisin (Sigma Aldrich, UK) 
dissolved in 10ul NH4CO3 (VWR International Ltd) was added to each tube and then incubated 
at 320C for 12 hours with gentle shaking (Stuart Roller Mixer SRT9D, Geneflow, UK).  The 
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addition of 2mg Subtilisin was repeated twice at 10 hours intervals.  Samples were 
homogenised between each digest to ensure that there was no formation of particulate matter 
(Gallenkamp Spin Mix, Rigal Bennett, UK).  25ul of digest was removed for protein 
measurement (RC DC protein assay, section 3.2.2.1).  1.5 mg of Pronase E (Sigma Aldrich, 
UK) dissolved in 10ul NH4CO3 was added to each tube and then incubated at 320C for 12 
hours with gentle shaking.  Samples were incubated at 1000C for 15 minutes to inactivate 
Pronase E.  Leucine amino peptidase (LAP) (NBS Biologicals, UK) was activated by addition 
of 22.75U of it to 10ul 50Mm Magnesium chloride (Sigma-Aldrich, UK) and 90ul 10Mm Tris-
HCL pH 8 (Sigma-Aldrich, UK) per sample and subsequent incubation at 370C for 2 hours. 
The enzyme Prolidase (NBS Biologicals, UK) was activated by addition of 38.6U of it to 20ul 
50 Mm MgCL2, 80ul 10 Mm Tris-HCL pH 8 and 80ul distilled water per sample.  180ul of 
activated LAP and 150ul of activated prolidase were added at the same time to each sample 
and then incubated at 370C for 10 hours. The addition of 1.5mg of Pronase E (Sigma Aldrich, 
UK) dissolved in 10ul NH4CO3 per tube was then repeated with incubation at 320C for 12 hours 
with gentle shaking.  
 
The pH of the samples was measured using litmus paper (Full Range pH 1-14 test paper, 
Whatman®, UK) and then adjusted to 6.75-7.00 by the addition of a small volume of 1M HCL.  
0.2mg of Carboxypeptidase Y (Sigma Aldrich, UK) dissolved in 10ul NH4CO3 was added to 
each sample and incubated at 300C for 12 hours.  Samples were placed overnight in a 
desiccator, under vacuum (Laboport Vacuum Pump, KNF Neuberger, USA), containing one 
beaker of 0.5M NaOH and 1M H2SO4 to remove ammonium carbonate.  Then, samples were 
freeze dried for 18 hours and could be stored as this stage to await amino acid analysis.  
Samples were subsequently resuspended in 500ul 0.1M HCL and 500ul of Lithium citrate 
loading buffer (pH 2.2, 0.2M) (Biochrom, UK) and filtered (4mm PTFE, 0.2um pore size; 
Chromacol LTD - UK) into an appropriate chromatography vial (2.0ml Chromacol glass vial 
with PTFE screw-top sealer).   
 
3.5.3. Proteolytic hydrolysis for Hydroxyproline measurement  
 
10mg of protein from a urine precipitate (TCA / Acetone precipitation, resuspended in 100ul 
H2O and 1900ul 0.1M NH4CO3, section 3.2.1.2.) was hydrolysed in 2ml of 6M HCL in an 
incubator at 1100C for 18 hours.  After hydrolysis, samples were centrifuged at 15000xg for 
10 mins at 40C using a Sigma 3-18K centrifuge (SciQuip Ltd, UK).  The supernatant was 
transferred to a fresh 20ml universal tube, freeze dried for 18 hours, resuspended in 1ml 
Lithium citrate loading buffer (pH 2.2, 0.2M) (Biochrom, UK) and then filtered into a 
chromatography vial (4mm PTFE, 0.2um pore size; Chromacol LTD – UK). 
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3.5.4. Principles of the Biochrom 30 Amino Acid Analyser physiological 
system procedure 
 
3.5.4.1. Biochrom 30 equipment preparation 
 
To utilize the Biochrom 30 Amino Acid Analyser (AAA) physiological system (figure 3.17), 
previous set up of the Biochrom 30 instrument, the autosampler and the PC with the BioSys 
software are required. 
 
Figure 3.17: The Biochrom 30 Amino Acid Analyser physiological system 
 
 
Figure 3.17: The Biochrom 30 Amino Acid Analyser (AAA) physiological system consists of a Biochrom 
30 instrument (in the middle), where the analytical column is present, the Autosampler Unit (right) 
and a PC with the BioSys and Ezchrom Elite sofwares installed. 
 
Biochrom 30 instrument set up: 
The Biochrom 30 instrument requires a nitrogen supply with a pressure of 75-80 psi / 5-6 Bar.  
Also, 9 bottles containing different solutions should be connected and placed above the 
instrument: five lithium citrate buffers of varying pH and ionic strength and one with lithium 
hydroxide (regeneration buffer) (table 3.5), one containing Ultrapure water, one with the coil 
flush (50:50% methanol in ultrapure water) and one with the Ninhydrin reagent.  The Ninhydrin 
reagent is prepared by bubbling 1750ml of Ultrasolve solution (Biochrom, UK) with nitrogen 
gas for 10 minutes (stirring) and addition of 250ml of Ninhydrin reagent.  This solution should 
be stirred under nitrogen gas for a further 10 minutes. 
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Table 3.5: Ion exchange process 
 
 Buffer Molarity pH 
Buffer 1 Lithium A 0.20 2.80 
Buffer 2 Lithium B 0.30 3.00 
Buffer 3 Lithium CII 0.50 3.15 
Buffer 4 Lithium DII 0.90 3.50 
Buffer 5 Lithium pH 3.55 1.65 3.55 
Buffer 6 Lithium Hydroxide 0.30  
 
Table 3.5:  Five lithium citrate buffers of varying pH and ionic strength are pumped through a cation-
exchange analytical column to release diverse amino acids which after reaction with Ninhydrin will 
form compounds that can be read in the photometer unit at 570nm and 440nm. 
 
Autosampler: 
The autosampler unit (MIDAS, Biochrom, UK) requires to be cooled down to a temperature of 
40C prior to use.  After cooling the system, the equipment should be connected in serial mode 
with the Biochrom 30 and the PC, this will enable the AAA system to be controlled by the 
BioSys program.  Also, the injection needle of the autosampler should be programmed to be 
washed with a solution containing 20% Isopropanolol (Analar Normapur®, VWR International 
Ltd) in ultrapure water and a waste bottle should be connected. 
 
BioSys: 
The BioSys software controls the injection of the samples (volume and appropriated 
separation program) in the autosampler as well as all other functions performed by the 
Biochrom 30 including the volumes of the lithium buffers, separation methods and timings, 
volume, speed and temperature of the ninhydrin reagent.  The BioSys Manual operation 
window (figure 3.18) shows the flow rate and pressures of the lithium buffers (green) and 
ninhydrin (purple) as well as the temperature of the resin column, which should be above 500C 
for optimal performance.  All these functions are only possible to be performed when the 
reaction coil achieves a temperature above 1000C. 
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Figure 3.18: The BioSys Manual operation window 
 
 
 
Figure 3.18:  Injection of samples into the Autosampler is controlled by the BioSys software. Control 
parameters can be adjusted via this manual operation window. 
 
3.5.4.2. Loading of the samples  
 
To set up the instrument for running samples it is required to open the Program Control window 
(figure 3.19) from BioSys and create a list containing the samples required for the analyses to 
be performed. This will indicate the vial position in the autosampler as well as the volume used 
for injection in the system and the analytical separation program to be used. For ε (γ glutamyl) 
lysine and Hydroxyproline measurements, samples were fractionated using the 96361 LiHP 
control program using a partial fill loop. After each run, files will be saved in the Data directory 
and can be operated via a second software called EzChrom Elite. 
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Figure 3.19: The BioSys Program Control window 
 
 
Figure 3.19:  Running list is initiated by the regeneration program and contains the standard solution 
with aminoacids and re-suspended samples. 
3.5.4.3. Fractionation of amino acids  
 
After loading the samples in the autosampler, these are pumped to a cation-exchange column 
present in the Biochrom 30 AAA.  The positively charged amino acids present in the sample 
are bound to the analytical resin present in the cation-exchange column, which is negatively 
charged.  This resin consists of spherical beads of polystyrene which are crosslinked by the 
incorporation of divinylbenzene groups and are also sulphonated to give it a negative charge.  
The column is kept at a controlled high temperature (above 1000C), so that it can 
accommodate the influx of a series of Lithium Citrate buffer counter ions (Biochrom, UK) at 
increasing pH and concentrations (table 3.5) and allow ion exchange to take place between 
the positively charged groups in the Lithium buffers which are attached to the matrix by 
heteropolar bonds, and the amino acids which diffuse into it.  When the isoionic point of an 
amino acid is reached, the ionic attraction to the resin is lost and the amino acid elutes from 
the column.  
 
The eluent is then mixed with Ninhydrin (Biochrom, UK), a powerful oxidising reagent, in the 
reaction coil at 1350C to form coloured compounds through the Ruhemann`s purple reaction 
(figure 3.20-A).  The intensity of coloured compounds is directly proportional to the quantity of 
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amino acid present in the solution.  Those compounds are read in the spectrophotometer unit 
at two wavelengths, 570 nm and 440 nm.  α-amino groups will be better monitored at 570 nm 
and imino acids, such as proline and hydroxyproline, which do not have free α-amino groups 
are better monitored at 440 nm as their reaction with Ninhydrin will produce a bright yellow 
compound instead of purple (figure 3.20-B).  The concentration of amino acids is recorded as 
a series of peaks read at EZChrom Elite software (Biochrom, UK). The retention time of each 
peak identifies the aminoacid and the area under the peak indicates its concentration.  This 
separation into individual peaks is determined by the ionic charge difference in the eluted 
amino acids caused by different pK values of their side chains and also by the hydrophobic 
interactions of these side chains with the polystyrene matrix.  
 
Figure 3.20: Simplified reaction between Ninhydrin, amino acids and imino acids  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: A) Reaction between ninhydrin and amino acids leads to the oxidative deamination of the 
alpha-amino group, liberating ammonia, carbon dioxide, an aldehyde and hydridantin.  The reaction 
between ammonia and hydridantin yields a purple substance (Ruhemann’s purple) that absorbs 
maximally around 570nm. B) The imino acids Proline and Hydroxyproline do not have free alpha-
amino groups. Their reaction with ninhydrin forms a bright yellow compound monitored at 440nm. 
 
3.5.5. Calibration of the Amino Acid Analyser 
 
A physiological standard solution was prepared to calibrate the EZchrom Elite software by the 
addition of 100ul Basic amino acids (Sigma-Aldrich, UK) and 100ul Acidic and Neutral amino 
acids (Sigma-Aldrich, UK) to 300ul 0.2M Lithium Citrate loading buffer, pH 2.20 (Biochrom, 
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UK).  20ul of the standard solution was loaded using a partial fill loop onto the Biochrom 30 
AAA and fractionation was controlled using the EZChrom Elite 96361 LiHP BioSys control 
program (figure 3.21).  This solution contained a total of 56 amino acids and derivatives.  
However, ε (γ-glutamyl) lysine is not present in this composition.  So, 10nmols ε (γ Glutamyl) 
Lysine in 20ul of physiological standard solution was prepared using a commercial lyophilised 
crosslink (H-Glu (H-Lys-OH)-OH, 250mg – MW=275.31, Bachem AG, Switzerland). 
 
Following post column derivatization with Ninhydrin each amino acid elutes as an individual 
peak at specific retention times, with ε (γ Glutamyl) Lysine eluting between the amino acids 
Leucine and Tyrosine at approximately 77 minutes.  All amino acids present in this standard 
solution are at a concentration of 10nmols/20ul.  A typical chromatogram generated by a 
physiological standard solution spiked with 10nmols/20ul ε (γ Glutamyl) Lysine is shown on 
figure 3.22. Main amino acids, imino acids and peptides quantified by the amino acid analyser 
are listed on table 3.6. 
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Figure 3.21: EZChrom Elite 96361 LiHP BioSys program 
 
 
 
Figure 3.21:  The EZChrom Elite 96361 LiHP BioSys control program regulates the fractionation of 
samples into individual amino acids by using 5 different Lithium Buffers and the Ninhydrin reagent.  
Buffers are sent at different rates of infusion to the analytical column, which is kept at varies 
temperatures. 
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Table 3.6: Main Amino acid and peptides classification and retention times 
 
Amino Acid / Peptide Abbreviation Retention Time 
Phosphoserine Pser 4.2 
Taurine Taur 6.5 
Urea Ur 10.5 
L-aspartate Asp 21.3 
Hydroxyproline Hypro 24.9 
L-threonine Thr 27.6 
Serine Ser 29.8 
Asparagine Asn 34.2 
Glutamate Glu 36.5 
Proline Pro 47.0 
Glycine Gly 48.8 
Alanine Ala 50.4 
Valine Val 56.9 
Cysteine Cys 62.0 
Methionine Met 65.8 
Isoleucine Ileu 71.3 
Leucine Leu 75.7 
Glutamyl-Lysine Glu-Lys 77.0 
Tyrosine Tyr 79.4 
Phenylalanine Phe 81.9 
Homocysteine Homocyst 87.3 
Gamma-aminobutyric acid Gaba 89.5 
Ethanolamine Ethan 92.5 
Lysine Lys 105.7 
Histidine His 109.6 
Arginine Arg 124.2 
 
Table 3.6:  List of main amino acids and peptides detected by the AAA with their respective retention 
times. Adapted from “The Biochrom Handbook of amino acids” 
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3.5.6. Calculation of the results after calibration 
 
To analyse the data results, it is necessary to access the EzChrom Elite server and first 
graphically define each peak and determine their retention times in both channels: 570nm and 
440nm (figure 3.23).  As the amino acid analyser is a comparative instrument, a calibration 
analysis must be performed before commencing a series of analyses at every run, thus 
producing a standard trace for comparison purposes.  After this, the estimated concentration 
of each amino acid will be given and a report generated. 
 
At the end of each sample analysis, the column is regenerated by pumping a strong base 
through the column followed by low pH Lithium buffer, which equilibrates the column prior to 
the next analysis. 
 
Figure 3.23: Graphical definition of peaks 
 
 
 
Figure 3.23:  The full range of peaks generated by the end of the chromatography is graphically 
analysed for appropriated retention times. Then, the concentration of amino acids present in the 
samples can be estimated by reference to an amino acid solution used to calibrate the system in the 
beginning of every run. 
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3.5.7. Quantitative estimation of amino acids and di amino acids  
 
Following exhaustive proteolytic digestion for ε (γ-glutamyl) lysine crosslink iso-dipeptide 
(section 3.5.2.) or hydrolysis for Hydroxyproline measurement (section 3.5.3.), 20ul of re-
suspended sample containing a mixture of amino acids and di amino acids  was placed into 
the autosampler unit (MIDAS, Biochrom, UK) and run on the cation-exchange Biochrom 30 
Amino Acid Analyser (AAA) using a partial fill loop injection. 
3.5.7.1. ε (γ-glutamyl) lysine crosslink iso-dipeptide  
 
ε (γ-glutamyl) lysine crosslink peak ε (γ Glutamyl) Lysine clearly elutes as an individual peak 
between Leucine and Tyrosine using the 96361 LiHP program with a retention time of 
approximately 77 minutes.  Estimated concentration of ε (γ-glutamyl) lysine crosslink iso-
dipeptide in 20ul was calculated by reference to the 10nmols/20ul physiological standard 
solution (section 3.5.6.) taking reading of Ninhydrin derivatised peaks at 570nm (figure 3.22). 
3.5.7.2. Hydroxyproline 
 
Hydroxyproline peak elutes between the amino acids Aspartate and Threonine with a retention 
time of approximately 26 minutes.  Estimated concentration of Hydroxyproline in 20ul was 
calculated by reference to the 10nmols/20ul physiological standard solution (section 3.5.6.) 
taking reading of Ninhydrin derivatised peaks at 440nm (figure 3.22). 
 
 
 
 
 
 
 
 
 
 
 
127 
 
3.6. In vitro crosslinking of TG2 substrates  
 
250ug of Recombinant Human Tissue Transglutaminase (Zedira, UK) was reconstituted in 
250ul of Ultrapure H2O and 10ul Aliquots (1ug/ul) were stored at -80oC until required.  TG2 in 
each aliquot was activated by the addition of 200mM Ca2+ in 50mM Tris, pH 7.4 (Sigma-
Aldrich, UK) to a final Ca+2 concentration of 10mM and the addition of 100mM Dithiothreitol 
(DTT) (Sigma-Aldrich, UK) in 50mM Tris (pH 7.4) to a final concentration of 5mM (i.e. 0.5ul). 
A 1mg/ml solution of the following substrates was made in 5mM Tris pH 7.4 or ultrapure H20 
depending on the lyophilised material:  Albumin from Human Serum, Human Collagen Type I, 
Human Collagen Type III, Human Collagen Type IV, Human Collagen Type V, Fibronectin 
from Human Plasma (FN) and Human Dimethyl casein (DMC) (all from Sigma-Aldrich, UK). 
Collagens were heated to 37oC for 30 mins to aid solubilisation.  10ul of activated rhTG2 was 
added to 100ul of 1mg/ml solution of Collagen I, III, IV, V, Albumin, FN and DMC and incubated 
overnight at 370C.  Protein was precipitated by addition of TCA (Trichloroacetic acid) to a final 
volume of 10% (wlv); i.e., 22ul of 50% TCA to 100ul TG2 substrate solution. Then, the 
precipitated solution was centrifuged at 7000xg for 15 minutes at 40C using a Sigma 3-18K 
centrifuge (SciQuip Ltd, UK).  Each sample was resuspended in 10ul H20, 190ul 0.1M NH4C03 
at room temperature with the release of -glutamyl lysine di peptide in the potential TG2 
substrates undertaken by exhaustive proteolytic digestion following the protocol described in 
section 3.5.  Samples were re suspended in 200ul of 1:1 Solution of 0.1N (0.1M) HCI / Lithium 
Citrate Loading Buffer pH 2.2, 0.20M (Biochrom, UK).  Separation and quantification of ε (γ-
glutamyl) lysine was done by reverse phase HPLC (Biochrom 30 AAA).  40ul was loaded into 
the equipment using a partial fill loop.  Fractionation and identification of ε (γ-glutamyl) lysine 
peak was performed as described in section 3.5.7.1.  A schematic representation of the 
process involved in the detection of crosslink in TG2 substrates can be seen in figure 3.24. 
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Figure 3.24: Determination of crosslinking in Transglutaminase 2 substrates 
 
 
 
   
 
 
 
 
                                                                                                                                   
 
 
 
Figure 3.24: Schematic representation of the In vitro protocol for the measurement of ε (γ-glutamyl) 
lysine crosslinking in TG2 substrates. Briefly, this assay comprised: activation of Recombinant Human 
Transglutaminase 2, crosslinking of TG2 substrates, breakdown of TG2 substrates by exhaustive 
proteolytic digestion, samples freeze dry and separation and quantification of XL by reverse phase 
HPLC (Biochrom 30 Amino Acid Analyser).  
 
 
3.7. ECM proteolytic activity 
 
3.7.1. Rationale behind the MMP proteolytic activity assay 
 
Matrix Metalloproteinases are able to digest collagen, gelatin (denatured collagen) and most 
ECM components.  Each MMP can specifically digest a number of ECM molecules.  For 
example, MMP-2 (gelatinase A) is primarily responsible for the breakdown of the helical 
domains of type IV collagen, whilst MMP-1 is more specific against to type I collagen.  As 
MMPs can be found in latent forms and they have natural inhibitors (TIMPs) determining the 
true biological contribution of MMPs is difficult purely with antigen assays.  Therefore, in order 
to analyse the overall ECM proteolytic activity in human urine due to  MMPs, the Molecular 
Probes’ EnzChek® Gelatinase/Collagenase Assay system was used (Invitrogen Corporation, 
EvoQuest™ Laboratory Services, USA) to measure overall MMP enzyme activity.  The activity 
TG2 in activation buffer 
+ 
1mg/ml solution of 
substrates: 
Collagen I 
Collagen III 
Fibronectin 
DMC 
Albumin 
 
370
C 
Enzymatic 
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of interstitial collagenase type MMPs (MMP-1, 7 and 13) was measured using a collagen 1 
substrate, whereas the gelatinase type MMP activity (MMP-2, 9) was measured using a 
Collagen IV substrate.  Overall MMP activity was measured using a gelatin substrate. 
 
3.7.2. Principal of EnzChek® Gelatinase/Collagenase Assay 
 
The EnzChek Gelatinase/Collagenase Assay Kit provides a fast and highly sensitive 
fluorometric method for measuring gelatinase or collagenase activity.  In this assay, the 
substrate used is the fluorescein-labeled DQ™ gelatin or collagen conjugate, which are 
complete gelatin or collagen molecules (rather than peptides) that is highly labeled with 
fluorescein. The fluorescence signal is quenched by the protein itself until enzymatic digestion 
releases protein fragments containing the FITC which become highly fluorescent when 
released from the larger protein (figure 3.25). The Gelatin substrate is efficiently digested by 
all MMPs to yield highly fluorescent peptides.  The increase in fluorescence is proportional to 
the MMP proteolytic activity and can be monitored with a fluorescent microplate reader, 
minifluorometer or standard fluorometer.  Collagenase purified from Clostridium histolyticum 
can be used as a control enzyme to confirm proteolytic activity.  A metal chelator and general 
inhibitor of metalloproteinases, 1,10-phenanthroline, can be used as a control for effective 
inhibition of the collagenase activity. 
 
Figure 3.25: Mechanism of Action from EnzChek® Gelatinase/Collagenase Assay 
 
 
Figure 3.25:  Principle of MMP activity detection via the disruption of intramolecular self-quenching. 
Enzyme-catalysed hydrolysis of the heavily fluorescein-labelled and almost totally quenched DQ™ 
gelatin substrate provided in the EnzChek Protease Assay, releases cleavage products which are highly 
fluorescent and can be analysed in a standard fluorescent microplate reader. 
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3.7.3. Materials 
 
The following reagents were used for measurement of ECM proteolytic activity: 
 DQ gelatin fluorescein conjugates.  Gelatin was isolated from pig skin. Each vial 
containing 1mg of substrate lyophilized from 1ml of PBS, pH 7.2 
 10 X Reaction Buffer: 50ml of 0.5M Tris-HCL, 1.5M NaCl, 50Mm CaCl2, 2mM sodium 
azide, pH 7.6. 
 30mg of 1,10-Phenanthroline, monohydrate (MW=198.2) 
 500U of type IV Collagenase from Clostridium histolyticum.  One unit is defined as the 
amount of enzyme required to liberate 1µmole of L-leucine equivalents from collagen 
in 5 hours at 370C, Ph 7.5. 
 
3.7.4. Reagents preparation 
 
 1.0mg/ml stock solution of the DQ gelatin fluorescein conjugate was prepared by 
addition of 1.0ml of deionized water (dH2O) directly to the vial containing the lyophilized 
substrate.  After reconstitution the stock solution was aliquoted and stored at -80°C 
until use.  The solution was left for 5 minutes in an ultrasonic water bath with agitation 
and heat to 500C to facilitate dissolution prior to use. 
 1 X Reaction Buffer was prepared by dilution of 2ml of the 10 X Reaction Buffer in 18ml 
dH2O 
 1000U/ml of Clostridium histolyticum stock solution was prepared by dissolving the 
500U in 0.5ml dH2O.  After reconstitution, it was aliquoted and stored at -80°C until 
use. 
 9.9mg of 1,10-Phenanthroline was dissolved in 25µl ethanol. A 10mM working solution 
was prepared by adding 10µl of this solution to 2ml of 1 X Reaction Buffer. 
 
3.7.5. Assay procedure 
 
 
80µl per well of 1 X Reaction Buffer was added to half (48 wells) of a black polystyrene 96-
well microplate for fluorescence (Corning® NBS™ 96 well plates, Corning Incorporated, USA).  
In the other half of the plate (48 wells), 70µl per well of 1 X Reaction Buffer and 10ul per well 
of the inhibitor solution (1,10-Phenanthroline) was added.  The addition of this inhibitor enable 
the confirmation of the extent of the proteolytic activity due to the MMP action, as collagens 
and gelatins can be degraded to some degree by other proteases.  A seven point standard 
curve was prepared by a 2-fold serial dilution using the collagenase from Clostridium 
histolyticum.  The highest point was 0.2U/ml.   100µl of the diluted enzyme was added in 
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duplicates in both halves of the plate.  100ul of 1 X Reaction Buffer acted as a blank.  
100µl/well of undiluted human urine was added in duplicates to both halves of the plate.  Next, 
20µl of the 1.0mg/ml stock solution of DQ gelatin or collagen conjugate was added to each 
well immediately prior to reading in a multi-well fluorescent plate reader equipped with 
standard fluorescein filters (Fusion Plate Reader, Packard BioScience Company, USA) with 
Excitation/Emission at 485/530nm, respectively.  Samples were incubated for 48 hours at 
room temperature, protected from light.  As the reaction is continuous, fluorescence intensity 
was read at multiple time points (every 15 minutes for the first 3 hours, then every hour for the 
following 6 hours, then a final time 48 hours after the addition of the DQ gelatin). This ensured 
the best linear reaction possible for each sample. For each time point, background 
fluorescence was corrected by subtracting the values derived from the no-enzyme control. 
3.8. Statistical Analysis 
 
Nominal categorical data such as gender, postal address, smoking habit and CKD ethiology 
were expressed as a percentage of the total number of patients and graphically illustrated by 
either bar or pie charts. 
 
Discrete numerical data such as the number of patients with anaemia or any other co morbidity 
and continuous numerical data such as patient’s age, height, weight and all laboratorial results 
were expressed as mean ± standard error of the mean (mean ± SEM) or standard deviation 
(mean ± SD) as appropriate. They were displayed either by dot plots, Histograms or Box and 
Whisker plots. 
 
All generated laboratorial results were plotted to analysis of their shape of the distribution. 
Data which showed a bell shaped and symmetrical distribution with around 95% of the 
observations lying within two standard deviations (SD) was classified as having normal 
distribution, whilst other data results could be classified as skewed or ranked. The choice of 
statistical method of analysis was done according to the distribution pattern of the outcome 
data; parametric methods such as t-test, analysis of variance (ANOVA) and linear regression 
techniques were used to test normally distributed data.  Comparison between two ordinal 
independent groups was performed by using Mann-Whitney U test. 
 
The statistical significance of experimental CKD samples was assessed using either Mann-
Whitney U test, Independent samples t-test or a single factor analysis of variance (ANOVA) 
with Bonferroni post test as appropriate.   
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Analysis of Human samples results were performed using two- way ANOVA with Bonferroni 
post test.  Correlation analysis between variables was determined by performing Pearson’s 
correlation.  Multiple linear regression analysis was applied to determine the correlation and 
association among more than two parameters and also to select predominant impact factor.  
The null hypothesis (H0) was set as the negation of the research hypothesis and therefore, 
that there was no difference in the average values of the urine ECM biomarkers between 
controls or healthy volunteers and diseased animals or CKD patients.  The probability of 
obtaining results if the null hypothesis was true was defined as the p value. A p value >0.5 
was taken as statistically significant difference and a p value of < 0.001 confirmed that it was 
very unlikely to observe the data if H0 was true and thus there was a strong difference in the 
mean values (highly statistical significance difference).  Receiver Operating Characteristic 
(ROC) curve analysis was used for all biomarkers to evaluate accuracy in prediction of CKD 
progression.  ROC curve is a powerful instrument to measure the prognostic value of a 
molecule by determining the number of true positive cases (sensitivity) versus false positive 
cases (1-specificity). An area under the curve of 1 (or 100%) represents a perfect diagnostic 
test, whilst an area of 0.5 (50%) represents a worthless test.  Statistical analysis was 
performed using Microsoft Excel 2013 software package, Graphpad prism 6 (Graphpad 
software Inc, California, USA) or SPSS version 21 (IBM, New York, USA).  
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Chapter 4 
The urine excretion of Transglutaminase type 2 
and ε (γ glutamyl) lysine as biomarkers of renal 
fibrosis in animal models of Chronic Kidney 
Disease 
 
 
 
 
 
 
 
 
 
134 
 
4.1 Introduction 
 
Transglutaminase type 2 (tTG; TGase2; TG2) is a multifunctional enzyme associated with a 
wide range of biological processes including ECM stabilization (Johnson et al. 1997) , 
angiogenesis suppression (Jones et al. 2006), modulation of apoptosis (Fesus et al. 1987, 
Fesus et al. 1996, Oliverio et al. 1999), wound healing (Verderio et al. 2004), skin barrier 
formation (Harrison et al. 2007), TGFβ1 activation (Douthwaite et al. 1999, Huang et al. 2009) 
amongst a diversity of other cellular functions.  
 
Out of all these biological functions, one of the most well established function of TG2 is its 
ability to promote ECM stabilization.  TG2 catalyses the post-translational modification of ECM 
proteins by the formation of covalent bonds between epsilon-amino groups of peptide-bound 
lysine and the gamma-carboxamine group of glutamine residues (Folk and Finlayson 1977).  
This reaction is dependent of Ca2+ and can be inhibited by GTP (Achyuthan and Greenberg 
1987, Zhang et al. 1998).  Several ECM proteins such as collagens I, III, IV, fibronectin and 
dermatane sulphate proteoglycans can act as substrates for the formation of this highly stable 
ε (γ glutamyl) lysine crosslink (Aeschlimann and Thomazy 2000, Fisher et al. 2009, Verderio 
et al. 2009).  For this reason, TG2 intermolecular crosslinking of ECM proteins leads to 
resistance to degradation by MMPs and subsequent ECM accumulation (Fisher et al. 2009). 
 
Extensive studies have established that TG2 and its crosslink product play an important role 
in the development of kidney disease.  In the rat 5/6th subtotalnephrectomy model of renal 
scarring, Johnson et al demonstrated that increased matrix expansion and fibrosis was linked 
to elevated levels of TG2 and ε (γ glutamyl) lysine (Johnson et al. 1997).  In addition, 
transglutaminase inhibition proved to reduce the development of glomerulosclerosis and 
tubulointerstitial fibrosis by decreasing the depositing of collagens I and III indicating the 
importance of TG2 in the renal scarring process (Johnson et al. 2007).  
 
In the streptozotocin induced model of diabetic nephropathy, elevated levels of TG2 and its 
crosslink product were found in the peritubular interstitial space resulting in increased ECM 
deposition (Skill et al. 2001).  In the same model, treatment with a TG inhibitor was associated 
with decreased levels of ε (γ-glutamyl) lysine, hydroxyproline and fibronectin with consequent 
reduction on ECM accumulation (Skill et al. 2004).  In a further study using a different TG 
inhibitor it was shown a reduction of myofibroblasts, collagens I, III and IV, as well as 
decreased ECM deposition and improvement of kidney function (Huang et al. 2009). 
Numerous others publications have also demonstrated the role of TG2 as one of the mediators 
of scarring and fibrosis in human renal disease.  In human Diabetic Nephropathy, El Nahas et 
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al showed increased levels of TG2 and ε (γ-glutamyl) lysine in renal biopsies (El Nahas et al. 
2004).  In CKD patients, a strong correlation between tissue levels of TG2 and its crosslink 
product was associated with progressive renal scarring suggesting a role in the accumulation 
of renal matrix (Johnson et al. 2003).  
 
There is clearly a strong relationship between fibrosis progression in the kidney and kidney 
TG2 levels, but to date no research has investigated if these changes in renal ε (γ glutamyl) 
lysine and TG2 are reflected in the urine.  If this was possible, then this could be highly 
beneficial as it may provide a non-invasive biomarker of either the degree of fibrosis in the 
kidney or the rate at which the fibrotic program may be running.  We have therefore 
hypothesised that TG2 and ε (γ-glutamyl) lysine crosslink are found in the urine and could be 
used as specific and non-invasive diagnostic markers of kidney fibrosis. 
 
To test this hypothesis, this chapter aims to: 
1. Determine TG2 and -glutamyl) lysine levels in urines obtained from 3 
different animal models of CKD (SNx, DN and CAN model)  
2. Relate these to the development of disease in these models 
3. Determine if the changes in TG2 and -glutamyl) lysine have value as 
biomarkers of CKD progression that may be translated into clinical studies. 
  
For this study an in-house Sandwich ELISA was developed to detect TG2 levels in the urine.  
An anti TG2 goat polyclonal was used as capture Antibody and anti TG2 monoclonal CUB7402 
(both from AbCam, UK) as the detection antibody. For the urine excretion of ε (γ-glutamyl)-
lysine a technique was developed to measure this in urine protein by cation-exchange HPLC 
using an amino acid analyser (Biochrom 30, Biochrom, UK). 
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4.2. Transglutaminase type 2 measurement in urine from 5/6th 
subtotal nephrectomised rats  
 
4.2.1. Experimental animals 
 
For this study archival material was used from a previous rat SNX study using TG inhibitors 
(Johnson et al. 2007).  In brief, a total of 33 rats were subjected to SNx including 20 rats which 
were treated with 2 different irreversible pan TG inhibitors (NTU 281 and NTU 283).  Sham 
operated rats (SNc, n = 19) were used as controls.  Groups of rats were sacrificed at 7 (n=3-
4), 28 (n=3-4) and 84 (n=3-11) days post SNx.  Blood and urine samples were collected at all 
termination time points as well as recording of blood pressure.  Renal function was assessed 
by analysing these samples for total proteinuria, serum creatinine and creatinine clearance 
(table 10.1 and figure 10.1 in Appendix).  Kidney tissue was retrieved upon sacrifice & 
processed for histology and ECM protein immunohistochemistry 
 
Quantification of Masson’s Trichrome staining 
 
For estimation of kidney scarring, the amount of fibrotic tissue and the cellular content were 
assessed by Masson’s Trichrome as described in methods section 3.1.5.5.2. Degree of 
glomerulosclerosis was accomplished by Multiphase image analysis (figure 4.1). 
By 7 days after surgery, few changes were noticed in the tubulointerstitium and glomeruli of 
SNx kidney samples (figure 4.1-B).  Glomerulosclerosis and dilation in the tubules was 
observed at 1 month (figure 4.1-C).  By day 84, there was clear ECM deposition associated 
with tubular atrophy and flattening of the tubular epithelial cells.  At this time point, all SNx 
animals had developed significant glomerulosclerosis and advanced tubulointerstitial scarring 
(figure 4.1-D). 
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 Figure 4.1: Representative Masson’s Trichrome stained sections of the SNx model 
     
     
Figure 4.1: Multiphase image analysis of Masson’s Trichrome stained SNx kidneys: A – Control. B – 1 
week post SNx C – 1 month post SNx. D – 3 months post SNx (200X magnification). 
 
4.2.2. Measurement of Urine Transglutaminase type 2 using enzyme-linked 
immunosorbent assay (ELISA) 
 
To quantify the amount of TG2 present in urine, an in-house sandwich enzyme-linked 
immunosorbent assay (ELISA) was developed (see methods section 3.5.1 for full details). For 
this assay, commercially available antibodies were used.  A goat Polyclonal anti TG2 antibody 
was used to capture and CUB7402 (both from AbCam) as a detection antibody.  Rat 
recombinant TG2 was used to generate a standard curve (section 3.5.1).  Inter and intra Assay 
Coefficients of Variability were 1.2% and 3.9% respectively.  The limit of detection was 
31.25pg/ml.   
 
TG2 protein was readily detectable in rat urines.  Urine TG2 concentration was elevated by 
83% over control urines in the SNx group at 7 days, though this difference did not achieve 
statistical significance (figure 4.2-A).  By day 28, the urine concentration of TG2 was 9.3 fold 
higher in the SNx when compared to the time matched control group (p=0.0004) and reached 
C. 
  C. 
A. 
D. 
B. 
  C. 
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a peak by day 84, where its average concentration (522 ± 135ng/ml) was 38.5 fold higher 
(p=0.0045, 2 way ANOVA with Bonferroni post test). 
 
Rats that were treated with TG inhibitors showed no difference in mean urine TG2 
concentration to control animals at all time points.  However, by 28 days post surgery, TG 
inhibitor treatment saw levels of urine TG2 significantly reduced in both groups compared to 
SNx (p=0.0133 for NTU C7 and p=0.0436 for NTU C56).  By day 84, NTU C7 treated rats still 
had significantly lower levels of urine TG2 when compared to SNx (p=0.0437), but no statistical 
significance was found between NTU C56 treated animals and SNx (p=0.0589) (figure 4.2-A). 
 
4.2.3. 24 hour urine excretion of TG2 in the SNx Model  
 
To estimate total excretion of TG2 in 24 hours, its urine concentration was multiplied by the 
total volume of urine voided in 24 hours.  Findings were similar to the ones found when 
expressed as a concentration, with TG2 excretion significantly increasing with disease 
progression (figure 4.2-B). 
 
Interestingly, due to the high urine output in rats treated with TG inhibitors, there was no 
significant difference in estimated total TG2 excretion in 24 hours between these two groups 
and SNx animals at any time point (figure 4.2-B). 
 
4.2.4. Transglutaminase type 2/creatinine ratio in the SNx Model 
 
To address the problem of variability in the urine output, a correction for urine creatinine was 
applied. After correction, the urine TG2:creatine ratio was 7.6 fold higher in the SNx compared 
to the controls as early as 1 week, 42.1 fold higher by 1 month and 130 fold higher at 3 months 
after surgery (p<0.05 at all time points) (figure 4.2-C).  
 
Likewise, NTU C7 and NTU C56 treated animals also had TG2/creatinine measurements 
greater than controls. However, NTU C56 animals had significant lower levels of 
TG2/Creatinine than SNx at 28 days (p=0.0345).  By 84 days after SNx, both groups of animals 
had a reduced TG2 creatinine ratio with NTU C7 reduced by 83% (p=0.0340) and NTU C56 
by 81% (p=0.0376) (figure 4.2-C). 
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 Figure 4.2: TG2 measurement in urine post SNx 
 
  
 
Figure 4.2: TG2 excretion in SNx urine samples was measured by ELISA at 7, 28 and 84 days post 
Subtotal nephrectomy in animals treated with 2 different TG inhibitors (NTU C56 and NTU C7).  A - 
Urine TG2 concentration (mean ± SEM, pg/ml) in control, SNx and samples treated with two different 
pan TG inhibitors, B - 24 hr urine TG2 excretion ± SEM in the SNx model of CKD, C - TG2 / Creatinine 
ratio with y axis at log 2 scale. Statistical significance is shown by 2 Way ANOVA with Bonferroni post 
hoc test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between SNx and normal 
urine, a = p<0.05, b = p<0.01, c = p<0.001 between NTU C7 and SNx and 1 = p<0.05, 2 = p<0.01, 3 = 
p<0.001, between NTU C56 and SNx.   
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4.3. Transglutaminase type 2 measurement in urine from the 
streptozotocin induced model of diabetic nephropathy  
 
4.3.1. Experimental animals 
 
For this study an archived set of urines was used from a previously published diabetic study 
in the rat (Huang et al. 2009).  A total of 25 rats subjected to diabetic nephropathy (DN) 
induction and 10 sham operated rats (DC) were used (full method is given on section 3.1.3).  
After 7 days post surgery, hyperglycaemia was induced by infusion of 35 mg/kg streptozotocin 
(STZ) in 0.1 mol/L Sodium Citrate buffer (pH 4.0) by injection into the tail vein.  Two days after 
surgery, blood glucose was measured and a level above 15mM/L considered diabetic.  
Glycaemia was controlled between 20 and 25mmol/L by subcutaneous insulin implants to 
prevent animal wasting.  Control rats received 0.3ml of a 0.1mol/L sodium citrate (pH 4.0) 
solution.  Groups of rats were sacrificed at 1 (n=3-4), 4 (n=3-7) and 8 (n=3-5) months post 
STZ administration and creatinine clearance, total proteinuria, albuminuria and glycaemia 
were analysed at these time points (table 10.2 and figure 10.2 in Appendix). 
 
4.3.2. Urine Transglutaminase type 2 concentration in the UNx STZ model of 
DN  
 
Transglutaminase type 2 was measured in diabetic urines using the same in-house sandwich 
enzyme-linked immunosorbent assay described on section 4.1.2. 
 
Across all time points, the urinary concentration of TG2 on DN samples was significantly 
higher than controls (p=0.0006, p=0.0224, p=0.0335, figure 4.3-A).  Urine TG2 levels went up 
from 192 ± 28ng/ml at 1 month to 450 ± 142ng/ml at 4 months, reaching an average of 470 ± 
144ng/ml by 8 months.  This represented a respective 18, 32.11 and 38.76 fold increase when 
compared to controls.  Concentration in sham-operated rats ranged between 7 and 16ng/ml 
during the study. 
 
4.3.3. 24 h urine excretion of TG2 in the UNx STZ model of DN 
  
Total TG2 excretion in 24 hours was determined by adjustment to total volume of urine 
produced in 24 hours.  At 1 month, total TG2 excretion had a massive 151 fold increase when 
compared to controls (p=0.0328).  This impressive increment was maintained through the 
study time course, going up to 532 fold at 4 months (p=0.0099) and 551 fold by 8 months 
(p=0.0179) (figure 4.3-B). 
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 Figure 4.3: TG2 measurement in urine from the UNx STZ model of DN 
  
    
    
Figure 4.3: TG2 excretion in DN urine samples at 1, 4 and 8 months post UNx STZ induction shown as  
A - : Urine TG2 concentration in the UNx STZ model of DN, data represents mean TG2 in pg/ml ± SEM.  
B - 24 hr urine TG2 excretion ± SEM. C - TG2 / Creatinine ratio with y axis plotted as a log 2 scale. 
Statistical significance is shown by 2 Way ANOVA with Bonferroni post test: NS= not statistically 
significant * p<0.05, **p<0.01, ***p<0.001 between experimental groups and normal urine.  
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4.3.4. Transglutaminase type 2/creatinine ratio in the UNx STZ model of DN 
 
Urinary TG2 concentration was adjusted by creatinine as described on section 4.1.5. 
After correction, control samples displayed a TG2/creatinine ratio ranging from 0.32 to 
1.20ng/mmol over the full length of the study.  The TG2/Creatinine ratio steadily increased in 
DN animals throughout the time course showing 91.75, 265 and 443 fold increase at 1, 4 and 
8 months respectively (p=0.0345, p=0.0054, p=0.0181, 2 way ANOVA with Bonferroni post 
test) when compared to sham-operated controls (figure 4.3-C). 
4.4. Transglutaminase type 2 measurement in urine from the Fisher to 
Lewis transplant model of Chronic Allograft Nephropathy 
 
4.4.1. Experimental animals 
 
For this model of Chronic Allograft Nephropathy (CAN), male Fisher (F334, RT1v1) and male 
Lewis (Lew, RT1) rats, weighing 200-300g were used (Shrestha et al. 2014). Donor kidneys 
obtained from Lewis (L-L isograft, n =12) or Fisher (F-L allograft, n=12) rats were transplanted 
into Lewis rats.  Twelve rats did not survive the transplant.  A full description of the procedure 
is given in section 3.1.4.  The surviving isografts (n=5) and allografts (n=7) were longitudinally 
studied at 2, 8, 17, 24, 33 and 52 weeks post transplantation. Biochemical measurements 
(serum and urine creatinine, creatinine clearance, proteinuria) were analysed at all these time 
points (table 10.3 in Appendix) and histopathology at the time of termination at 52 weeks 
(figure 4.4). 
 
Quantification of Masson’s Trichrome staining 
 
Representative examples from sections of light microscopy are shown in figure 4.4. Renal 
scarring was estimated at 52 weeks by Masson’s Trichrome staining (section 3.1.5.5.2).  
Terminal kidney tissue from the F-L allograft showed the development of glomerulosclerosis 
(b), obliterative arteriopathy and tubulointerstitial fibrosis with a marked increase in 
extracellular matrix protein (d) whereas the L-L isograft showed normal glomeruli with thin 
GBM (a), intact arterioles within the glomerular capillary and unexpanded mesangium (c). 
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 Figure 4.4:  Representative micrographs of the Fisher to Lewis transplant model of CAN 
at 52 weeks  
 
Figure 4.4: Representative photomicrophraphs of Masson’s Trichrome stained kidney tissue. (A)  
Normal glomeruli and (C) tubulointerstitium from L-L isograft kidney, (B)  glomerulosclerosis and (D) 
tubular atrophy (         ) and interstitial fibrosis  (         )   from F-L allograft kidney. From Mr Badri 
Shrestha 
 
 
4.4.2. Urine Transglutaminase type 2 concentration in the Fisher to Lewis 
transplant model of CAN 
 
Urine TG2 excretion was markedly increased in the Fisher-to-Lewis transplanted animals from 
early after surgery (figure 4.5-A).  At 2 weeks, L-L isografts had an average urine TG2 
concentration of 12 ± 1ng/ml compared to 22 ± 1.9ng/ml of F-L allografts (p=0.0043). 
 
By 17 weeks, F-L allografts had over a 5 fold increase in urine TG2 concentration in 
comparison to L-L allografts (p=0.0381).  Maximum levels of TG2 in the urine were observed 
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6 months after transplantation (5.2 fold increase, p=0.0095).  At termination, F-L allografts had 
an average urinary TG2 concentration of 45 ± 8ng/ml whilst L-L isografts kept their baseline 
concentration at 11 ± 0.3ng/ml (p=0.0189). 
 
4.4.3. 24 h urine excretion of TG2 in the Fisher to Lewis transplant model of CAN 
 
Twenty-four hour TG2 excretion was 119% higher on F-L allografts compared to L-L isografts 
at 2 weeks after the transplantation (p=0.0198, figure 4.5-B).  Levels peaked by 6 months, 
with a total TG2 excretion 6.5 fold higher on allograft transplanted rats (p=0.0366) and were 
kept elevated until the end of the study (11.8 fold, p=0.0231). 
 
4.4.4. Transglutaminase type 2/creatinine ratio in the Fisher to Lewis 
transplant model of CAN 
 
The TG2/creatinine ratio was determined as reported in section 4.1.5. 
 
Rats that received an allotransplantation had a significantly higher TG2/creatinine ratio 
through the whole study (figure 4.5-C).  Average TG2/creatinine ratio were respectively 7.9 ± 
1.7ng/mmol, 10.9 ± 3.5ng/mmol, 10.1 ± 0.2ng/mmol, 16.9 ± 4.5ng/mmol, 13.8 ± 4.9ng/mmol 
and 15.1 ± 4.5ng/mmol at 2, 8, 17, 24, 33 and 52 weeks after transplant (p<0.05 at all time 
points).  L-L isografts presented a TG2/creatinine ratio varying between 2.7 ± 0.4ng/mmol in 
the beginning of the study and 1.1 ± 0.1ng/nmol at termination. 
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 Figure 4.5: TG2 measurement in urine from the Fisher to Lewis model of CAN 
  
    
    
Figure 4.5: A - Urine TG2 concentration in the Fisher to Lewis transplant model of CAN over 12 months 
quantified by an in-house sandwich enzyme-linked immunosorbent assay. Data represents mean TG2 
in pg/ml ± SEM.  B - 24 hr urine TG2 excretion ± SEM,  C - Average TG2 / Creatinine ratio in F -L allografts 
and L-L isografts.  Statistical significance was shown by 2 Way ANOVA with Bonferroni post hoc test: 
NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between F -L allografts and L-L 
isografts.   
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4.5. Correlation between urine Transglutaminase type 2 and clinical 
markers of renal function and damage 
 
4.5.1. 24h proteinuria 
 
In the 5/6th subtotalnephrectomy model of renal scarring, correlation between 24 hour urine 
TG2 excretion and 24 hour proteinuria showed a strong positive association (Pearson’s 
r=0.8227, 95% Confidence interval (CI): 0.6335 to 0.9191, p<0.0001) (figure 4.6-A). 
 
TG2 excretion was also correlated with proteinuria in the UNx STZ model of DN (n=25, 
Pearson’s r = 0.5967, 95% CI: 0.2637 to 0.8027 p=0.0016, figure 4.6-B).  
 
A similar correlation was also found in the Fisher to Lewis model of CAN (n=56, Pearson’s r = 
0.5739, 95% CI: 0.3662 to 0.7271, p<0.0001, figure 4.6-C).  
 
4.5.2. Creatinine clearance (CrCl) 
 
To determine whether the urine excretion of TG2 was associated with changes in kidney 
function, a correlation of TG2 urine concentration with creatinine clearance was performed.  In 
the SNx model, there was a negative association (Pearson’s r=-0.4533, 95% CI: -0.7243 to -
0.0609 p=0.0261) with CrCl, indicating that the higher the TG2 excretion the lower the 
creatinine clearance (figure 4.6-D). The same inverse correlation was found on CAN samples 
Pearson’s r = -0.4128, 95% CI: -0.6080 to -0.1705, p=0.0014, figure 4.6-F). 
 
Surprisingly, there was a positive correlation between TG2 excretion and creatinine clearance 
in diabetic samples (Pearson’s r=0.4829, 95% CI: 0.1083 to 0.7374.  p=0.0145, figure 4.6-E). 
 
4.5.3. Renal scarring levels 
 
SNx samples (n=18) were used to quantify kidney scarring. The presence of interstitial fibrosis 
and glomerulosclerosis was assessed by Masson’s Trichrome staining as described in section 
3.1.5.5.2.  A positive association between scarring and elevated levels of 24 hour TG2 in SNx 
rat urines was seen (Pearson’s r = 0.6573, 95% CI: 0.2746 to 0.8602, p=0.0030, figure 4.7-
A). 
 
DN samples (n=25) did not present a correlation between 24 hour urine TG2 and renal scarring 
(Pearson’s r = 0.1060, 95% CI: -0.3018 to 0.4811, p=0.6139, figure 4.7-B). 
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 Figure 4.6: Correlation plots of urine TG2 excretion with markers of kidney function and 
damage in experimental models of renal scarring 
 
 
     
  
         
 
       
 
Figure 4.6:  Pearson’s correlations were performed for 24 hour urine TG2 excretion vs. 24 hour 
proteinuria in SNx (A), DN (B) and CAN (C) and then for 24 hour urine TG2 excretion vs. creatinine 
clearance in SNx (D) -, DN (E) and CAN (F) Statistical significance was shown by 2 Way ANOVA with 
Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001. n=25 in SNx 
and DN and n=56 in CAN. 
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 Figure 4.7: Correlation plots of 24 hr TG2 excretion with scarring index  
  
 
 
 
 
 
 
 
Figure 4.7:  Association between 24h TG2 excretion and Scarring Index in (A) 18 SNx, Pearson’s r = 
0.6573, 95% CI: 0.2746 to 0.8602, p=0.0030 and in (B) 25 DN, Pearson’s r = 0.1060, 95% CI: -0.3018 to 
0.4811, p=0.6139. 
 
 
 
 
 
Correlation between urinary excretion of TG2 and
 Scarring Index - SNx samples
0.000 0.002 0.004 0.006 0.008
0
5000
10000
15000
20000
Scarring Index (green/red)
2
4
h
 u
ri
n
e
 e
x
c
re
ti
o
n
 o
f 
T
G
2
 -
 n
g
/2
4
h
Correlation between urinary excretion of TG2 and
 Scarring Index - DN samples
0 1 2 3 4
0
20000
40000
60000
80000
Scarring Index (green/red)
2
4
h
 u
ri
n
e
 e
x
c
re
ti
o
n
 o
f 
T
G
2
 -
 n
g
/2
4
h
A. SNx – TG2 vs. Scarring Index 
B. DN – TG2 vs. Scarring Index 
r2=0.4320 
r2=0.1060 
149 
 
 
4.6. ε (γ-glutamyl) lysine analysis in urine by cation exchange 
chromatography  
 
4.6.1. Optimisation of chromatography 
 
To determine clean fractionation of peaks into individual amino acids by the AAA and to 
determine retention time of each amino acid and di amino acid, 20ul of a standard solution 
was loaded using a partial fill loop onto the Biochrom 30 AAA.  Fractionation was controlled 
using the 96361 LiHP program (figure 4.8). 
 
Figure 4.8: Physiological standard solution derivatised peaks 
 
Figure 4.8: Calibration of the Amino Acid Analyser using a physiological standard solution. 
Fractionation was controlled using the 96361 LiHP program.  Amino acids concentrations were 
measured at two different wavelengths: 440nm (red trace) and 570nm (blue trace).  Each peak 
represents 20nmols of each amino acid in a 10ul load volume. 
 
To establish the correct retention time for ε (γ Glutamyl) Lysine peak, a 20nmols/10 ul solution 
of ε (γ Glutamyl) Lysine was prepared using a commercial lyophilised crosslink (H-Glu (H-Lys-
OH)-OH, 250mg – MW=275.31, Bachem AG, Switzerland). 20ul was loaded using a partial fill 
loop onto the Biochrom 30 AAA. A retention time of approximately 77 minutes was seen (figure 
4.9). 
150 
 
 Figure 4.9: Determination of ε (γ glutamyl) lysine retention time 
 
 
 
Figure 4.9:  ε (γ glutamyl) Lysine solution (20nmols/10ul) was loaded onto the AAA and its retention 
time determined at around 77 minutes, trace at 570nm. 
 
 
The physiological standard solution was then spiked with 10nmols / 10ul ε (γ Glutamyl) Lysine 
solution to check the ε (γ Glutamyl) Lysine peak could be distinguished from other amino acids. 
20ul was loaded using a partial fill loop onto the Biochrom 30 AAA, at both 440nm and 570nm 
(figure 4.10).  Adjustments to programming were done by increasing the loading time of buffer 
3 in 2 minutes and also by raising the temperature settings in 10C.  ε (γ Glutamyl) Lysine 
clearly eluted as an individual peak between Leucine and tyrosine using Biochrom standard 
96361 LiHP program. 
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 Figure 4.10: Clean fractionation of -glutamyl) lysine di peptide from other amino acids 
on a Biochrom 30 analyser 
  
 
 
 
 
Figure 4.10: Physiological standard solution was spiked with 10nmols/10ul ε (γ Glutamyl) Lysine and 
fractionated using the Biochrom standard 96361 LiHP program (A) The ε (γ Glutamyl) Lysine peak 
eluting at 77 minutes on the 440nm trace. The same peak at a higher resolution (B) - The same ε (γ 
Glutamyl) Lysine peak produced a bigger peak at 570nm (C).  
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4.6.2. Validation of ε (γ Glutamyl) Lysine measurement in urines 
 
To confirm and validate the identification and measurement of ε (γ-glutamyl) lysine in urine, 2 
proteolytic digested urine samples were spiked with 5nmols / 10ul of commercial ε (γ-glutamyl) 
lysine and 20ul was loaded onto the Biochrom 30 AAA and fractionated with the 96361 LiHP 
control program (figure 4.9).  Overlay of urine spiked with ε (γ-glutamyl) lysine (green) with un 
spiked urine (blue) shows that the spiked ε (γ-glutamyl) lysine peak detected in figure 4.11 
elutes at the same time point as the ε (γ-glutamyl) lysine in un spiked urine as the same peak 
is amplified. This confirms successful detection of ε (γ-glutamyl) lysine in urine. 
 
 Figure 4.11: Establishing accurate detention of ε (γ Glutamyl) Lysine in urines  
 
                                                                                                                                       
 
Figure 4.11: ε (γ-glutamyl) lysine (white arrow) was detected in a proteolytic digested urine sample 
(A). The same sample was spiked with 5nmols / 10ul ε (γ-glutamyl) lysine and re run (B).   The overlay 
of traces confirmed co elution with non-spiked urine shown in blue with the addition of ε (γ-glutamyl) 
lysine shown in green (C).   
 
B. A. 
C. 
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4.6.3. Determination of ε (γ glutamyl) lysine detection, sensitivity and range 
on a Biochrom 30 amino acid analyser  
 
Following optimisation of ε (γ glutamyl) lysine detection, a multilevel calibration of the AAA 
system was performed by measuring ε (γ glutamyl) lysine levels in physiological standard 
solutions spiked with 0.25, 0.5, 1, 2, 5, 10 and 15nmols/20ul solution of this dipeptide (figures 
4.12 and 4.13). 
 
Multiple samples containing known concentrations of ε (γ glutamyl) lysine were used to 
produce a standard curve (figure 4.12).  Area under the curve (plotted on Y axis) was 
calculated and used to estimate concentrations (X axis).  The curve started to saturate at 
10nmols/20ul solution, therefore this was the chosen as the upper concentration for ε (γ 
glutamyl) lysine detection.  Minimum detection level was 500 mols/20ul. 
 
 
Figure 4.12:  ε (γ glutamyl) lysine standard curve 
 
 
Figure 4.12: To determine the ε (γ glutamyl) lysine detection range on the Biochrom 30, an ε (γ 
glutamyl) lysine standard curve was generated by spiking buffer with commercial H-Glu(H-Lys-OH)-OH 
from Bachem at 0.25, 0.5, 1, 2, 5, 10 and 15nmols/20ul and then determining the AUC from the traces 
shown in Figure 4.16.  
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 Figure 4.13: ε (γ glutamyl) lysine multilevel calibration 
 
    
    
  
Figure 4.13: The range of ε (γ glutamyl) lysine quantitative detection was determined by using a 
physiological standard solution spiked with 0.25, 0.5, 1, 2, 5, 10 and 15nmols/20ul of ε (γ glutamyl) 
lysine.   ε (γ Glutamyl) Lysine peaks eluted at 77 minutes on 570nm.  
0nmol/20ul 0.25nmol/20ul 0.5nmol/20ul 1nmol/20ul 
2nmol/20ul 5nmol/20ul 10nmol/20ul 15nmol/20ul 
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4.7. ε (γ glutamyl) lysine measurement in urine from 5/6th subtotal 
nephrectomised rats  
 
4.7.1. ε (γ glutamyl) lysine levels per mg of urine protein  
 
Having established and validated ε (γ-glutamyl) lysine measurement in urine, this was then 
applied to the same urine samples from an archived SNx model of CKD used in section 4.1.1. 
 
Successful fractionation of amino acids from proteins collected from both normal and SNx 
urine was achieved.  The ε (γ-glutamyl) lysine peak (77 mins) was visibly larger in late SNx 
urines compared to controls (figures 4.14 and 4.15) being clearly discernible by the software 
in samples 1 month post SNx and beyond.  
 
Average concentration of ε γ-glutamyl) lysine in normal urine was stable at 1.63 ± 0.17nmol/mg 
protein.  Post SNx urine levels were unchanged at 1 week averaging 1.74 ± 0.44nmol/mg 
protein (p=0.7232), but increased over 84 days reaching 3.69 ± 0.60nmol/mg (p=0.005).  The 
TG inhibitor treated urines had lower levels of urine XL as would have been predicted from 
the use of TG inhibitors, reaching only 2.52 ± 0.23nmol/mg protein and 2.37 ± 0.41nmol/mg 
protein levels for C7 and C56 respectively (figure 4.16-A).  Despite this reduction, there was 
no statistical difference between SNx and SNx animals treated with TG inhibitor at all time 
points.  
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 Figure 4.14: Overall amino acid excretion in the SNx Model 
 
 
 
 
  
Figure 4.14:  SNx urines were exhaustively digested as in section 3.6, freeze dried and reconstituted 
in 200ul of lithium loading buffer.   20ul was then loaded onto a Biochrom 30, fractionating using 
program 96361 LiHP.  Full amino acids traces with Glu-Lys peak (white arrow) situated between 
Leucine and Tyrosine peaks in Control samples (A), 1 week (B), 1 month (C) and 3 months (D) post SNx. 
 
A. Control 
B. 1 week SNx 
C. 1 month SNx 
D. 3 months SNx 
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 Figure 4.15: Urine ε (γ Glutamyl) Lysine excretion in the SNx Model 
 
         
 
Figure 4.15: ε (γ Glutamyl) Lysine was measured in SNx urines by precipitating 2mg of protein from a 
24 hour urine collection, exhaustively digesting this as in section 3.6, freeze drying and reconstituting 
in 200ul of lithium loading buffer.   20ul was then loaded onto a Biochrom 30, fractionating using 
program 96361 LiHP and the peak concentration calculated by the area under the curve.  Control 
samples (SNc) showed a barely discernible Glu-Lys peak (white arrow) situated between Leucine and 
Tyrosine peaks (A). Glu-Lys peak at 1 week (B), 1 month (C) and 3 months (D) post SNx. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Control B. 1 week SNx C. 1 month SNx D. 3 months SNx 
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4.7.2. 24 hour urine excretion of ε (γ-glutamyl) lysine in the SNx Model  
 
Twenty four hour ε (γ glutamyl) lysine excretion was estimated by adjustment of concentration 
with 24 hour urine volume to generate 24 hour ε (γ glutamyl) lysine measurements. 
 
Urine excretion of ε (γ glutamyl) lysine in 24 hours was 2 fold higher in the SNx compared to 
the controls as early as 1 week, 2.4 fold by 1 month and 7 fold higher at 3 months, however 
this increase achieved statistical significance only at the latest time point (p<0.001) (figure 
4.16-B).  Both groups of TG inhibitor treated animals did not show statistical difference in 24 
hours ε (γ glutamyl) lysine measurements to either controls or SNx by 7 and 28 days, but were 
significantly reduced when compared to untreated SNx by 84 days post SNx (p=0.0053 for 
NTU C7 and p=0.0031 for NTU C56). 
 
4.7.3. ε (γ-glutamyl) lysine/creatinine ratio in the SNx Model 
 
ε (γ glutamyl) lysine measurements were corrected by urine creatinine in order to better reflect 
24 hour excretion.  After correction, urine levels of ε (γ glutamyl) lysine were significantly 
increased at all time points post SNx (figure 4.16-C). 
 
Seven days post SNx, ε (γ glutamyl) lysine/Creatinine ratio was significantly increased in the 
SNx group (0.4718 ± 0.011mg/ml) compared to controls (0.1078 ± 0.032mg/ml, p=0.0005) and 
this increase remained unchanged over the duration of the study with a 4.5 fold increase at 1 
month (p=0.0002) and 15.2 at 3 months (p<0.0001).  Rats treated with TG inhibitors showed 
a significant reduction in urinary ε (γ glutamyl) lysine excretion when compared to SNx rats at 
all time points following surgery (1 week: NTU C7, p=0.0310, NTU C56,  p=0.0060, 1 month:  
NTU C7, p=0.0084, NTU C56, p=0.0011 and 3 months:  NTU C7,  p<0.001, NTU C56, 
p=0.0003).    
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 Figure 4.16: ε (γ glutamyl) lysine measurement in urine post SNx 
 
  
 
   
        
Figure 4.16: ε (γ glutamyl) lysine was measured in SNx urine samples at 7, 28 and 84 days post Subtotal 
nephrectomy as in figure 4.18 and displayed as concentration with mean ε (γ Glutamyl) Lysine given 
per mg urine protein ± SEM (A). 24 hr urine ε (γ Glutamyl) Lysine ± SEM calculated by adjustment to 
24h urine protein and volume (B). The ε (γ glutamyl) lysine / Creatinine ratio was subsequently 
calculated.  Statistical significance was calculated by 2 Way ANOVA with a Bonferroni post hoc test.   
NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001 between SNx and normal urine, a = 
p<0.05, b = p<0.01, c = p<0.001 between NTU C7 and SNx and 1 = p<0.05, 2 = p<0.01, 3 = p<0.001, 
between NTU C56 and SNx.   
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4.8. ε (γ glutamyl) lysine measurement in urine from the streptozotocin 
induced model of diabetic nephropathy  
 
 4.8.1 ε (γ glutamyl) lysine levels per mg protein 
  
After establishing ε (γ-glutamyl) lysine measurement in SNx urines, 1, 4 and 8 months DN 
urines were used to assess ε (γ-glutamyl) lysine in the same way (figure 4.17).  There was no 
significant change in ε (γ-glutamyl) lysine concentration between normal and disease animals 
when expressed per mg of urine protein (figure 4.18-A).  Sham operated rats had XL levels 
ranging from 0.66 to 1.33nmol/mg protein.  At 1 month, DN rats had an average XL 
concentration of 0.94 ± 0.16nmol/mg protein (n=3, p=0.4357).  Interestingly, there was a peak 
of XL excretion by 4 months (n=7, x̄=3.35 ± 1.41nmol/mg protein).  However, in spite of this 
elevated level, it failed to achieve significance (p=0.1601).  At 8 months, XL excretion had 
fallen at 0.82 ± 0.11nmol/mg protein (n=5, p=0.3631). 
 
Figure 4.17: Urine ε (γ Glutamyl) Lysine excretion in the UNx STZ model of DN 
 
       
 
Figure 4.17: ε (γ Glutamyl) Lysine was measured in DN urines by precipitating 2mg of protein from a 
24 hour urine collection, exhaustively digesting this as in section 3.6, freeze drying and reconstituting 
in 200ul of lithium loading buffer.   20ul was then loaded onto a Biochrom 30, fractionating using 
program 96361 LiHP and the peak concentration calculated by the area under the curve.  A – Control 
sample (DC) showing the Glu-Lys peak (white arrow) situated between Leucine and Tyrosine peaks. 
Glu-Lys peak at 1 month (B), 4 months (C) and 8 months (D) after UNx STZ. 
A. Control B. 1 month DN C. 4 months DN D. 8 months DN 
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4.8.2. 24 h urine excretion of ε (γ glutamyl) lysine  
 
To estimate 24 hours ε (γ glutamyl) lysine excretion, its concentration in mg/protein was 
multiplied by 24 hour urine volume. 
 
When expressed per 24h, ε (γ glutamyl) lysine increased significantly by 4 months with levels 
15.6 fold higher than controls (p=0.0167). Furthermore, a 9.8 fold increase was observed at 8 
months (p=0.0357).  No statistical difference was found between controls and diabetic animals 
at 1 month (p=0.867).  24 hours ε (γ glutamyl) lysine measurements in sham-operated ranged 
between 72.88 and 82.46nmols/24h throughout the study (figure 4.18-B). 
 
4.8.3. ε (γ glutamyl) lysine/creatinine ratio  
 
Urine XL excretion was calculated as a creatinine ratio as in section 4.2.3.4.  Sham operated 
rats had a ε (γ glutamyl) lysine/ creatinine ratio ranging from 0.04 to 0.12mg/ml throughout the 
study.  The XL/Creatinine ratio was 3.92, 20.84 and 11.89 fold higher on DN animals 
compared to controls at 1, 4 and 8 months post STZ injection respectively (p=0.1413, 
p=0.0043, p=0.0292, figure 4.18-C).  The maximum ε (γ Glutamyl) Lysine to creatinine ratio 
was observed at 4 months where an average of 1.75 ± 0.37mg/ml was seen.  
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 Figure 4.18: ε (γ glutamyl) lysine measurement in urine from the UNx STZ model of DN 
  
       
 
Figure 4.18: ε (γ glutamyl) lysine was measured in DN urine samples at 1, 4 and 8 months post STZ DN 
induction:  (A) Mean ε (γ Glutamyl) Lysine per mg urine protein ± SEM calculated by AUC of peaks as 
displayed in figure 4.19. (B) 24 hr urine ε (γ Glutamyl) Lysine ± SEM calculated by adjustment to 24h 
urine protein and volume.  (C) - XL/ Creatinine ratio. Statistical significance was calculated by 2 Way 
ANOVA with a Bonferroni post hoc test: NS= not statistically significant, * p<0.05, **p<0.01, 
***p<0.001 between DN and normal urine.  
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4.9. ε (γ glutamyl) lysine measurement in urine from the Fisher to Lewis 
transplant model of Chronic Allograft Nephropathy 
 
 4.9.1. ε (γ glutamyl) lysine levels per mg protein  
 
The urine concentration of ε (γ-glutamyl)-lysine in CAN samples was measured by cation-
exchange HPLC using an amino acid analyser (Biochrom 30, Biochrom, UK) as described in 
section 4.5.  Following derivatisation with ninhydrin, samples were read at 570nm with a 
retention time of 77 minutes and quantified from the area under the peak (figure 4.19).  Urine 
crosslink concentration from L-L isografts (n=5), two weeks after transplantation was 1.89 ± 
0.16nmol/mg protein which remained unchanged for 52 weeks at 1.28 ± 0.08nmol/mg protein.  
F-L allografts (n=7) had an initial crosslink concentration of 3.03 ± 0.25nmol/mg protein 
(p=0.0066 to L-L isografts) and this peaked by 6 months at 4.67± 1.44 nmol/mg protein 
(p=0.0667).  At termination, average ε (γ Glutamyl) Lysine levels at F-L isografts were 1.15 ± 
0.07nmol/mg protein (p=0.3230) (figure 4.20-A). 
 
4.9.2. 24 h urine excretion of ε (γ glutamyl) lysine 
  
Two weeks after transplantation, total urine ε (γ-glutamyl)-lysine excretion in 24 hours from L-
L isografts was 28.61 ± 2.89mmol/24h.  Excretion on F-L allografts was significantly higher at 
57.17 ± 4.06mmol/24h (p=0.0004), and this gradually increased over 52 weeks to 534.2 ± 
198.9mmol/24h (p=0.0051), 10 fold higher than L-L isografts (49.13 ± 24.72mmol/24h, figure 
4.21-B). 
 
4.9.3. ε (γ glutamyl) lysine/creatinine ratio  
 
Urine crosslink excretion was corrected by creatinine as detailed in section 4.6.3.  L-L isografts 
had a ε (γ glutamyl) lysine / Creatinine ratio ranging from 0.111 to 0.655mg/ml throughout the 
study.  At 2 weeks post transplantation, F-L allografts had an average ε (γ glutamyl) lysine / 
Creatinine ratio 2.6 fold higher than L-L isografts (1.03 ± 0.220 mg/ml, p=0.0413).  
Crosslink/creatinine levels progressively increased until 6 months post kidney transplantation 
(4.6 fold higher than L-L isografts, p=0.0268) after which there was a reduction in ε (γ glutamyl) 
lysine / Creatinine ratio in the F-L allografts at 33 and 52 weeks post transplantation (0.4648 
± 0.1536mg/ml and 0.3743 ± 0.070 mg/ml correspondingly).  However, these were still 
significantly above values for L-L kidney transplants (p=0.0357 and p= 0.0369, figure 4.22-C).  
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 Figure 4.19: Urine ε (γ Glutamyl) Lysine excretion in the Fisher to Lewis Model of CAN  
    
 
    
 
Figure 4.19: ε (γ glutamyl) lysine elution profile from L-L Isografts and F-L Allografts over 12 months. 
(A)  Sample tracing of L-L Isograft at 2 weeks post kidney transplantation showing a 77 minute elution 
time for the crosslink peak (white arrow). F-L Allografts traces at: (B) 2 weeks, (C) 8 weeks, (D) 17 
weeks, (E) 24 weeks, (F) 33 weeks and (H) 52 weeks. (G) Glu-Lys peak in a L-L Isograft urine sample at 
termination by 52 weeks. 
  
A.  2 weeks L-L isografts  B.  2 weeks F-L allografts  C.  8 weeks F-L isografts  D.  17 weeks F-L isografts  
E.  24 weeks F-L isografts  F.  33 weeks F-L isografts  G.  52 weeks F-L isografts  H.  52 weeks L-L isografts  
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 Figure 4.20: ε (γ glutamyl) lysine measurement in urine from the in the Fisher to Lewis 
model of CAN 
 
  
  
        
Figure 4.20:  A – Mean urine ε (γ-glutamyl)-lysine concentration ± SEM over a 12 month period in the 
L-L isograft (n=5) compared to the F-L allograft (n=7).  B - 24 hr urine ε (γ glutamyl) lysine excretion ± 
SEM, C - XL / Creatinine ratio in F -L allografts and L-L isografts transplanted rats. Statistical significance 
was shown by 2 Way ANOVA with Bonferroni post hoc test: NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between F -L allografts and L-L isografts.  
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4.10. Correlation between urine ε (γ glutamyl) lysine and clinical 
markers of renal function and damage 
 
4.10.1. 24h proteinuria 
 
To analyse the relationship between urinary excretion of ε (γ glutamyl) lysine and markers of 
disease progression, a series of correlations were performed.  In the 5/6th subtotal 
nephrectomy model, twenty four hour urine excretion of ε (γ glutamyl) lysine from 30 SNx and 
TG inhibitors treated rats were plotted against 24 hour proteinuria (figure 4.21-A).  A strong 
positive relationship between these two variables (Pearson’s r = 0.8979, 95% CI: 0.7918 to 
0.951, p<0.0001) was seen.   
 
Twenty five Diabetic urine samples were used to analyse the effects of protein excretion on ε 
(γ Glutamyl) Lysine output.  Proteinuria levels had a steady increase throughout the study; XL 
levels peaked at 4 months, declining at 8 months.  Urine ε (γ Glutamyl) Lysine was therefore 
not associated with changes in proteinuria in DN animals (Pearson’s r = 0.3897, 95% CI: -
0.0163 to 0.6854, p=0.0598, figure 4.21-B).  
 
Correlating 24 hour urine excretion of ε (γ glutamyl) lysine in 72 CAN samples and twenty four 
hours proteinuria revealed a strong linear positive relationship (Pearson’s r=0.6483, p<0.0001, 
figure 4.21-C). 
 
4.10.2. Creatinine clearance 
 
Urine ε (γ glutamyl) lysine had a negative correlation with Creatinine Clearance in 30 SNx and 
TG inhibitors treated samples (Pearson’s r = -0.5355, 95% CI: -0.7541 to -0.2102, p=0.0028).  
Therefore, the lower the kidney function (low CrCl), the higher the excretion of ε (γ glutamyl) 
lysine dipeptide in this model of renal scarring (figure 4.21-D). 
 
In the same way as urine TG2, its product ε (γ Glutamyl) Lysine, did not manifest a clear 
association with creatinine clearance in DN urine samples (Pearson’s r = 0.2210, 95% CI: -
0.2004 to 0.5733 p=0.2994, figure 4.21-E). 
 
In the Fisher to Lewis transplant model of CAN, 24 hour urine ε (γ-glutamyl)-lysine excretion 
showed a negative correlation (figure 4.21-F) with creatinine clearance (Pearson’s r = -0.5260, 
95% CI: -0.6881 to -0.3140 p<0.0001), indicating that the higher the kidney damage and 
dysfunction, the higher will be the urinary crosslink output. 
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Figure 4.21: Correlation plots of urine ε (γ glutamyl) lysine excretion with markers of 
kidney function and damage in experimental models of renal scarring 
 
     
  
      
 
             
 
Figure 4.21: Pearson’s correlations were performed for 24 hour urine ε (γ-glutamyl)-lysine excretion 
vs. 24 hour proteinuria in SNx (A),  DN ( B)  and CAN (C) and then for 24 hour urine ε (γ-glutamyl)-
lysine  excretion vs. creatinine clearance in SNx (D),  DN (E) and CAN (F) Statistical significance was 
shown by 2 Way ANOVA with Bonferroni post hoc test: NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001. . n=25 in SNx and DN and n=56 in CAN.  
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4.10.3. Renal scarring levels 
 
Scarring Index, obtained by Masson’s Trichrome staining, was calculated by dividing the 
fibrotic areas (phase 1 - green) by all stroma (phase 2 - red) as described in methods section 
3.1.5.5.2.  Correlation analysis revealed a high level of association between total urinary 
crosslink excretion and scar formation in the SNx model of renal scarring (n=25, Pearson’s r 
= 0.7215, 95% CI: 0.4565 to 0.8689, p<0.0001), (figure 4.22-A).  Hence, the higher the 
presence of fibrotic tissue in SNx kidney biopsy samples, the higher greater the excretion of 
crosslink in urine. 
 
No correlation was observed between 24 hour urine ε (γ-glutamyl) lysine excretion in DN 
samples (n=25) and renal scarring (Pearson’s r = 0.1434, 95% CI: -0.2760 to 0.5170, 
p=0.5037, figure 4.22-B). 
 
Figure 4.22: Correlation plots of 24 hr ε (γ glutamyl) lysine urine excretion and Scarring 
Index   
 
 
 
 
 
Figure 4.22:  Association between 24h ε (γ-glutamyl)-lysine excretion in 18 post SNx (A) and (B) 25 DN 
urines and Scarring Index.  
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4.11. Discussion 
 
In this study, assays have been established and validate assays to detect Transglutaminase 
type 2 and ε (ᵞ glutamyl) lysine in urine. While it is possible to assess TG2, ε (ᵞ glutamyl) lysine, 
collagens and other ECM related molecules in kidney tissue as well as study the histology 
(Johnson et al. 1997, Skill et al. 2001, Johnson et al. 2003, Johnson et al. 2007, Fisher et al. 
2009, Huang et al. 2009), it is not ethical or practical to submit all patients to kidney biopsy.  
Therefore measurement of molecules involved in ECM regulation and scarring in the urine 
might represent an ideal non-invasive test to assess disease stage and its progression.  
 
Following establishment of urine assays for TG2 and ε (ᵞ glutamyl) lysine measurement, to 
assess if these molecules were of any potential value in CKD, measurements were undertaken 
in 3 animal models of renal scarring.  An archived set of urines was obtained from the 5/6th 
subtotal nephrectomy (Johnson et al. 2007), the Streptozotocin Diabetic Nephropathy (Huang 
et al. 2009) and the Fisher to Lewis transplant model of CAN (Shrestha et al. 2014). 
 
Quantification of TG2 protein was achieved using the developed sandwich enzyme-linked 
immunosorbent assay which showed no cross-reactivity with other molecules such as Factor 
XIII.  This ensured we were not measuring other TGs in the urine.  Analysis of TG2 activity 
was performed by assessment of its crosslink product, ε (ᵞ glutamyl) lysine.  
 
Measurement of ε (ᵞ glutamyl) lysine can be done through indirect or direct methods (Griffin 
and Wilson 1984).  Indirect methods include inhibition of ε (ᵞ glutamyl) lysine by covalent 
incorporation of small molecular weight amine substrates such as histamine and cystamine 
into the ε (ᵞ glutamyl) lysine groups of the protein, quantification of masked lysines within 
proteins and use of SDS-gel electrophoresis.  Direct methods are done after release of ε (ᵞ 
glutamyl) lysine from the sample by exhaustive proteolytic digestion with a series of endo and 
exopeptidases of broad specificity.  It is a consensus that direct estimation of this dipeptide is 
the ultimate technique for analysing it as it gives better quantitative assessment of this 
crosslink.  This is why it has been applied here. 
 
There are several techniques used to analyse and separate amino acids and dipeptides from 
other components of the sample such as paper chromatography (involves the separation of 
amino acids on layers of cellulose paper), thin-layer chromatography (through the use of 
ready-coated systems), gas liquid chromatography (uses volatile derivatives such as 
trimethlsilyl), reversed phase HPLC (operates at high pressures and solvent flow rates), 
capillary electrophoresis (amino acids are separated by application of high voltages across 
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silica or coated polyamide tubing of 50-150 micron diameter), mass spectrometry (separation 
of molecules according to their atomic and molecular mass) and microbiological assays (using 
microorganisms such as Lactobacillus casei and Tetrahymena pyriformis to establish growth 
response under addition of samples containing specific amino acids). However, those 
techniques have several limitations.  Amino Acid analysis uses highly specialised ion 
exchange chromatography to fractionate, identify and quantify directly amino acids.  It is seen 
as the most accurate way to measure amino acids and again this is why this approach was 
selected for this study. 
A key decision in presenting the data generated in this study was what to normalise data to. 
TG2 protein urine concentration was increased in 1 and 3 months SNx and at all time points 
in DN and F-L allografts which effectively means that TG2 measurements could be made on 
spot urine.  On the other hand, rats that were treated with TG inhibitors showed reduced TG2 
concentration when compared to SNx animals by 28 days in both NTU C7 and NTU C56 and 
by 84 days in NTU C7.  Considering that these compounds should only block TG activity and 
not the production of this protein, we therefore realised that either twenty four urine excretion 
or a correction by urinary creatinine could provide a better way of expressing the urine 
measurement of this biomarker as changes to kidney physiology may affect urine flow and 
consequently its concentration. 
 
Twenty four hour TG2 urine excretion was estimated by adjustment of concentration with 24 
hour urine volume.  Total TG2 was significantly elevated at all time points in SNx, DN and F-
L allografts.  But, as NTU C7 and NTU C56 treated animals had high urine production no 
difference was observed between these groups and SNx rats.   So, one of the drawbacks to 
this way of expressing its measurement is the variability of the urine output. Also, twenty four 
hours urine collection is often impractical in a clinical outpatient environment with a random 
spot urine collection recommended more feasible option. For this reason, an adjustment of 
the concentration of the measured analyte by the level of urine creatinine was perceived as 
the most useful correction. 
 
The crosslink product ε (γ-glutamyl) lysine was increased in the 3 months SNx and in the 2, 8 
and 33 weeks F-L allografts when expressed per mg protein.  In addition, 24 hour urine 
excretion of ε (γ-glutamyl) lysine was significantly elevated in late SNx and F-L allografts at all 
time points.  However, in the DN group, no changes were detected per mg of protein.  The 
reason for this could be down to the fact that the most common type of protein present in 
diabetic urines is albumin.  The majority of DN patients typically progress with increased 
excretion of albumin and gradual decline in GFR until ESRD occurs (Ayodele et al. 2004, 
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Chang 2008, Jefferson et al. 2008, Woredekal 2008) and although a large number of 
substrates for TG2 have been identified, so far there is no published evidence that albumin 
could act as one of them.  As concentrations given by the AAA are related to the amount of 
that amino acid or di amino acid present in 2mg of urine protein (amount used to digest), 
therefore the expression of ε (γ-glutamyl) lysine related to this amount of protein used to digest 
might not represent an ideal way to express it as in diseased urines most of the content would 
be due to the increased presence of albumin and not collagen, fibronectin, β2-microglobulin or 
other proteins of interest that could be crosslinked in the ECM.  To investigate this we 
conducted an in vitro study which reported no crosslinking of albumin through TG2 (section 
7.7). This could partially explain why diabetic rats with remarkable proteinuria showed reduced 
levels of ε (γ Glutamyl) Lysine. 
 
Twenty four hour ε (γ glutamyl) lysine excretion was elevated at 4 and 8 months in diabetic 
samples. This was mostly caused by the increased proteinuric state observed at later stages 
of the disease.  This is also in keeping with the fact that longstanding Diabetes Mellitus should 
be present before nephropathy develops.  Gradual onset of diabetes leads to progressive 
kidney disease caused by angiopathy of capillaries in the kidney glomeruli.  As diabetic 
nephropathy progresses, growing numbers of glomeruli are destroyed by progressive nodular 
glomerulosclerosis and this give rise to protein leakage. 
 
In both groups of TG inhibitor treated animals lower levels of urine XL was observed as would 
have been predicted from the use of inhibitors.  However, despite this reduction, there was no 
statistical difference between SNx and SNx animals treated with TG inhibitor when expressed 
per mg protein.  After adjustment to 24 hour urine excretion ε (γ glutamyl) lysine was 
significantly reduced in both groups when compared to untreated SNx by 84 days.  
 
ε (γ glutamyl) lysine measurements were also corrected by urine creatinine in order to better 
reflect XL excretion.  After correction, urine levels of ε (γ glutamyl) lysine were significantly 
increased at all time points post SNx and allotransplantation. Furthermore, NTU C7 and NTU 
C56 treated animals showed reduced XL/Cr levels when compared to SNx animals throughout 
the study.  In streptozotocin induced diabetic animals, XL/Cr levels were significantly elevated 
by 4 and 8 months with maximum ε (γ Glutamyl) Lysine to creatinine ratio observed at 4 
months. This coincides with the clinical data which revealed increased glomerular 
hyperfiltration at this stage.  The reduction in ε (γ Glutamyl) Lysine to creatinine ratio at 8 
months DN and at late stages of the allotransplantation study could be due to the advanced 
level of disease which causes a lower glomerular filtration rate and therefore a decreased 
capability of the kidneys to excrete waste products. 
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SNx and CAN samples showed a positive correlation between both TG2 and ε (γ Glutamyl) 
Lysine with 24 hour proteinuria.  However, highly proteinuric Diabetic animals did not present 
higher levels of ε (γ Glutamyl) Lysine. This could be due to the fact that albumin is not a 
preferential substrate for TG2 crosslinking (section 7.7). To minimise this effect of increased 
albuminuria steps could be added to remove albumin from samples.  Application of albumin 
depletion methods could potentially improve ε (ᵞ glutamyl) lysine detection as presence of high 
albuminuria impedes equivalent analysis of this molecule in diseased samples compared to 
samples where lower abundance of albumin occurs.  Thus there is an increased concentration 
of other proteins when expressed per mg of total protein in disease urines.  However, albumin 
depletion is costly and certainly not a “clean” technique, potentially removing proteins of 
interest. 
 
Analysis of the correlation between 24 hour urine excretion of TG2 and ε (γ Glutamyl) Lysine 
indicated that both are negatively associated with creatinine clearance in the SNx and in the 
Fisher to Lewis transplant model of CAN.  Also, Masson’s Trichrome staining of subtotal 
nephrectomised kidney samples revealed that the higher the presence of renal scarring and 
fibrosis the higher were the levels of 24 hr TG2 and its crosslink product in rat urines.  This 
corroborates previous studies from our group (Johnson et al. 2007) where scarred rat kidneys 
presented high measurements of TG2 catalysed ε (γ glutamyl) lysine as well as high levels of 
in situ TG2 activity. 
 
Overall, this chapter shows that TG2 and ε (γ Glutamyl) Lysine can be measured in urine, that 
overall this reflects the levels in the renal tissue and thus the degree of scar tissue formation.  
Further that correction for volume, either by 24 hour collection or by ratio to urine creatinine 
offers the most promising way to look at urine TG2 and ε (γ Glutamyl) Lysine levels. 
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Chapter 5 
Urine plasminogen activator inhibitor type 1, 
matrix metalloproteinases and theirs inhibitors 
in experimental renal scarring 
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5.1. Introduction 
 
Matrix Metalloproteinases are a group of more than 25 zinc-dependent endopeptidases 
secreted by a variety of cells that are capable of cleaving most of the components of the ECM, 
such as proteoglycans, laminin, fibronectin, and collagens III, IV and V.  They can also process 
a number of bioactive molecules, such as apoptotic ligands, as well as being known to be play 
a role in chemokine activation, cell proliferation, cell adhesion, differentiation, angiogenesis 
and host defence (Clark et al. 2008, Manicone and McGuire 2008, Rydlova et al. 2008).  
Previous studies have demonstrated that MMPs 1, 2, 3, 8, 9 and 13 are significantly expressed 
in the kidneys (reviewed by (Lenz et al. 2000)). 
 
MMP activity is regulated at the level of transcription as well as by the activation of the 
precursor zymogens and through tight control from their endogenous inhibitors such as α2 
macroglobulin and specifically by tissue inhibitors of metalloproteinases (TIMPs), which 
comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4 (Visse R, 
Circulation research 2003).  From these, TIMPs 1, 2 and 3 are significantly expressed by the 
kidneys (Engelmyer et al. 1995, Norman et al. 1995).  MMPs and TIMPs play a central role in 
the maintenance of ECM levels and thus, ECM remodelling and accumulation. 
 
In addition to its major classical role in the coagulation and fibrinolysis cascades in the blood, 
the plasminogen/plasmin system also acts alongside the MMP system to degrade most ECM 
components.  Although plasmin can directly degrade only part of ECM components such as 
fibronectin and laminin, it has an important function in ECM degradation as it contributes to 
the activation of several pro-MMPs including pro-MMP 2 and 9 (Galis and Khatri, 2002, Monea 
et al 2002).  Plasminogen activator inhibitor 1 (PAI-1) is the main regulator of tissue-type 
plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), the two main 
physiological activators of the precursor plasminogen into plasmin.  Thus, an increase in PAI-
1 levels is believed to contribute to fibrosis by decreasing plasmin production and therefore, 
ECM breakdown (Schaller and Gerber, 2011). 
 
Recent data suggests that PAI-1, MMPs and their inhibitors are involved in many pathological 
processes, including the development of kidney scarring due to a decreased proteolytic activity 
leading to  accumulation of ECM components (Ahmed et al. 2007). However, most of the 
published data about the pathological effects of PAI-1, MMPs and TIMPs in kidney disease 
were obtained from in vitro studies with cell lines and in vivo studies using tissue homogenates 
and circulatory levels of these molecules.  In this chapter, we hypothesised that PAI-1, MMPs 
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and TIMPs are excreted in urine and therefore could predict the progression of renal fibrosis 
in a non-invasive way.   
 
To test this hypothesis, this chapter aims to: 
1. Validate measurements of MMP-1, MMP-9, TIMP-1, TIMP-2, TIMP-3 and PAI-
1 in urine obtained from three experimental models of CKD (SNx, DN and CAN)  
2. Correlate urine levels of MMPs and their inhibitors with the development of 
disease in these models 
3. Determine if the changes in MMPs, TIMPs and PAI-1 levels could be used as 
indicators of CKD progression and if these could be applied to the human study. 
 
Analyses of urine MMP-1, MMP-9, TIMP-1, TIMP-2, TIMP-3 and PAI-1 levels were 
performed by immunoassays as described in section 3.4.4. 
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5.2. Urine levels of Matrix Metalloproteinases in experimental CKD 
 
5.2.1. MMP-1 (Interstitial collagenase) 
 
Quantification of Matrix Metalloproteinase 1 (MMP-1; Interstitial collagenase) was done by the 
Gentaur immunoassay (Uscn Life Science Inc., USA) as described in section 3.10.4.1. The 
minimum detectable dose (M.D.D.) of rat MMP-1 was 1.7pg/ml. 
 
MMP-1 levels were measured in two experimental models of renal scarring: the 5/6th 
Subtotalnephrectomy (SNx) and the UNx STZ model of Diabetic Nephropathy (DN).  Archival 
urine samples from the Fisher to Lewis transplant model of Chronic Allograft Nephropathy 
were unavailable for use as they became exhausted during studies in chapter 4.  Experimental 
animals and full methods are described in detail in chapter 3, sections 3.1.1.1, 3.1.2 and 3.1.3. 
 5.2.1.1. Measurement of MMP-1 in urine from the 5/6th Subtotal Nephrectomy 
model  
 
In the SNx model, MMP-1 concentration in control animals (n=10) ranged between 3.61 to 
35.75pg/ml (figure 5.1-A).  SNx animals had a steady increase in urine MMP-1 concentration, 
with an average of 754.92 ± 255.18pg/ml (n=3, p=0.0422), 1077.77 ± 65.94pg/ml (n=3, 
p<0.001) and 1073 ± 28.22pg/ml (n=6, p<0.001) at 7, 28 and 84 days after surgery 
respectively. 
 
MMP-1 excretion over 24 hours (figure 5.1-B) was 12 fold higher in SNx animals at 7 and 28 
days (p=0.0446 and p=0.0195 respectively), reaching an average of 35 676 ± 4 115pg/24h by 
3 months (p<0.0001, one way ANOVA with Bonferroni post test).  Sham operated rats (n=10) 
displayed an average MMP-1 excretion in 24 hours ranging from 12.98 to 445.46pg/24h during 
the study. 
 
Urine MMP-1 concentration was adjusted by creatinine as described in section 4.1.5. 
After correction, MMP-1: Creatinine ratio ranged between 0.22 to 3.86ng/mmol in sham 
operated rats.  Average MMP-1: Creatinine ratio were respectively 85, 98 and 139 fold higher 
at 7, 28 and 84 days, respectively  (p=0.0418, p=0.0074 and p=0.0098,  one way ANOVA with 
Bonferroni post test) when compared to sham-operated controls (figure 5.1-C). 
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 Figure 5.1:  MMP-1 measurement in urine post SNx 
 
           
 
 
 
 
Figure 5.1: Urine MMP-1 levels were measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by the Gentaur rat MMP-1 Immunoassay and presented as concentration expressed in 
pg/ml (A) 24 hour excretion (B) and as a Creatinine ratio (C). Data represents mean ± SEM. Statistical 
significance was tested using one way ANOVA with Bonferroni post test with NS= not statistically 
significant, * p<0.05, **p<0.01, ***p<0.001 between SNx and the time matched control. 
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5.2.1.2.  Measurement of total MMP-1 in the UNx STZ model of Diabetic 
nephropathy 
 
Sham operated rats (n=10) displayed a MMP-1 concentration ranging from 2.26 to 12.76pg/ml 
during the study (figure 5.2-A).  MMP-1 concentration had a sustained rise in DN animals 
throughout the time course, with a 354% increase at 1 month after STZ administration (n=4, 
p<0.0001), to 429% (n=6, p<0.0001) at 4 months, peaking at 464% increase (n=4, p<0.0001, 
2 way ANOVA with Bonferroni post test) at termination.  
 
At 1 month, DN animals had a 24 hour MMP-1 excretion of 32.88 ± 14.44pg/24h (n=3, 
p=0.0418), increasing to 181.17 ± 32.41pg/24h (n=3, p=0.0066) by 4 months and then to 
146.72 ± 51.57pg/24h at termination.  Although by 8 months, 24h MMP-1 concentration was 
24 fold higher than controls, this difference failed to reach significance due to the variability of 
urine output (n=6, p=0.0614, 2 way ANOVA with Bonferroni post test).  Total MMP-1 excretion 
in sham operated rats ranged 8.65-60.16pg/24hours throughout the study (figure 5.2-B). 
 
To correct for the broad variability of urinary output within diabetic samples, MMP-1 excretion 
was converted to a creatinine ratio as described in details in section 4.2.3.4. Corrected MMP-
1 excretion (MMP-1: Creatinine ratio) was elevated in DN animals when compared to sham 
operated animals at 1 month (357.6 ± 67.2pg/mmol), but this difference was not significant 
(p=0.0509). However, MMP-1: Creatinine ratio showed a significant increase on DN animals 
by 4 and 8 months after DN induction (1099 ± 156 and 992 ± 180pg/mmol, p= 0.0019 and 
p=0.0056 respectively) (figure 5.2-C). 
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Figure 5.2: MMP-1 measurement in urine from the UNx STZ model of DN  
 
  
 
 
        
 
Figure 5.2: Urine MMP-1 levels in DN samples at 1, 4 and 8 months post DN induction were measured 
by Gentaur rat MMP-1 Immunoassay and presented as  concentration expressed in pg/ml (A) 24 hour 
excretion, (B) and as a Creatinine ratio (C). Values are mean ± SEM. Statistical significance was tested 
using one way ANOVA with Bonferroni post test with NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between DN and the time matched control. 
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5.3.2. Correlation between urine MMP-1 and clinical markers of kidney 
function and damage  
5.3.2.1. 24h proteinuria 
 
To determine whether the urine excretion of MMP-1 was associated with the presence of 
glomerular damage, a correlation of MMP-1 urine concentration with 24 hour proteinuria was 
performed.  In the 5/6th subtotalnephrectomy model of renal scarring, there was a positive 
correlation between urinary MMP-1 excretion in 24 hours with twenty four hours protein 
excretion (Pearson’s r = 0.8658, 95% Confidence interval: 0.6782 to 0.9474. p<0.0001, 
r2=0.7495, figure 5.3-A).  A similar, but slightly weaker association was found in DN samples 
(Pearson’s r = 0.7488, 95% Confidence interval: 0.4868 to 0.8872. p<0.0001, r2=0.5607, figure 
5.3-B).  
5.3.2.2. Creatinine Clearance 
 
A strong negative association was observed when correlating urine MMP-1 with Creatinine 
clearance (CrCl) in the SNx model (figures 5.3-C), showing that MMP-1 excretion increased 
as diseased progressed (Pearson’s r = -0.6860. 95% CI: -0.8732 to -0.3223, p=0.0017, 
r2=4706).  Conversely, Diabetic samples (figure 5.3-D) did not show any correlation between 
MMP-1 excretion and decreased kidney function (Pearson r = 0.2991, 95% CI: -0.1291 to 
0.6333, p=0.1656, r2=0.08947).   
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Figure 5.3: Correlation plots of urine MMP-1 excretion with markers of kidney function 
and damage in experimental models of renal scarring 
 
 
 
     
 
 
 
  
 
  
Figure 5.3:  Pearson’s correlations were performed for 24 hour urine MMP-1 excretion vs. 24 hour 
proteinuria in SNx (A) and DN (B) and then for 24 hour urine MMP-1 excretion vs. creatinine clearance 
in SNx (C) and DN (D). NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001. n= 20 in SNx 
and 25 DN. 
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5.2.2. MMP-9 (Gelatinase-B) 
 
Matrix metalloproteinase 9 (MMP-9), is a 92 kDa type IV collagenase.  Levels were measured 
in rat urines by the Quantikine rat total MMP-9 Immunoassay as described in section 3.10.4.2.   
Total levels of the enzyme were measured, including its Pro-, active- and TIMP-complexed 
forms of the protein. 
 
Total MMP-9 levels were measured in two experimental models of renal scarring: the 5/6th 
Subtotalnephrectomy (SNx) and the UNx STZ model of Diabetic Nephropathy (DN).  Archival 
urine samples from the Fisher to Lewis transplant model of Chronic Allograft Nephropathy 
were unavailable for use as they became exhausted in studies performed in chapter 4.  
Experimental animals and full methods are described in detail in chapter 3, sections 3.1.1.1., 
3.1.2 and 3.1.3. 
 5.2.2.1. Measurement of total MMP-9 in urine from 5/6th subtotal nephrectomised 
rats  
 
 The Minimum Detectable Dose (MDD) of rat MMP-9 was 0.013ng/ml.  However, MMP-9 
levels were not detected in control animals (n=9) at any time points following sham operation 
and was very low in SNx samples (figure 5.4-A).  At 7 day s, MMP-9 concentration was 1.31 
± 0.95ng/ml (n=3), decreasing to 0.46 ± 0.27ng/ml (n=3) by day 28 before rising to 3.83 ± 
2.25ng/ml at termination (n=7). 
 
To calculate 24 hour MMP-9 excretion urine concentration was multiplied by total urinary 
volume.  Total MMP-9 excretion was 24.9 ± 17.7ng/24h at 7 days, compared to 12.2 ± 
6.0ng/24h and 103.7 ± 53.6ng/24h at 28 and 84 days respectively (figure 5.4-B).  No statistical 
difference was found between these groups.   
 
Conversion of MMP-9 to a creatinine ratio also showed an increase by 84 days (1.52 ± 0.63 
when compared to 7 and 28 days (0.31 ± 0.22 and 0.12 ± 0.05), but this elevation also didn’t 
reach significance (p= 0.1095 and p=0.0628) (figure 5.4-C). 
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Figure 5.4: MMP-9 measurement in urine post SNx 
   
           
 
 
 
 
Figure 5.4: Urine MMP-9 levels were measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by the Quantikine rat total MMP-9 Immunoassay and presented as concentration (A) 24 
hour excretion (B) and as a Creatinine ratio (C). Values are mean ± SEM. Statistical significance was 
tested using one way ANOVA with Bonferroni post test with NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between SNx and the time matched control 
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5.2.2.2.  Measurement of total MMP-9 in the UNx STZ model of Diabetic 
nephropathy 
 
Similarly to the results seen in the SNx model, MMP-9 was undetectable in all control samples 
(n=10) (figure 5.5-A).  Diabetic samples had a steady increase in urine MMP-9 concentration, 
although variability within sample groups was high.  Average urine MMP-9 concentration was 
0.51 ± 0.41ng/ml (n=3), 4.75 ± 4.26ng/ml (n=7) and 13.29 ± 7.28ng/ml (n=5) at 1, 4 and 8 
months post streptozotocin respectively. 
 
When converted to MMP-9 excretion over 24 hours (figure 5.5-B) variability remained high. 
Total urine MMP-9 excretion was 25.39 ± 22.85ng/24h at 1 month, rising to 743.55 ± 
714.66ng/24h by 4 months, and remaining elevated at termination at 1446.63 ± 835.40ng/24h.  
One of the diabetic samples had persistent low MMP-9 levels through the study and this 
resulted in high standard error values.  
 
Once corrected to a creatinine ratio, MMP-9 was 0.30 ± 0.272 month after DN induction (figure 
5.5-C).  This had over a 15 fold increase by 4 months and subsequent 31 fold by 8 months.  
However, this difference was not significant due to the large variation that remained post 
volume correction. 
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 Figure 5.5: MMP-9 measurement in urine from the UNx STZ model of DN  
 
 
 
 
        
 
Figure 5.5: Urine MMP-9 levels in DN samples at 1, 4 and 8 months post DN induction were measured 
by Quantikine rat total MMP-9 Immunoassay and presented as  concentration expressed in ng/ml (A) 
24 hour excretion, plotted at log 10 scale for better visualization of differences (B) and as a Creatinine 
ratio (C). MMP-9 was undetectable on controls and had a steady, but not significant rise in Diabetic 
animals. Values are mean ± SEM. Statistical significance was tested using one way ANOVA with 
Bonferroni post test with NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between 
DN and the time matched control. 
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5.3. Urine levels of Tissue inhibitors of Metalloproteinases in 
experimental CKD 
 
5.3.1. Tissue inhibitor of metalloproteinase 1 
 
To investigate the urine expression of TIMP-1 and its subsequent potential as a non-invasive 
biomarker of kidney scarring progression, samples from three different animal models of renal 
scarring (SNx, DN and CAN) were used.  TIMP-1 levels were analysed by an immunosorbent 
assay as described in section 3.11.1.1.  Minimum detectable dose (MDD) of rat TIMP-1 was 
3.5pg/ml. 
5.3.1.1. Measurement of urine TIMP-1 in the 5/6th Subtotal nephrectomy model  
 
Urine TIMP-1 concentration on Sham operated rats ranged between 2.9 to 5.1ng/ml 
throughout the study (figure 5.6-A).  SNx animals presented an average urinary TIMP-1 
concentration of 6.0 ± 0.9ng/ml (n=3) at 7 days and 6.2 ± 1.0ng/ml (n=3) at 28 days after 
surgery.  No statistical difference was found between SNx and control animals during these 
time points (p=0.0858 and p=0.1283, 2 way ANOVA with Bonferroni post test). By 84 days, 
urine TIMP-1 concentration was 233% higher than controls, with an average value of 14.1 ± 
0.5ng/ml (n=7, p<0.0001). 
 
Total TIMP-1 excretion (figure 5.6-B) had a sustained rise in the SNx animals throughout the 
time course showing 849%, 881% and 841% increase at day 7, 28 and 84 respectively 
(p=0.0007, p<0.0001, p<0.0001, 2 way ANOVA) when compared to sham-operated controls.  
Total TIMP-1 excretion in sham operated rats ranged 8.9-56ng/24hours throughout the study. 
 
To correct for the wide difference in the variability of urine output within samples, an 
adjustment of TIMP-1 excretion was performed based on the levels of creatinine in the urine 
(as outlined in session 4.2.3.4).  Corrected TIMP-1 excretion (TIMP-1/Creatinine ratio) was 
raised in SNx animals when compared to sham operated animals at all time points after 
subtotalnephrectomy: 6.4, 6.7 and 15.3 fold increase (*p=0.0025, **p=0.0007, ***p=0.0160, 
two way ANOVA, figure 5.6-C).  Sham-operated rats had an average TIMP-1/Creatinine ratio 
ranging from 0.230-0.480pg/mmol from 7 to 84 days after surgery. 
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 Figure 5.6: TIMP-1 measurement in urine post SNx 
  
           
 
        
 
 
Figure 5.6:  Urine TIMP-1 levels were measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by the Quantikine rat TIMP-1 Immunoassay and presented as concentration in pg/ml 
(A) 24 hour excretion (B) and as a Creatinine ratio (C). Values are mean ± SEM. Statistical significance 
was tested with one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * 
p<0.05, **p<0.01, ***p<0.001, between diseased samples and time matched control. 
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5.3.1.2.  Measurement of urine TIMP-1 in the UNx STZ model of Diabetic 
nephropathy 
 
Consistent with the SNx model, no difference could be found in urine TIMP-1 concentration in 
the early stages of the Diabetic disease (figure 5.7-A).  At 1 month after DN induction, control 
animals (n=3) had an average TIMP-1 concentration of 1.8 ± 0.7ng/ml against 3.5 ± 1.1ng/ml 
of DN rats (n=3, p=0.2478).  As diseased progressed, TIMP-1 levels became significantly 
higher in DN urine samples (n=5, 4.1 ± 0.3ng/ml, p=0.0047) when compared to controls at 4 
months.  At the time of termination, TIMP-1 levels remained elevated on urine from DN rats 
(n=5, 7.4 ± 3.3ng/ml).  However, it failed to achieve statistical significance (p=0.2106) at this 
point. 
 
Total TIMP-1 excretion in Diabetic samples (figure 5.7-B) was elevated 1 month post STZ 
injection, showing a 15 fold increase compared to sham animals, however this difference was 
not significant (p=0.0571,  2 way ANOVA).  At 4 months, this raised to a significant 50 fold 
increase in total urine TIMP-1 measurements between SNx and sham controls (p=0.0021, 2 
way ANOVA).  Between 4 and 8 months, although total TIMP-1 excretion in Diabetic urine 
samples had a decrease to 43 fold difference compared to control animals,  it remained 
significantly elevated (p=0.0337). 
 
After normalizing for urine creatinine concentration, corrected TIMP-1 excretion (TIMP-
1/Creatinine ratio) was significantly increased in Diabetic samples at 4 and 8 months after DN 
induction (figure 5.7-C). At 4 months, TIMP-1/creatinine ratio was over 25 fold higher on 
Diabetic animals compared to controls (p=0.0006), whereas by termination this difference was 
elevated to 37 fold increase (p=0.0422). 
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 Figure 5.7: TIMP-1 measurement in urine from the UNx STZ model of DN  
 
  
 
 
        
 
Figure 5.7: Urine TIMP-1 levels in DN samples at 1, 4 and 8 months post DN induction were measured 
by the Quantikine rat TIMP-1 Immunoassay and presented as  concentration expressed in pg/ml (A), 
24 hour excretion(B) and as a Creatinine ratio (C).  Statistical significance was tested with one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001, 
between diabetic samples and time matched control. Values are mean ± SEM.  
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5.3.1.3. Measurement of urine TIMP-1 in the Fisher to Lewis transplant model of 
CAN  
 
Similar urine concentrations of TIMP-1 were found between F-L allografts and L-L isografts 
during the entire study (figure 5.8-A).  In the early phase of CAN, urine TIMP-1 concentration 
was 4.3 ± 0.4ng/ml in isografts and 4.4 ± 0.8ng/ml in allografts (p=0.9051) and remained 
unchanged over 33 weeks (isografts 4.5 ± 0.4ng/ml and allografts 5.0 ± 0.9ng/ml) p=0.6255.  
At 52 weeks, there was a slight increase in TIMP-1 concentration in the allograft group (6.5 ± 
3.4ng/ml), but this failed to achieve significance (p=0.3097).  
 
As it can be seen in figure 5.8-B, there was no statistical difference in total TIMP-1 excretion 
between L-L isografts and F-L allografts in the initial stages of the study (2 and 8 weeks).  
Interestingly, it became significantly increased on F-L allografts at 17 (149% higher than L-L 
isografts, p=0.0288) and 24 weeks post transplantation (134% higher, p=0.0360). 
Nevertheless, by 33 weeks after surgery until termination, the difference in total TIMP-1 
excretion between these two groups remained insignificant. 
 
F-L allografts and L-L isografts showed similar urinary TIMP-1 levels, even when corrected by 
creatinine ratio (figure 5.8-C).  No statistical difference was found between these two groups 
throughout the time course of this study despite a reduction on TIMP-1 levels noticed on L-L 
isografts.  This interesting fact reflects the improvement on renal function observed on this 
group of animals towards the end of the study (figure 11.4-C appendix).  F-L allografts had an 
average TIMP-1/creatinine ratio ranging from 0.984-2701pg/mmol, whilst in L-L isografts it 
was 0.231-0.945pg/mmol. 
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 Figure 5.8: TIMP-1 measurement in urine from the in the Fisher to Lewis transplant 
model of CAN   
 
  
 
 
        
 
Figure 5.8: Urine TIMP-1 levels in the Fisher to Lewis transplant model of CAN over 12 months 
quantified by the Quantikine rat TIMP-1 Immunoassay and presented as  concentration expressed in 
pg/ml (A), 24 hour excretion(B) and as a Creatinine ratio (C).  Statistical significance was tested with 2 
Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, 
***p<0.001, between F -L allografts and L-L isografts. Values are mean ± SEM.  
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5.3.2. Correlation between urine TIMP-1 and clinical markers of kidney 
function and damage 
  
5.3.2.1. 24h proteinuria 
 
Correlating total urinary TIMP-1 excretion in 24 hours with twenty four hours protein excretion 
showed a positive association in SNx samples (Pearson’s r = 0.8715. 95% confidence interval: 
0.6822 to 0.9513, p<0.0001, r2=0.7596, figure 5.9-A).  The same association was observed 
on DN samples (Pearson’s r = 0.7556. 95% confidence interval: 0.4806 to 0.8953. p<0.0001, 
r2=0.5709, figure 5.9-B) and in a smaller scale, with CAN samples (number of XL pairs=54, 
Pearson r = 0.3490. 95% confidence interval: 0.06523 to 0.5805. p=0.0174, r2= 0.1218, figure 
5.9-C). 
5.3.2.2. Creatinine Clearance 
 
When correlating total urine TIMP-1 with Creatinine clearance (CrCl), TIMP-1 excretion was 
inversely correlated with renal function in both SNx and CAN models (figures 5.9-D and 5.9-
F).  Therefore, the lower the kidney function, the higher the excretion of TIMP-1 in these 
models of renal scarring.  SNx samples were negatively correlated with CrCl; Pearson’s r = -
0.5837. 95% CI: -0.8312 to -0.1430. p=0.0139, r2=0.3407 with CAN samples having a lower 
correlation (Pearson’s r = -0.3931. 95% CI: -0.5980 to -0.1705. p=0.0033, r2=0.1546.  
Conversely, Diabetic samples (figure 5.9-E) did not demonstrate any relationship between 
TIMP-1 and reduced kidney function (Pearson r = 0.3448. 95% CI: -0.1022 to 0.6760. 
p=0.1258, r2= 0.1189).   
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 Figure 5.9: Correlation plots of urine TIMP-1 excretion with markers of kidney function 
and damage in experimental models of renal scarring 
 
 
     
  
      
   
   
 
Figure 5.9:  Pearson’s correlations were performed for 24 hour urine TG2 excretion vs. 24 hour 
proteinuria in SNx (A), DN (B) and CAN (C) and then for 24 hour urine TG2 excretion vs. creatinine 
clearance in SNx (D), DN (E) and CAN (F). Statistical significance was shown as: NS= non statistical 
significant, * p<0.05, **p<0.01, ***p<0.001. n=25 in SNx and DN and n=56 in CAN. 
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5.3.3. Tissue inhibitor of metalloproteinase 2 
 
In order to examine the presence of TIMP-2 in urines from rats submitted to experimental 
models of renal scarring (SNx, DN and CAN), TIMP-2 levels were analysed by the Gentaur 
Immunosorbent assay as described in section 3.11.1.2. Minimum detectable dose (MDD) of 
rat TIMP-2 was 0.36ng/ml. 
5.3.3.1. Measurement of urine TIMP-2 in the 5/6th Subtotal nephrectomy model  
 
Urine TIMP-2 excretion on sham-operated rats was constant during the study (figure 5.10-A), 
ranging from 14.62ng/ml to 15.78ng/ml.  Levels between controls and SNx rats was not 
different at 7 and 28 days after subtotal nephrectomy (*p=0.6446, **p=0.1160, one way 
ANOVA). However, increased urinary levels of TIMP-2 were observed in SNx samples by 3 
months post subtotal nephrectomy, with a 10 fold increase in diseased animals (p=0.0390).   
 
A comparison of 24 hour TIMP-2 excretion between SNx and sham-operated rats showed a 
significant increase from seven days after subtotal nephrectomy (figure 5.10-B). At one week, 
controls had an average TIMP-2 concentration of 52.76 ± 21.38ng/24h whereas SNx was 
370.1 ± 41.23ng/24h (p=0.0024).  By 1 month, SNx animals had a substantial increase to 
727.0 ± 199.1ng/24h (p=0.0279) and two months later, SNx animals had a 23 fold increase 
when compared to controls (p=0.0331). 
 
Normalising TIMP-2 excretion to creatinine showed progressive increases as renal scarring 
developed (figure 5.10-C).  Early increases (1 week) are five times normal levels, p=0.0029.  
At 1 month, TIMP-2: Creatinine ratio was 7.6 fold greater than sham-operated rats, p =0.0379, 
while at 3 months this difference elevated to are 41.9 fold normal (p=0.0477) The TIMP-2: 
Creatinine ratio in sham operated rats ranged 0.87-1.90pg/mmol throughout the study. 
 
 
 
 
 
 
 
 
 
 
 
195 
 
 Figure 5.10: TIMP-2 measurement in urine post SNx 
 
   
           
 
        
 
 
Figure 5.10: Urine TIMP-2 levels were measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by the Gentaur  rat TIMP-2  Immunoassay and presented as concentration in pg/ml (A) 
24 hour excretion (B) and as a Creatinine ratio (C). Statistical significance was tested with one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001, 
between diseased samples and time matched control. Values are mean ± SEM. 
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5.3.3.2. Measurement of urine TIMP-2 in the UNx STZ model of Diabetic 
nephropathy 
 
TIMP-2 concentration in diabetic urine samples followed a similar pattern to that in SNx 
samples, with controls rats’ levels ranging from 12.56ng/ml to 18.04ng/ml (figure 5.11-A).  At 
1 month after STZ administration, urine TIMP-2 concentration was 13.77 ± 2.37ng/ml, 
remaining at similar levels at 4 months (14.41 ± 4.27ng/ml).  By 8 months after hyperglycaemic 
induction, diseased animals had a mean urine TIMP-2 concentration 3.7 fold greater than 
controls.  However, at no stage there was a significant difference between TIMP 2 levels in 
control and DN animals. 
 
Sham-operated rats had a 24 hour TIMP-2 urine excretion varying from 43.45ng/24h to 
123.32ng/24h, maximum excretion was noted at four months after surgery (figure 5.11-B).  24 
hour TIMP-2 excretion steadily rose in the DN animals throughout the time course showing 
10.9, 12.1 and 56.4 fold increase at month 1, 4 and 8 respectively (*p=0.0571, **p=0.0155, 
***p=0.0365, one way ANOVA) when compared to controls. 
 
Urine TIMP-2 when corrected by creatinine was significantly elevated in 4 and 8 months 
diabetic animals only (figure 5.11-C).  One month controls had an average TIMP-2: Creatinine 
ratio of 0.801 ± 0.0.122pg/mmol, whilst in DN this was 5.178 ± 2.671pg/mmol (p=0.1081).  By 
four months, control rats had a slight increase to1.449 ± 0.2459pg/mmol, but diabetic animals 
were over six times higher at 9269 ± 2.299pg/mmol (p=0.0148). At the end of the study, 
diabetic samples displayed an impressive 44.7 fold increase in the TIMP-2: Creatinine when 
compared to controls (37.90 ± 12.41 pg/mmol, p=0.0405). 
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 Figure 5.11: TIMP-2 measurement in urine from the UNx STZ model of DN  
 
  
 
 
          
 
Figure 5.11: Urine TIMP-2 levels in DN samples at 1, 4 and 8 months post DN induction were measured 
by the Gentaur  rat TIMP-2  Immunoassay and presented as  concentration expressed in pg/ml (A), 24 
hour excretion(B) and as a Creatinine ratio (C).  Statistical significance was tested with one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001, 
between diabetic samples and time matched control. Values are mean ± SEM.  
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5.3.3.3. Measurement of urine TIMP-2 in the Fisher to Lewis transplant model of 
CAN  
 
Urine TIMP-2 levels ranged between 16.69ng/ml to 20.36ng/ml on L-L isograft transplanted 
animals throughout the study (figure 5.12-A).  F-L allografts showed significantly higher levels 
of TIMP-2 as early as two weeks after transplantation (38.45 ± 7.89ng/ml, p=0.0334) and this 
gradually increased over 52 weeks to 82.10 ± 43.31ng/ml, nonetheless this difference was 
significant only up to twenty four weeks (54.16 ± 7.51ng/ml, p=0.0036). 
 
24 hour urine excretion of TIMP-2 from L-L isografts, two weeks after transplantation was 
286.3 ± 73.16ng/24h (n=5) which remained unchanged for 52 weeks when the value was 
231.7 ± 60.48ng/24h (figure 5.12-B).  F-L allografts progressively developed proteinuria, but 
they presented stable total volume of urine in twenty four hours.  Two weeks after 
transplantation, total urinary TIMP-2 excretion from F-L allografts was significantly higher at 
774.3 ± 260.1ng/24h (n=7, p=0.00242), and this gradually increased over 52 weeks to 3347 ± 
2160ng/24h.  In spite of this, again the difference was statistically significant only up to 24 
weeks post transplantation. 
 
L-L isografts presented a slight decrease in the TIMP-2: Creatinine ratio during the study 
(figure 5.12-C).  It declined from 3.81 ± 1.15pg/mmol at two weeks to 2.10 ± 0.63pg/mmol at 
termination by fifty two weeks.  Interestingly, F-L allografts expressed significant increases in 
the TIMP-2: Creatinine ratio from week two up to 33 weeks of the study.  However, it was not 
significant at termination.  The TIMP-2: Creatinine varied from 12.21 ± 2.90pg/mmol, p=0.0311 
at the beginning of the study to 17.45 ± 10.76pg/mmol, p=0.0357 at 33 weeks.  By 52 weeks 
after kidney transplantation, F-L allografts had an average of 34.14 ± 21.02pg/mmol of TIMP-
2: Creatinine, p=0.1143 when compared to L-L isografts. 
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  Figure 5.12: TIMP-2 measurement in urine from the in the Fisher to Lewis transplant 
model of CAN   
 
  
 
 
        
 
Figure 5.12: Urine TIMP-2 levels in the Fisher to Lewis transplant model of CAN over 12 months 
quantified by the Gentaur rat TIMP-2  Immunoassay and presented as  concentration expressed in 
pg/ml (A), 24 hour excretion(B) and as a Creatinine ratio (C).  Statistical significance was tested with 
one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, 
***p<0.001, between F -L allografts and L-L isografts. Values are mean ± SEM.  
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5.3.4. Correlation between urine TIMP-2 and clinical markers of kidney 
function and damage  
5.3.4.1. 24 hours proteinuria 
 
24 hour urine TIMP-2 showed a positive linear association with twenty four hours proteinuria 
in all three models of renal scarring (figure 5.13-A, -B and -C).  The strongest relationship was 
found with diabetic samples, where the higher the proteinuria excretion, the higher the total 
TIMP-2 levels (Pearson’s r = 0.8623. 95% CI: 0.7085 to 0.9379. p<0.0001, r2=0.7435).  A 
positive correlation was also found with CAN samples (Pearson’s r = 0.7799. 95% CI: 0.6503 
to 0.8654. p<0.0001, r2=0.6083) and in a smaller scale, with SNx samples (Pearson’s r = 
0.6315. 95% CI: 0.2859 to 0.8317. p=0.0016, r2=0.3988).  
5.3.4.2. Creatinine Clearance 
 
A correlation between 24 hour urine TIMP-2 and creatinine clearance demonstrated that the 
lower the kidney function, the higher the excretion of TIMP-2 in the SNx and CAN models of 
renal scarring.  Animals submitted to SNx surgery presented a small, but significant negative 
relationship between urinary TIMP-2 and creatinine clearance (Pearson’s r = -0.4893. 95% CI: 
-0.7604 to -0.07296. p=0.0244, r2=0.2394, figure 5.13-D).  In the same way, transplanted 
animals had an inverse correlation between TIMP-2 excretion and kidney function (Pearson’s 
r = -0.4117. 95% CI: -0.6088 to -0.1668. p=0.0016, r2=0.1695, figure 5.13-E).  On the other 
hand, diabetic samples exhibited no correlation between urinary TIMP-2 and creatinine 
clearance (Pearson’s r = 0.003345. 95% CI: -0.3666 to 0.4231. p=0.8739, r2=0.0011, figure 
5.13-F).   
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 Figure 5.13: Correlation plots of urine TIMP-2 excretion with markers of kidney function 
and damage in experimental models of renal scarring 
 
 
     
  
        
 
        
 
Figure 5.13:  Pearson’s correlations were performed for 24 hour urine TIMP-2 excretion vs. 24 hour 
proteinuria in SNx (A), DN (B) and CAN (C) and then for 24 hour urine TIMP-2 excretion vs. creatinine 
clearance in SNx (D), DN (E) and CAN (F) Statistical significance was shown as: NS= non statistical 
significant, * p<0.05, **p<0.01, ***p<0.001. n=25 in SNx and DN and n=56 in CAN. 
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5.3.5. Tissue inhibitor of metalloproteinase 3 
 
To evaluate the urine excretion of TIMP-3, we have used samples from two animal models of 
renal scarring (SNx and DN).  Rat urine TIMP-3 was measured by an optimised Enzyme-
linked immunosorbent assay from Gentaur Molecular products (section 3.11.1.2).  Minimum 
detectable dose of rat TIMP-3 was 0.156ng/ml. 
5.3.5.1. Measurement of urine TIMP-3 in the 5/6th Subtotal nephrectomy model  
 
Urine TIMP-3 concentration on sham-operated rats varied between 0.18ng/ml to 0.56ng/ml 
throughout the study (figure 5.14-A).   Opposingly to results for TIMP-1 and TIMP-2 levels, 
there was no statistical significance on uncorrected urine TIMP-3 concentration between 
controls and SNx rats at all time points of this study.  Average urine TIMP-3 levels on SNx 
samples were 0.217 ± 0.116ng/ml at seven days after surgery (*p=0.8179), than it had a slight 
increase at one month 0.370 ± 0.186ng/ml (**p=0.5289), decreasing to a final concentration 
of 0.140 ± 0.026ng/ml (p=0.3893) at 84 days post subtotalnephrectomy. 
 
To quantify total urine TIMP-3 excretion, previously uncorrected TIMP-3 values were 
multiplied by the total volume of urine voided in twenty four hours (figure 5.14-B).  Along with 
uncorrected TIMP-3 values, total TIMP-3 levels were not different between SNx and controls 
at 7, 28 and 84 days after SNx surgery (* p=0.1738, **p=0.0785, ***p=0.3925, respectively 
 
In contrast to TIMP-1 and TIMP-2, urine TIMP-3 to creatinine ratio was not significantly 
elevated on SNx samples even after correction by creatinine (figure 5.14-C). Average TIMP-
3/Creatinine ratio ranged between 0.009 to 0.052pg/mmol on sham-operated rats during the 
three months of the study. On SNx animals, the TIMP-3: Creatinine ratio was 0.053 ± 
0.002pg/mmol, 0.090 ± 0.032pg/mmol and 0.068 ± 0.018pg/mmol at 7, 28 and 84 days 
respectively (* p=0.2348, **p=0.0817, ***p=0.2037 to controls). 
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 Figure 5.14: TIMP-3 measurement in urine post SNx 
   
           
 
        
 
 
Figure 5.14: Urine TIMP-3 levels were measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by the Gentaur  rat TIMP-3  Immunoassay and presented as concentration in pg/ml (A) 
24 hour excretion (B) and as a Creatinine ratio (C). Statistical significance was tested with one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant between diseased samples and 
time matched control. Data represents mean ± SEM. 
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5.3.5.2. Measurement of urine TIMP-3 in the UNx STZ model of Diabetic 
nephropathy 
 
Diabetic samples had significant urine levels of TIMP-3 at four and eight months after STZ 
injection (figure 5.15-A).  At four months, urine TIMP-3 concentration was 63% higher in 
diabetic animals compared to controls (p=0.0340) and this difference increased to 142% by 
eight months (p=0.0041).  Urine TIMP-3 concentration on controls was stable, with an average 
of 0.205ng/ml during the study. 
 
In diabetic animals, 24 hour TIMP-3 levels were much higher than in SNx (figure 5.15-B).  This 
fact was due to the elevated volume of urine that diabetic animals produced. Nevertheless, 
sham-operated rats presented a similar range of total TIMP-3 excretion in both models of renal 
scarring (0.58 to 3.15ng/24h). 
 
Total TIMP-3 excretion was markedly increased on diabetic rats at four months (29 fold higher 
than controls, p=0.0032, one way ANOVA with Bonferroni post test) and this persisted over 
the following four months reaching a 50 fold increase (p=0.0224) at termination time. 
 
Diabetic animals showed progressive increase in the TIMP-3: Creatinine ratio, suggesting that 
the pattern on TIMP-3 excretion follows disease progression in this disease (figure 5.15-C).  
One month after STZ injection, the TIMP-3:creatinine ratio in diabetic rats was around nine 
times higher than controls, however due to the large spread of measurements it failed to 
achieve significance (p=0.1082, two way ANOVA with Bonferroni post test).  Four months after 
DN induction, the TIMP-3: creatinine excretion from diabetic animals was significantly higher 
at 0.3236 ± 0.0527pg/mmol (p=0.0012), and persisted at eight months with a 32 fold increase 
compared to controls. 
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 Figure 5.15: TIMP-3 measurement in urine from the UNx STZ model of DN  
 
  
 
 
          
 
Figure 5.15: Urine TIMP-3 levels in DN samples at 1, 4 and 8 months post DN induction were measured 
by the Gentaur rat TIMP-3  Immunoassay and presented as  concentration expressed in pg/ml (A), 24 
hour excretion(B) and as a Creatinine ratio (C).  Statistical significance was tested with one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001, 
between diabetic samples and time matched control. Values are mean ± SEM.  
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5.3.6. Correlation analysis for urine TIMP-3 
5.3.6.1. 24h proteinuria 
Total urinary TIMP-3 was not associated with twenty four hours proteinuria in the SNx model 
(Pearson’s r = 0.3449. 95% CI: -0.0491 to 0.6460. p=0.0844, r2=0.1190, figure 5.16-A).  
However, a linear positive correlation was observed in diabetic samples (Pearson’s r = 0.5955. 
95% CI: 0.2620 to 0.8020. p=0.0017, r2=0.3547, figure 5.16-B). 
5.3.6.2. Creatinine Clearance 
Urine TIMP-3 was not correlated with variations in kidney function in the neither the SNx model 
(Pearson’s r = -0.2434. 95% CI: -0.5765 to -0.1500. p=0.2308, r2=0.0592, figure 5.16-C), nor 
the diabetic model (Pearson’s r = -0.2141. 95% CI: -0.1979 to 0.5618. p=0.3041, r2=0.0458 
figure 5.16-D). 
 
Figure 5.16: Correlation plots of urine TIMP-3 excretion with markers of kidney function 
and damage in experimental models of renal scarring 
 
 
     
  
 
          
 
 Figure 5.16:  Pearson’s correlations were performed for 24 hour urine TIMP-3 excretion vs. 24 hour 
proteinuria in SNx (A) and DN (B) and then for 24 hour urine TIMP-3 excretion vs. creatinine clearance 
in SNx (C) and DN (D). Statistical significance was shown as: NS= non statistical significant, * p<0.05, 
**p<0.01, ***p<0.001. n=25 in SNx and DN. 
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5.4. Plasminogen activator inhibitor type 1 (PAI-1) 
 
5.4.1. Measurement of PAI-1 in urine from the 5/6th Subtotal Nephrectomy 
model  
 
Average concentration of PAI-1 in normal urine was 1.59 ± 0.19pg/ml at 1 week after subtotal 
nephrectomy and remained stable at 2.04 ± 0.10pg/ml until termination at 3 months.  Post 
SNx urine PAI-1 levels were not significantly higher than controls at 1 week (1.93 ± 0.09pg/ml, 
p=0.1927) and at 1 month (3.85 ± 1.31pg/ml, p=0.2385).  However, it increased by 84 days 
reaching 18.18 ± 5.77pmol/mg (p=0.0162, figure 5.17-A). 
 
After adjustment of concentration with 24 hour urine volume, urine PAI-1 excretion in twenty 
four hours in control urines ranged between 5.38 to 26.17pg/24h (figure 5.17-B).   Urine PAI-
1 excretion in 24 hours was significantly increased in the SNx at 1 week and 3 months 
(p=0.0211 and p=0.0154 respectively), however this increase was not significance at 1 month 
post SNx (p=0.1115). Despite correction by creatinine ratio, figures were similar to 24 hour 
excretion where no statistical difference was observed between controls and SNx animals at 
one month (p=0.0959, figure 5.17-C).  
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Figure 5.17: PAI-1 measurement in urine post SNx 
 
 
  
       
        
                        
 
Figure 5.17: Urine PAI-1 excretion was measured in SNx samples at 7, 28 and 84 days post Subtotal 
nephrectomy by cation-exchange chromatography and presented as concentration in nmols/mg 
protein (A) 24 hour excretion (B) and as a Creatinine ratio (C). Statistical significance was tested with 
one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, 
***p<0.001, between diseased samples and time matched control. Data represents mean SEM. 
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5.4.2. Measurement of PAI-1 in urine from the UNx STZ model of Diabetic 
Nephropathy 
 
In a similar manner to the SNx model, urine samples from the UNx STZ model of Diabetic 
Nephropathy did not present increased levels of PAI-1 at early stages of the disease 
(p=0.3425 at 1 month after DN induction, figure 5.18-A).  Urine PAI-1 concentration in DN 
samples was only significantly elevated by 8 months (p=0.0114) when levels reached 6.64 ± 
1.29ng/ml, whereas sham operated controls had urine PAI-1 concentration ranging from 0.35 
to 0.85ng/ml throughout the study. 
 
PAI-1 urine concentration was also adjusted to 24 hours excretion in DN samples. 
Interestingly, after adjustment to daily volume, values were significantly increased in 1 and 4 
months diabetic animals (p=0.0366 and p=0.0384 respectively, figure 5.18-B).  Nonetheless, 
despite the high PAI-1 levels by 8 months, it didn’t reach significance when compared to 
controls (p=0.0766) to a large data spread. 
 
Expressing urine PAI-1 excretion as a creatinine ratio showed that it was significantly elevated 
at all time points (figure 5.18-C).  Urine PAI-1 to creatinine ratio was 6, 41 and 108 fold higher 
than matched controls at 1, 4 and 8 months after STZ injection (p=0.0022, p=0.0320 and 
p=0.0222 respectively).  Average values in controls ranged from 0.287 to 0.0467.  
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Figure 5.18: PAI-1 measurement in urine from the UNx STZ model of DN  
 
  
   
       
        
                      
 
Figure 5.18: Urine PAI-1 excretion was measured in DN samples at 1, 4 and 8 months post STZ injection 
by cation-exchange chromatography and presented as concentration in nmols/mg proteins (A) 24 
hour excretion (B) and as a Creatinine ratio, with in set paragraph showing differences at 1 month (C). 
Statistical significance was tested with one Way ANOVA with Bonferroni post hoc test: NS= non 
statistical significant, * p<0.05, **p<0.01, ***p<0.001, between diabetic samples and time matched 
control. Data represents mean ± SEM. 
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5.4.3. Correlations between PAI-1 and clinical markers of renal function and 
damage 
 
5.4.3.1. 24h proteinuria 
 
In the 5/6th subtotal nephrectomy model of renal scarring, correlation between 24 hour urine 
PAI-1 excretion and 24 hour proteinuria showed a strong positive association (n=28, 
Pearson’s r=0.5217, 95% CI: 0.1848 to 0.7491, r2=0.2722, p=0.0044) (figure 5.19-A). 
 
A similar correlation was also found in the UNx STZ model of DN where PAI-1 excretion was 
highly correlated with proteinuria (n=25, Pearson’s r = 0.8816, 95% CI: 0.7422 to 0.9479, 
r2=0.7773, p<0.0001) (figure 5.19-B).  
5.4.3.2. Creatinine clearance 
 
To determine whether the urine excretion of PAI-1 was associated with changes in kidney 
function, a correlation of PAI-1 urine concentration with creatinine clearance was performed.  
In the SNx model, there was a negative association (Pearson’s r=-0.4475, 95% CI: -0.7073 to 
-0.08121, r2=0.2003, p=0.0193) with CrCl, indicating that the higher the PAI-1 excretion the 
lower the creatinine clearance (figure 5.19-C).  
 
In the same way, there was a negative correlation between PAI-1 excretion and creatinine 
clearance in Diabetic samples. However, it did not reach any statistical significance (Pearson’s 
r=-0.02820, 95% CI: -0.4268 to 0.3796, r2=0.0008, p=0.8959, figure 5.19-D). 
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Figure 5.19: Correlation plots for PAI-1 
 
                   
 
 
    
   
  
Figure 5.19: Pearson’s correlations were performed for 24 hour urine PAI-1 excretion vs. 24 hour 
proteinuria in SNx (A) and DN (B) and then for 24 hour urine PAI-1 excretion vs. creatinine clearance 
in SNx (C) and DN (D). NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001. n= 28 in SNx 
and 25 DN. 
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5.5. Discussion 
 
In this study, we have been able to quantify MMPs 1 and 9 as well as their inhibitors; TIMPs 
1, 2 and 3 plus PAI-1 in rat urines obtained from three different models of kidney scarring.  
This was obtained by using commercially available immunoassays.  We observed that urine 
MMP-1 when corrected to creatinine ratio was significantly increased in SNx animals at all 
time points and in 4 and 8 months diabetic animals. On the other hand, MMP-9 excretion was 
undetectable on all control samples and it had a steady, but not significant rise on SNx and 
Diabetic animals even when correcting by creatinine. 
 
Urine TIMP-1 concentration showed no difference between diseased (SNx and DN) and 
control samples at early stages of the disease. However, diabetic samples presented a 
significantly higher excretion of TIMP-1 at 4 months. Reduction on this excretion by 8 months 
could be due to a decrease on glomerular filtration rate found on very late stages of the 
disease.  After normalizing for urine creatinine concentration, corrected TIMP-1 excretion was 
significantly higher on SNx samples at all time points and on DN samples at 4 and 8 months.  
In the Fisher to Lewis transplant mode of CAN, urine concentrations of TIMP-1 were similar 
between F-L allografts and L-L isografts during the entire study, with significant increase on 
F-L allografts at 17 and 24 weeks only when values were expressed as total excretion in 24 
hours.  Overall, urine TIMP-1 excretion showed a very good correlation with disease 
progression in SNx and CAN samples.  However, there was a lack of relationship with 
creatinine clearance in DN samples which also occurred with previous biomarkers (TG2 and 
ε (γ-glutamyl) lysine). 
 
SNx, DN and CAN animals had a similar pattern in relation to urine TIMP-2 excretion. Urine 
TIMP-2 concentration in SNx samples was only elevated by 3 months post subtotal 
nephrectomy. However, by correcting to a creatinine ratio, TIMP-2 excretion showed a 
substantial increase in SNx animals as early as 7 days until the end of the study suggesting 
that it might have a good potential as a biomarker of kidney scarring caused by hypertension.  
F-L allografts also showed significantly higher levels of TIMP-2 as early as two weeks after 
transplantation when compared to L-L isografts, but not by the end of the study.  Interestingly, 
TIMP-2: Creatinine ratio in F-L allografts was significantly increased from week two up to 33 
weeks of the study.  However, it was not significant at termination. In diabetic animals, TIMP-
2: Creatinine ratio was significantly elevated at 4 and 8 months only. In addition, correlating 
urine TIMP-2 and creatinine clearance demonstrated that the lower the kidney function, the 
higher the excretion of TIMP-2 in the SNx and CAN models of renal scarring.  Nevertheless, 
no relationship was observed between urine TIMP-2 and creatinine clearance in diabetic 
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animals. This discrepancy on diabetic samples may be due to hyperfiltration observed at initial 
stages of the disease and the prolonged onset until the disease has been established.  
 
Urinary TIMP-3 excretion was not linked to decreased renal function on both models of renal 
scarring (SNx and DN).  This indicates that urinary TIMP-3 measurements by itself have little 
value as a marker of kidney disease progression 
 
The second part of this study is concerned with the measurement of Plasminogen Activator 
Inhibitor 1.  PAI-1 was specifically quantified in SNx and DN samples as CAN archival samples 
became depleted. Its quantification was performed by using a commercially available ELISA 
kit.  PAI-1 measurement was not significantly increased at earlier stages of both diseases, 
displaying a similar behaviour as TIMP-1 excretion which substantiates their action on ECM 
clearance.  Urine PAI-1 concentration was especially elevated at 3 months SNx (p=0.0162) 
and 8 months DN (p=0.0114).  Although the PAI-1/creatinine ratio became elevated as 
diseased progressed on DN samples, it did not follow the same pattern in SNx. This was an 
interesting outcome as previous research had showed an over expression of both TIMP-1 and 
PAI-1 in kidney tissue in CKD.   This suggests that the TIMP-1 clearance system displays a 
much greater and earlier changes than PAI-1.  Thus, as our main interest is to detect 
molecules that could act as better early biomarkers of all CKD causes, we excluded PAI-1 as 
a suitable candidate for pursuing further research in human urine samples. 
From this chapter, the one point that is apparent is the current relationship between twenty 
four hours proteinuria and clinical markers of kidney scarring.  Such outcome could suggest 
that the increase in the urine levels of the above markers might be a reflection of the protein 
excretion.  However, correction to a creatinine ratio allowed control for variation in urine flow 
rate and better reflection on their truthful output.  Furthermore, a strong negative relationship 
with CrCl was observed, which correlates with disease progression and agrees with previously 
published literature in tissue levels.  
 
Of all measured biomarkers in this chapter, TIMPs 1 and 2 as well as MMP-1 have most 
potential to move forward to human studies as highly significant levels were observed in early 
stages of disease and such elevations were in line with disease progression. Whereas PAI-1 
levels in the urine were either undetectable or close to limit of detection and therefore, 
unworthy of further investigations. 
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Chapter 6 – Urine Hydroxyproline quantification 
in experimental renal scarring as a measure of 
total collagen levels 
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6.1. Introduction 
 
The progression of Chronic Kidney Disease is characterised by a relentless fibrosis of the 
kidneys due to an excessive accumulation of extracellular matrix.  Histologically, this 
progressive accumulation of ECM is driven by the increased deposition of structural proteins 
such as collagen I, III and IV, laminin, nidogen, fibronectin and proteoglycans.  As well as 
increased deposition of its components, a decrease in the activity of ECM degrading enzymes 
such as plasmin and MMPs, either due to increased expression of their respective inhibitors 
or reduced activation of the latent enzyme, can lead to ECM accumulation.   
 
Collagens are the most abundant proteins in connective and interstitial tissues being the major 
component of the extracellular matrix.  So far 27 types subdivided into 9 subfamilies based on 
their structures had been found in humans; the most important ones are the fibrilar collagens 
such as Type I (major component of tendon, ligament and, bones), Type II (cartilage) and 
Type III (arteries, intestine, uterus and renal interstitium), and basement membrane collagens 
such as Type IV that form network-like structures (basal lamina of epithelia, glomerular and 
tubular basements membranes) (Kadler et al. 2007).  They are mainly synthesized by 
fibroblasts (especially collagen types I and III), osteoblasts, chondrocytes and mesangial cells, 
although epithelial cells (especially collagen IV) can also synthesise them.  Collagen 
maturation is a multistep process characterised by a large number of co and post-translational 
modifications mediated by highly specific enzymes (e.g. prolyl 3-hydroxylase, prolyl 4-
hydroxylase, & Lysyl Hydroxylase amongst others).  The final collagen molecule will consist 
of three hydrogen bonded polypeptide α chains forming a super helix with non-collagenous 
sequences at their termini. Collagens are composed of polypeptide chains containing at least 
one domain with Gly-X-Y sequences  (X; Proline and Y; 4-Hydroxyproline) (Prockop and 
Kivirikko 1995).  They are formed by the amino acids glycine, proline, Hydroxyproline and 
Hydroxylysine. As Hydroxyproline (C5H9O3N) is the major component of the collagens and 
found in few other proteins rather than collagen (e.g.; elastin), its measurement is commonly 
used an indicator of the presence of collagen. 
 
 Previous studies have established that an increased synthesis and deposition of collagen into 
the ECM underlies the development of CKD.  However, most studies are limited to the 
investigation of tissue collagen, although there are some studies where urine and circulating 
levels of collagens III and IV respectively were also found to be increased in patients with 
nephropathies (Soylemezoglu et al. 1997).  The limitations of these studies are both a small 
number of CKD cases studied and the fact that they had a very restricted subset of collagens 
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investigated which makes the robustness of the analysis difficult to interpret.  Hydroxyproline 
has been used as a measure of total collagen successfully before, but this has been in acute 
kidney injury in rats due to melamine and cyanuric acid nephrotoxicity (Schnackenberg et al. 
2012) rather than CKD.  Given that CKD is characterised by an excessive accumulation of 
numerous collagens, there is therefore a strong reason to believe these increases in collagen 
can be measured in the urine of patients with CKD by hydroxyproline levels, and if so does 
the level of hydroxyproline reflects the rate of disease progression or stage.  Therefore, this 
chapter will test the hypothesis that the measurement of urinary Hydroxyproline could be used 
as a non-invasive indicator of kidney scaring as its presence is an indicator of ECM deposition. 
 
To test this hypothesis, this chapter aims to:  
1. Establish if it is possible to detect hydroxyproline in urine robustly. 
2. Determine the presence of the urinary collagen metabolite Hydroxyproline in 
urine samples obtained from three animal models of renal scarring: SNx, DN 
and CAN. 
3. Determine whether changes in urine levels of Hydroxyproline are reflected by 
parallel changes in kidney function. 
4. Determine if the analysis of the urinary levels of Hydroxyproline could provide a 
non-invasive tool for CKD assessment in clinical studies. 
 
For Hydroxyproline measurement, samples containing 10mg of protein were submitted to 
complete hydrolysis in a 6M solution of HCl at 1100C for 18 hours followed by freeze drying 
and fractionation onto a Biochrom 30 Amino acid Analyser (AAA) using a standard lithium and 
pH gradient.  The concentration of Hydroxyproline was obtained from a 440 nm profile by 
reference to a 10 nmols / 20ul standard (full method is described in section 3.5.3.).   
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6.2. Optimization of Hydroxyproline measurement by cation exchange 
chromatography  
 
A Hydroxyproline peak is observed in the standard physiological solution at a retention time 
of approximately 24-26 minutes (full methodology in section 3.5.7.2) when fractionated on a 
AAA.  However the initial run of hydrolysed urines from both normal and SNx containing 2mg 
of protein each, showed a Hydroxyproline peak just on the limit of detection for the AAA (figure 
6.1-A) and thus it was necessary to establish if this was both the correct peak and the 
sensitivity of the system.  Therefore, two samples were spiked with 1mg/ml Collagen type I 
(Sigma-Aldrich, UK) to confirm the hydroxyproline peak. Both spiked samples showed an 
amplified hydroxyproline peak at around 24-26 minutes, confirming its detection and correct 
retention time.  Considering the amount of Collagen that was added to each sample (1mg) 
and the amount of hydroxyproline detected without its addition, it was possible to calculate a 
percentage recovery percentage of 77% and that hydroxyproline detection by the AAA could 
be optimised by decreasing the temperature in which the lithium citrate buffer 1, pH 2.80 runs 
from 310C to 300C and also by increasing the loading to 10mg protein (figure 6.1). 
 
 
Figure 6.1: Validation of Hydroxyproline measurement in urines 
 
                                
Figure 6.1: (A) The Hydroxyproline peak should be between Aspartate and Threonine, but it couldn`t 
be detected in initial samples. (B); the same sample spiked with 1mg Collagen type I. A Hydroxyproline 
peak is clearly detected (arrow) at around 25 minutes. (C); overlay of both traces showing in Blue urine 
without and in Green, with addition of 1 mg Collagen type I. Peaks at 440 nm. 
 
 
A. B. C. 
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6.3 Hydroxyproline measurement in urine from 5/6th subtotal 
nephrectomised rats  
 
Having established Hydroxyproline detection is possible in urine, this was then applied to 
analyse urine from SNx samples (19 SNx and 14 Controls) as used in previous chapters. 
Representative traces obtained from AAA analysis (figure 6.2)) show clear peaks for 
hydroxyproline which were greater in the earlier samples. The average concentration of 
Hydroxyproline was statically significant in SNx samples only at the beginning of the study 
(seven days after surgery) when it was expressed per mg protein (11.92 ± 3.86nmol/mg 
protein in the control group vs. 43.10 ± 9.69nmol/mg protein in the SNx, (p=0.0404), figure 
6.3-A). However, no difference was observed after this (p=0.4337 at 1 month and p=0.1878 
at 3 months).  
6.3.1. 24 hour urine excretion of Hydroxyproline in the SNx Model   
 
Twenty four hours Hydroxyproline excretion was estimated by adjustment to total volume and 
proteinuria.  Total excretion of Hydroxyproline in 24 hours was 6.8 fold higher in the SNx 
compared to the controls as early as one week (p=0.0121), 6.5 fold by one month (p=0.0109) 
and 8.1 fold higher at three months (p=0.0003) after subtotalnephrectomy (figure 6.3-B).  Total 
Hydroxyproline excretion remained between 788.8 and 1838nmol/24h on sham operated rats. 
 
6.3.2. Hydroxyproline/Creatinine ratio in the SNx model 
 
Urine Hydroxyproline excretion was corrected for creatinine as described in section 4.2.3.4.  
Sham operated rats presented a Hydroxyproline/creatinine ratio ranging from 0.711 to 
1.18ng/mmol throughout the study (figure 6.3-C).  The Hydroxyproline/creatinine ratio was 
raised in SNx animals when compared to controls throughout the study time course showing  
a robust 15, 11 and 9.8 fold increases at day 7, 28 and 84 respectively (p<0.05, one-way 
ANOVA) was seen. 
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Figure 6.2: Hydroxyproline detection in urine from 5/6th subtotal nephrectomised rats  
 
     
Figure 6.2:  Measurement of Hydroxyproline in SNx samples was performed using a Biochrom 30 
Amino acid Analyser. Hydroxyproline peak (white arrow) is situated between Aspartate and Threonine 
at around 24-26 minutes in A – Control Sample, B – 1 week, C – 1 month and D – 3 months after 
Subtotal Nephrectomy. Representative peaks at 440 nm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. Control B. 1 week SNx C. 1 month SNx D. 3 months SNx 
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 Figure 6.3: Hydroxyproline measurement in urine post SNx 
 
  
   
       
        
 
 
Figure 6.3: Urine Hydroxyproline excretion was measured in SNx samples at 7, 28 and 84 days post 
Subtotal nephrectomy by cation-exchange chromatography and presented as concentration in 
nmols/mg proteins (A) 24 hour excretion (B) and as a Creatinine ratio (C). Statistical significance was 
tested with one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, 
**p<0.01, ***p<0.001, between diseased samples and time matched control. Values are mean ± SEM. 
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6.4. Hydroxyproline measurement in urine from the streptozotocin 
induced model of diabetic nephropathy  
 
Measurement of Hydroxyproline in diabetic samples was performed in the same way as in 
SNx (section 6.3).  The concentration of Hydroxyproline was obtained from a 440 nm profile 
by reference to a 10 nmols/20ul standard.  Hydroxyproline peak had at a retention time of 
around 25 minutes (figure 6.4). 
 
Hydroxyproline excretion was increased by 190% in the DN group as early as one month 
when expressed per mg of urine protein (p=0.0463) and by 171% at four months (p=0.0047).  
However, there was surprisingly no increase at later stages of the disease (i.e. 8 months).  
Hydroxyproline peaks measured in eight months DN urines (3 normal, 5 DN) were very small 
and barely detectable (figure 6.5-A) with values lower than normal samples:  controls – 10.35 
± 1.025 vs. 0.798 ± 0.251nmol/mg protein in DN, (p=0.0008).  
 
6.4.1. 24 h urine excretion of Hydroxyproline in the UNx STZ model of DN  
 
Total excretion of Hydroxyproline in 24 hours was 5.7 fold higher in diabetic animals compared 
to the controls at one month (p=0.0460) and 12.3 fold by four months (p<0.0001) after STZ 
administration (figure 6.5-B). Notwithstanding, no difference was observed between diabetic 
and control rats at eight months (p=0.9319).  
 
6.4.2. Hydroxyproline/Creatinine ratio in the UNx STZ model of DN 
 
The Hydroxyproline/Creatinine ratio on sham-operated rats ranged between 0.57-0.69ng/ml 
(figure 6.5-C). One month after DN induction, Hydroxyproline/creatinine ratio from diabetic 
animals was significantly higher at 11.25 ± 1.65ng/ml (n=4, p=0.0246) and steadily increased 
over four months to 18.87 ± 3.88ng/ml (p=0.0049), higher than controls by over 30-fold. No 
significant difference was established at eight months (p=0.942).  
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Figure 6.4: Hydroxyproline detection in Diabetic Nephropathy urines 
 
                                                                          
 
 Figure 6.4: Representative traces of Hydroxyproline peaks (white arrow) in a Control sample (A) and 
DN samples at 1 month (B), 4 months (C) and 8 months after streptozotocin injection (D). 
Representative peaks at 440 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. 8 Months DN A. Control B. 1 Month DN C. 4 months DN 
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 Figure 6.5: Hydroxyproline measurement in urine from the UNx STZ model of DN  
 
   
       
        
 
 
Figure 6.5: Urine Hydroxyproline excretion was measured in DN samples at 1, 4 and 8 months post 
STZ injection by cation-exchange chromatography and presented as concentration in nmols/mg 
proteins (A) 24 hour excretion (B) and as a Creatinine ratio (C).  Statistical significance was tested with 
one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, 
***p<0.001, between diabetic samples and time matched control. Values are mean ± SEM. 
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6.5. Hydroxyproline measurement in urine from the Fisher to Lewis 
transplant model of Chronic Allograft Nephropathy 
 
47 urine samples urine from the Fisher to Lewis transplant model of Chronic Allograft 
Nephropathy were used to measure Hydroxyproline concentration.  The full set of samples 
(n=72) as used in previous chapters was not available as archived samples became depleted.  
Therefore samples were only measured (for statistical evaluation) at weeks 8, 17, 24, 33 and 
52 post Transplantation.   Hydroxyproline levels per mg of urine protein were measured by 
cation-exchange HPLC using an amino acid analyser (Biochrom 30, Biochrom, UK) as 
described in section 3.5.7.2.  Hydroxyproline retention time of 25 minutes was read at a 
wavelength of 440nm and quantified from the area under the peak (figure 3.22). No urine 
samples at the 2 weeks post transplantation sampling point were available for analysis in the 
L-L isografts.  Eight weeks after transplantation, urine Hydroxyproline concentration from L-L 
isografts (n=5) was 4.77 ± 0.37nmol/mg protein.  This increased to 7.09nmol/mg protein (n=1) 
at 33 weeks. F-L allografts (n=7) had a Hydroxyproline concentration of 6.23 ± 0.99nmol/mg 
protein at 8 weeks (p=0.2182 to L-L isografts), then 5.25 ± 1.18nmol/mg protein at 17 weeks 
(n= 7, p=0.3762 to L-L isografts), 10.42 ± 2.84nmol/mg protein at 24 weeks (n=5, p=0.2046 to 
L-L isografts), 13.83 ± 2.21nmol/mg protein at 33 weeks (n=5) and this peaked at termination 
reaching 18.08 ± 2.94 nmol/mg protein.  Statistical analysis was not performed in these two 
final points as there was insufficient number of L-L isografts (n=1 at 33 weeks and n=0 at 52 
weeks) to make a comparison (figure 6.6-A).  However a clear trend of increasing 
hydroxyproline can be seen. 
 
6.5.1. 24 h urine excretion of Hydroxyproline  
 
Eight weeks after transplantation, total urine Hydroxyproline excretion in 24 hours from L-L 
isografts was 75.59 ± 13.57nmol/24h and this remained stable at 133.29nmol/24h by 33 weeks 
with no evidence of a rapidly increasing trend.  Hydroxyproline excretion in 24 hours on F-L 
allografts showed a steady increase during the study time course (figure 6.6-B).  It rose from 
136.0 ± 27.46nmol/24h at 8 weeks to 4569.69 ± 13.57nmol/24h at 52 weeks. However, there 
was no statistical difference between L-L isografts and F-L allografts up to 33 weeks due to 
the large variability in the urine output of the latter. 
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6.5.2. Hydroxyproline/creatinine ratio  
 
L-L isografts had a Hydroxyproline / Creatinine ratio ranging from 0.723 to 1.121 throughout 
the study.  F-L allografts had a significantly increased Hydroxyproline / Creatinine ratio which 
was 1.8 fold higher than L-L isografts at 8 weeks post transplantation only (1.312 ± 0.212, 
p=0.0439).  It slightly dropped by 17 weeks to 1.213 ± 0.561, p=0.9010).  After this, 
Hydroxyproline/creatinine levels progressively increased until 52 weeks post kidney 
transplantation (2.9 fold higher than L-L isografts at 33 weeks, p=0.3152), but it failed to reach 
significance (figure 6.6-C). 
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 Figure 6.6: Hydroxyproline measurement in urine from the in the Fisher to Lewis model 
of CAN 
 
  
  
        
Figure 6.6:  A – Mean urine Hydroxyproline concentration ± SEM over a 12 month period in the L-L 
isograft (n=5) compared to the F-L allograft (n=7).  B - 24 hr urine Hydroxyproline lysine excretion ± 
SEM, C - Hydroxyproline / Creatinine ratio in F -L allografts and L-L isografts transplanted rats. 
Statistical significance was tested by 2 Way ANOVA with Bonferroni post hoc test: NS= not statistically 
significant, * p<0.05, **p<0.01, ***p<0.001 between F -L allografts and L-L isografts.  
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6.6. Correlation between Hydroxyproline and clinical markers of renal 
function and damage 
 
6.6.1. 24h proteinuria 
 
Total urine Hydroxyproline was associated with changes in proteinuria in thirty one urine 
samples from the SNx study (Pearson’s r = 0.5316, R2 = 0.2826, 95% CI: 0.2184 to 0.7456, 
p=0.0021) and in thirty nine samples from the Fisher to Lewis model of CAN (Pearson’s r = 
0.5417, R2 = 0.2934, 95% CI: 0.2684 to 0.7342, p=0.0004), but not in diabetic samples (figures 
6.7-A, 6.7-B and 6.7-C).  
 
As albumin counts for the greatest amount of protein found on urines from diabetic patients, it 
was expected that an elevation in total proteinuria would not be a direct result of changes in 
urine Hydroxyproline excretion.  As a consequence of this, total urine Hydroxyproline excretion 
showed very weak and not significant correlation with 24h proteinuria (Pearson’s r = 0.2184, 
R2 = 0.0477, 95% CI: -0.1685 to 0.5470, p=0.2641). 
 
6.6.2. Creatinine Clearance 
 
Urine excretion of Hydroxyproline was associated with changes in renal function in SNx 
samples (figure 6.7-D).  A correlation between total urine Hydroxyproline and creatinine 
clearance has demonstrated that the lower the kidney function, the higher hydroxyproline 
excretion in the SNx model of renal scarring (Pearson’s r = -0.4240, R2 = 0.1798, 95% CI: -
0.6804 to -0.0078, p=0.0195). 
 
In diabetic samples, there was a poor positive correlation between Hydroxyproline excretion 
and creatinine clearance (Pearson’s r = 0.3835, R2 = 0.1470, 95% CI: 0.0120 to -0.6619, 
p=0.0440, figure 6.7-E).  The high levels of Hydroxyproline excretion at early stages of the 
disease where kidney function had not deteriorated and the fall of hydroxyproline 
measurements at more advanced stages underlie this lack of association. 
 
CAN samples did not present a correlation between 24 hour urine Hydroxyproline and CrCl 
(Pearson’s r = -0.07415, 95% CI: -0.3848 to 0.2516, R2 = 0.0055, p=0.6582, figure 6.7-F). 
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 Figure 6.7: Correlation plots for Hydroxyproline  
 
  
                 
 
    
  
 
 
  
Figure 6.7: Pearson’s correlations were performed for 24 hour urine Hydroxyproline excretion vs. 24 
hour proteinuria in SNx (A), DN (B)  and CAN (C) and then for 24 hour urine Hydroxyproline excretion 
vs. creatinine clearance in SNx (D), DN (E) and CAN (F).  Statistical significance was shown by one Way 
ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, **p<0.01, ***p<0.001. 
n= 31 in SNx, 25 DN and 39 in CAN. 
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6.7. Discussion 
 
Urines obtained from the 5/6th  Subtotal nephrectomy, the Streptozotocin Diabetic 
Nephropathy and the Fisher to Lewis transplant model of Chronic Allograft Nephropathy, 
which are well characterised and established models of kidney scarring, were used for 
hydroxyproline measurement.  Assessment of Hydroxyproline in urines was undertaken as it 
has been widely reported in histopathological studies that development of scarring is 
correlated to increased synthesis and deposition of particularly fibrilar collagens with collagen 
acting as a key component of scar tissue.  Measurement of urine collagen can be performed 
by commercially available immunoassays for individual collagen types or indirectly by the 
analysis of Hydroxyproline content.  In our research, we chose to quantify hydroxyproline as 
it represents a measure of total collagen present in urine samples. Release of Hydroxyproline 
from the samples was achieved by hydrolysis followed by fractionation of amino acids by 
cation exchange chromatography. 
 
To date, there are surprisingly few studies correlating the use of urine collagen as a possible 
marker of kidney scarring given its role in kidney fibrosis.  Urine amino terminal peptide of 
procollagen III (PIIINP) was positively correlated to interstitial fibrosis in humans, although it 
was not correlated to increased serum creatinine (Soylemezoglu et al. 1997).  The urine 
carboxy terminal fragment of type IV procollagen was found increased in Minimal Change 
disease, but again it was not correlated to increased serum creatinine and neither to CrCl or 
other nephropathies (Keller et al. 1992).  Irrespective of the limitations of these early studies 
of urine collagen in CKD, we hypothesised that measurement of urinary Hydroxyproline could 
be used as a non-invasive indirect indicator of collagen presence and subsequently fibrosis.  
 
In this study, initial assessment of Hydroxyproline showed increased concentration at initial 
stages of both SNx and DN groups when expressed per mg protein. But, no difference was 
observed at later stages of both diseased groups. However if Hydroxyproline secreted per 24 
hours was calculated it increased markedly in the SNx group at all time points, indicating that 
pathological changes in the kidney were being carried through to the urine.  In contrast, similar 
changes were surprisingly not seen in the DN animals despite an equivalent level of tissue 
scarring.  Diabetic animals showed significantly increased levels of urine Hydroxyproline in 24 
hours at 1 and 4 months only, but not at the last end point.  Hydroxyproline peaks were very 
small and barely detectable at 8 months post STZ injection (figure 6.4) with values lower than 
normal samples expressed as either nmol per mg of urine or twenty four hours excretion. Also, 
no correlation was found between urine excretion of Hydroxyproline and 24 hour proteinuria.  
As discussed earlier, later stages of the diabetic disease are characterised by excessive 
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excretion of albumin in the urine.  This albuminuria can vary from small amounts (30 to 300 
mg/24h – Microalbuminuria) up to larger amounts (>300mg/24h – Macroalbuminuria).  
Biochemistry tests were performed in our samples and showed significant increased 
macroalbuminuria in diabetic rats by 8 months of study.  Thus, the relative expression of 
hydroxyproline in such urines could be masked by the abundant amounts of albumin present 
in the urine. Another possible explanation for this, could be the fact that as ECM becomes 
increasingly crosslinked in the kidney (e.g. by TG2), this could prevent collagen on finding its 
way into the urine.  Alternatively, it can also not be excluded that it could have been an artefact 
of the analysis given what occurs in the two other animal models. 
 
On the other hand, in a further evaluation of the data, the Hydroxyproline/Creatinine ratio was 
calculated and it confirmed significant increase in the diseased samples in SNx at all time 
points and in DN at 1 and 4 months only.   As to the CAN samples, although the set was 
incomplete, a trend was observed with increase in the Fisher-to-Lewis Allografts compared to 
the Lewis-to-Lewis Isograft group. However, no statistical difference was observed, mainly 
because there were not enough samples at the latter stages in order to draw a comparison. 
In SNX and CAN there was a similar trend of increased Hydroxyproline/Creatinine ratio at the 
late stages of disease.  Thus in all models it is a good early indicator of the potential for CKD 
development, but not a late stage indicator in DN and this requires more studies to better 
understand why this occurred. 
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Chapter 7 
Human Chronic Kidney Disease and the urine 
excretion of Transglutaminase type 2 and ε (γ 
glutamyl) lysine as biomarkers of CKD 
progression 
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7.1. Introduction 
 
Chronic Kidney Disease (CKD) is recognised as a major public health problem with an 
estimated prevalence of approximately 10% of the adult population in Western Countries 
(McCullough et al. 2012).  Novel CKD classification established by the KDIGO in 2012 divides 
it into 6 categories according to eGFR (G1 to G5) with G3 split into 3A (eGFR between 45 – 
59ml/min/1.73m2) and 3b (eGFR between 30-44ml/min/1.73m2) and it is also based in three 
levels of albuminuria: A1 (normal to mildly increased albuminuria, <30mg/g), A2 (moderately 
increased albuminuria, 30-300mg/g) and A3 (severely increased albuminuria, >300mg/g) 
(KDIGO 2012).  The new definition of CKD subdivides it into community CKD (cCKD) and 
referred CKD (rCKD).  cCKD in Western countries is mainly a disease of old people due to 
age related abnormalities whilst in Eastern countries it is related to poverty, infections such as 
malaria, schistosomiasis and hepatitis, exposure to environmental pollution (air, water), use 
of traditional herbal remedies, malnutrition, low birth weight, drug toxicity and changes in life 
style (Westernisation).  rCKD is associated with primary or secondary nephropathies including 
vasculitis, SLE, CGN, Interstitial Nephritis and PKD (Floege 2013). 
 
Recent studies have stressed the importance of prevention, early detection and management 
of progressive kidney disease (Turner et al. 2012).  Hence the crucial importance of 
developing tests for identification of CKD.  Current kidney function and damage tests have 
several limitations including the delayed detection of dysfunction which happens only after 
significant damage has occurred and the inability to precisely establish disease stage.  The 
limitations of these tests have instigated the search for early and reliable non invasive 
biomarkers of kidney disease. 
 
CKD function is currently based on estimated GFR (eGFR), which is derived from the 
calculation of serum creatinine levels, or serum Cystatin C, or a combination of creatinine and 
Cystatin C (Delaine et al, BMC nephrology 2013).  The most used equation is derived from 
the Modification of Diet in Renal Disease (MDRD) study and this utilizes standardised serum 
creatinine, age, sex and race to estimate GFR adjusted for body surface area.  However, it 
was found that this equation overestimates the measured GFR (mGFR) within individuals that 
have a mGFR above 60 ml/min/1.73m2.  This can lead to a misclassification of large number 
of patients with CKD 1, 2 and CKD3a.  The Chronic Kidney Disease-Epidemiology 
Collaboration study (CKD-EPI) equation was recently developed and it also uses serum 
creatinine, age, sex and ethnicity (black) to estimate GFR. /it performs better than the MDRD 
when the GFR > 60ml/min/1.73m2.  CKD-EPI has less bias and it showed a mean measured 
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eGFR of 2.5ml/min/1.73m2 in the CKD-EPI compared to 5.5ml/min/1.73m2 in the MDRD 
(Delanaye et al. 2013).  Although the CKD-EPI showed an improved precision and better risk 
prediction, it also had some limitations as this study used a low number of elderly and ethnic 
minorities to measure GFR.  In addition, no difference was found in the ROC curves from both 
equations (Levey et al. 2009).  The CKD-EPI cys (based on cystatin C) and the CKD-EPI mix 
(uses both creatinine and cystatin C) both use plasma cystatin C levels as it has shown good 
biomarker characteristics.  Studies comparing the performance of these cystatin C based 
equations concluded that they present a better prediction of GFR, especially in individuals at 
CKD stage 3 (Delanaye et al, 2013).  Other molecules studied as alternative filtration 
biomarkers include beta-trace protein (BTP) and beta-2-microglobulin (B2M).  
 
Microalbuminuria or low level albuminuria (mA, A2 category) has been used as the gold 
standard definer of CKD development and progression.  However, it is a common feature of 
aging, obesity, extensive exercise, pregnancy, tobacco consumption, infections such as HIV, 
Scabies, Hepatitis C and H. Pylori, while it can also be associated with a large number of acute 
and chronic vascular as well as inflammatory pathologies including IBD, ATS, Psoriasis and 
periodontitis.  Additionally, microalbuminuria is often regarded as an important risk factor for 
cardiovascular disease. Furthermore, mA is often transitory and irresolute thus not a specific 
and reliable marker of CKD, especially at early stages of the disease.  So, although mA carries 
the title of the best CKD marker at the moment, it lacks specificity to kidney disease 
progression and therefore its sole use as such should be questioned.  
 
Defining CKD progression is a point of ample controversy due to the issues raised by the 
eGFR equations when the GFR is greater than 60ml/min/1.73m2.  Also, the variability of serum 
creatinine levels represents a barrier for precise estimation of eGFR assessment and 
subsequent CKD progression.  The KDIGO guidelines suggests classifying progressive kidney 
disease as a sustained decline in eGFR greater than 5 ml/min/1.73m2 per year or a decline of 
over 25% in eGFR from baseline (KDIGO 2012), others  have suggested a classification of 
progressive CKD when the eGFR decline is above 3 ml/min/1.73m2 per year (Rosanski, Am 
Journal of Nephrology 2012).  We have decided to extend this classification and subdivide it 
into two distinct categories: progressive CKD (eGFR decline above 2 ml/min/1.73m2 per year) 
and rapidly progressive CKD (eGFR decline above 5 ml/min/1.73m2 per year).  The rationale 
for our sub classification is that a normal decline of eGFR in healthy individuals is bellow 1 
ml/min/1.73m2 per year from around 40 years of age, so we used a tighter definition of 
progression (double the normal loss of function), in order to potentially identify subjects at 
early stages of decline.  Thus, earlier identification of individuals at potential risk for CKD 
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progression would enable clinicians to apply interventions aimed at slowing its progression 
and could decrease the number of patients reaching ESKD. 
 
In previous chapters using urine samples obtained from three different animal models of 
kidney scarring (5/6th subtotal nephrectomy, the Streptozotocin Diabetic Nephropathy and the 
Fisher to Lewis transplant model of CAN (results chapter 4), effective assays for the detection 
of Transglutaminase type 2 and its crosslink product ε (ᵞ glutamyl) lysine (Vass et al. 2012) 
were established.  Urine expression of both molecules demonstrated a good correlation with 
disease status suggesting that they may have great potential as biomarkers of human chronic 
kidney disease.  TG2 was remarkably increased in diseased urines when compared to time 
matched controls in all three animal models especially when converted to a TG2:creatinine 
ratio.  Changes were detected in ε (ᵞ glutamyl) lysine levels per mg of protein in SNx and CAN 
models, but surprisingly not in diabetic nephropathy samples. 
 
Thus in this chapter it was hypothesised that similar changes in TG2 & ε (ᵞ glutamyl) lysine 
also occurred in patients with CKD and may potentially have both diagnostic and prognostic 
value.  To test this translational hypothesis this chapter aims to quantify Transglutaminase 
type 2 and its crosslink product ε (ᵞ glutamyl) lysine in human urine samples.  TG2 levels in 
the urine were quantified by an in-house Sandwich ELISA.  For this assay, an anti TG2 goat 
polyclonal was used as capture antibody and anti TG2 monoclonal CUB7402 (both from 
AbCam, UK) as the detection antibody.  A standard curve was generated by performing a 
serial dilution of human recombinant TG2 (methods section 3.4.3).  In addition to the urine 
samples, serum and plasma samples were also collected in order to compare excretion and 
circulating levels.  For the urine excretion of ε (γ-glutamyl)-lysine, a technique previously 
developed in the animal study was used.  In this, 5 mg of urine protein was digested through 
a combination of five different proteolytic enzymes and products were analysed by cation-
exchange HPLC using an amino acid analyser (AAA) (Biochrom 30, Biochrom, UK) (methods 
section 3.5.3). 
 
Specifically, work in this chapter aimed to: 
 
 Recruit CKD patients above 18 years old with any CKD ethiology or stage attending 
the SKI outpatient clinic facilities 
 Collect bio-samples (blood and urine) from all controls and CKD patients involved in 
this study, including the patients undergoing renal biopsies to correlate these findings 
with histological changes as well as clinical parameters 
 Identify relevant demographic, social, and medical conditions in this group of patients 
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 Determine the prevalence of progressive and non-progressive CKD patients within this 
group and then to stratify subjects by levels of CKD progression 
 Define the prognostic value of  TG2 and ε (ᵞ glutamyl) lysine in identifying patients with 
progressive CKD 
 Determine the relative advantages of  urine and circulating levels of TG2 as a 
prognostic marker 
 
The first part of this chapter established a prospective observational cohort of adult CKD 
patients from stages 1 to 5.  The investigation was performed under an ethics application 
entitled “The study of the natural history and biomarkers of Chronic Kidney Disease” (ethics 
reference application number STH 15004) and was conducted at the Sheffield Kidney Institute 
(SKI) located in the Northern General Hospital site of the Sheffield Teaching Hospitals NHS 
Foundation Trust.  In this study, we collected urine and blood samples from 292 CKD patients 
and 33 Controls (section 3.2).  The outcomes of the bio-clinical and laboratory assessment 
undergone by patients, as well as their anthropomorphic and socio-economic status are 
reported in this chapter. 
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7.2. Study population & Clinical Sample Collection 
 
7.2.1. Study design 
 
The study consisted of a prospective observational cohort of adult CKD patients over a period 
of 3 years.  A total of 292 CKD patients from stages 1 to 5, including 41 which underwent 
kidney biopsy and 33 controls were included in this study.  From this total of 292 CKD patients, 
91 presented with Diabetic Nephropathy plus 201 patients which had non-diabetic CKD of 
various aetiologies.  Full details of the study design are described in the methods chapter 3, 
section 3.2.1.  Briefly, CKD patients above 18 years old with any type of CKD were recruited 
after appropriated consent procedures and initial screening of urine samples.  Major CKD 
causes were: diabetic kidney disease (DKD), chronic glomerulonephritis (CGN), hypertensive 
nephrosclerosis (HTN), atherosclerotic renovascular disease (ARVD), chronic interstitial 
nephritis (CIN) and ADPKD.  All patients underwent a detailed bio-clinical assessment at 
baseline and at every outpatient’s clinical appointment for the period of enrolment in the study.  
Ten millilitres of blood (5ml of serum and 5ml of plasma) as well as a target of 220 ml of fresh 
Mid-Stream Urine (MSU) were collected at the time of recruitment.  Recordings of eGFR and 
all clinical and laboratorial data were securely stored in the Sheffield Kidney Institute (SKI) 
CKD database. 
 
7.2.2. Demographic and socio-economical characteristics of the study 
population 
 
The CKD population consisted of: 38.69% Females and 61.31% Males, with 90.41% 
Caucasian and 9.59% from other ethnicities.  The age range of these patients consisted of a 
median of 63.9 years with 25% percentile at 56.50 years and 75% at 75.70 years, with 61.9% 
aged above 65 years. 
The control group consisted of: 30.30% Females and 69.70% Males, with 63.64% Caucasian 
and 36.36% from other ethnicities.  The mean age of controls in this study was 38.48 ± 7.61 
years. 
As for the smoking habits; 11.30% of CKD patients were smokers, 36.99% past smokers and 
51.71% non-smokers. In the control group only 3.03% were actual smokers, 6.06% were past 
smokers and 90.91% never smoked in their lives. 
Majority of the CKD patients enrolled in this study were either retired (42.67%) or unemployed 
(14.68%), whilst only 42.65% were active workers (18.81% skilled/professionals and 23.84% 
manual workers). Most patients lived either in Sheffield (55.68%), Rotherham (22.29%) or in 
Barnsley (14.03%). 
 
238 
 
The overall demographic data is depicted in figure 7.1. 
 
Figure 7.1: Frequency distribution of CKD patients’ demographic data 
 
Figure 7.1: Demographic data from 292 CKD patients enrolled in the study.  The frequency distribution 
of their gender, race, age, employment status, residence location and smoking habits are displayed as 
a percentage of the total study population. 
 
7.2.3. Anthropomorphic data 
 
All patients had their weight, height and Body Mass Index (BMI) ascertained when bio-samples 
were collected.  Body mass index was calculated as weight/height2 (kg/m2).  A BMI bellow 
18.5 kg/m2 was used to classify patients as underweight, then between 18.5 and 24.9 kg/m2 
as normal weight, between 25 and 29.9 kg/m2 as overweight and greater than 30 kg/m2 for 
obesity. 
 
Overall, the majority of CKD patients were either obese (46.47%) or overweight (34.85%). 
17.17% of CKD patients had normal weight and only 1.51% were underweight, which included 
a patient suffering from anorexia nervosa (figure 7.2-B).  The mean BMI ± SD of the CKD 
study population was 30.83 ± 6.07 kg/m2 against 22.34 ± 2.71 kg/m2 in the healthy volunteer 
population.  CKD patients had an average weight of 79.73kg for females and 91.07 kg for 
males (p<0.0001, figure 7.2-A) whilst male healthy volunteers also presented higher average 
Gender Race Age Employment Address Smoking Habit
0
20
40
60
80
100
Male
Female
Caucasian
Others
> 65 y
< 65 y
Retired
Working
Unemployed
Sheffield
Rotherham
Barnsley
Others
Non-
smokers
Past
Smokers
Smokers
P
e
rc
e
n
ta
g
e
 d
is
tr
ib
u
ti
o
n
239 
 
weight (75.09kg) than females (63.24kg, p=0.0094, figure 7.2-C).  The vast majority of healthy 
volunteers had normal weight (58.06%), with 38.71% being overweight (figure 7.2-D). 
 
Figure 7.2: Anthropomorphic data from CKD patients and healthy volunteers 
 
 
 
 
 
 
  
Figure 7.2: Anthropomorphic data from 292 CKD patients and 31 healthy volunteers (out of 33) 
enrolled in the study. Body weight of female and male participants (A, C) Body Mass Index (B, D).  
Underweight = <18.5 kg/m2, Normal = 18.5-24.9 kg/m2, Overweight = 25-29.9 kg/m2 and Obese, BMI 
of 30 kg/m2 or greater. 
 
7.2.4. CKD diagnosis and co-morbidities 
 
Primary aetiologies of CKD were: diabetic kidney disease (n=91, 31.17%), chronic 
glomerulonephritis (n=66, 22.60%), hypertensive nephrosclerosis (n=53, 18.15%), 
atherosclerotic renovascular disease (n=29, 9.93%), chronic interstitial nephritis (n=15, 
5.14%) and ADPKD (n=13, 4.45%) (figure 7.3-A).  Other causes of CKD (n=25, 8.56%) 
included cases of cast nephropathy (Multiple Myeloma), amyloidosis, idiopathic 
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thrombocytopenic purpura, Henoch Scholein purpura, monoclonal gammopathy of 
undetermined significance (MGUS), microscopic polyarteritis, familial renal disease, medullary 
sponge kidney, sarcoidosis, lupus nephritis, HIV-associated Nephritis, Tacrolimus toxicity and 
renal cell carcinoma.  Patients with chronic glomerulonephritis had a biopsy diagnosis (n=41) 
of: Membranous nephropathy (36.59%), IgA nephropathy (34.15%), Focal and Segmental 
Glomerulosclerosis (FSGS) (12.20%), Membranoproliferative glomerulonephritis (7.32%), 
Minimal change (4.88%) and Rapidly Progressive glomerulonephritis (RPGN) (4.88%) (figure 
7.3-B).  
 
The main co-morbidities presented by CKD patients are displayed in table 7.1.  Hypertension 
was the condition with highest prevalence amongst our study population, accounting for 
81.16% of participants.  Individuals were classified as having hypertension on the basis of 
receiving anti-hypertensive medication or by presenting high blood pressure measurements 
at the time of enrolment, this was done in accordance with the guidelines of the Eight Joint 
National Committee for Definition and Classification of Hypertension (JNC 8) (Chobanian et 
al. 2003).  Hypercholesterolemia and obesity were present in nearly half of subjects (49.66% 
and 46.47% respectively).  The presence of cardiovascular disease (CVD) was noted in over 
one third of this population (40.41%).  Other important co-morbidities included: mineral bone 
disease (17.13%), peripheral vascular disease (16.44%), gout (14.04%) and anaemia 
(11.30%). Anaemia was classified as haemoglobin < 12 g/dl. 
 
Table 7.1: Frequency distribution of main co-morbidities presented by CKD patients 
 
Co-morbidity Percentage 
Hypertension 81.16% 
Hypercholesterolemia 49.66% 
Obesity 46.47% 
Cardiovascular Disease 40.41% 
Bone disease 17.12% 
Peripheral vascular disease 16.44% 
Gout 14.04% 
Anaemia 11.30% 
COPD 9.59% 
Cerebral vascular disease 8.90% 
Hypothyroidism 8.56% 
Cancer * 8.22% 
Psychological disease 4.11% 
Recurrent UTI 1.71% 
 
Table 7.1: The prevalence of the most common co-morbidities found in the study population is shown 
as a percentage of those affected. * Cases of cancer include the following organs: Lung, Prostate, 
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Penis, Testicular, Pancreas, Intestinal, Liver, Bladder, Kidney, Skin and Breast cancer. COPD = Chronic 
obstructive pulmonary disease. 
 
Figure 7.3: CKD Ethiology 
 
 
 
 
Figure 7.3: The pie charts illustrate the main CKD diagnosis presented as a percentage of the total 
study population (A) and the sub-classification of 41 Chronic Glomerulonephritis patients given by 
biopsy (B). 
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7.2.5. CKD stages  
 
The mean follow up time for this study was 2.19 ± 0.68 years.  The majority of patients were 
either at CKD stage 3 (38.36%) or stage 4 (45.21%) at recruitment.  The full stratification into 
CKD stages, including the sub-division into stages 3A and 3B (figure 7.4) and  the frequency 
distribution of CKD stages 1 to 5 in each cause of CKD (figure 7.5) demonstrated wide 
inclusion into the study.  
 
Figure 7.4: CKD stages 
 
 
 
Figure 7.4: The bar chart shows the frequency distribution of the study population grouped by CKD 
stage.  Classification of CKD stages is as defined in the K/DOQI guidelines: CKD stage 1, eGFR >90 
ml/min/1.73m2, CKD stage 2, eGFR = 60-89 ml/min/1.73m2, CKD stage 3A, eGFR = 45-59 
ml/min/1.73m2, CKD stage 3B, eGFR = 30-44 ml/min/1.73m2, CKD stage 4, eGFR = 15-29 
ml/min/1.73m2 and CKD stage 5, eGFR < 15 ml/min/1.73m2.  Data represents the percentage of the 
total number of CKD participants in the study (n=292). 
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Figure 7.5: Frequency distribution of CKD stages according to CKD ethiology 
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7.2.6. Clinical and Laboratorial assessment 
 
Serum creatinine, urine creatinine, blood urea nitrogen, albuminuria, serum cholesterol, 
triglycerides, calcium, phosphorus and PTH were analysed by standard autoanalyser 
techniques by the Clinical Chemistry Department at the Northern General Hospital (section 
3.2.5.3).  Total proteinuria was measured by the BCA assay (section 3.3.2.2) and urine 
sedimentoscopy was performed using a Microalbustix® urine test strip (section 3.2.5.2). 
 
Tables 7.2 and 7.3 summarise the main biochemical as well as demographic characteristics 
from the study population.  
 
7.2.6. Rate of eGFR decline and CKD progression by aetiology  
 
The risk factors associated with CKD progression are described in section 1.5.1.  CKD 
progression was evaluated by the rate of eGFR decline calculated by the regression analysis 
of 10 different eGFR values obtained over a period of approximately 3 years (figure 7.6).  The 
mean rate of eGFR decline of the entire study population was -0.79 ml/min/1.73m2 (n=292).  
Overall, around one third of all CKD patients were classified as progressors (eGFR decline > 
- 2 ml/min/1.73m2/year) and 184 patients were classified as stable or non-progressors (eGFR 
decline < - 2 ml/min/1.73m2/year). The pathologies that caused the highest incidences of CKD 
progression were diabetic kidney disease (44.56%), chronic glomerulonephritis (42.42%) and 
hypertension (31.7%) (tables 7.2 and 7.3).  Hypertensive patients presented the fastest rate 
of eGFR decline (-1.25 ml/min/1.73m2).  Similar levels of kidney function reduction were 
observed in patients with CGN (-1.22 ml/min/1.73m2) and DKD (-1.17 ml/min/1.73m2).  
Interestingly, patients which presented chronic interstitial nephritis, atherosclerotic 
renovascular disease, polycystic renal disease and other causes of CKD showed lower levels 
of eGFR decline: -0.49, 0.33, -0.16 and 0.32 ml/min/1.73m2/ year, respectively (figure 7.7).  Of 
note, around 17% of patients were classified as regressors as an improvement of kidney 
function was observed. 
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Figure 7.6: Regression analysis for estimation of eGFR decline 
  
 
 
Figure 7.6: eGFR slope against time estimated by regression analysis showing in (A) an example of a 
CKD progressive patient with an estimated decline from 48 to 41.63 ml/min/1.73m2 after a year (x=365 
days, Δ eGFR = 41.63 – 48 = -6.37 ml/min/1.73m2/year) and (B) a non-progressive patient with eGFR 
ranging from 56 to 53 over a 3 years period and an estimated decline to 55.45 ml/min/1.73m2 after a 
year (x=365 days, Δ eGFR = 55.45 – 56 = -0.55 ml/min/1.73m2/year),Y axis shows measured GFR and 
X axis when the test was performed. 
 
 
The comparisons between the main demographic and clinical characteristics of the study 
population in each CKD aetiology were subdivided by levels of CKD progression (tables 7.4 
to 7.10).  Statistical analysis from contingency data was performed by Z-test for proportions 
and from biochemical measurements by Independent-samples T test.  In DKD, the non-
progressive group was significantly older and from white ethnicity, but not in any other 
aetiologies.  Progressive DKD patients presented higher HbA1c (%), albuminuria, total 
proteinuria and co-morbidities at sampling.  eGFR was lower in progressive patients at 
sampling in CGN and ADPKD only.  Differences in CKD stage were only evident in patients 
with CGN (significantly more cases of CKD 1 and 2 in non-progressive), hypertensive (more 
cases of CKD 3B in non progressors), and ARVD (higher percentage of CKD 5 in progressive 
patients).  In addition, both ADPKD patients with progressive CKD were at stage 4. 
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Table 7.2:  Clinical and laboratory characteristics of CKD patients, their subgroups and 
controls 
 
Variable Controls Total CKD 
patients 
DKD CGN HTN ARVD CIN ADPKD Others 
Number (n) 33 292 91 66 53 29 15 13 25 
Gender: 
Male, n (%) 
23 
(69.70%) 
179 
(61.31%) 
57 
(62.64%) 
41 
(62.12%) 
31 
(51.5%) 
22 
(75.86%) 
7 
(46.67%) 
7 
(53.85%) 
14  
(56%) 
Age (years) 38.48 ± 
7.6 
63.9 ±  
16.58 
68.17 ± 
11.61 
49.81 ± 
17.81 
71.63 ± 
12.04 
75.41 ± 
6.35 
62.07 ± 
13.05 
47.23 ± 
17.88 
61.91 ± 
19.05 
Race: 
Caucasians,  
n (%) 
21 
(63.64%) 
264 
(90.41%) 
83 
(90.22%) 
57 
(86.36%) 
46 
(86.79%) 
27 
(93.10%) 
15 
 (100%) 
13  
(100%) 
23  
(92%) 
BMI 22.34 ± 
2.71 
30.83  
± 6.07 
31.81 ± 
5.64 
29.31 ± 
5.72 
31.18 ± 
8.89 
29.33 ± 
4.04 
27.94 ± 
3.21 
29.4 ± 
6.64 
25.89 ± 
2.61 
Smokers,  
n (%) 
1  
(3.03%) 
33  
(11.30%) 
9  
(9.89%) 
3  
(4.55%) 
8 
(15.09%) 
6 
(20.69%) 
2 
(13.33%) 
2 
(15.38%) 
3  
(12%) 
CKD Stage 1,  
n (%) 
NA 11  
(3.77%) 
0 9 
(13.64%) 
0 1  
(3.35%) 
0 1  
(7.69%) 
0 
CKD Stage 2,  
n (%) 
NA 21  
(7.19%) 
0 12 
(18.18%) 
2  
(3.77%) 
2  
(6.90%) 
0 3 
(23.08%) 
2  
(8%) 
CKD Stage 3A,  
n (%) 
NA 39  
(13.01%) 
13 
(14.29%) 
14 
(21.21%) 
5 
 (9.43%) 
2  
(6.90%) 
1  
(6.67%) 
2 
(15.38%) 
2  
(8%) 
CKD Stage 3B,  
n (%) 
NA 73 
(25.00%) 
26 
(28.57%) 
13 
(19.70%) 
13 
(24.53%) 
9 
(31.03%) 
5 
(33.33%) 
2 
(15.38%) 
5  
(20%) 
CKD Stage 4,  
n (%) 
NA 132 
(45.55%) 
49 
(53.84%) 
16 
(24.24%) 
28 
(52.83%) 
12 
(41.38%) 
8 
(53.33%) 
4 
(30.77%) 
15 (60%) 
CKD Stage 5,  
n (%) 
NA 16 (5.48%) 3 (3.30%) 2 (3.03%) 5 (9.43%) 3(10.34%) 1 (6.67%) 1 (7.69%) 1 (4%) 
eGFR  at sampling 
(ml/min/1.73m2) 
>90 36.70 ± 
21.19 
30.94 ± 
11.01 
55.05 ± 
29.87 
29.47 ± 
14.36 
30.20 ± 
18.11 
28.38 ± 
9.66 
46.25 ± 
31.01 
37.14 ± 
20.16 
CKD progression 
(%) 
NA 108 
(36.97%) 
41 
(44.56%) 
28 
(42.42%) 
20 
(37.74%) 
6 
(20.69%) 
5  
(33.335) 
2 
(15.38%) 
6 
(22.58%) 
Serum creatinine 
(µmol/L) 
81.12 ± 
12.49 
183.39 ± 
74.68 
188.15 ± 
63.55 
143.43 ± 
76.85 
208.23 ± 
87.94 
207.32 ± 
65.65 
188.77 ± 
66.52 
177.64 ± 
82.68 
185.78 ± 
68.35 
Urine Creatinine 
(µmol/L) 
11.4 ± 
6.08 
7.17 ± 
 4.94 
6.45 ± 
3.57 
9.49 ± 
6.60 
7.76 ± 
5.94 
6.58 ± 
4.05 
6.01 ± 
5.16 
5.23 ± 
4.23 
6.81 ± 
2.98 
Albuminuria 
(mg/L) 
1.8 ± 
3.65 
540.36 ± 
1207.67 
351.62 ± 
633.21 
1512.47± 
2273.06 
362.34 ± 
611.79 
296.83 ± 
651.76 
113.54 ± 
218.64 
165.35 ± 
388.63 
303.78 ± 
505.92 
Proteinuria 
(mg/L) 
0.06 ± 
0.03 
0.92 ±  
1.62 
0.72 ± 
0.95 
1.97 ± 
3.05 
0.82 ± 
0.87 
0.52 ± 
0.99 
0.52 ± 
0.56 
0.43 ± 
0.49 
0.68 ± 
1.08 
BUN (mmol/L) 4.44 ± 
1.16  
13.86 ± 
6.71 
14.05 ± 
6.66 
12.69 ± 
4.58 
13.78 ± 
4.91 
13.24 ± 
5.13 
12.07 ± 
4.89 
13.15 ± 
5.82 
13.91 ± 
6.94 
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Table 7.3: Clinical and laboratory characteristics of CKD patients, their subgroups and 
controls 
 
Variable Controls Total CKD 
patients 
DKD  CGN HTN ARVD CIN ADPKD Others 
Serum 
Cholesterol 
(mmol/L) 
NA 4.51 ±  
1.59 
3.80 ± 
1.07 
5.95 ± 
2.29 
4.59 ± 
1.29 
4.38 
±1.16 
4.69 ± 
1.40 
4.32 ± 
0.79 
4.97 ± 
1.22 
Triglycerides 
(mmol/L) 
NA 2.03 ±  
1.44 
1.86 ± 
0.11 
2.42 ± 
1.82 
2.14 
±1.93 
1.84 ± 
1.18 
1.68 
±1.02 
1.61 ± 
1.00 
2.19 ± 
1.30 
Serum calcium 
(mmol/L) 
NA 2.33 ±  
0.10 
2.34 ± 
0.11 
2.35 ± 
0.09 
2.31 ± 
0.09 
2.32 ± 
0.10 
2.27 ± 
0.10 
2.34 ± 
0.10 
2.33 ± 
0.11 
Serum 
Phosphorus 
(mmol/L) 
NA 1.20 ±  
0.23 
1.18 ± 
0.25 
1.21 ± 
0.22 
1.17 ± 
0.20 
1.28 ± 
0.26 
1.21 ± 
0.17 
1.25 ± 
0.27 
1.16 ± 
0.20 
Ca x P (mmol2/L2) NA 2.78 ±  
0.53 
2.76 ± 
0.54 
2.86 ± 
0.52 
2.71 ± 
0.45 
2.96 ± 
0.68 
2.75 ± 
0.45 
2.88 ± 
0.60 
2.70 ± 
0.47 
PTH (pmol/L) NA 146.58 ± 
111.17 
155.68 ± 
112.01 
93.12 ± 
75.32 
172.03 ± 
131.04 
148.79 ± 
93.56 
132.44 ± 
94.01 
149.83 ± 
126.22 
139.24 ± 
109.92 
 
 
 
Tables 7.2 and 7.3: The tables show the main clinical and biochemical characteristics of the 
participants of this study.  Data is given as total number (n), percentage of total study population (%) 
and as mean ± SD, where applicable.  Abbreviations: DKD = diabetic kidney disease, CGN = chronic 
glomerulonephritis, HTN = hypertensive nephrosclerosis, ARVD = atherosclerotic renovascular 
disease, CIN = chronic interstitial nephritis, ADPKD = adult polycystic kidney disease, BMI= Body Mass 
Index, eGFR = estimated glomerular filtration rate, BUN = blood urea nitrogen, Ca = calcium, P= = 
phosphorus, PTH = Para thyroid hormone. Other causes of CKD included cases of: cast nephropathy 
(Multiple Myeloma), amyloidosis, idiopathic thrombocytopenic purpura, Henoch Scholein purpura, 
monoclonal gammopathy of undetermined significance (MGUS), microscopic polyarteritis, familial 
renal disease, medullary sponge kidneys, sarcoidosis, lupus nephritis, HIV-associated nephritis, 
Tacrolimus toxicity and renal cell carcinoma. NA = not applicable. 
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Table 7.4: Main demographic and clinical characteristics of Diabetic Kidney Disease 
patients (n=91) analysed by CKD progression 
 
Variables Progressors Non-Progressors p-value 
Number (n) 41 50 -- 
Gender: Male, n (%) 28 (68.29%) 29 (58%) 0.1563 
Age (years) 64.89 ± 12.65 70.98 ± 10.04 0.0101 
Race: Caucasians, n (%) 35 (85.37%) 48 (96%) 0.0376 
Type of diabetes: T1DM 
                               T2DM 
8 (19.51%)     
33 (80.49%) 
7 (14%)  
43 (86%) 
0.4777 
0.4777 
BMI 31.05 ± 6.59 32.47 ± 4.64 0.2460 
Co-morbidities, n (%) 41 (100%) 46 (92%) 0.0312 
Systolic BP (mmHg) 147.18 ± 23.43 145.88 ± 16.48 0.7575 
Diastolic  BP (mmHg) 73.31 ± 12.33 73.87 ± 8.84 0.8025 
CKD Stage 1, n (%) 0 0 -- 
CKD Stage 2, n (%) 0 0 -- 
CKD Stage 3A, n (%) 6 (14.63%) 7 (14%) 0.4641 
CKD Stage 3B, n (%) 12 (29.27%) 14(28%) 0.4483 
CKD Stage 4, n (%) 21 (51.22%) 28 (56%) 0.3228 
CKD Stage 5, n (%) 2 (4.88%) 1 (2%) 0.2207 
eGFR  at sampling 
(ml/min/1.73m2) 
31.09 ± 11.29 30.89 ± 10.65 0.9287 
Serum creatinine (µmol/L) 192.42 ± 73.41 184.72 ± 53.58 0.5607 
Urine Creatinine (µmol/L) 5.28 ± 2.27 7.38 ± 4.16 0.0021 
Albuminuria (mg/L) 542.82 ± 745.02 186.15 ± 460.43 0.0063 
Proteinuria (mg/L) 1.03 ± 1.16 0.45 ± 0.61 0.0017 
BUN (mmol/L) 14.84 ± 6.96 13.43 ± 6.42 0.5313 
HbA1c (%) 8.1 ± 1.9 7.0 ± 1.4 0.0109 
Serum Cholesterol 
(mmol/L) 
3.91 ± 1.03 3.71 ± 1.10 0.4305 
Triglycerides (mmol/L)  1.82 ± 1.22 1.90 ± 0.92 0.3341 
Serum calcium (mmol/L) 2.34 ± 0.09 2.34 ± 0.12 0.1255 
Serum Phosphorus 
(mmol/L) 
1.23 ± 0.28 1.15 ± 0.21 0.9169 
Ca x P (mmol2/L2) 2.83 ± 0.54 2.71 ± 0.53 0.9040 
PTH (pmol/L) 148.20 ± 114.30 161.94 ± 110.85 0.0008 
 
Table 7.4: Baseline characteristics from diabetic kidney disease patients subdivided into progressors 
(eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors (eGFR decline < - 2 
ml/min/1.73m2/year).  Data presented as percentage of the sub number of cases or as mean ± SD 
unless otherwise stated. p values marked in red represent statistically significant difference (p<0.05). 
Abbreviations: T1DM = Type 1 Diabetes Mellitus, T2DM = Type 2 Diabetes Mellitus, BP = Blood 
Pressure, HbA1c = glycosylated haemoglobin.  
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Table 7.5: Main demographic and clinical characteristics of Chronic Glomerulonephritis 
patients (n=66) analysed by CKD progression 
 
Variables Progressors Non-Progressors p-value 
Number (n) 28 38 -- 
Gender: Male, n (%) 16 (57.14%) 25 (65.79%) 0.2358 
Age (years) 55.13 ± 15.35 45.94 ± 18.98 0.0504 
Race: Caucasians, n (%) 23 (82.14%) 34 (89.47%) 0.1949 
BMI 27.78 ± 6.89 30.62 ± 4.32 0.2317 
Membranous Nephropathy,  
n (%)* 
5 (12.20%) 10 (24.39%) 0.2119 
IgA Nephropathy, n (%)* 6 (14.63%) 8 (19.51%) 0.4483 
FSGS, n (%)* 2 (4.88%) 3 (7.32%) 0.4721 
Membranoproliferative GN,  
n (%)* 
2 (4.88%) 1 (2.44%) 0.1788 
Minimal Change, n (%)* 0 2 (4.88%) 0.1112 
RPGN, n (%)* 2 (4.88%) 0 0.0427 
Co-morbidities, n (%) 24 (85.71%) 25 (65.79%) 0.0672 
Systolic BP (mmHg) 140.47 ± 18.47 137.96 ± 16.13 0.6356 
Diastolic  BP (mmHg) 79.37 ± 7.64 78.78 ± 9.39 0.8157 
CKD Stage 1, n (%) 1 (3.57%) 8 (21.05%) 0.0202 
CKD Stage 2, n (%) 2 (7.14%) 10 (26.32%) 0.0227 
CKD Stage 3A, n (%) 7 (25%) 7 (18.42%) 0.2579 
CKD Stage 3B, n (%) 5 (17.86%) 8 (21.05%) 0.3745 
CKD Stage 4, n (%) 12 (42.86%) 4 (10.53%) 0.0012 
CKD Stage 5, n (%) 1 (3.57%) 1 (2.63%) 0.4129 
eGFR  at sampling 
(ml/min/1.73m2) 
41.04 ± 20.99 65.90 ± 31.46 0.0009 
Serum creatinine (µmol/L) 166.90 ± 65.15 126.04 ± 81.29 0.0624 
Urine Creatinine (µmol/L) 7.75 ± 5.19 10.44 ± 7.29 0.1264 
Albuminuria (mg/L) 2216.40 ± 2944.30 989.45 ± 1506.93 0.0897 
Proteinuria (mg/L) 2.38 ± 4.32 1.62 ± 1.59 0.5067 
BUN (mmol/L) 13.04 ± 6.18 12.34 ± 5.25 0.3732 
Serum Cholesterol (mmol/L) 6.23 ± 1.92 5.71 ± 2.59 0.4775 
Triglycerides (mmol/L)  2.27 ± 1.56 2.55 ± 2.04 0.6237 
Serum calcium (mmol/L) 2.36 ± 0.09 2.35 ± 0.09 0.7778 
Serum Phosphorus (mmol/L) 1.28 ± 0.19 1.15 ± 0.23 0.0429 
Ca x P (mmol2/L2) 3.04 ± 0.49 2.71 ± 0.50 0.0306 
PTH (pmol/L) 68.08 ± 39.76 120.25 ± 95.45 0.0999 
 
Table 7.5: Baseline characteristics from patients with chronic glomerulonephritis subdivided into 
progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors (eGFR decline < - 2 
ml/min/1.73m2/year).  Data is presented as percentage of the sub number of cases or as mean ± SD 
unless otherwise stated. p values marked in red represent statistically significant difference (p<0.05). 
Abbreviations: FSGS = Focal and Segmental Glomerulosclerosis, GN = glomerulonephritis, RPGN = 
Rapid and Progressive glomerulonephritis. *Total number of cGN cases = 66, with 41 biopsies done 
during the time of this study. Cases of * Calculated as a percentage of the number of biopsied cases 
(n=41). 
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Table 7.6: Main demographic and clinical characteristics of patients with Hypertensive 
Nephrosclerosis (n=53) analysed by CKD progression 
 
Variables Progressors Non-Progressors p-value 
Number (n) 20 33 -- 
Gender: Male, n (%) 11 (55.56%) 20 (60.61%) 0.3446 
Age (years) 70.67 ± 12.13 72.15 ± 12.14 0.6702 
Race: Caucasians, n (%) 18 (88.89%) 28 (84.85%) 0.2946 
BMI 31.71 ± 8.48 32.55 ± 9.52 0.8265 
Co-morbidities, n (%) 17 (85%) 24 (72.73%) 0.3030 
Systolic BP (mmHg) 138.18 ± 24.27 144.13 ± 18.29 0.4006 
Diastolic  BP (mmHg) 75.65 ± 12.98 73.75 ± 10.92 0.6264 
CKD Stage 1, n (%) 0 0 -- 
CKD Stage 2, n (%) 2 (10%) 0 0.0322 
CKD Stage 3A, n (%) 1 (5%) 4 (12.12%) 0.1949 
CKD Stage 3B, n (%) 2 (10%) 11 (33.33%) 0.0281 
CKD Stage 4, n (%) 12 (60%) 16 (48.48%) 0.2089 
CKD Stage 5, n (%) 3 (15%) 2 (6.06%) 0.1401 
eGFR  at sampling 
(ml/min/1.73m2) 
29.00 ± 16.90 29.77 ± 12.79 0.8470 
Serum creatinine 
(µmol/L) 
215.76 ± 87.41 199.00 ± 90.63 0.5484 
Urine Creatinine (µmol/L) 7.92 ± 7.36 7.57 ± 4.32 0.8974 
Albuminuria (mg/L) 472.76 ± 631.69 337.91 ± 646.80 0.5305 
Proteinuria (mg/L) 1.06 ± 1.08 0.70 ± 0.74 0.2414 
BUN (mmol/L) 14.31 ± 4.63 11.85 ± 4.99 0.1094 
Serum Cholesterol 
(mmol/L) 
4.45 ± 2.06 4.12 ± 1.58 0.7347 
Triglycerides (mmol/L)  2.62 ± 2.88 1.6 ± 0.94 0.2135 
Serum calcium (mmol/L) 2.29 ± 0.10 2.32 ± 0.09 0.3746 
Serum Phosphorus 
(mmol/L) 
1.21 ± 0.22 1.16 ± 0.18 0.4268 
Ca x P (mmol2/L2) 2.75 ± 0.49 2.71 ± 0.43 0.6982 
PTH (pmol/L) 191.86 ± 189.75 133.70 ± 86.60 0.1818 
 
Table 7.6: Baseline characteristics from patients diagnosed with hypertensive nephrosclerosis 
subdivided into progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors (eGFR 
decline < - 2 ml/min/1.73m2/year).  Data is presented as percentage of the sub number of cases or as 
mean ± SD unless otherwise stated. p values marked in red represent statistically significant difference 
(p<0.05). Abbreviations: see table 7.2. 
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Table 7.7: Main demographic and clinical characteristics of patients with 
Atherosclerotic Renovascular disease (n=29) analysed by CKD 
progression 
 
Variables Progressors Non-Progressors p-value 
Number (n) 6 23 -- 
Gender: Male, n (%) 3 (50%) 19 (72.22%) 0.0485 
Age (years) 74.83 ± 6.91 75.57 ± 6.35 0.8208 
Race: Caucasians, n (%) 6 (100%) 19 (91.30%) 0.1357 
BMI 30.90 ± 5.62 28.99 ± 3.81 0.8775 
Co-morbidities, n (%) 4 (66.67%) 13 (56.52%) 0.3264 
Systolic BP (mmHg) 149.60 ± 16.96 145.10 ± 15.66 0.6101 
Diastolic  BP (mmHg) 78.60 ± 18.20 72.65 ± 7.53 0.5107 
CKD Stage 1, n (%) 0 1 (4.35%) 0.3015 
CKD Stage 2, n (%) 1 (16.67%) 1 (4.35%) 0.1446 
CKD Stage 3A, n (%) 0 2 (8.70%) 0.2266 
CKD Stage 3B, n (%) 2 (33.33%) 7 (30.43%) 0.4443 
CKD Stage 4, n (%) 2 (33.33%) 10 (43.48%) 0.3264 
CKD Stage 5, n (%) 1 (16.67%) 2 (8.70%) 0.0217 
eGFR  at sampling 
(ml/min/1.73m2) 
24.60 ± 11.61 31.60 ± 19.38 0.3241 
Serum creatinine (µmol/L) 219.60 ± 84.97 204.25 ± 62.24 0.7197 
Urine Creatinine (µmol/L) 6.53 ± 2.02 6.59 ± 4.48 0.9669 
Albuminuria (mg/L) 452.68 ± 832.93.17 254.32 ± 610.04 0.6039 
Proteinuria (mg/L) 1.10 ± 2.12 0.38 ± 0.44 0.1499 
BUN (mmol/L) 13.68 ± 6.12 10.18 ± 4.02 0.6906 
Serum Cholesterol 
(mmol/L) 
5.43 ± 0.59 4.13 ± 1.13 0.0351 
Triglycerides (mmol/L)  1.63 ± 0.85 1.89 ± 1.26 0.6560 
Serum calcium (mmol/L) 2.37 ± 0.10 2.30 ± 0.10 0.4917 
Serum Phosphorus 
(mmol/L) 
1.42 ± 0.31 1.27 ± 0.29 0.7678 
Ca x P (mmol2/L2) 3.31 ± 0.67 2.89 ± 0.68 0.7586 
PTH (pmol/L) 92 ± 20.70 163.93 ± 100.02 0.0331 
 
Table 7.7: Baseline characteristics from patients with atherosclerotic renovascular disease subdivided 
into progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors (eGFR decline < - 2 
ml/min/1.73m2/year).  Data presented as percentage of the sub number of cases or as mean ± SD 
unless otherwise stated. p values marked in red represent statistically significant difference (p<0.05). 
Abbreviations: see table 7.2 
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Table 7.8: Main demographic and clinical characteristics of patients with Chronic 
Interstitial Nephritis (n=15) analysed by CKD progression 
 
Variables Progressors Non-Progressors p-value 
Number (n) 5 10 -- 
Gender: Male, n (%) 2 (40%) 5 (50%) 0.3557 
Age (years) 62.2 ± 13.10 62 ± 13.74 0.9788 
Race: Caucasians, n (%) 5 (100%) 10 (100%) -- 
BMI 26.6 ± 1.22 28.95 ± 4.06 0.3401 
Co-morbidities, n (%) 4 (80%) 7 (70%) 0.6818 
Systolic BP (mmHg) 145.00 ± 22.11 141.25 ± 26.18 0.7882 
Diastolic  BP (mmHg) 75.40 ± 18.02 74.13 ± 12.73 0.8947 
CKD Stage 1, n (%) 0 0 -- 
CKD Stage 2, n (%) 0 0 -- 
CKD Stage 3A, n (%) 0 1 (10%) 0.4654 
CKD Stage 3B, n (%) 3 (60%) 2 (20%) 0.1211 
CKD Stage 4, n (%) 1 (20%) 7 (70%) 0.0672 
CKD Stage 5, n (%) 1 (20%) 0 0.1443 
eGFR  at sampling 
(ml/min/1.73m2) 
27.6 ± 10.14 28.88 ± 10.02 0.8298 
Serum creatinine (µmol/L) 209.8 ± 94.88 192.63 ± 81.64 0.7469 
Urine Creatinine (µmol/L) 8.34 ± 6.03 4.92 ± 4.58 0.3038 
Albuminuria (mg/L) 248.98 ± 408.82 56.02 ± 66.73 0.3522 
Proteinuria (g/L) 0.56 ± 0.50 0.47 ± 0.59 0.7805 
BUN (mmol/L) 12.94 ± 4.57 11.13 ± 4.41 0.6905 
Serum Cholesterol (mmol/L) 5.20 ± 2.09 4.25 ± 0.75 0.4384 
Triglycerides (mmol/L)  2.48 ± 1.39 1.27 ± 0.18 0.1795 
Serum calcium (mmol/L) 2.24 ± 0.15 2.29 ± 0.08 0.5378 
Serum Phosphorus 
(mmol/L) 
1.2 ± 0.16 1.22 ± 0.19 0.8693 
Ca x P (mmol2/L2) 2.70 ± 0.48 2.78 ± 0.47 0.7710 
PTH (pmol/L) 334.00 ± 128.01 93.14 ± 48.06 0.0018 
 
 
Table 7.8: Baseline characteristics from patients with Chronic Interstitial Nephritis subdivided into 
progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors (eGFR decline < - 2 
ml/min/1.73m2/year).  Data presented as percentage of the sub number of cases or as mean ± SD 
unless otherwise stated. Abbreviations: see table 7.2 
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Table 7.9: Main demographic and clinical characteristics of ADPKD patients (n=13) 
analysed by CKD progression 
 
 
Variables Progressors Non-
Progressors 
p-value 
Number (n) 2 11 -- 
Gender: Male, n (%) 1 (50%) 6 (54.55%) 0.9045 
Age (years) 53.5 ± 20.51 46.09 ± 18.23 0.7005 
Race: Caucasians, n (%) 2 (100%) 11 (100%) -- 
BMI 25.05 ± 8.13 32.3 ± 4.85 0.4071 
Co-morbidities, n (%) 2 (100%) 6 (54.55%) 0.2225 
Systolic BP (mmHg) 128 ± 0 135.25 ± 10.96 0.2390 
Diastolic  BP (mmHg) 72.5 ± 6.36 81 ± 8.09 0.3567 
CKD Stage 1, n (%) 0 1 (9.09%) 0.6599 
CKD Stage 2, n (%) 0 3 (27.27%) 0.4009 
CKD Stage 3A, n (%) 0 2 (18.18%) 0.5092 
CKD Stage 3B, n (%) 0 2 (18.18%) 0.5092 
CKD Stage 4, n (%) 2 (100%) 2 (18.18%) 0.0209 
CKD Stage 5, n (%) 0 1 (9.09%) 0.6599 
eGFR  at sampling 
(ml/min/1.73m2) 
18.00 ± 0 51.9 ± 31.02 0.0072 
Serum creatinine (µmol/L) 273.5 ± 28.99 156.33 ± 75.05 0.0160 
Urine Creatinine (µmol/L) 3.4 ± 1.13 5.59 ± 4.56 0.2196 
Albuminuria (mg/L) 23.00 ± 20.08 193.87 ± 423.25 0.2355 
Proteinuria (g/L) 0.19 ± 0.02 0.38 ± 0.52 0.2821 
Serum Cholesterol (mmol/L) 3.55 ± 0.21 3.98 ± 1.75 0.0186 
Triglycerides (mmol/L)  1.65 ± 1.63 1.60 ± 0.94 0.9727 
Serum calcium (mmol/L) 2.31 ± 0.20 2.34 ± 0.09 0.8566 
Serum Phosphorus (mmol/L) 1.13 ± 0.36 1.28 ± 0.27 0.6581 
Ca x P (mmol2/L2) 2.56 ± 0.61 2.96 ± 0.61 0.5168 
PTH (pmol/L) 159.3 ± 207.47 146.67 ± 117.83 0.9461 
 
 
Table 7.9:  Baseline characteristics from patients Autosomal dominant Polycystic Renal Disease 
(ADPKD) subdivided into progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-progressors 
(eGFR decline < - 2 ml/min/1.73m2/year).  Data presented as percentage of the sub number of cases 
or as mean ± SD unless otherwise stated. p values marked in red  represent statistically significant 
difference (p<0.05). Abbreviations: see table 7.2 
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Table 7.10:  Main demographic and clinical characteristics of patients with other* 
causes of CKD (n=25) analysed by levels of CKD progression 
 
Variables Progressors Non-
Progressors 
p-value 
Number (n) 6 19 -- 
Gender: Male, n (%) 4 (66.67%) 10 (52.63%) 0.2743 
Age (years) 74.80 ± 6.65 58.33 ± 19.92 0.0077 
Race: Caucasians, n (%) 6 (100%) 17 (89.47%) 0.2033 
BMI 27.13 ± 1.65 25.52 ± 2.91 0.3917 
Multiple Myeloma (cast nephropathy),  
n (%) 
2 (33.33%) 2 (10.53%) 0.0918 
Amyloidosis, n (%) 1 (16.67%) 0 0.0344 
Lupus Nephritis, n (%) 1 (16.67%) 2 (10.53%) 0.3446 
MGUS, n (%) 0 2 (10.53%) 0.2033 
Familial renal disease, n (%) 0 2 (10.53%) 0.2033 
Medullary sponge kidney, n (%) 0 2 (10.53%) 0.2033 
Microscopic Polyarteritis, n (%) 1 (16.67%) 1 (5.26%) 0.1841 
Sarcoidosis, n (%) 0 1 (5.26%) 0.2843 
Idiopathic thrombocytopenic purpura, n 
(%) 
0 1 (5.26%) 0.2843 
Henoch Scholein purpura, n (%) 0 1 (5.26%) 0.2843 
Renal stone disease, n (%) 0 2 (10.53%) 0.2033 
Renal cell carcinoma, n (%) 1 (16.67%) 1 (5.26%) 0.1841 
Tacrolimus toxicity, n (%) 0 1 (5.26%) 0.2843 
HIV-associated nephropathy, n (%) 0 1 (5.26%) 0.2843 
CKD Stage 1, n (%) 0 0 -- 
CKD Stage 2, n (%) 1 (16.67%) 1 (5.26%) 0.1841 
CKD Stage 3A, n (%) 1 (16.67%) 1 (5.26%) 0.1841 
CKD Stage 3B, n (%) 0 5 (26.32%) 0.081 
CKD Stage 4, n (%) 3 (50%) 12 (63.16%) 0.2843 
CKD Stage 5, n (%) 1 (16.67%) 0 0.0301 
eGFR  at sampling (ml/min/1.73m2) 33.80 ± 20.71 38.12 ± 20.53 0.6945 
Serum creatinine (µmol/L) 199.80 ± 114.45 168.69 ± 53.34 0.5843 
Urine Creatinine (µmol/L) 9.50 ± 5.96 6.06 ± 3.23 0.2751 
Albuminuria (mg/L) 645.22 ± 464.28 82.19 ± 82.56 0.0002 
Proteinuria (g/L) 1.10 ± 0.99 0.30 ± 0.32 0.0136 
Serum Cholesterol (mmol/L) 4.46 ± 0.46 5.19 ± 1.45 0.1131 
Triglycerides (mmol/L)  1.70 ± 0.42 2.36 ± 1.70 0.1989 
Serum calcium (mmol/L) 2.32 ± 0.08 2.33 ± 0.13 0.8491 
Serum Phosphorus (mmol/L) 1.04 ± 0.20 1.18 ± 0.21 0.2087 
Ca x P (mmol2/L2) 2.40 ±0.42 2.74 ± 0.50 0.1713 
PTH (pmol/L) 153.20 ± 177.43 131.29 ± 94.81 0.8033 
 
Table 7.10: Baseline characteristics from patients diagnosed with other causes of CKD (for details see 
section 7.2.4) subdivided into progressors (eGFR decline > - 2 ml/min/1.73m2/year) and non-
progressors (eGFR decline < - 2 ml/min/1.73m2/year). Data presented as percentage of the sub 
number of cases or as mean ± SD unless otherwise stated. p values marked in red  represent 
statistically significant difference (p<0.05). Abbreviations: MGUS = monoclonal gammopathy of 
undetermined significance, and the rest in table 7.2. 
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7.2.7. Baseline demographic and clinical characteristics in different age 
groups  
 
The mean age of CKD patients was 63.9 ± 16.58 years, with 61.9% of the study population 
aged above 65 years.  The risk for decline in kidney function and subsequent incidence of 
CKD progression is higher in older people (section 1.5.1.1.).  For this reason, an analysis of 
the demographic parameters of the study population by different age groups (above and below 
65 years old) was performed (figure 7.11).  This showed that older patients presented higher 
systolic and diastolic blood pressure, lower eGFR, lower albuminuria and proteinuria levels as 
well as lower cholesterol levels at sampling. 
 
Table 7.11: Comparison of main clinical parameters between different age groups 
 
Variables < 65 years old ≥ 65 years old p-value 
Number (n) 111 181 -- 
Mean Age (years) 46.63 ± 13.82 74.40 ± 6.25 < 0.0001 
Gender: Male, n (%) 67 (60.36%) 112 (61.88%) 0.3974 
Race: Caucasians, n (%) 91 (81.98%) 173 (95.58%) <0.0001 
BMI 31.05 ± 6.99 30.69 ± 5.48 0.7147 
Systolic BP (mmHg) 139.98 ± 18.26 145.26 ± 19.55 0.0371 
Diastolic  BP (mmHg) 77.66 ± 10.55 74.33 ± 10.43 0.0174 
CKD Stage 1, n (%) 11 (9.91%) 0 <0.0001 
CKD Stage 2, n (%) 17 (15.32%) 4 (2.21%) <0.0001 
CKD Stage 3A, n (%) 22 (19.82%) 17 (9.39%) 0.0055 
CKD Stage 3B, n (%) 14 (12.61%) 59 (32.60%) <0.0001 
CKD Stage 4, n (%) 43 (38.74%) 89 (49.17%) 0.0409 
CKD Stage 5, n (%) 4 (3.60%) 12 (6.63%) 0.1357 
eGFR  at sampling 
(ml/min/1.73m2) 
46.81 ± 27.80 30.05 ± 11.72 < 0.0001 
CKD progression 39 (35.24%) 69 (38.12%) 0.3050 
Serum creatinine (µmol/L) 167.64 ± 80.15 192.62 ± 69.90 0.0094 
Urine Creatinine (µmol/L) 7.60 ± 6.13 6.96 ± 4.09 0.3060 
Albuminuria (mg/L) 981.08 ± 1785.44 285.20 ± 539.96 0<0001 
Proteinuria (g/L) 1.38 ± 2.33 0.64 ± 0.82 0.0003 
BUN (mmol/L) 13.59 ± 6.53 14.68 ± 7.31 0.4859 
Serum Cholesterol (mmol/L) 5.11 ± 1.86 4.22 ± 1.21 <0.0001 
Triglycerides (mmol/L)  2.17 ± 1.56 1.98 ± 1.35 0.3357 
Serum calcium (mmol/L) 2.34 ± 0.10 2.32 ± 0.11 0.2884 
Serum Phosphorus 
(mmol/L) 
1.19 ± 0.22 1.20 ± 0.23 0.9280 
Ca x P (mmol2/L2) 2.79 ± 0.53 2.78 ± 0.54 0.9597 
PTH (pmol/L) 128.93 ± 109.61 155.15 ± 111.31 0.1135 
 
Table 7.11:  The main demographic and biochemical characteristics from patients under and above 65 
years old.  Data presented as percentage of the sub number of cases or as mean ± SD unless otherwise 
stated. p values marked in red represent statistically significant difference (p<0.05). Abbreviations: 
see table 7.2. 
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7.2.8. CKD progression by ethiology 
 
Patients from different CKD ethiologies (diabetic kidney disease (n=91), chronic 
glomerulonephritis (n=66), hypertensive nephrosclerosis (n=53), atherosclerotic renovascular 
disease (n=29), chronic interstitial nephritis (n=15) and ADPKD (n=13) and other causes (n= 
25)) were also subclassified according to their levels of CKD progression (figure 7.7). 
 
7.2.9. Renal biopsy from CGN patients 
 
Forty one patients diagnosed with chronic glomerulonephritis were submitted to renal biopsy 
during the study.  Recommendation for renal biopsy was made when CGN cause was not 
clear and upon presence of persistent haematuria, heavy proteinuria along with signs of kidney 
function deterioration. Main diagnosis were: membranous nephropathy (36.59%), IgA 
nephropathy (34.15%), focal and segmental glomerulosclerosis (FSGS) (12.20%), 
membranoproliferative glomerulonephritis (7.32%), minimal change (4.88%) and rapidly 
progressive glomerulonephritis (RPGN) (4.88%) (figure 7.3-B).  Kidney tissue samples were 
analysed by light and electron microscopy by the Department of Renal Histopathology of the 
Northern General Hospital (Sheffield, UK).  A fibrosis classification (mild, moderate or severe) 
was achieved by the estimation of a percentage score calculated through the evaluation of 
morphologic features of glomerulosclerosis and tubulointerstitial scarring. 46.34% (n=19) 
presented mild features of renal fibrosis, compared to 41.46% (n=17) which had moderate 
and 12.20% (n=5) with severe renal scarring.  The average fibrosis percentage score for non-
progressive patients was 16.41 ± 2.19, whilst progressive and rapidly progressive presented 
43.19 ± 5.24 and 73.07 ± 6.36 respectively. 
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Figure 7.7: CKD progression in different ethiologies 
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Figure 7.7: Percentage of CKD patients from 
different aethiologies classified as non-progressive 
(rate of eGFR decline < - 2 ml/min/1.73m2/year), 
progressive (eGFR decline between - 2 and -5 
ml/min/1.73m2/year) and rapidly progressive (eGFR 
decline > - 2 ml/min/1.73m2/year) 
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7.2.10. Clinical and biochemical parameters of healthy volunteers 
 
 
A total of 33 adult healthy volunteers were recruited as a control group. This group consisted 
of subjects above 18 years old, without history of any type of kidney disease, hypertension, 
diabetes or any other chronic condition (section 3.2.3.1).  The control group consisted of 10 
females and 23 males, with 63.64% caucasian and 36.36% from other ethnicities.  The mean 
age of controls in this study was 38.48 ± 7.61 years, which was significantly lower than CKD 
patients.  The main clinical and biochemical characteristics of healthy volunteers (table 7.12) 
indicated that albuminuria was below detectable levels in majority of healthy volunteers. 
 
Table 7.12: Baseline clinical characteristics of healthy volunteers 
ID Age Gender Ethnicity Albuminuria 
mg/L 
Proteinuria Urine Creatinine 
µmol/L 
ACR PCR 
1 48 Female Caucasian 0 0.02 6.0 0 0.003 
2 28 Male Caucasian 0 0.02 6.3 0 0.003 
3 38 Female Black 0 0.06 7.0 0 0.009 
4 36 Male Black 0 0.11 19.4 0 0.006 
5 44 Male Asian 0 0.06 6.5 0 0.009 
6 45 Male Asian 5.4 0.11 5.9 0.9 0.019 
7 51 Male Caucasian 0 0.02 11.8 0 0.002 
8 27 Female Caucasian 0 0.02 4.4 0 0.005 
9 48 Male Caucasian 4.0 0.10 4.9 0.8 0.02 
10 49 Male Caucasian 0 0.06 20.7 0 0.003 
11 38 Female Asian 0 0.06 13 0 0.005 
12 32 Male Black 0 0.06 19.6 0 0.003 
13 43 Female Asian 5.5 0.09 13.3 0.4 0.007 
14 41 Male Caucasian 0 0.04 10.8 0 0.004 
15 50 Male Caucasian 0 0.08 9.4 0 0.009 
16 37 Male Caucasian 0 0.03 2.2 0 0.014 
17 47 Male Caucasian 0 0.06 12.1 0 0.005 
18 44 Male Caucasian 0 0.06 9.6 0 0.006 
19 43 Male Caucasian 0 0.06 9.6 0 0.006 
20 39 Male Hispanic 12.8 0.10 24.7 0.5 0.004 
21 39 Female Hispanic 3.9 0.08 16.5 0.2 0.005 
22 34 Male Asian 0 0.06 5.9 0 0.01 
23 25 Female Caucasian 8.5 0.11 11.2 0.8 0.01 
24 31 Male Caucasian 0 0.07 25.7 0 0.003 
25 44 Male Caucasian 0 0.04 10.5 0 0.004 
26 35 Male Caucasian 5.8 0.09 18.9 0.3 0.005 
27 38 Male Caucasian 0 0.06 11.1 0 0.005 
28 30 Male Caucasian 0 0.06 10 0 0.006 
29 28 Female Hispanic 0 0.03 8.2 0 0.004 
30 31 Female Asian 0 0.02 5.8 0 0.003 
31 31 Male Caucasian 0 0.02 18.7 0 0.001 
32 29 Male Caucasian 0 0.02 4.2 0 0.005 
33 47 Male Caucasian 10.7 0.10 12.3 0.9 0.008 
 
Table 7.12: The main demographic and biochemical characteristics from healthy volunteers (control 
group, n=33). 
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7.3. Urine excretion of Transglutaminase type 2 in Human Chronic 
Kidney Disease  
 
7.3.1. Urine Transglutaminase type 2 measurement 
 
Measurement of Transglutaminase type 2 was performed in urines from 292 CKD patients 
and 33 controls using an in-house sandwich ELISA where a goat polyclonal anti TG2 antibody 
was used to capture and CUB7402 (both from AbCam) as a detection antibody.  In addition, 
19 diabetic patients without clinical evidence of kidney disease (eGFR > 90ml/min/1.73m2, 
normal serum creatinine and no proteinuria shown in dip sticks)  were also used for comparison 
with DKD patients.  Human recombinant TG2 was used to generate a standard curve (full 
method in section 3.5.1).  One way ANOVA with Bonferroni correction was applied to estimate 
differences between healthy volunteers (n=33), diabetic controls (n=19), all CKD patients and 
those with different CKD aetiologies (diabetic kidney disease: n=91, chronic 
glomerulonephritis: n=66, hypertensive nephrosclerosis: n=53, atherosclerotic renovascular 
disease: n=29, chronic interstitial nephritis: n=15, ADPKD: n=13 and other causes of CKD: 
n=25). A p value < 0.05 was considered statistically significant. 
 
7.3.2. Urine Transglutaminase type 2 levels  
 
TG2 concentration in the urine averaged 35 times higher in all cause CKD patients (3346 ± 
758.5 pg/ml) compared to the control group (94 ± 19 pg/ml,  p<0.0001) (figure 7.8-A). Diabetic 
controls (DM patients without kidney disease) presented an average concentration of TG2 in 
the urine of 295.5 ± 52.76 pg/ml.  This was significantly higher than the control group 
(p=0.0016), but significantly lower than CKD patients (p<0.0001) (figure 7.8-A). 
TG2 excretion was corrected to a creatinine ratio as described in section 4.1.4. to account for 
volume differences.  This gave a 61 fold increase in all cause CKD patient (figure 7.8-B) with 
healthy volunteers having an average TG2:creatinine ratio of 9.72 ± 1.92 compared to 599.4 
±118.9 in CKD, (p<0.0001). 
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 Figure 7.8: TG2 measurement in urine from all cause CKD patients 
   
 
  
 
 
 
Figure 7.8: Urine TG2 was measured by an in-house ELISA in patients with CKD irrespective of cause 
(n=292), controls (n=33) and DM patients without CKD and expressed as a concentration (ng/ml) (A). 
It was also expressed as TG2 / Creatinine ratio (B).  Results are displayed as mean ± SD.  Statistical 
significance is shown by Independent-samples T test: NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between CKD patients and healthy volunteers. Values are mean ± SD. 
 
 
7.3.3. Urine Transglutaminase type 2 in different causes of CKD 
 
Healthy volunteers had an average urine TG2 concentration of 94 ± 19 pg/ml (n=33).  Amongst 
CKD patients, the highest increase in urine TG2 concentration was observed on diabetic 
nephropathy patients (6071 ± 1989 pg/ml, p=0.0034) where 42.86% had CKD stage 3, 53.84% 
stage 4 and 3.30% stage 5.  Hypertensive patients also presented significant levels of urine 
TG2 (2700 ± 1397 pg/ml, p=0.0167) as well all patients with chronic glomerulonephritis (2157 
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± 451.8 pg/ml, p<0.0001), atherosclerotic renovascular disease (914.2 ± 298.9 pg/ml, 
p=0.0106), CIN (2070 ± 912.9 pg/ml, p=0.0483) and other CKD causes (1064 ± 434.7 pg/ml, 
p=0.0382).  ADPKD patients did not present a significant difference from controls due to its 
large variance (787.1 ± 561.9 pg/ml, p=0.2435) (figure 7.9-A).  Comparison of urine TG2 
concentration between patients with diabetic kidney disease and all cause non-diabetic of 
CKD showed levels were higher in the diabetic cohort (figure 7.9-B).  Furthermore, DKD 
patients had considerably higher values than diabetic controls (p=0.0046, figure 7.9-C). 
 
7.3.4. Transglutaminase type 2: Creatinine ratio in urine of CKD patients 
 
 
TG2: Creatinine ratio was 9.72 ± 1.92 on healthy volunteers vs. 599.4 ± 118.9 in all CKD 
patient urine (p<0.0001, figure 7.9-D).  TG2: Creatinine ratio was massively increased in DKD 
patients (twice as much all CKD patients, p=0.0008) and also significantly increased in CGN 
(40 fold increase compared to controls, p=0.0003), HTN (45 fold increase, p=0.0117), ARVD 
(14 fold increase, p=0.0060), CIN (38 fold increase, p=0.0191) and other causes of CKD (17 
fold increase, p=0.0166).  ADPKD patients did not give a significant increase in TG2 excretion 
even when corrected to a creatinine ratio (268.4 ± 218.5, p=0.2614) (figure 7.9-D).  The 
difference between DKD and non-diabetic CKD patients was also significant when TG2 was 
corrected for creatinine (figure 7.9-E). 
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 Figure 7.9: Urine TG2 excretion in patients with different causes of CKD 
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Figure 7.8: Urine TG2 was measured using an in-
house ELISA, Data is displayed as concentration 
(ng/ml) in patients with different causes of CKD 
(total n=292) and healthy volunteers (n=33) (A).  
Variation is displayed as a scatter plot of TG2 
concentration in DKD (n=91) versus non-diabetic 
CKD patients (n=201), with y axis in log 10 scale (B). 
Diabetic non-CKD compared to DKD patients. (C).  
Urine TG2 concentration was corrected to a 
creatinine ratio in healthy volunteers and patients 
with different CKD causes (D) and as a scatter plot 
of TG2/Cr in DKD (n=91) and non-DKD patients 
(n=201) (E), with y axis in log 10 scale.   
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7.3.5. Transglutaminase type 2: Creatinine ratio by CKD stage 
 
TG2: Creatinine was significantly increased at early stages of the disease compared to healthy 
volunteers (figure 7.10).  TG2: Creatinine ratio was 2.39 fold higher (p=0.0029) for CKD 1 
(n=11) and 18.5 fold higher (p=0.0181) for CKD 2 patients (n=21).  This increase became 
even more apparent at later stages of the disease; with a TG2: Creatinine ratio of 324.6 ± 
119.7 (p=0.0125), 911.3 ± 290.2 (p=0.0027) and 635.0 ± 196.4 (p=0.0018) at CKD stage 3A, 
3B and 4, respectively.  Patients presenting CKD stage 5 had a reduction on TG2: Cr (374.0 
± 162.0) when compared to CKD stages 3 and 4, however it remained significantly higher than 
health volunteers (p=0.0483). 
 
Figure 7.10: TG2: Creatinine ratio in different CKD stages 
  
 
 
Figure 7.10: Average TG2: Creatinine ratio in all CKD patients subdivided by the disease stages. Control 
group, n=33; CKD 1, n= 11; CKD 2, n=21; CKD 3A, n=39; CKD 3B, n=73; CKD 4, n=132; CKD 5, n=16. 
Statistical significance is shown by One Way ANOVA with Bonferroni post test: NS= not statistically 
significant, * p<0.05, **p<0.01, ***p<0.001 between CKD patients and healthy volunteers. Data 
represents mean ± SD. 
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7.3.6. Comparison of Urine Transglutaminase type 2 levels in CKD patients by 
age and gender groups 
 
No statistical difference was found between people aged above (n=181; 689.3 ± 249.6) or 
under 65 (n=111; 556.1 ± 124.7) years old (p=0.6339, figure 7.11-A) or between females 
(n=113; 400.4 ± 74.72) and males (n=179; 797.3 ± 262.3), (p=0.1480, figure 7.11-B) in terms 
of TG2: Creatinine ratio. 
 
Figure 7.11: TG2: Creatinine ratio by demographic data 
 
 
 
 
 
 
Figure 7.11: The average TG2: Creatinine ratio is shown in two different demographic subgroups: 
patients aged under or over 65 years (A) and by gender (B).    Statistical significance is shown by One 
Way ANOVA with Bonferroni post test: NS= not statistically significant, * p<0.05, **p<0.01, 
***p<0.001 between CKD patients and healthy volunteers.  Data represents mean ± SD. 
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7.3.7. Relationship between   Transglutaminase type 2: Creatinine ratio and 
CKD progression  
 
CKD progression was determined by the rate of eGFR decline calculated through regression 
analysis of 10 different eGFR values obtained over a period of around 3 years as previously 
described.  CKD patients who presented with a rate of eGFR decline below 2ml/min/1.73m2 
per year were classified as stable with non-progressive disease (or non-progressors).  Patients 
with eGFR decline between 2 and 5ml/min/1.73m2 were classified as having progressive 
disease (or progressors).  Subjects with eGFR decline above 5ml/min/1.73m2 per year were 
classified as having rapid disease progression (or rapid progressors).  
 
TG2 excretion was higher in patients with progressive CKD compared to those with non-
progressive disease.  Non-progressive or stable patients (n=184) had an average TG2: 
Creatinine ratio of 113 ± 14, compared to 1244 ± 366 in those with progressive disease (n=79, 
p=0.0029) and 1898 ± 509 in rapidly progressive CKD patients (n=29, p=0.0017).  Although 
the TG2: Creatinine was slightly more elevated in rapid progressive patients than in 
progressive, this difference did not reach any significance (p=0.3017, figure 7.12).  In addition, 
stable, progressive and rapidly progressive CKD patients presented significantly higher TG2: 
Creatinine ratio compared to healthy volunteers: p<0.0001, p=0.0012 and p=0.0010 
respectively. 
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 Figure 7.12: Urine TG2 excretion in patients with different rates of CKD progression 
  
   
Figure 7.12:  TG2: Creatinine ratio measurements in CKD patients were subdivided into groups 
according to their rate of disease progression: non-progressive (rate of eGFR decline 
<2ml/min/1.73m2/year, n=184), progressive (between 2-5ml/min/1.73m2/year, n=79) and rapidly 
progressive (>5ml/min/1.73m2/year, n=29) and data presented as a bar chart (A) and scatter plot (B), 
with y axis in log 10 scale. Statistical significance is shown by One Way ANOVA with Bonferroni post 
test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between non-progressive, 
progressive and rapidly progressive. HV = healthy volunteers.  Data represents mean ± SD. 
 
 
7.3.8. Receiver Operating Characteristic curve for Urine Transglutaminase 
type 2 as a predictor of CKD progression. 
 
Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the 
performance of TG2:Creatinine ratio (TG2CR) and Albumin:Creatinine ratio (ACR) in detecting 
CKD progression.  Accuracy of prediction was determined by the Area Under the ROC curve 
(θ) using the following calculation: 
 
                               θ =          1         ∑         S (x+, x_),  
                                             n+ n-         all possible 
                                                                         combinations 
                                                                         of (x+, x-) 
where n+ and n- are the sample sizes of the two variables, x+ denotes the number of values 
for cases with positive actual states, x- denotes the number of values for cases negative with 
negative actual states and S (x+, x_) is equal to 1 if x+ > x_ , ½ if x+ = x_ and 0 if x+ < x_. 
 
Area under the ROC curve determined a 86.4% accuracy in CKD progression prediction of a 
spot measurement in a single prospective urine for TG2CR compared to 73.5% for ACR (figure 
7.13). 
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Figure 7.13: Urine TG2 ROC curve 
 
 
 
 
Figure 7.13: The TG2CR ROC curve with sensitivity (probability of correctly identifying a positive 
finding) plotted in the Y axis and 1-specificity (false positives) in the x axis.  The higher the area under 
the curve the higher will be the accuracy of prediction of an event. a = under the nonparametric 
assumption, b = null hypothesis: true area = 0.5. 
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7.4. Urine ε (γ glutamyl) lysine measurement in Human Chronic Kidney 
Disease  
 
7.4.1. Urine ε (γ glutamyl) lysine measurement by cation exchange 
chromatography 
 
Human urine samples containing 5mg of protein each were precipitated with TCA followed by 
ether extraction.  Samples were resuspended in NH4CO3 , submitted to exhaustive proteolytic 
digestion (Subtilisin, Pronase E, Leucine Aminopeptidase, Prolidase and Carboxypeptidase 
Y), freeze dried and fractionated on a Biochrom 30 Amino acid Analyser (AAA).  Samples 
were read using the standard Biochrom 96361 LiHP control program as pre-programmed by 
the manufacturer.  The estimated concentration of ε (γ glutamyl) lysine was given at 570 nm 
at a retention time of around 77 minutes (figure 7.14).  Quantification was by reference to a 
10 nmols / 20ul ε (γ-glutamyl) lysine standard (full methods in section 3.5.7.1.  One way 
ANOVA with Bonferroni post test was applied to estimate differences between healthy 
volunteers (n=33) and CKD patients (n=292) and also from different CKD ethiologies (diabetic 
kidney disease: n=91, chronic glomerulonephritis: n=66, hypertensive nephrosclerosis: n=53, 
atherosclerotic renovascular disease: n=29, chronic interstitial nephritis: n=15, ADPKD: n=13 
and other causes of CKD: n=25). A p value < 0.05 was considered statistically significant.   
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Figure 7.14: Urine ε (γ Glutamyl) Lysine excretion in Human CKD  
 
 
                                                                             
 
 
Figure 7.14:: Precipitated protein from human urine samples were exhaustively digested by a 
combination of five different proteases, freeze dried and reconstituted in 500ul of lithium loading 
buffer as described in section 3.6.  ε (γ Glutamyl) Lysine was measured using a Biochrom 30 Amino 
Acid Analyser, fractionating using program 96361 LiHP and the peak concentration calculated by the 
area under the curve.  Healthy volunteers showed a small Glu-Lys peak (white arrow) situated 
between Leucine and Tyrosine peaks (A).  Maximum Glu-Lys peaks were observed on patients at CKD 
stage 3A (B), 3B (C) and CKD 4 (D). 
Healthy volunteer CKD stage 3A 
CKD stage 3B CKD stage 4 
Healthy volunteer 
CKD stage 3B 
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7.4.2. Urine ε (γ glutamyl) lysine concentration 
 
ε (γ glutamyl) lysine excretion was 6.7 fold higher in all cause CKD patient urines (1.304 ± 
0.075nmols per mg of protein) when compared to healthy volunteers (0.1945 ± 0.025nmols 
per mg of protein) (p<0.001, figure 7.15-A).  When corrected to a creatinine ratio, this 
difference became 12.5 times higher in patients with all cause CKD (0.2796 ± 0.0285) than 
controls (0.0222 ± 0.004) (p<0.001, figure 7.15-B). 
 
The highest levels of ε (γ glutamyl) lysine to creatinine ratio were observed in CIN patients 
(0.4857 ± 0.2810), however it failed to achieve significance when compared to healthy 
volunteers due to its large variance (p=0.1335).  Hypertensive patients also had a large ε (γ 
glutamyl) lysine:Cr (0.3405 ± 0.0986, p=0.0034) which is in line with the increased TG2 levels 
in this aetiology.  In addition, patients with diabetic kidney disease (0.2586 ± 0.0293, 
p<0.0001), CGN (0.2211 ± 0.0407, p<0.0001), ARVD (0.2090 ± 0.0395, p=0.0003), and other 
CKD causes (0.3451 ± 0.0901, p=0.0043) also had significant levels of ε (γ glutamyl) lysine:Cr 
ratio.  Similar to TG2, ADPKD patients did not present a significant difference from controls 
(0.3202 ± 0.1703, p=0.1551) (figure 7.15-C). 
  
The ε (γ glutamyl) lysine: Creatinine ratio in patients at different CKD stages was significantly 
increased from CKD 1 to 5 (figure 7.15-D).  At CKD 1, the ε (γ glutamyl) lysine:Cr ratio was 
0.1588 ± 0.0403 (p=0.0120 when compared to controls). This increased to 0.3325 ± 0.0892 
at CKD stage 2 (p=0.0037), then to 0.3913 ± 0.1429 (p=0.0183) at CKD 3A and 0.2696 ± 
0.03848 (p<0.0001) at CKD 3B.  Average ε (γ glutamyl) lysine:Cr levels were also highly 
elevated at stage 4 (0.2772 ± 0.0450, p<0.0001) and although it decreased at CKD stage 5, it 
remained significantly elevated (0.1268 ± 0.0228, p=0.0028) (figure 7.14-D). Such results 
mimicked urine TG2 levels.   
 
7.4.3. ε (γ glutamyl) lysine: Creatinine ratio relationship with the rate of CKD 
progression  
 
The ε (γ glutamyl) lysine: Creatinine ratio was significantly elevated in CKD patients with rapid 
progression when compared to those with stable disease.  Non-progressors (eGFR decline 
<2ml/min/1.73m2 per year) had an average ε (γ glutamyl) lysine: Creatinine ratio of 0.2345 ± 
0.0418, compared to 0.3106 ± 0.0356 in progressive disease (eGFR decline between 2 and 
5ml/min/1.73m2 per year, p=0.1591) and 0.4598 ± 0.0858 in highly progressive disease (eGFR 
decline >5ml/min/1.73m2 per year, p=0.0262).  All CKD patients had a significantly higher urine 
ε (γ glutamyl) lysine: Creatinine ratio compared to healthy volunteers: p<0.0001, p<0.0001 
and p=0.0001 respectively (figure 7.15-E). 
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 Figure 7.15: ε (γ glutamyl) lysine (XL) excretion in urine from CKD patients 
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Figure 7.15: ε (γ glutamyl) lysine crosslink (XL) 
was measured in protein precipitates from 
human urine samples by cation exchange 
chromatography:  (A) Mean XL per mg urine 
protein ± SD calculated by AUC of peaks as 
displayed in figure 7.14. (B) XL to Creatinine 
ratio.  (C) – XL: Creatinine ratio in different CKD 
aetiologies. (D) XL: Creatinine ratio at different 
CKD stages and (E) in different rates of CKD 
progression.  Statistical significance was 
calculated by one Way ANOVA with a 
Bonferroni post hoc test: NS= not statistically 
significant, * p<0.05, **p<0.01, ***p<0.001 
between CKD patients and healthy volunteers.  
Data represents mean ± SD 
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7.4.4. Receiver Operating Characteristic curve for Urinary ε (γ glutamyl) 
lysine as a predictor of CKD progression 
 
The ε (γ glutamyl) lysine to creatinine ratio (XLCR) presented a worse performance than 
TG2CR and ACR on predicting CKD progression.   ROC curve analysis determined a 73.3% 
progression prediction to XLCR ratio compared to 73.5% ACR (figure 7.16). 
 
Figure 7.16: Urine ε (γ glutamyl) lysine ROC curve 
 
 
 
Figure 7.16: The ε (γ glutamyl) lysine:CR (XLCR) ROC curve with sensitivity (probability of correctly 
identifying a positive finding) plotted in the Y axis and 1-specificity (false positives) in the x axis. The 
higher the area under the curve the higher will be the accuracy of prediction of an event. a = under 
the nonparametric assumption, b = null hypothesis: true area = 0.5. 
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7.5. Serum concentration of Transglutaminase type 2  
 
Transglutaminase type 2 was measured in blood samples from 130 CKD patients and in 10 
healthy volunteers in order to compare its levels in the circulation to urine excretion.  Out of 
these 130 patients, 58 presented with DKD (44.62%), 24 CGN (18.46%), 23 HTN (17.69%), 8 
ARVD (6.15%), 5 CIN (3.85%), 4 ADPKD (3.08%) and 8 had other CKD causes (6.15%). Full 
methods are described in section 3.4.3. 
 
Average serum concentration of TG2 in healthy volunteers was 523 ± 107pg/ml, which 
represented approximately 5 times their urine level (n=33).  CKD patients had a significantly 
higher serum concentration of TG2 (3994 ± 358pg/ml, p<0.0001) when compared to controls 
(figure 7.17).  Amongst these, patients with DKD (3831 ± 5513, p<0.0001), CGN (4704 ± 
931pg/ml, p=0.0002), HTN (3722 ± 692pg/m, p=0.0001l) and other CKD causes (2934 ± 
803pg/ml, p=0.0207) had significant higher serum TG2 levels than healthy volunteers.  
However, no significant difference was found in patients with ARVD (3085 ± 1133pg/ml, 
p=0.0591), CIN (7300 ± 2813pg/ml, p=0.0738) and ADPKD (3468 ± 2580, p=0.3371) due to 
large variation within these groups.   
 
Figure 7.17: Blood levels of Transglutaminase type 2 
 
 
 
Figure 7.17: Serum TG2 concentration was quantified by an in-house sandwich enzyme-linked 
immunosorbent assay. A – scatter plot of serum TG2 measurements in healthy volunteers (n=10) and 
CKD patients (n=130) and B - Average  serum TG2 concentration (pg/ml) in different CKDs where 
statistical significance was shown by one Way ANOVA with Bonferroni post hoc test: NS= not 
statistically significant, * p<0.05, **p<0.01, ***p<0.001.  Data represents mean ± SD. 
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7.6. Correlation analysis for Transglutaminase type 2  
 
Correlation between serum concentration of TG2 (n=130) and excreted TG2 in the urine did 
not quite reach statistical significance (r= 0.04788, 95% CI = -0.1234 to 0.2164, p = 0.0542 
(figure 7.18-C).  However, urine levels of TG2 had a highly positive correlation with ε (γ 
glutamyl) lysine excretion in the urine (r= 0.4913, 95% CI = 0.3721 to 0.5946, p < 0.0001 
(figure 7.18-B).  There was no correlation with urine TG2 excretion and proteinuria (r= 0.04709, 
95% CI = -0.07141 to 0.1643, p = 0.4359, figure 7.18-A) indicating the measurement of ε (γ 
glutamyl) lysine in urine was not simply a reflection of elevated proteinuria. 
 
7.6.1. Urinary Transglutaminase type 2 and ε (γ glutamyl) lysine association 
with histological changes 
 
To determine if urine excretion of TG2 and its crosslink product of ε (γ glutamyl) lysine were 
associated with histological changes and scarring formation present in the kidneys, a 
correlation analysis between these molecules and percentage of renal fibrosis was performed 
in a subset of chronic glomerulonephritis patients (n=41) which undergone kidney biopsy 
during this study (figures 7-19-A and 7.19-B). Interestingly, both molecules presented a 
positive correlation with percentage of fibrosis (Pearson’s r=0.5496, 95% CI: 0.2911 to 0.7332 
p=0.0002 for TG2CR and Pearson’s r=0.3812, 95% CI: 0.0094 to 0.6603, p=0.0454 for XLCR).  
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 Figure 7.18: Urine TG2 excretion in patients with different causes of CKD 
 
 
 
 
  
 
    
 
Figure 7.18: Correlation analysis of Urine TG2 with (A) proteinuria, (B) ε (γ glutamyl) lysine and (C) 
serum TG2.   
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Figure 7.18: Correlation plots of urine TG2 and ε (γ glutamyl) lysine excretion with 
percentage of kidney fibrosis in patients with chronic glomerulonephritis 
 
 
    
 
           
 
 
 
Figure 7.18:  Pearson’s correlations were performed for TG2CR (A) and XLCR (B) with percentage of 
kidney fibrosis in 41 CGN patients submitted to renal biopsy. Statistical significance was shown as, * 
p<0.05, **p<0.01, ***p<0.001.  
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7.7. TG2 substrates 
 
To try and understand which proteins present in urine were substrates for TG2 crosslinking, 
several proteins found in urine including some ECM proteins were incubated with TG2 and 
the amount of ε (γ glutamyl) lysine crosslinking assessed as described in chapter 3, section 
3.9.  Briefly, this assay comprised of activation of 10ug recombinant human Transglutaminase 
2 by a solution containing 2mM Ca2, followed by crosslinking a 1mg/ml solution of the following 
proteins; Albumin from human serum, human Collagen type I, human Collagen type III, human 
Collagen type IV, human Collagen type V, fibronectin from human plasma (FN) and  Dimethyl 
casein (DMC).  Following incubation with TG2, each protein was subjected to exhaustive 
proteolytic digestion, freeze drying and separation with quantification of ε (γ-glutamyl) lysine 
by reverse phase HPLC on a Biochrom 30 Amino Acid Analyser. 
 
Importantly, ε (γ-glutamyl) lysine was hardly detectable in human albumin (n=4, XL 
concentration of 0.001nmol/mg protein) (figure 7.18), whilst other proteins displayed higher 
levels of crosslinking: Human Collagen III (n=4, 0.026nmol/mg protein), DMC (n=4, positive 
control, 0.035nmol/mg protein), FN (n=4, 0.042nmol/mg protein) and Human Collagen I (n=4, 
0.079nmol/mg protein).  Human Collagen I without addition of TG2 was used as a negative 
control (figure 7.20). 
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Figure 7.20: In vitro crosslinking of TG2 substrates 
 
 
Figure 7.20:  Establishing which urine proteins are good TG2 substrates.  TG2 substrates: albumin 
from human serum, human collagen type I, human collagen type III, human collagen type IV, human 
collagen type V, fibronectin from human plasma (FN) and Dimethyl casein (DMC) were treated with 
10ug rhTG2 for X hours and then subjected to exhaustive proteolytic digestion, and separation with 
reverse phase HPLC on a Biochrom 30 Amino Acid Analyser for quantification of ε (γ-glutamyl) lysine 
dipeptide.  Collagen without TG2 was used as negative control.  
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7.8. Discussion 
 
The overall aim of this chapter was to recruit a good number of CKD patients which would 
replicate routine clinical presentation and test the hypothesis that urine TG2 and its crosslink 
product ε (γ-glutamyl) lysine could be better predictors of CKD progression than ACR.   
 
Our study consisted of a prospective observational cohort of 292 CKD adult patients from 
stages 1 to 5 followed over a period of 3 years. Nineteen patients with diabetes mellitus without 
any evidence of kidney dysfunction and 33 adult healthy volunteers were also recruited to this 
study. 
 
The sample size of the population study had sufficient power (power of 0.80(1-β), with Type I 
error or α of 0.05 and Type II error or β of 0.20).  It was representative of the breakdown of 
CKD patients attending the SKI and also matched with the national renal registry findings.  
Most groups were large enough and depictive of the CKD community.  The number of patients 
present in each CKD stage group was also a reflection of what is observed daily at the 
outpatients’ clinics. 
 
Urine TG2 concentration was over 35 fold higher in patients with all CKD causes (n=292) when 
compared to healthy volunteers (n=33).  Individuals with diabetic kidney disease presented 
the highest levels of urine TG2 when compared to all other groups, with nearly double the 
values found in the general CKD population. This was also significantly elevated when 
compared to patients presenting diabetes mellitus (n=19) without any evidence of kidney 
damage (p<0.0001).  All other ethiologies also presented significant urine levels of TG2, a part 
from ADPKD patients.  Similar results were found when urine TG2 excretion was corrected to 
a creatinine ratio, with TG2 levels around 60 times greater than controls. Once again, no 
statistical significance was observed in ADPKD patients. This corroborates with the 
peculiarities of this disease which progression is more dependent on known risk factors such 
as PKD-1 gene mutation, hypertension (Schrier 2015), total kidney volume (Corradi et al. 
2015) and urine copeptin levels (Nakajima et al. 2015). 
 
There were significant urine levels of ε (γ-glutamyl) lysine (6.7 fold higher in patients with all 
CKD causes).  When corrected to a creatinine ratio, ε (γ-glutamyl) lysine excretion was also 
substantially increased in all ethiologies, excluding ADPKD and CIN, where a wide spread of 
values were observed. This could be due to a higher presence of patients at early stages of 
the disease in both groups and also to the prevalence of non-progressive cases.   
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An analysis by age groups revealed a slight increase of urine TG2 and ε (γ-glutamyl) lysine in 
patients above 65 years, however this was not statistically significant. In addition, males also 
presented higher urine levels of both molecules than females. But, once again no statistical 
difference was found.  
 
TG2: Creatinine ratio was elevated in progressive and rapidly progressive CKD. Nonetheless, 
this was not reflected in terms of ε (γ-glutamyl) lysine excretion, where only rapid progressive 
patients displayed significant urine levels of the molecule.  This suggests either a limitation in 
the types of proteins crosslinked to the ECM or that there is a need for more advanced kidney 
dysfunction to be translated into increased ε (γ-glutamyl) lysine excretion. To our knowledge, 
this is the first study to analyse human urine levels of both TG2 and ε (γ-glutamyl) lysine.  
Thus, no comparisons could be made with published data. Therefore, this prompted us to 
perform subsequent studies to determine serum TG2 levels and also to investigate what 
proteins were crosslinked in the matrix. 
 
Serum TG2 levels were around five as much as urine levels.  Significant amounts were found 
in all ethiologies, excluding ARVD, CIN and ADPKD due to the large variability of values found 
in these groups.  Moreover, a correlation analysis between TG2CR and XLCR with percentage 
of kidney biopsies from 41 CGN biopsies revealed a remarkable association with scar 
formation indicating that urine measurement of these molecules could indeed constitute a 
good non-invasive way of tracking disease progression. Notwithstanding, urinary TG2 
presented a highly positive correlation with ε (γ glutamyl) lysine excretion in the urine, with no 
correlation to proteinuria (r= 0.04709, 95% CI = -0.07141 to 0.1643, p = 0.4359) indicating that 
measurement of TG2 in urine was not simply a reflection of elevated proteinuria. 
 
An in vitro investigation of which proteins present in human urine were substrates for TG2 
crosslinking was performed.  On this research, several proteins found in urine including some 
ECM proteins (albumin, collagens type I, III, IV and V, fibronectin, and DMC) were incubated 
with TG2 and the amount of ε (γ glutamyl) lysine determined by exhaustive proteolytic 
digestion with quantification by reverse phase HPLC (AAA).  This showed that the most likely 
proteins being crosslinked were fibronectin and collagen type I, confirming previously 
published studies. However, ε (γ-glutamyl) lysine was hardly detectable in human albumin.  
Numerous studies have identified potential ECM substrates for TG2, for instance, fibronectin 
has been shown to be a major TG2 substrates both in vivo and in vitro (Jones et al. 1997), as 
well as fibronectin-collagen (Mosher 1984), collagens type III (Bowness et al. 1987), types 
V/XI (Kleman et al. 1995),  lipoprotein(a) (Borth et al. 1991) and IGF-I (Sivaramakrishnan et 
al. 2013).  However, no evidence of albumin crosslinking by TG2 has yet been published and 
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the data presented here suggests it is a very poor substrate in isolation.  Structurally, it 
contains five to six internal disulfide bonds which could potentially suffer interaction with TG2.  
Interestingly, this supports our findings in terms of ε (γ glutamyl) lysine excretion in both 
experimental and human DKD.  In both groups, although high amounts of TG2 were excreted 
in the urine, this was not translated into higher amounts of its crosslink product.  This could be 
due to the fact that albumin is the major component found in both groups of diabetic subjects 
and as the proteolytic digestion of samples involved the breakdown of fixed amounts of protein 
(2-5mg in total, without albumin depletion), lower amounts of TG2 substrates were available 
for crosslinking and therefore ε (γ glutamyl) lysine levels were lower.  This implies that large 
amounts of albumins, which is a poor substrate, dilute out the XL per mg of protein. Thus, 
moving forward depletion of albumin could improve sensitity. However, this process would 
could also lead to loss of other proteins of interest. 
 
ROC curve analysis of TG2CR determined a 86.4% accuracy in CKD progression prediction, 
compared to 73.5% for ACR.  This data suggests that TG2CR could be a better prognostic 
tool than the currently used standard method.  On the other hand, XLCR did not display the 
same power of prediction, detecting 73.3% of cases. This could be a result of the selectivity 
for substrates by TG2 demonstrated in the in vitro study. 
 
This is the first study to present urine measurements of TG2 and ε (γ-glutamyl)-lysine crosslink 
in human CKD caused by different ethiologies.  The collection and analysis of forty one kidney 
biopsy samples made possible the correlation of their excretion with development of kidney 
scarring.  It was established that TG2 and ε (γ-glutamyl) lysine are significantly elevated in 
urine from CKD patients and that this fact was not only a result of increased proteinuria. In 
fact, the high serum levels of TG2 suggested that this molecule could be filtered, especially 
as levels were five times higher than the ones found in urine.   ROC-AUC analysis determined 
a much higher prediction of CKD progression for TG2CR (86.4%), being superior to the best 
conventional marker currently used (ACR, 73.5%). A panel combining these biomarkers could 
represent a more effective way of predicting progressive CKD. 
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Chapter 8 
Urine Matrix metalloproteinases and their 
inhibitors as prognostic markers in Human 
Chronic Kidney Disease 
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8.1. Introduction 
 
Excessive Extracellular Matrix (ECM) accumulation is the final pathway in kidney fibrogenesis.  
Kidney basement membrane homeostasis results from a continual turnover of the ECM 
resulting from the balance between synthesis and degradation of ECM components.  The 
renal ECM is formed by a complex framework of macromolecules which not only provides 
filtration and structural support to the kidneys, but also regulates cellular processes such as 
development, migration, differentiation and morphogenesis.  It is comprised of structural 
proteins including various collagens and non collagenous glycoproteins such as fibronectin, 
elastin, laminin, tenascin, SPARC (Secreted Protein Acidic and Rich in Cysteine), 
thrombospondin and proteoglycans.  Deposition onto the matrix occurs by up regulation of the 
transcription of these components by growth factors and cytokines such as TGF 1, FGF and 
IGF-1. Activated fibroblasts increase their production of fibronectin and interstitial collagens 
(Zeisberg et al. 2000) whilst mesangial and epithelial cells synthesise abnormal glomerular 
collagens I and III during renal disease.  In addition, there is the action of crosslinking enzymes 
such as TG2, LOXL2 and Lysyl oxidase, which also contribute to increased ECM accumulation 
by the crosslinking of proteins such as collagen and elastin (Kagan and Trackman 1991).   
ECM breakdown is mediated by specific enzymes such as the matrix metalloproteinases 
(MMPs; Matrixins), the cysteine/aspartic proteinases and the serine proteases.  Therefore, 
increased deposition and/or a decreased breakdown of its components favors a reduction in 
ECM turnover and subsequent expansion of normal kidney matrix as well as the appearance 
of abnormal ECM components which is also associated with phenotypic changes to resident 
renal cells. 
 
Studies suggest that decreased levels of MMPs or elevated levels of protease inhibitors are 
one of the major causes for this accumulation (Johnson et al. 2002).  Fibrogenic cytokines 
such as TGF-β1 can reduce the expression of these collagenolytic enzymes, as well as 
activate their endogenous inhibitors and up-regulate the integrin-mediated cell-matrix 
interactions.  However, due to its action in a number of non-ECM proteins and their multiple 
biological activities, reduced MMP expression, not only leads to ECM accumulation, but also 
to complex changes in cellular behavior and phenotypes (Nagase et al. 2006, Giannandrea 
and Parks 2014). For instance, a decrease in MMP-1 mediated cleavage of type I collagen 
will affect keratinocyte migration and re-epithelization (Pilcher et al. 1997), a reduction in the 
E-cadherin cleavage by MMP-3 will affect EMT and cause disrupted cell aggregation and 
increased cell invasion (Lochter et al. 1997) and limited cleavage of IL-2Rα by MMP-9 affecting 
IL-2 response (El Houda Agueznay et al. 2007). 
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Currently 25 MMP types have been identified in humans (Tan et al. 2012). They are subdivided 
into 6 groups according to their substrate specificity:  Collagenases (MMPs 1, 8, 13, 18), 
Gelatinases (MMPs 2, 9), Stromelysins (MMPs 3, 10, 11), Matrilysins (MMPs 7, 26), 
Metalloelastase (MMP 12), Membrane-type (MMPs 14, 15, 16, 17, 24, 25), Enamelysin (MMP 
20) and others (MMPs 19, 21, 23A, 23B, 27, 28) (Nagase et al. 2006).  The mechanisms of 
activation of proMMPs as well as the complete domain structure of all MMPs can be found in 
section 1.10.3.  MMPs are specifically inhibited by four TIMPs (TIMPs 1, 2, 3, 4) in a 1:1 
stoichiometry way, so an increase in TIMP levels can directly decrease levels of MMP activity.  
Several other proteins can also inhibit MMPs, for example; α-macroglobulins , tissue factor 
pathway inhibitor-2, β-amyloid precursor protein and the GPI-anchored glycoprotein RECK 
(reviewed in (Murphy and Nagase 2008)). 
 
Previous animal studies describing changes in protein and mRNA levels in kidney 
homogenates have showed that MMPs 1, 2, 3, 8, 9 and 13 as well as TIMPs 1, 2 and 3 have 
significant renal expression (Ahmed et al. 2007).  In the same manner, studies in human 
kidney disease have highlighted the renal expression of such molecules, however, majority of 
these studies are restricted to histological measurements of such molecules.  For instance, a 
recent study has performed an Immunohistochemistry examination of MMP-2 and TIMP-1 in 
kidney biopsy samples from transplanted patients with chronic allograft dysfunction (CD4+ 
antibody-mediated rejection) and reported increased expression in tubular interstitial cells 
from AMR patients when compared to health kidneys from controls (Yan et al. 2012).  Another 
study in ANCA-associated glomerulonephritis has showed an increase in glomerular and 
tubule-interstitial expression of MMPs 2, 3 and 9 and TIMP1 (Sanders et al. 2004).  However, 
there is a lack of studies showing if these changes are reflected in urine levels of these 
molecules, especially in human CKD as they could potentially give us an insight into the status 
of the renal fibrosis. 
 
In Chapter 5, MMPs 1 and 9 as well as their inhibitors TIMPs 1, 2 and 3 were quantified in rat 
urines obtained from three different models of kidney scarring (SNx, Streptozotocin induced 
DN and CAN).  Results showed increased MMP1:Creatinine ratio in SNx animals and at later 
stages of disease in Diabetic animals.  However, MMP-9 excretion did not present higher 
levels than controls.  The TIMP-1:Creatinine and TIMP-2:Creatinine ratio were significantly 
higher at all time points tested in SNx samples and at 4 and 8 months DN animals.  24 hour 
TIMP-1 excretion was markedly increased in F-L Allografts at 17 and 24 weeks post 
transplantation when compared to L-L Isografts, whilst the TIMP-2:Creatinine ratio was 
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significantly higher in F-L Allografts as early as two weeks post transplantation. However, this 
difference was not observed at the termination of the study when kidneys where completely 
scarred.  Urinary TIMP-3 excretion did not present a good correlation with disease progression 
in experimental kidney scarring.  Based on this there was good evidence to study MMPs 2, 9, 
TIMPs 1 and 2 in human patient samples 
 
It is therefore hypothesized that the changes seen in the MMPs and TIMPs in the 
aforementioned 3 animal models of CKD would also be altered in human urines from CKD 
patients and that the levels of these would correlate to the activity of fibrotic modeling and 
hence rate of loss of kidney function. 
 
To test this hypothesis the aim in this chapter is to use urine samples from the 292 CKD 
patients with different ethiologies and 33 healthy volunteers collected and characterised in 
chapter 7 to: 
 
1. Measure the total urinary ECM collagenolytic activity in cell free urines using DQ 
gelatin cleavage.  
2. Quantify MMPs 1, 2 and 9 as well as TIMPs 1, 2 and 3 and the complex formed 
between MMP-1 with TIMP-1 in these urine samples by using commercially available 
immunoassays.  
3. To evaluate the potential value of overall MMP-activity, MMPs 1, 2 and 9 as well as 
TIMPs 1, 2 and 3 in accurately predicting CKD progression and compare these 
outcomes with ACR by ROC curve analysis.  MMP-9 was included in this panel as 
parallel work done by cytokine array analysis indicated that this molecule had a 
potential as a CKD biomarker.  
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8.2 Urinary ECM collagenolytic activity  
 
The Molecular Probe’s EnzChek® Gelatinase/Collagenase Assay is a highly sensitive 
fluorometric method used to analyze total gelatinase and interstitial collagenase activity.  Full 
methods for measurement of urinary MMP activity are described in section 3.14.2.  Briefly, 
whole molecule gelatin pre-labeled with fluorescein (DQ™-gelatin conjugate), was incubated 
with undiluted human urine samples.  DQ gelatin is digested by MMPs in the urine to yield 
highly fluorescent peptides by cleavage of the molecule.  The intensity of the fluorescence is 
proportional to the MMP proteolytic activity, being read in a fluorescent Plate reader equipped 
with standard fluorescein filters.  Collagenase IV purified from Clostridium histolyticum was 
used to produce a seven point standard curve (figure 8.1).  Microplates were incubated at 
room temperature, protected from light, and read for 48 hours. 
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Figure 8.1:  Example of a total MMP activity standard curve 
A: Changes in Fluorescence with time at different collagenase concentrations 
                  
 
B: Standard curve generated from linear rates of enzyme activity in A 
 
Figure 8.1: The EnzCheck Gelatinase/ Collagenase assay Standard Curve.  
A - Collagenase from Clostridium histolyticum in a seven point serial dilution (0.1-0U/ml) was used to 
digest 100µg/ml DQ™-gelatin.  Microplates were incubated at room temperature and protected from 
light.  Incubation times were set for every 15 minutes for 4 hours, then every hour for the following 4 
hours.  Final incubation at 12, 24 and 48 hours were also used during this assay. Fluorescence was 
measured using a Fluorescent microplate reader set for excitation at 485 ± 10nm and emission 
detection at 530 ± 15nm.  Background fluorescence defined by a control sample without Collagenase 
was subtracted from each value.   
B – The change in Fluorescence (arbitrary Units) of each control sample was plotted in the y-axis 
against the Collagenase concentration (U/ml) in the x-axis.  Data points are average of duplicates. 
Values are mean ± SEM. 
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8.2.1. Measurement of Collagenase activity 
 
After validation and optimisation of the assay protocol, undiluted CFU were selected for 
measurement of the absolute urinary ECM proteolytic activity.  Collagenase IV purified from 
Clostridium histolyticum was used as a control enzyme to produce a seven point standard 
curve (figure 8.1).  DQ™-gelatin (denaturated collagen) is a substrate which is efficiently 
digested by all MMPs.  50 ul of a 100ug/ml of substrate was added to each well and the 
increase in fluorescence used to estimate the amount of collagenase present in the urine 
sample.  A 48 hours incubation period was used, with readings every 15 minutes for the first 
4 hours, then every hour for the following 4 hours and final recordings at 12, 24 and 48 hours.  
The assay could detect collagenase activity down to a final concentration of 2 x 10-3 U/ml, 
where one unit of collagenase was defined as the amount that can breakdown 1µmole of L-
Leucine equivalents from collagen within 5 hours at 370C, pH 7.5. 
 
Different patterns of MMP activity were observed in CKD patients.  Most patients presented a 
fluorescence level increasing steadily with time (figure 8.2-A).  However, some did not show 
significant changes during the 48 hour incubation period (figure 8.2-C) and some even had a 
decrease in activity over the time (figure 8.2-E) which is most likely an assay artefact.  Linear 
regression analysis was used to analyse fluorescence levels with time in every sample and 
used to calculate the gradient (Δ Fl / hr) and therefore indicate the proteolytic activity of each 
urine sample (figures 8.2-B, 8.2-D and 8.2-F). 
 
8.2.2. Urine MMP activity of CKD patients and healthy volunteers 
 
To determine the urine MMP activity of healthy volunteers and CKD patients, undiluted CFU 
were measured in duplicate with and without the addition of 1,10 phenanthroline and the 
proteolytic gradient calculated by linear regression analysis.  The rate of MMP specific activity 
was calculated by subtraction of the inhibitor containing sample rate from just the CFU rate.  
Healthy volunteers presented an overall MMP activity of 0.4997 ± 0.076 Δ Fl / hr, whilst 
patients with all CKD causes presented a substantial 4.7 fold increase (2.376 ± 0.191 Δ Fl / 
hr, p<0.0001, figure 8.3-A).  When corrected to a creatinine ratio, this difference increased to 
a 7.2 fold higher average values in the group of patients with all CKD causes (0.5394 ± 0.058 
Δ Fl / hr per µmol of creatinine, p<0.0001) when compared to healthy volunteers (0.0741 ± 
0.019 Δ Fl / hr per µmol of creatinine, figure 8.3-B).  Amongst the CKD group, hypertensive 
patients presented the highest elevation in the MMP activity: Creatinine ratio when compared 
to healthy volunteers (10.7 fold increase; 0.7919 ± 0.226 Δ Fl / hr per µmol of creatinine, 
p=0.0028) followed by CIN (8.3 fold increase; 0.6144 ± 0.193 Δ Fl / hr per µmol of creatinine, 
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p=0.0147) and diabetic kidney disease (7 fold increase; 0.5144 ± 0.08 Δ Fl / hr per µmol of 
creatinine, p<0.0001).  Patients with ARVD and CGN also had significant increases in the 
MMP activity: creatinine ratio (p=0.0142 and p=0.031 respectively).  However, ADPKD 
patients presented a wide range of values (average of 0.6408 ± 0.4408 Δ Fl / hr per µmol of 
creatinine) and consequently did not differ statistically from controls (p=0.2311,figure 8.3-C). 
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Figure 8.2: Fluorescence gradient in CKD urine samples 
 
 
 
  
 
 
  
Figure 8.2: Urinary MMP activity of CKD samples was performed by using the EnzCheck Gelatinase/ 
Collagenase assay and measured by plotting the fluorescence gradient which evaluated proteolytic 
activity over 48 hours.  Different profiles of MMP activity could be observed: A (SKI 42);  shows a typical 
pattern of increase in activity, B (SKI 56)  a stable profile and C (SKI 314) shows an uncommon decrease of 
activity over time.  The calculation of the gradient for each sample ((Δ Fl / hr) was done by linear regression 
analysis (D, E, F) of all readings done over the 48 hours period. 
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Figure 8.3: MMP activity in CKD urine samples 
 
 
 
 
 
 
 
 
Figure 8.3: MMP activity in human urine samples was measured by the EnzChek® 
Gelatinase/Collagenase Assay and presented as  MMP activity expressed in Δfl/h (A), as a creatinine 
ratio (B) and further sub classified by different CKD ethiologies (C).  Statistical significance was tested 
with one Way ANOVA with Bonferroni post hoc test: NS= non statistical significant, * p<0.05, 
**p<0.01, ***p<0.001, between controls and CKD patients. Values are mean ± SD.  
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8.2.3. Urine MMP activity and CKD progression 
 
Interestingly, CKD non-progressive and progressive patients had notably higher MMP activity 
(0.5567 ± 0.069 and 0.5749 ± 0.133 Δ Fl / hr per µmol of creatinine, respectively) than rapidly 
progressive (0.2158 ± 0.06 Δ Fl / hr per µmol of creatinine, p=0.0172, figure 8.4).  In addition, 
all three groups of CKD patients had considerably more MMP activity than healthy volunteers 
(p<0.001). 
 
Figure 8.4:  Urine MMP activity by CKD progression 
 
 
Figure 8.4:  MMP activity: Creatinine ratio measurements in CKD patients were subdivided into groups 
according to their rate of disease progression: non-progressors (rate of eGFR decline 
<2ml/min/1.73m2/year, n=184), progressors (between 2-5ml/min/1.73m2/year, n=79) and rapidly 
progressors (>5ml/min/1.73m2/year, n=29).  Statistical significance is shown by One Way ANOVA with 
Bonferroni post test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between non-
progressors, progressors and rapidly progressors.  Data represents mean ± SD. 
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8.2.4. ROC curve analysis for urine MMP activity to predict CKD progression  
 
A ROC curve analysis was used to evaluate the accuracy of ACR and MMP activity over 
creatinine ratio in predicting the annual decline of kidney function in rapid progressive CKD 
patients (eGFR decline > 5ml/min/1.73m2).  Overall, ACR presented a 73.0% prediction in this 
subgroup of patients when compared to 68.3% of urinary MMP activity (figure 8.5).  
 
Figure 8.5:  MMP activity ROC curve 
 
 
 
 
 
 
Figure 8.5: The MMP activity:CR ROC curve with sensitivity (probability of correctly identifying a 
positive finding) plotted in the Y axis and 1-specificity (false positives) in the x axis. The higher the area 
under the curve the higher will be the accuracy of prediction of an event. a= Under the nonparametric 
assumption. b= Null hypothesis: true area = 0.5. 
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8.3. Urine levels of Matrix Metalloproteinases in Human CKD 
 
8.3.1. Measurement of urine MMP-1  
 
Urinary MMP-1 was measured in human samples using a DuoSet immunoassay (section 
3.10.5).  Four randomly selected urine samples were spiked with 6.25ng/ml recombinant 
human MMP-1 to validate the assay protocol and evaluate the recovery of total human MMP-
1 (active and pro-MMP-1).  The average % recovery of MMP-1 ranged between 85-102% by 
reference to a MMP-1 standard curve (figure 8.6). 
 
MMP-1 levels were below limit of detection in the majority of human CKD urines (n= 277, 
94.86%), even after 10X concentration using a centrifugal evaporator.  Of note were 15 CKD 
urine samples with detectable MMP-1 concentrations (7 with significant amounts).  The 
samples with measurable MMP-1 were rather random, being regardless of their CKD 
ethiology, gender, age or rate of CKD progression.  The characteristics of these 15 remaining 
samples (5.14%) are displayed in table 8.1. 
 
 Figure 8.6:  Human Matrix Metalloproteinase 1 Immunoassay Standard Curve 
 
 
Figure 8.6: Human total MMP-1 immunoassay standard curve was obtained using recombinant human 
MMP-1 in duplicates and a R&D antibody DuoSet kit.  Absorbance was measured on a Labsystems 
Multiskan Ascent plate reader at a wavelength of 450nm using the Labsystems Genesis computer 
package.  Optical density (O.D.) of each sample was measured, plotted on the y-axis against the MMP 
concentration (pg/ml) on the x-axis.  Curve fit used was a four parameter regression model.  Data 
points are average of duplicates.  
 
 
 
0 2 5 5 0 7 5 1 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
4 .0
H u m a n  M M P -1  c o n c e n tra tio n  (p g /m l)
O
.D
.
295 
 
Table 8.1:  Detected Human Matrix Metalloproteinase 1 in urine 
ID CKD 
DIAGNOSIS 
AGE GENDER CKD 
STAGE 
PROGRESSION MMP-1 
(pg/ml) 
SKI 97 CGN 50 FEMALE 3A RAPIDLY PROGRESSIVE 6611.9 
SKI 105 HTN 63 MALE 3A RAPIDLY PROGRESSIVE 624.3 
SKI 108 ARVD 77 FEMALE 3B PROGRESSIVE 166.4 
SKI 121 DKD 69 FEMALE 4 PROGRESSIVE 13300 
SKI 135 CGN 68 MALE 3B NON-PROGRESSIVE 168.3 
SKI 156 DKD 74 FEMALE 4 NON- PROGRESSIVE 585.2 
SKI 182 CGN 60 FEMALE 2 RAPID PROGRESSIVE 1203.8 
SKI 221 CGN 43 FEMALE 4 PROGRESSIVE 358.9 
SKI 222 CGN 50 MALE 2 NON-PROGRESSIVE 17600 
SKI 235 ADPKD 39 FEMALE 4 PROGRESSIVE 517.0 
SKI 238 CGN 74 MALE 4 PROGRESSIVE 6304.2 
SKI 241 CGN 43 FEMALE 3A PROGRESSIVE 332.9 
SKI 251 CGN 22 MALE 3B NON- PROGRESSIVE 5987.1 
SKI 304 OTHERS 68 MALE 3B NON- PROGRESSIVE 690.2 
SKI 305 CGN 61 MALE 4 PROGRESSIVE 25200 
SKI 319 HTN 63 MALE 3A NON-PROGRESSIVE 17600 
 
Table 8.1: Demographic and clinical characteristics of 15 CKD patients (out of 292) which had 
detectable MMP-1 levels in the urine. CGN= chronic glomerulonephritis, HTN = hypertensive 
nephrosclerosis, ARVD = arterosclerosis renovascular disease, DKD = diabetic kidney disease, ADPKD 
= adult polycystic kidney disease. Patients subdivided into rapidly progressive (eGFR decline > - 
5ml/min/1.73m2/year), progressive (eGFR decline between - 2 and 5ml/min/1.73m2/year) and non-
progressive CKD (eGFR decline < - 2 ml/min/1.73m2/year). 
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8.3.2. Measurement of urine MMP-2  
 
To establish the levels of total Matrix metalloproteinase 2 (active and pro-MMP-2) in human 
CKD urine, the total MMP-2 DuoSet Immunoassay was used, as described in section 3.10.6.1.  
Reproducibility and specificity tests for this assay are shown in section 3.10.6.1.1. 
 
Initial analysis showed that urine MMP-2 concentration was 45.9% higher in patients with all 
CKD causes (n=292, 1341 ± 136pg/ml) when compared to health volunteers (n=33, 919 ± 
160, p=0.0481, figure 8.7-A).  However, MMP-2 concentration was below the levels of 
detection in 37 CKD patients and 2 controls. These patients belonged to the same group of 
patients with undetectable urine MMP-1. 
 
To address the issue of urine volume variability, the MMP-2 concentration was corrected to a 
creatinine ratio. MMP-2: Creatinine ratio was 2.4 fold higher in CKD patients (p<0.0001, figure 
8.7-B). Healthy volunteers presented an average MMP-2: Creatinine ratio of 118.6 ± 27.45 
ng/mmol. 
 
 
Figure 8.7: MMP-2 measurement in urine from CKD patients 
 
 
Figure 8.7: Urine MMP-2 was measured using the R&D DuoSet immunoassay system in patients with 
all cause CKD (n=292, with 255 detected) and controls (n=33, with 31 detected). A - Urine MMP-2 
concentration (pg/ml) and B – MMP-2 / Creatinine ratio.  Results are displayed as mean ± SD.  
Statistical significance is shown by Independent-samples T test, * p<0.05, **p<0.01, between CKD 
patients and healthy volunteers.  
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8.3.2.1. MMP-2: Creatinine ratio in different CKD ethiologies and stages 
 
Hypertensive patients showed the highest increase in the MMP-2: Creatinine ratio with an 
average 290 ± 61ng/mmol, p=0.0136 when compared to healthy volunteers (figure 8.8-A).  
Patients with chronic glomerulonephritis (275 ± 50ng/mmol, p=0.0079) and diabetic kidney 
disease (265 ± 57ng/mmol, p=0.0223) also had significantly increased MMP-2: Creatinine 
ratios.  Although patients which presented with other CKD causes also had elevated levels of 
MMP-2: Creatinine (atherosclerotic renovascular disease = 237 ± 83.96ng/mmol, p=0.1893), 
CIN (335.7 ± 185ng/mmol, p=0.2663), ADPKD (425 ± 214ng/mmol, p=0.1836) and other CKD 
causes (352 ± 141ng/mmol, p=0.1209), they failed to achieve significance.  
 
The MMP-2: Creatinine ratio was not elevated in early CKD stages (CKD 1, 2, 3B) nor 
advanced disease (CKD 5). p values were 0.2989, 0.0631, 0.0503 and 0.5270 respectively. 
But, significant levels were found in patients with CKD stage 3A, which had an average 406 ± 
124ng/mmol (p=0.0296), and at stage 4 with an average MMP-2: Creatinine ratio of 296 ± 
48ng/mmol (p=0.0018), these values represented a 3.4 and 2.5 fold increase, respectively, 
when compared to controls  (figure 8.8-B). 
8.3.2.2. Urine MMP-2 excretion vs. demographic variables 
 
Although the MMP-2: Creatinine ratio was higher in females (average: 327 ± 51ng/mmol), 
there was no statistical significance when compared to males (260 ± 40, p=0.3088, figure 8.8-
C). 
 
CKD patients aged below 65 years presented significantly elevated levels of MMP-2: 
Creatinine (415 ± 65ng/mmol), compared to patients above 65 years of age (216 ± 31ng/mmol, 
p=0.0081, (figure 8.8-D). 
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 Figure 8.8: MMP-2:Creatinine ratio in CKD patients 
 
 
 
 
  
  
 
Figure 8.8: Urine MMP-2 excretion was corrected to a creatinine ratio in 33 healthy volunteers and 
292 CKD patients.  Data is presented by (A) CKD cause (n=292), (B) CKD stage, (C) gender – Females 
(n=113) vs. Male (n=179) and (D) age – patients bellow (n=111) and above (n=181) 65 years old.  
Results are displayed as mean ± SD.  Statistical significance is shown by One Way ANOVA with 
Bonferroni post test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between CKD 
patients and healthy volunteers. Abbreviations: see figure 7.2. 
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8.3.2.3. MMP-2: Creatinine ratio by rate of CKD progression  
 
Overall, CKD patients presented with higher urine MMP-2: Creatinine ratios than healthy 
volunteers, regardless of their rate of eGFR decline (figure 8.9).  However, non-progressors 
(189.6 ± 36.12ng/mmol) and progressors (343.6 ± 110.8ng/mmol) were not significantly higher 
(p=0.1222 and p=0.0575, respectively).  Rapid progressors exhibit considerably higher MMP-
2: Creatinine ratio 705.0 ± 268.3ng/mmol (p=0.0425) when compared to healthy volunteers.  
 
No difference was found between non-progressors and progressors (p= 0.1949), but in 
patients presenting a rate of eGFR decline above 5ml/min/1.73m2/ year (rapid progressors) 
had considerately higher MMP-2 levels than non-progressors (p=0.0129) and progressors 
(p=0.0372) (figure 8.9). 
 
 
Figure 8.9: MMP-2: Creatinine ratio and CKD progression 
 
 
Figure 8.9: The average MMP-2: Creatinine ratio in CKD patients was subdivided by rate of eGFR 
decline: non-progressive (eGFR decline < 2ml/min/1.73m2/year, n=184); progressive (eGFR decline 
between 2-5 ml/min/1.73m2/year, n=79) and rapidly progressive (eGFR decline above 
5ml/min/1.73m2/year, n=29).  Statistical significance between groups is shown by One Way ANOVA 
with Bonferroni post test: NS= not statistically significant, * p<0.05.  Data represents mean ± SD. 
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8.3.2.4.  Receiver Operating Characteristic curve for Urine MMP-2 as a predictor of 
CKD progression 
 
ROC curve analysis was used to compare the accuracy of the MMP-2: Creatinine ratio 
(MMP2CR) and Albumin: Creatinine ratio (ACR) to predict CKD progression.  MMP2CR had 
a lower predictive potential compared to ACR, with an area under the ROC curve showing a 
53.2% prediction of CKD progression by MMP2CR compared to 73.5% of ACR, figure 8.10. 
 
Figure 8.10: Urine MMP-2 ROC curve 
 
 
Figure 8.10: The MMP2CR ROC curve with sensitivity (probability of correctly identifying a positive 
finding) plotted in the Y axis and 1-specificity (false positives) in the x axis.  ACR presented a higher 
area under the curve (73.5%) and therefore a higher accuracy of CKD progression prediction when 
compared to MMP2CR (53.2%). a = under the nonparametric assumption, b = null hypothesis: true 
area = 0.5.  
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8.3.3. Measurement of urine MMP-9 
 
Measurement of total MMP-9 (pro- and active MMP-9) in patient urine was performed using 
the Duoset immunoassay as described in section 3.7.10.1.3.  Reproducibility and specificity 
tests are shown in section 3.7.10.1.1. 
 
MMP-9 urine levels had the highest percentage of detection amongst all MMPs analysed in 
this study:  CKD patients (n= 278, 95.21%) and healthy volunteers (n=29, 87.88%).  MMP-9 
concentration was significantly elevated in patients with all CKD causes (1354 ± 116.pg/ml, 
p<0.0001) when compared to controls (327 ± 107.4pg/ml, figure 8.11-A).  This difference 
became even higher when urine MMP-9 excretion was corrected to a creatinine ratio (35 ± 
14ng/mmol in controls and 312 ± 40ng/mmol in CKD patients, p<0.0001, figure 8.11-B). 
 
 
 Figure 8.11: MMP-9 measurement in urine from CKD patients 
 
    
 
Figure 8.11: Urine MMP-9 was measured by the DuoSet immunoassay in patients with all CKD causes 
(n=292, with 278 detected) and controls (n=33, with 29 detected). A - Urine MMP-9 concentration 
(pg/ml) and B – MMP-9 / Creatinine ratio (ng/mmol).  Results are displayed as mean ± SD.  Statistical 
significance is shown by Independent-samples T test: NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between CKD patients and healthy volunteers.  
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8.3.3.1. MMP-9: Creatinine ratio in different CKD aetiologies and stages 
 
An analysis of the data from different CKD aetiologies showed that ADPKD patients presented 
the highest variability in the MMP-9: Creatinine ratio (716 ± 405ng/mmol, p=0.1208).  Patients 
with all other CKD causes had significant increase in the MMP-9: Creatinine ratio when 
compared to healthy volunteers: DKD (274 ± 62ng/mmol, p=0.0004), CGN (201.8 ± 
50.22ng/mmol, p=0.0023), HTN (337.1 ± 109.5ng/mmol, p=0.0093), ARVD (345.0 ± 
106.5ng/mmol, p=0.0083), CIN (367.2 ± 115.8ng/mmol, p=0.0146) and other causes of CKD 
(327.6 ± 117.8ng/mmol, p=0.0245) (figure 8.12-A). 
 
The MMP-9: Creatinine ratio was not elevated at either CKD stage 1 or at CKD 5. However, 
significant increased levels of MMP9:Cr were observed in CKD patients from stage 2 to 4 
(figure 8.12-B).  
8.3.3.2. Comparison of Urine MMP-9 levels in different demographic variables 
 
Interestingly, female patients presented a 2.5 fold higher MMP9:Cr levels than males 
(p<0.0001, figure 8.12-C).  In addition, elderly patients aged above 65 years old had a 1.96 
fold increase in MMP9: Cr levels when compared to younger patients (p=0.0227, figure 8.12-
D). 
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 Figure 8.12: MMP-9:Creatinine ratio in CKD patients 
 
 
 
 
  
 
 
Figure 8.12: Urine MMP-9 excretion was corrected to a creatinine ratio and is displayed as: (A) healthy 
volunteers (n=33) and patients with different CKD causes (n=292), (B) – CKD stages 1 to 5, (C) – 
Females (n=113) vs. Male (n=179) and in (D) – patients bellow (n=111) and above (n=181) 65 years 
old.  Results are displayed as mean ± SD.  Statistical significance is shown by One Way ANOVA with 
Bonferroni post test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between CKD 
patients and healthy volunteers. Abbreviations: see figure 7.2. 
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8.3.3.3. MMP-9: Creatinine ratio by rate of CKD progression  
 
Patients classified into non-progressive (average MMP9:Cr = 303 ± 53ng/mmol), progressive 
(329.7 ± 71.22ng/mmol) and rapidly progressive (328.0 ± 122.0ng/mmol) groups and had 
approximately an 8.6, 9.4 and 9.3 fold increase compared to healthy volunteers (p<0.0001, 
p=0.0002 and p=0.0288 respectively).  However, no difference was found between these 
groups: (p=0.7645 between non-progressive and progressive, p=0.8525 between non-
progressive and rapidly progressive and p=0.9906 between progressive and rapidly 
progressive, figure 8.13). 
 
Figure 8.13: MMP-9: Creatinine ratio and CKD progression 
 
 
 
Figure 8.13: The bar chart shows the average MMP-9: Creatinine ratio in CKD patients subdivided by 
rate of eGFR decline: non-progressive (eGFR decline < 2ml/min/1.73m2/year, n=184); progressive 
(eGFR decline between 2-5ml/min/1.73m2/year, n=79) and rapidly progressive (eGFR decline above 
5ml/min/1.73m2/year, n=29).  Statistical significance between groups is shown by One Way ANOVA 
with Bonferroni post test: NS= not statistically significant.  Data represents mean ± SD 
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8.3.3.4. Receiver Operating Characteristic curve for Urinary MMP-9 
 
MMP-9:Creatinine ratio (MMPCR) and Albumin:Creatinine ratio (ACR) accuracy in predicting 
CKD progression were evaluated by ROC curve analysis.  ACR presented a superior 
performance (73.5% prediction of CKD progression) when compared to MMP9:CR (58.3%), 
figure 8.14. 
 
Figure 8.14: Evaluation by ROC curve analysis of MMP-9 ability to predict CKD 
progression 
 
 
Figure 8.14: The MMP9:CR ROC curve with sensitivity (probability of correctly identifying a positive 
finding) plotted in the Y axis and 1-specificity (false positives) in the x axis. ACR presented a higher 
area under the curve (73.5%) and therefore a higher accuracy of CKD progression prediction when 
compared to MMP9: CR (58.3%). a = under the nonparametric assumption, b = null hypothesis: true 
area = 0.5. 
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8.4. Urine levels of Tissue Inhibitors of Metalloproteinases in Human 
CKD 
 
Midstream urine samples from 292 patients with Chronic Kidney Disease stages 1-5 and 33 
healthy volunteers were used to measure TIMPs 1, 2, 3 and the MMP-1/TIMP-1 complex, 
using a modification of the R&D systems duo set ELISA system (methods section 3.4.5).  
Results were obtained using optimised dilutions and data was analysed with SPSS and Graph 
Pad prism software. 
   
8.4.1. Tissue inhibitor of metalloproteinase 1 
 
TIMP-1 is strongly elevated in the urine of CKD patients.  Mean TIMP-1 concentration was 
12.75 fold higher in the urine of patients with all CKD causes (2383 ± 206pg/ml, p<0.0001) 
when compared to healthy volunteers (185 ± 37pg/ml, figure 8.15-A).  To account for volume 
variability, TIMP-1 values were corrected to a creatinine ratio as done previously.  Average 
TIMP-1: Creatinine ratio in healthy volunteers was 19 ± 3ng/mmol and with a 23 fold increase 
at 426 ± 42ng/mmol in CKD patients (p<0.0001, figure 8.15-B). 
 
8.4.1.1. Tissue inhibitor of metalloproteinase 1 complexed with Interstitial 
Collagenase 
 
To study the amount of MMP-1 complexed with TIMP-1, an immunoassay was performed 
pairing a recombinant human anti MMP-1 as a capture antibody with a recombinant human 
anti TIMP-1 as a biotinylated detection antibody (full methods in section 3.4.5).  Assay 
optimisation as well as reproducibility and specificity tests are shown in section 3.4.5.1. 
 
MMP-1/TIMP-1 complex was undetectable in all urine samples obtained from healthy 
volunteers.  Assays were repeated twice (samples in quadruplicates) and using undiluted 
urines to confirm results.  Limit of detection for MMP-1/TIMP-1 was 62pg/ml.  In CKD patients, 
MMP-1/TIMP-1 complex was detected in 100 urine samples (34.25% of total number of 
samples) and had an average value of 491pg/ml (range from 62.13 to 8014pg/ml, figure 8.17-
A).  MMP-1/TIMP-1 complex was also corrected to a creatinine ratio and its average in CKD 
samples was 76± 16ng/mmol (range from 2.99 to 917.91ng/mmol).  Further comparison by 
CKD aetiology showed no statistical difference between the average MMP1TIMP1: Creatinine 
ratio in urine samples from different CKD causes (figure 8.17-B): DKD (95 ± 31ng/mmol, 
n=35), CGN (116 ± 36ng/mmol, n=21), HTN (61 ± 27ng/mmol, n=17), ARVD (179 ± 2ng/mmol, 
n=5), CIN (39 ± 8ng/mmol, n=6), ADPKD (71 ± 50ng/mmol, n=4) and other CKD causes (16 
± 2ng/mmol, n=12). 
307 
 
 
An analysis by stages of CKD did not show any statistical differences (figure 8.17-C): CKD 1 
(n=1, 152ng/mmol), CKD 2 (498 ± 365ng/mmol, n=9), CKD 3A (635 ± 235, n=20), CKD 3B 
(264 ± 79ng/mmol, n=23), CKD 4 (584 ± 224ng/mmol, n=43) and CKD 5 (142 ± 22ng/mmol, 
n=4).  
 
8.4.2. Tissue inhibitor of metalloproteinase 2 
 
Oppositely to TIMP-1, no difference was found between the average urine TIMP-2 
concentration in healthy volunteers (2726 ± 363pg/ml) and CKD patients (2857 ± 196pg/ml, 
p=0.7516, figure 8.15-C). Nonetheless, TIMP-2 corrected to a creatinine ratio in CKD patients 
was nearly double the value of controls (259 ± 44ng/mmol, p<0.0001, figure 8.15-D). 
 
8.4.3. Tissue inhibitor of metalloproteinase 3 
 
Considerably lower levels of TIMP-3 were detected in human urines when compared to TIMPs 
1 and 2 levels.  Urines were assayed undiluted and each sample run in quadruplicate (in two 
different microplates).  However, TIMP-3 was below detectable levels in 8% of healthy 
volunteers and in 20.74% of CKD patients’ urine samples.  Mean urine TIMP-3 concentration 
was higher in controls (302 ± 86pg/ml) compared to patients with all CKD causes (199 ± 
16pg/ml, p=0.2532, figure 8.15-E) and even after rectification to a creatinine ratio, no 
difference was found between healthy volunteers (33 ± 7ng/mmol) and CKD patients (38 ± 3, 
p=0.5150, figure 8.15-F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
308 
 
 Figure 8.15: Urine TIMP levels in CKD patients 
  
   
 
 
  
 
 
 
 
Figure 8.15: Urine TIMPs were measured by the DuoSet immunoassay in patients with all CKD causes 
(n=292) and controls (n=33).  Scatter plots showing the concentration (pg/ml) of:  A - TIMP-1, C – TIMP-
2 and E – TIMP-3 and bar graphs showing their concentrations corrected to a creatinine ratio 
(ng/mmol): B – TIMP-1:Creatinine, D – TIMP-2:Creatinine and F – TIMP-3:Creatinine.  Statistical 
significance is shown by Independent-samples T test: NS= not statistically significant, * p<0.05, 
**p<0.01, ***p<0.001 between CKD patients and healthy volunteers.  Data represents mean ± SD. 
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Figure 8.16: Measurement of MMP-1/TIMP-1 complex in 100 CKD patients 
 
 
 
 
   
 
Figure 8.16: MMP-1/TIMP-1 complex was measured by the DuoSet immunoassay in CKD patients 
(n=292) and health volunteers (n=33).  However, it was detectable in only 100 urine samples obtained 
from CKD patients (A).  The MMP-1/TIMP-1 complex was corrected to a creatinine ratio and is shown 
in different CKD ethiologies (B) and stages (C).  Data represents mean ± SD. 
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8.4.4. Tissue inhibitors of MMPs in different CKD aetiologies and stages 
 
Urine TIMP-1 was significantly increased in nearly all causes of CKD when expressed as a  
creatinine ratio, excluding only patients with CIN (610.7 ± 474.4ng/mmol, p=0.2362). All other 
diseases had impressive increases in TIMP:CR when compared to healthy volunteers: DKD 
had a substantial 28 fold (533 ± 76ng/mmol, p<0.0001), whilst CGN (400 ± 75ng/mmol, 
p<0.0001), 21 times higher. HTN and ARVD patients presented similar figures (380 ± 
74ng/mmol, p<0.0001 and 328 ± 75ng/mmol, p=0.0003, respectively), whereas ADPKD (233 
± 85ng/mmol, p=0.0295) and others (211 ± 32ng/mmol, p<0.0001) presented 12 and 11 times 
more TIMP1CR levels. Healthy volunteers presented an average TIMP1CR of 19 ± 3ng/mmol; 
figure 8.17-A). 
 
Changes in TIMP2: CR were less consistent across diseases where only patients with DKD 
(605 ± 98ng/mmol, p=0.0012), CGN (512 ± 61ng/mmol, p=0.0005) and HTN (491 ± 
90ng/mmol, p=0.0199) having a significant TIMP2:CR increase compared to controls (figure 
8.17-B). 
 
In contrast with previous TIMP results, patients with CIN (52 ± 16ng/mmol, p=0.2949) and 
ADPKD (77 ± 44ng/mmol, p=0.1336) had apparently higher TIMP3CR levels amongst 
patients.  However, no statistical difference in TIMP3:CR values was found between these 
and any other type of CKD compared to healthy volunteers (33 ± 7ng/mmol; figure 8.17-C). 
 
Average TIMP1:CR was significantly higher as early as in CKD stage 1 (158.5 ± 40ng/mmol, 
p=0.0113) and gradually increased to stage 4 (523.7 ± 67.71ng/mmol, p<0.0001).  There was 
a slight reduction in the TIMP1:CR at stage 5, but this remained significantly elevated (441 
173ng/mmol, p=0.0347; figure 8.17-D). TIMP2:CR was significantly elevated only at CKD 
stages 3A (378 ± 41ng/mmol, p=0.0228), 3B (521 ± 83ng/mmol, p=0.0042) and 4 (587 ± 
85ng/mmol, p=0.0004; figure 8.17-E). No statistical difference was found in the average 
TIMP3CR between CKD patients and healthy volunteers at any stage of the disease (figure 
8.17-F). 
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  Figure 8.17:  Urine TIMP levels in CKD patients by cause and stage 
 
 
     
   
       
         
Figure 8.17: Urine TIMP-1 (A; D), TIMP-2 (B; E) and TIMP-3 (C; F) excretion was corrected to a 
creatinine ratio and  presented in patients with different CKD causes and stages respectively. Results 
are displayed as mean ± SD.  Statistical significance is shown by One Way ANOVA with Bonferroni post 
test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between CKD patients and 
healthy volunteers. Abbreviations: see figure 7.2. 
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8.4.5. Tissue Inhibitors of Matrix Metalloproteinases in different 
demographic variables  
 
Overall, there were slightly higher values of TIMP1:CR, TIMP2:CR and TIMP3:CR in females 
than in males (figures 8.18-A, 8.18-B and 8.18-C, respectively). However, no statistical 
difference was found in any of these groups: p=0.5980, p=0.1668 and p=0.3039. 
Additionally, younger people (aged under 65 years old) presented higher figures of TIMP1:CR, 
TIMP2:CR and TIMP3:CR than people aged above 65 years. Notwithstanding, it only reached 
significance in TIMP1CR, where values were nearly double in the younger group (p=0.0239, 
figure 8.18-D-F). 
  
8.4.6. TIMPs excretion by rate of CKD progression  
 
As described in section 7.2.6, patients with CKD were sub classified according to their rate of 
eGFR decline. Patients classified into non-progressors, progressors and rapid progressors 
had significantly higher TIMP1:CR (p<0.0001, p<0.0001 and p=0.0032) and TIMP2:CR 
(p=0.0150, p=0.0010 and p=0.0355, respectively) values than healthy volunteers. However, 
no difference was seen in relation to TIMP3:CR values (p=0.6949, p=0.3025, p=0.7377). 
 
Despite a clear mean elevation of the TIMP1:CR and TIMP2: CR ratios from non-progressive 
to rapidly progressive patients, no statistical difference was observed within these three 
groups when using Bonferroni post test (figures 8.19-A and 8.19-C, respectively). Opposing, 
TIMP3CR values did not increase as the rate of disease progression increased.  Rather, there 
was a drop of around 37% in rapidly progressively patients (figure 8.19-B). Nevertheless, no 
statistical difference was seen. 
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 Figure 8.18:  MMPs inhibitors by different demographic variables 
 
 
     
 
   
       
 
         
Figure 8.18: Urine TIMP-1 (A; D), TIMP-2 (B; E) and TIMP-3 (C; F) excretion was corrected to a 
creatinine ratio and is presented in patients by gender and age (< and >65 years), respectively. Results 
are displayed as mean ± SD.  Statistical significance is shown by One Way ANOVA with Bonferroni post 
test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between CKD patients and 
healthy volunteers. Abbreviations: see figure 7.2. 
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 Figure 8.19:  Urine TIMPs 1, 2 and 3 levels by rate of CKD progression 
 
 
   
 
 
 
Figure 8.19: Scatter plots showing the TIMP1:CR (A), TIMP2:CR (B) and TIMP3:CR (C) in healthy 
volunteers compared to CKD patients ranked according to rate of disease progression. Y axis is plotted 
in log 10 scale in graphs A and B.  Statistical significance is shown by One Way ANOVA with Bonferroni 
post test: NS= not statistically significant, * p<0.05, **p<0.01, ***p<0.001.  
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8.4.7. Determination of the predictive potential of urine TIMPs 1, 2 and 3 for 
rate of disease progression by Receiver Operating Characteristic curve 
analysis 
 
To examine if MMP inhibitors TIMPs 1, 2 and 3 were a better predictor of progressive CKD 
than albuminuria we performed a ROC curve analysis of these biomarkers corrected to a 
creatinine ratio.  Using this approach we observed that TIMP1CR presented the highest 
prediction rate at 75.7%, compared to 71.2% for both TIMP2CR and ACR.  TIMP3:CR at   only 
46.6% was not a good predictor (figure 8.20).  
 
Figure 8.20: TIMPs 1, 2 and 3 ability to predict CKD progression by ROC curve analysis 
 
 
 
Figure 8.20: The TIMP1CR, TIMP2CR and TIMP3CR ROC curves with sensitivity (probability of correctly 
identifying a positive finding) plotted in the Y axis and 1-specificity (false positives) in the x axis. 
TIMP1CR presented a higher area under the curve (75.7.5%) and therefore a higher accuracy of CKD 
progression prediction when compared to all other biomarkers; ACR (71.2%), TIMP2CR (also 71.2%) 
and TIMP3CR (46.6%). a = under the nonparametric assumption, b = null hypothesis: true area = 0.5. 
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8.5. Discussion 
 
Matrix metalloproteinase activity can be measured in human urine from patients with different 
types of CKD. The level of  MMP activity in the urine is not consistent with that reported in the 
kidneys in that while urine MMP activity is elevated in CKD, the levels in the kidney fall almost 
certainly due to the over expression of TIMPs (Johnson et al. 2002).  The urine activity level 
of MMPs is highest in non-progressive patients which had over 7 times more than healthy 
volunteers. Similar levels were found in progressive patients. However, significantly lower 
MMP activity was observed in patients with rapid loss of kidney function which may have 
prognostic value in detecting such group of patients. Very similar results were reported in a 
recent publication just in diabetic kidney disease (Altemtam et al. 2012) suggesting this is a 
robust finding.  This raises a series of questions – why the disconnection with the levels in the 
kidney and how is the overall MMP activity achieved?    
 
To address the first of these, then perhaps there is not such a difference as the data may 
initially suggest.  The elevated MMP activity in patients with stable CKD is certainly different 
to previous tissue studies where MMP activity in renal tissue is all put lost in the fibrotic 
process; at least in animal model studies (ref).  However in the study here in those patients 
with more aggressive disease progression we also see a loss of activity mirroring what we 
“anticipate” in the renal tissue.  Thus the disconnect between tissue and urine activity mainly 
sits in those patients with no progressive or slightly progressive CKD – which could be an 
artefact of that most of the studies of MMP activity come from animal models where by default 
rapidly progressing disease has been induced (Ahmed et al. 2007) and thus the MMP activity 
in stable CKD would never be observed in animal models.  What is clear is that progressive 
patient have less MMP activity which may underlie the progression. 
With regard to the second point, then in progressive patients MMP-2 and MMP-9 are elevated 
in rapidly progressing patients urine, but TIMP-1 is massively elevated in the same cohort and 
thus it seems logical (notwithstanding all MMP and TIMP have not been evaluated) that this 
massive TIMP-1 level is what blocks activity in the rapidly progressing group despite the clear 
elevations in TIMPs. 
One could further speculate that CKD progression is slowed by elevated MMP activity 
arresting scar tissue accumulation  in stable patients and that its only when that activity 
becomes compromised CKD enters a more progressive stage.  This could further be 
supported by our previous results shown in experimental renal scarring (chapter 5). 
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Hypertensive patients presented the highest levels of MMP activity when compared to other 
CKD aetiologies. This represented a 10 fold increase when compared to healthy control 
subjects, but although more elevated, did not differ statistically from other group of CKD 
patients. DKD patients represented the second group with largest increase in MMP activity 
levels (7 fold increase). This agrees with previously reported results shown by our group 
(Altemtam et al. 2012). ADPKD patients represented the only group in this cohort which did 
not show significant increased mean levels of MMP activity. This might be due to the large 
spread of CKD stages within this group (from 1 to 5) or indeed, on some aspect of the 
pathology of the disease itself. 
 
Although the activity of metalloproteinases was elevated in CKD, the quantity of MMPs 1, 2 
and 9  detected in the urine was not  high quantity which possibly indicates that other MMPs 
were also present that were not measured by ELISA.  Urine MMP-1 was undetected in 94.86% 
of human CKD urines, whilst MMP-2 and MMP-9 were detected in approximately 88% and 
95% of CKD samples respectively. As MMP-1 levels were uncountable in urine, we 
hypothesised that it could be mostly bound to TIMP-1. Therefore, we performed an additional 
analysis of MMP-1 complexed to TIMP-1, but this proved to be difficult as only 34.25% had 
detectable urine levels. MMP-2 corrected to a creatinine ratio was 2.4 fold higher in CKD 
patients when compared to healthy volunteers and once again Hypertensive patients showed 
the largest increase. Similarly, MMP-9: Creatinine ratio was massively increased in CKD 
patients (9 fold increase) where patients with HTN and CIN presented the highest significant 
increases of the molecule. Although rapidly progressing patients had higher amounts of the 
metalloproteinases 2 and 9 in the urine, the overall activity of these enzymes was drastically 
reduced. 
 
There was an increase in both tissue inhibitor of metalloproteinase 1 and 2 in the urine of CKD 
patients. However, there was no difference between the urine levels of TIMP-3 in CKD and 
control subjects. Similar results in mRNA levels of TIMP-3 were previously showed in 
experimental animals (Johnson et al. 2002). Interestingly, ADPKD patients presented the 
highest amount of TIMP-3 present in the urine, but this difference was not statically relevant. 
Thus, it corroborated with the results showed in the previous chapter (TG2 and ε (γ glutamyl) 
lysine measurement) and supports the presupposition that ADPKD progression is more linked 
to other pathways involved in scaring process such as an increase in cyst size and kidney 
volume, development of hypertension and PKD-1 gene mutations. 
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Chapter 9 
General Discussion 
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9.1.   Summary analysis 
 
A summary of the mean concentrations of all biomarkers studied in the human CKD cohort 
and presented in this thesis is displayed in table 9.1 
 
 
Table 9.1: Summary of human ECM biomarkers data 
 
 
* Bellow detectable levels in 2 controls and 37 CKD patients 
 Control 
(n=33) 
all CKD 
(n=292) 
DKD 
(n=91) 
CGN 
(n=66) 
HTN 
(n=53) 
ARVD 
(n=29) 
CIN  
(n=15) 
ADPKD 
(n=13) 
Others 
(n=25) 
TG2 
pg/ml 
94.18 ± 
19.99 
3346 ± 
758.5 
p<0.001 
6071 ± 
1989 
p=0.0034 
2157 ± 
451.8 
p<0.0001 
2700 ± 
1397 
p=0.0167 
914.2 ± 
298.9 
p=0.0106 
2070 ± 
912.9 
p=0.0483 
787.1 ± 
561.9 
p=0.2435 
1064 ± 
434.7 
p=0.0382 
XL 
nmols/mg 
protein 
0.1945 ± 
0.025 
1.304 ± 
0.075 
p<0.001 
1.317 ± 
0.1644 
p<0.0001 
1.305 ± 
0.1284 
p<0.0001 
1.425 ± 
0.2173 
p<0.0001 
1.120 ± 
0.1475 
p<0.0001 
1.324 ± 
0.3021 
p=0.0047 
0.7210 ± 
0.2033 
p=0.0611 
1.512 v 
0.2751 
p=0.0006 
TG2 
BLOOD 
pg/ml 
523.9 ± 
107.3 
3994 ± 
358.8 
P<0.0001 
3831 ± 
5513 
P<0.0001 
4704 ± 
931.3 
P=0.0002 
3722 ± 
692.2 
p=0.0001 
3085 ± 
1133 
P=0.0591 
7300 ± 
2813 
P=0.0738 
3468 ± 
2580 
P=0.3371 
2934 ± 
803.3 
P=0.0207 
MMP 
activity 
Δ Fl / hr 
0.4997 ± 
0.076  
2.376 ± 
0.191 
p<0.0001 
2.407 ± 
0.3090 
p<0.0001 
1.769 ± 
0.309  
p=0.0002 
3.305 ± 
0.6553 
p=0.0001 
1.589 ± 
0.2957 
p=0.0013 
2.340 ± 
0.8308 
p=0.0443 
1.361 ± 
0.4767 
p=0.1065 
3.303 ± 
0.8071 
p=0.0026 
MMP-1 undetec
table 
undetecta
ble in 277 
patients 
       
MMP-2 
pg/ml* 
919 ± 
160 
1341 ± 
136 
p=0.0481 
1107 ± 
210 
p=0.4770 
2114 ± 
477 
p=0.0209 
1446 ± 
292 
p=0.1178 
957 ± 
244 
p=0.8966 
949 ± 324 
p=0.9339 
1082 ± 
340 p = 
0.6695 
1272 ± 
413 
p=0.4333 
MMP-9 327 ± 
107 
1354 ± 
116 
p<0.0001 
1243 ± 
237 
p=0.0008 
1119 ± 
215 
p=0.0016 
1356 ± 
273 
p=0.0010 
1612 ± 
383 
p=0.0033 
1601 ± 
453 
p=0.0167 
1864 ± 
568 
p=0.0211 
1437 ± 
373 
p=0.0094 
TIMP-1 186.84 ± 
37.25 
2383 ± 
206.3 
p<0.0001 
2740.9 ± 
361.8 
p<0.0001 
2832.7 ± 
544.6 
p<0.0001 
2080.8 ± 
417.9 
p<0.0001 
2127.3 ± 
491.4 
p=0.0005 
2477.2 ± 
1592.0 
p=0.1759 
863.15 ± 
230.5 
p=0.0139 
1518 ± 
190.6 
p=0.0005 
MMP-
1/TIMP-1 
complex 
Undetec
table 
Undetect
able 
       
TIMP-2 2725.5 ± 
363.11 
2857 ± 
363.1 
p=0.7516 
3060.0 ± 
370.17 
p=0.5208 
3583.3 ± 
439.02 
p=0.1370 
2852.6 ± 
447.26 
p=0.8262 
1963.51 
± 483.57 
p=0.2158 
2756.29 ± 
1201.53 
p=0.9809 
1798.14 ± 
397.24 
p=0.0957 
1885.12 v 
292.72 
p=0.0799 
TIMP-3 302.35 ± 
86.35 
199.5 ± 
16.71 
p=0.2532 
202.87 ± 
23.51 
p=0.1970 
239.04 ± 
66.63 
p=0.4919 
184.18 ± 
23.93 
p=0.1519 
202.57 ± 
31.65 
p=0.2056 
158.35 ± 
28.01 
p=0.0881 
242.43 ± 
111.47 
p=5560 
119.38 ± 
25.52 
p=0.0322 
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The Albumin: Creatinine ratio (ACR) was significantly elevated in overall CKD patients when 
compared to healthy volunteers. However, it failed to show differences between patients with 
rapid progression and those with progressive disease (figures 9.1-A and B). 
 
Figure 9.1: Albuminuria vs. CKD progression 
 
 
 
 
Figure 9.1: Albuminuria was measured in spot human urine samples by ELISA and adjusted to a 
creatinine ratio (ACR). (A) ACR according to CKD progression and (B) with X axis in log scale to better 
visualise the spread of the data. 
 
 
Receiver Operating Characteristic (ROC) curve analysis of ACR and all urinary ECM 
biomarkers used in this study is shown in table 9.2. 
 
ROC curve analysis demonstrated that the TG2/CR ratio (86.4%) and TIMP1/CR ratio (75.7%) 
are better predictors of patients with progressive CKD than ACR (73.5%). The ROC curve 
analysis of ε (γ-glutamyl) lysine / CR ratio (73.3%) and TIMP2/ CR ratio (71.2%) presented 
similar levels of accuracy of prediction as ACR, whereas all other candidates were inferior to 
ACR.  Measurement of MMP-1 activity had a remarkable predictive value in detecting rapid 
progressive patients, as very low levels were found in this subgroup of patients.  A combo ROC 
curve analysis using TG2CR, XLCR, TIMP1CR and ACR as prognostic tools of CKD 
progression generated a remarkable 87.7% risk prediction (figure 9.2). 
 
A. B. 
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Table 9.2: ROC AUC values of ACR and Urinary ECM biomarkers 
 
 Healthy 
Volunteers 
CKD patients p value ROC AUC (%) 
ACR 0.3061 ± 0.1787 80.49 ± 8.635 p<0.0001 73.5 
TG2CR 9.72 ± 1.92 599.4 ±118.9 
 
p<0.001 86.4 
XLCR 0.0222 ± 0.004 0.2796 ± 0.0285  p<0.001 73.3 
TIMP1CR 19.05 ± 3.475 426.1 ± 41.96 p<0.0001 75.7 
TIMP2CR 259.9 ± 28.64 513.6 ± 44.69 p<0.0001 71.2 
TIMP3CR 33.38 ± 7.675 38.90 ± 3.403 p=0.5150 46.6 
MMP1CR Undetectable  Undetectable in 
94.86% patients 
n/a n/a 
MMP2CR 118.6 ± 27.45   285.3 ± 31.48 p=0.0001 53.2 
MMP9CR 34.67 ± 14.05 312.0 ± 40.71 p<0.0001 58.3 
MMP1TIMP1 
complex/Cr 
Undetectable Undetectable n/a n/a 
MMPactivityCR 0.0741 ± 0.019 0.5394 ± 0.058 p<0.001 *68.3 
*ROC AUC calculated in rapid progressive patients (eGFR decline > 5ml/min/1.73m2) 
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Figure 9.2: ACR, TG2CR, XLCR and TIMP1CR combo ROC curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Area Under the Curve 
 
 
Test Result Variable(s):   Predicted probability   
Area Std. Errora Asymptotic Sig.b Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.877 .021 .000 .836 .918 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
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9.2. General discussion 
 
  
The overall aim of this study was to determine if ECM proteins and related processing 
enzymes could be used as urine biomarkers of kidney fibrosis. To do this, we initially used 
archive urine samples from three different animal models of renal scarring: the 5/6 th Subtotal 
nephrectomy, the UNx STZ model of diabetic nephropathy and the Fisher to Lewis model of 
chronic allograft nephropathy. In total, 153 urine samples from the above animal models were 
screened for 10 different potential biomarkers: TG2, ε (γ-glutamyl) lysine, hydroxyproline, 
Metalloproteinases 1, 2 and 9, TIMPs 1, 2 and 3, and PAI-1.  Following establishment and 
optimization of urine assays for determination of such molecules, measurements were 
undertaken in 292 CKD patients, having 33 healthy volunteers and 19 patients with diabetes 
mellitus without laboratorial and clinical evidence of kidney dysfunction, as control groups.  In 
addition to the above molecules, human patients were also screened for serum TG2, TIMP-
1/MMP-1 complex and total MMP activity. 
 
Numerous studies have demonstrated that TG2, ε (ᵞ glutamyl) lysine, collagens and other 
ECM related molecules can be detected in kidney tissue from either animals (Norman et al. 
1995, Johnson et al. 1997, Johnson et al. 2002, Ahmed et al. 2007) or humans (El Nahas et 
al. 2004, Thrailkill et al. 2009, Altemtam et al. 2012). Nonetheless, few studies have been 
performed in urine, which could represent an optimal non-invasive way to assess ECM 
regulation and consequently disease stage and progression. The few studies to date have 
been positive showing a positive correlation between tissue levels of ECM molecules and 
scarring histology. This study has assessed the predictive value of ECM in urine through RO-
AUC curve analysis based on progression 3 years post sampling. 
 
In this study, we used three animal models of CKD as their mechanisms of disease 
progression could be translated into human pathology. In the SNx model, a reduction in the 
number of functioning nephrons followed by glomerular and hemodynamic adaptive changes 
take place which leads to the development of hyperfiltration, proteinuria and systemic 
hypertension. The Streptozocin model of DN causes Type I diabetes by the administration of 
streptozotocin; an agent that promotes pancreatic β cell failure. Whilst the pathogenesis of 
CAN model involves the development of immune reaction (acute rejection, alloantibody, 
allorecognition) and existence of non-immune risk factors like the presence of ischaemia-
reperfusion injury.  Nonetheless, all three models are characterised by progressive loss of 
renal tissue and ECM deposition, culminating in kidney fibrosis and failure.  Although these 
rodent models offer a good insight into human kidney disease manifestation, there are also 
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some disadvantages and limitations to these experiments such as the limited amount of 
experimental material produced, inter-animal variation and not an exact replication of the 
human pathophysiology of the disease (lack of vascular damage and some other 
morphological and histological changes).  Other model that could have been useful to 
reproduce kidney injury due to interstitial fibrosis, the ureteral obstruction with reversal of 
obstruction, can cause ischaemia and consequently decrease in kidney function. However, 
this model is better associated with the development of AKI rather than CKD and may also 
prevent the collection of urine samples at early stages of the disease as there is a natural 
development of anuria as a consequence of the ligation of the ureters. 
 
Initial results from our animal data suggested that TG2 and its crosslink product ε (γ-glutamyl) 
lysine could have value as urine biomarkers of CKD as levels were significantly increased 
earlier in all animal models and also correlated well with disease progression in SNx and CAN.  
However, in the DN study, no changes were detected by 8 months, with an increased level 
only achieved when its concentration was converted to a creatinine ratio or expressed per 
total amount excreted in 24 hours.  This could be due the large amounts of diluted urine 
produced by diabetic animals. 
 
It is know that the majority of patients with DKD typically progress with increased excretion of 
albumin and gradual decline in GFR until ESRD occurs (Ayodele et al. 2004, Chang 2008, 
Jefferson et al. 2008, Woredekal 2008).  This albuminuria can vary from small amounts (30 to 
300 mg/24h – Microalbuminuria) up to larger amounts (>300mg/24h – Macroalbuminuria). 
Concentrations given by the AAA are related to the amount of that amino acid or di amino acid 
present in 10 mg of urine protein (amount used to digest), therefore the expression of ε (γ-
glutamyl) lysine related to this amount of protein digested might not represent an ideal way to 
express it as in diseased urines most of the protein load would be due to the increased 
presence of albumin and not collagen, fibronectin or other proteins of interest that could be 
crosslinked in the ECM.  To investigate if albumin could be crosslinked by TG2, in chapter 7, 
an in vitro experiment testing different ECM substrates was conducted. This revealed little 
crosslinking of albumin and could justify the decrease in measured ε (γ-glutamyl) lysine levels 
in late DN.  To minimise the effect of increased albuminuria steps could be added to remove 
albumin from samples. Application of albumin depletion methods could potentially improve ε 
(ᵞ glutamyl) lysine detection as albuminuria impedes equivalent analysis of those molecules in 
diseased samples where a high abundance of albumin has more influence than control 
samples where potentially there is a lower abundance of albumin as a fraction of the total 
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protein load.   However, albumin depletion is costly and certainly not a flawless technique, and 
so could potentially remove proteins of interest from samples. 
 
In chapter 5, MMPs 1 and 9 as well as TIMPs 1, 2 and 3 and PAI-1 were measured in urines. 
MMPs 1, 2, 3, 8, 9 as well as TIMPs 1, 2, 3 have been shown to have significant renal 
expression (Engelmyer et al. 1995, Lenz et al. 2000). Confirming published data in renal 
tissues from the same animals used in this study (Johnson et al. 2002), urine measurements 
of MMP-1 were significantly increased in diseased animals. On the other hand, MMP-9 
excretion was undetectable on all control samples and it had a steady, but not significant rise 
on SNx and Diabetic animals even when correcting by creatinine. A comparison of urine levels 
of MMP inhibitors showed that TIMP-1 was the most attractive biomarker and this 
substantiates the published tissue findings. TIMP-1 levels were highly increased as early as 7 
days post subtotal nephrectomy and from 4 months post STZ injection.  Similar findings were 
observed in relation to TIMP-2 excretion when corrected to a creatinine ratio. However, TIMP-
3 levels were no different from diseased to controls in SNx, once again confirming previously 
published data from our group.  Interestingly, urine TIMP-3 levels were quite significantly 
elevated in DN from 4 months after induction. In the CAN study, no difference was found in 
terms of TIMP-1 excretion between L-L isografts and F-L Allografts. However, the TIMP2/CR 
ration was significantly increased as early as 8 weeks post transplantation up to 33 weeks of 
the study.  Urine PAI-1 concentration was elevated only at early stages of the disease in SNx 
and highly increased at all time points in the UNx STZ model of Diabetic nephropathy. Such 
results ratify literature findings in which PAI-1 was shown to be highly expressed in fibrotic 
kidneys promoting migration of macrophages and myofibroblasts through interactions with 
uPA receptor, LDL receptor-associated protein-1 and leukocytes (Eddy 2009). 
 
The third part of this study is concerned with the measurement of Hydroxyproline (chapter 6).  
Hydroxyproline is a major component of collagen and is found in few proteins other than 
collagen (e.g. elastin). It has been widely reported in histopathological studies that 
development of scarring is strongly associated with increased synthesis and deposition of 
particularly fibrilar collagens with collagen acting as a key component of scar tissue. 
To date, there are surprisingly few studies correlating the use of urinary collagen as a possible 
marker of kidney scarring given its role in kidney fibrosis.  Urinary amino terminal peptide of 
procollagen III (PIIINP) was positively correlated to interstitial fibrosis in humans, although it 
was not correlated to increased serum creatinine (Soylemezoglu et al. 1997).  The urinary 
carboxy terminal fragment of type IV procollagen was found increased in Minimal Change 
disease, but again it was not correlated to increased serum creatinine and neither to CrCl or 
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other nephropathies (Keller et al. 1992).  Irrespective of the limitations of these early studies 
of urine collagen in CKD, we hypothesised that measurement of urinary Hydroxyproline could 
be used as an useful non-invasive indirect indicator of total collagen, suppressing the need of 
processing fragments of individual collagens. 
Initial assessment of Hydroxyproline showed no difference in both SNx and DN groups at later 
stages of the disease when expressed per mg of protein. Thus, urine excretion of 
hydroxyproline was not increased as a percentage of the total proteinuria.  Such results could 
be due to an artefact, failure of analysis or be an authentic decrease in collagen excretion as 
disease progresses.  There is also the possibility that hydroxyproline could be extensively 
crosslinked in the ECM and therefore excretion in the urine could be reduced.  However, when 
corrected to a creatinine ratio, hydroxyproline excretion was markedly increased in the SNx 
and DN during all time points of both studies indicating that pathological changes in the kidney 
were being carried through to the urine.   
In chapter 7, the epidemiological data from our cohort of 292 CKD patients as well as the 
measurements of TG2 and its crosslink ε (ᵞ glutamyl) lysine is presented. 
According to a wide range of adult population screening studies, overall CKD prevalence is 
estimated to be around 10% in the general population, with community prevalence screening 
ranging from 0.8% to 42.6% depending of the country of data collection (systematic review 
from (McCullough et al. 2012).   Studies showed that the prevalence of community CKD in the 
USA is hardly detectable under the age of 60 (2-3%), over the age of 60 it is >30% and over 
70 years, it is almost 40%, therefore this is a disease mostly diagnosed in elderly people which 
could suggest an overestimation in the number of CKD cases.  However, there are several 
issues in the CKD screening programs; for instance, equating isolated microalbuminuria or 
microscopic haematuria to CKD (which per se defines CKD stages 1 and 2), the use of single 
collection and testing of samples during screening (which cannot guarantee the chronic status) 
and the use of imprecise formulas to calculate eGFR (for example, the MDRD formula is not 
applicable to general population and it uses creatinine which has large variability). In addition, 
there is a pathophysiological decline in kidney function of 0.79 to 1.2ml/min/year (average 
1ml/min/year from around 40 years onward) and this is due to a normal shrinkage of kidneys 
with age (around 60% size at 60 years old), arteriosclerosis, vascular damage, reduction in 
effective renal plasma flow and hypoperfusion leading to ischaemia and the presence of risk 
factors such as hypertension. 
 
Although communities studies show that around 10% of the general population has CKD, only 
0.2% will progress to ESRD and this is specially present in people aged above 60 years (with 
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up to 30-40% of subjects at this age group having a low GFR). The Baltimore longitudinal 
study on aging had a 5 years observational period and showed three patterns of CKD 
progression: stable, with ageing subjects without co-morbidity with normal renal function; 
decline, subjects with co-morbidities such as CVD, HTN and DM, decline of eGFR (CrCl) 
between 1 to 1.5ml/min/1.73m2/year and fast decline, people with overt proteinuria, rCKD, DN, 
Nephrotic syndrome – CGN - eGFR decline above 5ml/min/1.73m2/year. Predictors of CKD 
development included the presence of Atherosclerosis with internal carotid intima media 
thickness more than 1.8cm, Coronary Heart disease (CHD), Stroke and Heart Failure.  The 
outcomes of this large study showed that the risk of death from the underlying problem (i.e.; 
CVD) is higher than reaching ESRD. In addition, the Oregon study (n=27.988 people, (Keith 
et al. 2004)) confirmed that the risk of progression to ESRD in the elderly population is lower 
than the risk of death from CVD. However, on younger individuals with rCKD, there is a higher 
risk of reaching ESRD than death and the progression of CKD is mainly due to the presence 
of hypertension and proteinuria. 
 
Early studies (Mitch et al, 1976) believed that CKD progression complied with a linear slope 
of decline. However, later studies showed that some individuals decline in a linear fashion, 
some do not even have a decline and remain stable and majority which have a decline of 
kidney function over time do not present it in a linear way. This may be due to the presence 
of acute or chronic insults and improvement in the slope can be due to improvement in blood 
pressure control, reduction on proteinuria/albuminuria and improvement of other risk factors 
of progression or removal of the insulting agent (for example, NSAIDs or other nephrotoxic 
drugs / herbs). 
 
Risk models of CKD progression (Cheugui and Kengne, 2012) recommended that new 
biomarkers should be compared or added to previously established biomarkers such as 
severity of hypertension, severity of proteinuria, level of kidney function impairment at 
presentation in order to provide a more precise accuracy of progression to ESRD. Previous 
studies have showed that Albumin predicts CKD progression by 60%, whereas HTN predicts 
70% (guidelines 2002). So far hypertension is the single most important factor for CKD 
progression.  Patients with uncontrolled HTN will progress fast and that is why the KDIGO 
2012 supported an aim of BP < 130/80mmHg in DN and heavy proteinuric states and bellow 
140/90mmHg in others ethiologies. 
 
With the above in mind, in the human section of this study, the aim was to recruit a significant 
cohort size which could be reflective of the general CKD population. Our study consisted of a 
prospective observational cohort of 292 CKD adult patients from stages 1 to 5 over a period 
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of 3 years. 19 patients with diabetes mellitus without any evidence of kidney dysfunction and 
33 adult healthy volunteers were also recruited to this study. From those 292 CKD patients, 
91 had diabetic kidney disease, 66 chronic glomerulonephritis, 53 hypertensive 
nephrosclerosis, 29 atherosclerotic renovascular disease, 15 chronic interstitial nephritis and 
13 had ADPKD. 25 patients presented other causes of CKD such as Multiple Myeloma, 
amyloidosis, idiopathic thrombocytopenic purpura, Henoch Scholein purpura, monoclonal 
gammopathy of undetermined significance (MGUS), microscopic polyarteritis, familial renal 
disease, medullary sponge kidneys, sarcoidosis, lupus nephritis, HIV-associated nephritis, 
Tacrolimus toxicity and renal cell carcinoma. From this total, 41 patients were recruited at the 
time of renal biopsy.  
 
Majority of the CKD population in this study was formed by caucasians (90.41%), males 
(61.31%), above the age of 65 years old (61.9%). Hypertension was the most common 
comorbidity within this group. In addition, most patients were either at CKD stage 3 (38.36%) 
or stage 4 (45.21%) at time of recruitment, and 108 patients were classified as progressors 
(rate of eGFR decline > - 2 ml/min/1.73m2/year) throughout the study. Such outcomes 
represented a good reflection of what is commonly found in an average nephrology outpatients 
clinic. 
 
Urine TG2 and its crosslink ε (γ-glutamyl) lysine were significantly elevated in CKD patients. 
TG2 concentration was over 35 fold higher in patients with all CKD causes (n=292) when 
compared to healthy volunteers (n=33). When corrected to a creatinine ratio, TG2 levels 
became around 60 times greater than controls.  In the same manner, ε (γ-glutamyl) lysine was 
significantly elevated in CKD individuals, with a 6.7 fold rise in its excretion when compared to 
healthy volunteers.  DKD subjects presented the highest levels of urine TG2 when compared 
to all other groups, with nearly double the values found in the general CKD population.  This 
was also significantly elevated when compared to patients presenting Diabetes Mellitus (n=19) 
without CKD (p<0.0001).  The only group of patients without significantly elevated urine TG2 
was ADPKD, the only group without rapidly progressive patients. 
 
Likewise, ε (γ-glutamyl) lysine: creatinine was also substantially increased in all ethiologies, 
excluding ADPKD and CIN, where a wide spread of values were observed. This could be due 
to a higher presence of patients at early stages of the disease in both groups and also to the 
prevalence of non-progressive cases.  Alternatively, in ADPKD patients, this could be due to 
peculiarities of this disease which progression is more dependent on known risk factors such 
as PKD-1 gene mutation, hypertension (Schrier 2015), total kidney volume (Corradi et al. 
2015) and urine copeptin levels (Nakajima et al. 2015). 
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While TG2: Creatinine ratio was elevated in progressive and rapidly progressive CKD, this 
was not reflected in terms of ε (γ-glutamyl) lysine excretion, where only rapid progressive 
patients displayed significant urine levels of the molecule. This suggests either a limitation in 
the types of proteins crosslinked to the ECM or that there is a need for more advanced kidney 
dysfunction to be translated into increased ε (γ-glutamyl) lysine excretion.  To our knowledge, 
this is the first study to analyse human urine levels of both TG2 and ε (γ-glutamyl) lysine.  
Thus, no comparisons could be made with published data.  An analogy could be traced with 
a previous study done by our group, in which the expression of TG2 and its crosslink product 
were significantly elevated in renal biopsies from CKD patients (Johnson et al. 2003). 
However, this study was done by immunofluorescence analysis and therefore, is not a 
quantitative method which could enable direct comparisons.  Similar findings were also found 
in another work published by our group, where  measurements in diabetic kidney disease 
patients showed tissue levels of TG2 much higher than ε (γ glutamyl) lysine (El Nahas et al. 
2004). Nevertheless, such findings could also be attributed to higher affinity for the TG2 
antibody rather than ε (γ glutamyl) lysine. 
 
Measurement of circulating levels of TG2 provided valuable insight about how TG2 could be 
passing into urine.  Serum levels of TG2 were five times higher than those found in the urine, 
suggesting a possible filtration mechanism of this molecule. The absence of correlation 
between urine TG2 and proteinuria also implied that increased TG2 excretion in the urine was 
not simply about raised proteinuria per se generating higher urine levels. 
 
In chapter 8, we were able to measure the Matrix Metalloproteinase activity in human urine. 
Urine concentrations of MMP-1, 2, 9, MMP-1/TIMP-1 complex, as well as TIMPs 1, 2 and 3 
were also quantified.  MMP activity levels were not consistent with that reported in the kidneys 
where low levels were observed, mostly caused by an over expression of TIMPs (Johnson et 
al. 2002).  Instead, our study showed elevated MMP activity in CKD urine, with non-
progressive patients presenting over 7 times more than healthy volunteers. Progressive 
patients also presented significant higher urine MMP activity. However, patients presenting 
with rapid loss of kidney function had significant lower MMP activity and this could be used as 
an important tool for detecting such group of patients. The addition of the specific MMP 
inhibitor 1,10 phenanthroline to reactions largely implies that the proteolysis against the protein 
substrates occurs as a consequence of the gelatinase (MMPs 2 and 9) activity as this inhibitor 
presents minimal activity against serine proteases.  A recent publication just in diabetic kidney 
disease (Altemtam et al. 2012) showed very similar findings, suggesting this is a robust 
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outcome. Thus, it seems that there is an up-regulation of MMP activity in non-progressive and 
stable patients, with a decrease of its levels as disease progresses. 
 
Despite the increase in MMP activity in CKD, the quantity of MMPs 1 and 2 detected in the 
urine was not high. This suggests that other MMPs such as MMP-7 and MMP-13 could also 
be present and were not measured by ELISA.  Urine MMP-1 was undetected in 94.86% of 
human CKD urines, whilst MMP-2 and MMP-9 were detected in approximately 88% and 95% 
of CKD samples respectively. As MMP-1 levels were below detection limits in urine, we 
hypothesised that it could be mostly bound to TIMP-1. For this reason, we performed an 
additional analysis of MMP-1 complexed to TIMP-1, but only 34.25% had detectable urine 
levels. MMP-2 corrected to a creatinine ratio was 2.4 fold higher in CKD patients when 
compared to healthy volunteers. Interestingly, MMP-9 urine levels were the highest among all 
MMPs evaluated in this study, presenting a 9 fold increased in CKD patients.   This contrasted 
with our animal data, where high levels of MMP-1 were found and MMP-9 was hardly 
detectable.  Also, MMP-9 levels in renal tissue are much lower than MMP-1 and 2 (Ahmed et 
al. 2012), however increased tissue levels were also found in diabetic individuals (Tashiro et 
al. 2004). 
 
Tissue inhibitor of metalloproteinase 1 and 2 were significantly elevated in the urine of CKD 
patients. However, there was no difference between the urine levels of TIMP-3 in CKD and 
control subjects. Similar finding have been observed before.   TIMP-1 levels in urine were 
significant higher in CKD patients (n=54) and also correlated with Tenascin levels (Horstrup 
et al. 2002).   
 
Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the accuracy 
of prediction of CKD progression in all biomarkers tested (table 9.2). Overall, ACR confirmed 
to be a valuable marker of disease progression as it presented 73.5% of accuracy in predicting 
the rate of annual eGFR decline. In the literature, ROC analysis of ACR ranged from 64%  
(Altemtam et al. 2012) to 71.5% (n= 1808,however, this was a retrospective study) (Methven 
et al.).  Amongst all molecules evaluated by ROC curve analysis in our study, TG2/CR ratio 
showed the highest power of prediction. TG2/CR rate gave an impressive 86.4% accuracy in 
predicting CKD progression in a spot urine.  This data suggests that TG2/CR ration could be 
a better prognostic tool than the currently used standard method (ACR).  Measurement of 
urine TG2 was performed through a fast, reliable and non-invasive method which could easily 
be applied to clinical practice.  Other good predictors of CKD progression were TIMP-1, which 
detected 75.7% of cases, and XLCR with a 73.3% prediction.  All other markers were inferior 
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to ACR in detecting CKD progression. Combining TG2CR, ACR, TIMP1CR and XLCR as 
prognostic tools of CKD progression generated a remarkable 87.7% risk prediction by ROC-
AUC analysis (figure 9.1). 
 
In conclusion, our study has made novel observations on biomarkers of kidney fibrosis. This 
is the first to present urine measurements of TG2 and its crosslink ε (γ-glutamyl) lysine in a 
CKD cohort. The data presented in this thesis has shown significant increases of these 
molecules as well as TIMPs 1 and 2 and MMP activity in human urine. However, this study 
also has some limitations as the small number of subjects in some groups such as ADPKD 
and CIN.  Although, the smaller proportion of this individuals mimics real findings in an average 
renal outpatient’s clinic and in the national registry. We also acknowledge the small proportion 
of individuals at CKD stages 1 and 5.  Once again, this is a reflexion of what is found in a 
routine clinical scenario.   Nevertheless, our findings have potential implications for the clinical 
care of CKD patients as a combination of conventional (ACR) and novel biomarkers (TG2CR, 
TIMP-1CR and ε (γ-glutamyl) lysine levels) may represent a potential way of better detecting 
individuals which will progress from CKD to ESRD and this could enable prevention and 
possibly targeted therapeutic intervention. 
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10.1. 5/6th Subtotalnephrectomy study 
 
 Assessment of renal function and damage in the SNx Model 
 
Table 10.1: SNx study renal function data 
Experimental Group Number of 
animals 
Proteinuria 
(mg/24h) 
Ur. Creatinine 
(µmol/L) 
CrCl  (ml/min)  24h urine 
volume (ml) 
SNC 1 week 3 68.32 ± 9.5 16759 ± 1191 1.16 ± 0.67 3.48 ± 0.92 
SNX 1 week 3 128.31 ± 0.5 * 4051.33 ± 138 * 0.61 ± 0.35 *  20.86 ± 1.51 ** 
SNC 1 month 3 118.7 ± 27.1 15899.33 ± 212 1.32 ± 0.29 4.52 ± 0.92 
SNX 1 month 3 299.94 ± 77.9 * 3787.33 ± 607 * 0.97 ± 0.11 * 28 ± 6.03 ** 
SNC 3 months 11 143.05 ± 15.9 13443.58 ± 1239 1.94 ± 0.19 9.42 ± 0.95 
SNX 3 months 7 574.94 ± 53.3 ** 2379.86 ± 312 * 0.32 ± 0.18 ** 38.79 ± 2.25 ** 
NTU C7 1 week 3 109.45 ± 17.5 6947 ±  276 0.54 ± 0.31 27.27 ± 2.89 
NTU C56 1 week 3 136.89 ± 8.1 7109.67 ± 248 0.63 ± 0.36 25.74 ± 0.92 
NTU C7 1 month 3 168.58 ± 21.1 a 7061.66 ± 213 0.76 ± 0.06 29.67 ± 0.33 
NTU C56 1 month 3 148.59 ± 7.9 a 6516.33 ± 318 0.86 ± 0.13 21.57 ± 1.39 
NTU C7 3 months 4 259.67 ± 46.3 a 5638.25 ± 319 0.86 ± 0.05 a 39.5 ± 2.77 
NTU C56 3 months 4 214.38 ± 11.2 a 5749.25 ± 627 0.93 ± 0.10 b 35.61 ± 6.76 
 
Table 10.1: Renal function was assessed in sham-operated (SNc), diseased (SNx) and SNx rats treated 
with TG inhibitors (NTU C7 and NTU C56) at 7, 28 and 84 days post SNx. Total urine volume, proteinuria 
and creatinine levels were assessed. Serum and urine creatinine was measured and used to calculate 
creatinine clearance.  Data represents mean value ± SEM. *= p<0.05, **=p<0.01, ***= p<0.001 
between SNx and normal urine, a = p<0.05, b = p<0.01, c = p<0.001 between either NTU C7 or NTU 
C56 and untreated SNx, 2 way ANOVA, with Bonferroni post test. 
 
Total proteinuria and albuminuria 
 
Protein excretion (figure 10.1-A) steadily increased in the SNx animals throughout the time 
course showing 1.8, 2.5 and 4.2 fold increase at day 7, 28 and 84 respectively (p<0.05,  2 way 
ANOVA, with Bonferroni post test) when compared to sham-operated controls. Protein 
excretion in sham operated rats ranged 68.32-143.09mg/24hours throughout the study.  Rats 
treated with two different TG2 inhibitors also showed significant increase on proteinuria levels 
at 7 days post SNx; NTU C7 (109.45 ± 17.5mg/24h) and NTU C56 (136.89 ± 8.1mg/24h) 
compared to SNc (p<0.05,  2 way ANOVA, with Bonferroni post test. By 28 days post surgery, 
protein excretion reached a plateau on both treated groups; NTU C7 (168.58 ± 21.1mg/24h) 
and NTU C56 (148.59 ± 7.9mg/24h). There was no statistical significance on the average 
protein excretion between the two treatment groups and SNc at 28 and 84 days post surgery. 
Albuminuria (figure 10.1-B) followed a similar pattern to total protein excretion, with SNx 
animals having a progressive increase. At 7 days post Subtotalnephrectomy, albuminuria 
levels were an average 27.85 ± 9.0mg/24h in SNx animals, this was increased by 1.7 and 10.5 
fold at day 28 and 84 respectively (p<0.05 and p<0.001, 2 way ANOVA, with Bonferroni post 
test) compared to SNc.  NTU C7 and NTU C56 displayed a similar trend on albuminuria 
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excretion trough the study time course. At day 84, NTU C7 and NTU C56 had significant lower 
excretion of albuminuria when compared to SNx animals (p<0.05 and p<0.01, 2 way ANOVA, 
with Bonferroni post test). 
 
Urine creatinine and creatinine clearance 
 
Urinary creatinine was significantly higher in Sham-operated rats compared to SNx, NTU C7 
and NTU C56 treated SNx rats at all time points (p<0.05,  2 way ANOVA, with Bonferroni post 
test).  Creatinine Clearance (CrCl), which is a measure for approximating the GFR, ranged 
from 1.16-1.94ml/min in SNc animals (figure 11.1-C).  Renal function of SNx animals was 50% 
lower than SNc at day 7 due to loss of the renal mass.  In response to compensatory renal 
growth, there was a slight elevation of CrCl by day 28 before a fall to 16.5% of control levels 
at day 84 (p<0.01, 2 way ANOVA) due to disease progression. 
Creatinine Clearance of NTU C7 and NTU C56 was 46% and 54% of SNc levels respectively 
at day 7, due to the reduction on renal mass. Then, CrCl of both groups progressively 
increased throughout the time course. By day 84, there was a significant improvement on 
renal function of both groups.  At this time point, CrCl was significantly higher at NTU C7 and 
NTU C56 treated animals (p<0.05 and p<0.01, 2 way ANOVA, with Bonferroni post test) when 
compared to SNx. 
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Figure 10.1: Assessment of kidney function and damage in the SNx Model 
 
 
   
 
 
 
Figure 10.1: (A) 24h Proteinuria and (B) albuminuria were used to assess Glomerular damage in all 
groups at 7, 28 and 84 days post SNx. The first was assessed by using the Lowry assay and the second 
by a commercial ELISA kit. Kidney function and fibrosis were evaluated by creatinine clearance (C) and 
the degree of glomerulosclerosis (D) assessed in Masson’s Trichrome stained sections respectively. 
Data represents mean values ± SEM. *p<0.05, ** = p<0.01, SNx to sham group, a = p<0.05, b = p<0.01, 
between NTU C7 and SNx and 1 = p<0.05, 2 = p<0.01, between NTU C56 and SNx. 
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10.2. Diabetic Nephropathy study 
 
 Assessment of renal function and damage in the UNx STZ model of DN 
Table 10.2: UNx STZ model of DN renal function data 
Experimental 
Group 
Number of 
animals 
Proteinuria 
(mg/24h) 
Ser. Creatinine 
(µmol/L) 
CrCl  
(ml/min) 
Glycaemia 
(mmol/L) 
Control 1 month 4 76.45 ± 11.81 44.90 ± 5266 0.92 ± 0.12 4.81 ± 0.09 
DN 1 month 3 151.25 ± 31.53 49.03 ± 2738 1.28 ± 0.12 12.43 ± 0.68 * 
Control 4 months 3 74.69 ± 7.89 35.62 ± 1001 1.57 ± 0.29 4.83 ± 0.23 
DN 4 months 7 379.13 ± 46.63 ** 76.16 ± 373 1.97 ± 0.36 22.61 ± 1.62 * 
Control 8 months 3 77.09 ± 5.86 33.75 ± 513 1.83 ± 0.24 4.92 ± 0.03 
DN 8 months 5 853.15 ± 180.67 * 216.50 ± 212 1.21 ± 0.33 * 22.51 ± 1.41 * 
 
Table 10.2: Average proteinuria, serum Creatinine, Creatinine Clearance and glycaemia on Controls 
and DN samples after 1, 4 and 8 months post DN induction.  Data represents mean value ± SEM. *= 
p<0.05, **=p<0.01, ***= p<0.001 between DN and sham operated rats 
 
 
Total proteinuria 
 
Protein excretion was used as a measure of glomerular damage and leakage (figure 10.2-A). 
Sham operated animals never exceeded 99.2mg/24hrs proteinuria throughout the study.  
Diabetic animals showed a steady increase in protein excretion, reaching significance by 4 
months with a level of 379.1 ± 46.63mg/24hrs (p=0.0033).  By 8 months, protein excretion 
reached an average of 853.2 ± 180.7mg/24hrs (p=0.0181).  
 
Glycaemia 
 
At 1 month post STZ administration, blood glucose concentration was 2.5 fold higher than 
controls with average levels of 12.43 ± 0.68mmol/L (p<0.05, figure 10.2-B). Glycaemia was 
significantly increased in diabetic rats being 22.61 ± 1.62mmol/L at 4 months and 22.50 ± 
1.41mmol/L at 8 months (p<0.05 at both time points).  
 
Serum creatinine and creatinine clearance 
 
There was no difference in the serum creatinine concentration between diabetic and sham 
operated rats at 1 month post STZ administration. Serum creatinine was significantly higher 
in DN rats compared to controls at 4 and 8 months (2.1 and 6.4 fold increase respectively) 
(p<0.05, 2 way ANOVA, with Bonferroni post test).   
 
Measurement of kidney function by creatinine clearance showed a 1.3 and 1.4 fold increase 
at 1 and 4 months post STZ injection on diabetic animals compared to controls. This prompt 
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rise in CrCl on diseased animals was associated with the typical glomerular hyperfiltration that 
occurs in the initial stages of Diabetic Nephropathy.  As result of the elevation of glucose 
levels, it is expected that a 25 to 50 percent increase in the GFR will occur.  By 8 months, CrCl 
was 34% lower in diabetic rats (p<0.05), confirming disease progression (figure 10.2-D). 
 
Figure 10.2: Assessment of kidney function and damage in the UNx STZ model of DN  
 
 
   
 
 
  
Figure 10.2: (A) 24h Proteinuria was used to assess glomerular damage in all groups at 1, 4 and 8 
months post STZ injection using the Lowry assay.   (B) Average blood glucose. Kidney function and 
fibrosis were evaluated by creatinine clearance (C) and the degree of glomerulosclerosis (D) assessed 
in Masson’s Trichrome stained sections respectively. Data represents mean values ± SEM. *p<0.05, ** 
= p<0.01, to sham group using 2 way ANOVA, with Bonferroni post test 
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10.3. Chronic Allograft Nephropathy study 
 
 Assessment of renal function and damage in the in the Fisher to Lewis transplant 
model of CAN 
Table 10.3: Fisher to Lewis transplant model of CAN renal function data 
  
Experimental 
Group 
Number of 
animals 
Proteinuria 
(mg/24h) 
Ur. Creatinine 
(µmol/L) 
CrCl  
(ml/min) 
 24h urine vol  
(ml) 
Isograft 2 weeks 5 15.32 ± 1.38 5240 ± 787 0.97 ± 0.17 14.40 ± 2.62 
Allograft 2 weeks 7 19.36 ± 1.42 3600 ± 604 0.57 ± 0.08 19.80 ± 3.14 
Isograft 8 weeks 5 16.60 ± 4.04 7040 ± 997 1.25 ± 0.14 11.22 ± 1.11 
Allograft 8 weeks 7 29.65 ± 8.26 4657 ± 836 1.03 ± 0.09 22.57 ± 4.34 
Isograft 17 weeks 5 19.70 ± 7.33 6025 ± 495 1.43 ± 0.11 8.80 ± 1.69 
Allograft 17 weeks 7 44.67 ± 13.62 5671 ± 1042 1.12 ± 0.18 22.38 ± 3.89 
Isograft 24 weeks 5 28.00 ± 14.41 6775 ± 1122 1.48 ± 0.14 15.12 ± 3.54 
Allograft 24 weeks 7 74.54 ± 22.13 * 5683 ± 1156 0.99 ± 0.21 * 19.67 ± 2.86 
Isograft 33 weeks 5 14.87 ± 2.69 8000 ± 901 1.63 ± 0.18 11.00 ± 1.52 
Allograft 33 weeks 7 133.07 ± 34.73 ** 5280 ± 1220 0.88 ± 0.21 * 22.60 ± 6.49 
Isograft 52 weeks 5 18.16 ± 2.36 10133 ± 721 1.57 ± 0.19 11.23 ± 0.76 
Allograft 52 weeks 7 282.59 ± 77.44 *** 4080 ± 1332 0.62 ± 0.17 * 28.00 ± 6.79 
 
Table 10.3:  Average proteinuria, urinary Creatinine, Creatinine Clearance and total volume of urine 
in 24 hours on Isografts and Allografts samples after 2, 8, 17, 24, 33 and 52 weeks post kidney 
transplantation.  Data represents mean value ± SEM. *= p<0.05, **=p<0.01, ***= p<0.001 between F-
L Allografts and L-L Isografts. 
 
 
Total proteinuria 
Urinary protein excretion at 2 weeks was similar between L-L isografts and F-L allografts 
(15.32 ± 1.38 vs. 19.36 ± 1.42mg/24h). L-L isografts showed a consistent pattern of urinary 
protein excretion during the study. In contrast, F-L allografts had a significant increase in 
urinary protein excretion over the 52 week observation period (figure 10.4-A). At termination, 
F-L allografts average proteinuria was 15 fold higher than the L-L isografts (18.16 ± 2.36 vs. 
282.59 ± 77.44mg/24h, p<0.001). 
 
Urine creatinine and creatinine clearance 
 
Two weeks post transplantation, creatinine clearance was raised in both L-L isograft and F-L 
allograft groups (0.97 ± 0.17 and 0.57 ± 0.08ml/min, respectively).  This rise was supported 
up to 17 weeks by the right kidney, at which point it was removed to allow functional monitoring 
of the transplanted kidney.  Over the 17-52 week period, CrCl was stable in the L-L isograft 
but declined progressively in the F-L allograft together with an elevation in the serum creatinine 
(figure 10.4-B).  At termination, creatinine clearance was significantly lower (1.57 ± 0.19 vs. 
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0.62 ± 0.17 ml/min, p<0.05) and serum creatinine significantly higher (0.058 ± 0.005 vs. 0.194 
± 0.048μmol/ml, p<0.05) in the F-L allograft than the L-L isograft group (figure 10.4-C). 
 
Figure 10.2: Assessment of kidney function and damage in the Fisher to Lewis 
transplant model of CAN 
   
 
 
 
 
Figure 10.4: Serial measurements of (A) 24h urine protein (B) serum creatinine and creatinine 
clearance (C) are compared for the L-L isograft (n=5) and the F-L allograft (n=7) over 52 weeks.  Results 
were expressed as mean values ± SEM, * p<0.05, ** p<0.01, *** p<0.001, 2 way ANOVA, with 
Bonferroni post test.   
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Study Number: 
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Title of Project: Study of the natural history of diabetic & non-diabetic chronic kidney 
disease). 
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3. Dr Bisher Kawar, PhD, FRCP, 
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2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason and without my medical care or legal rights being affected.        
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may be looked at by individuals from the University of Sheffield, from regulatory 
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4.  I agree to take part in the above study.   
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T S Johnson BSc PhD         University of Sheffield 
Professor of Kidney Science        Medical School 
Sheffield Kidney Institute       Sheffield, S10 2RZ, UK 
 
Direct line: 0114 2712842         
Direct fax: 0114 2431575 
Email: t.johnson@sheffield.ac.uk 
 
 
Version 3, 10th July 2013 
  
1. Study title: Study of the natural history of diabetic & non-diabetic chronic kidney 
disease. 
 
2. Invitation paragraph 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve.  Please take time to 
read the following information carefully and discuss it with others if you wish.  Ask us if there 
is anything that is not clear or if you would like more information.  Take time to decide (up to 
2 hours) whether or not you wish to take part. 
Thank you for reading this. 
 
3. What is the purpose of the study? 
This is an educational research study aims to collect blood and urine samples from patients 
who have Chronic Kidney Disease (CKD) and are investigated and followed up at the 
Sheffield Kidney Institute (SKI). The blood and urine collected will allow us to study proteins 
patterns that may reflect the severity of kidney damage and predict the progression of the 
kidney disease and its fate. Proteins identified in such a way will be studied in relation to 
patient’s existing kidney damage (histology), function and its progression. This may in turn 
identify predictors of the future course of the kidney function. We will continue to follow you 
up at the outpatient clinic and monitor your kidney function and compare it with the proteins 
we would have found in the urine or blood.  
 
4. Why have I been chosen? 
We intend to study patients with CKD attending the outpatient clinic at the Sheffield Kidney 
Institute but also those admitted to the Sheffield Kidney Institute for a kidney biopsy. This will 
allow us to compare the nature of the proteins found in their blood and urine with the degree 
of damage noted on the kidney biopsy. It is hoped that such an approach can give in the long 
term more information on the degree of kidney damage by analysing blood and urine sample 
that reflect the severity of the damage. 
  
5. Do I have to take part? 
No, it is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. You can take 
the necessary time (up to 2 hours) to read this information sheet, discuss it with friends and 
relatives if you deem appropriate before you make your mind up about your involvement in this 
study.  If you decide to take part you are still free to withdraw at any time and without giving 
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giving a reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
6. What will happen to me if I take part? 
If you decide to take part, we will ask you to donate a blood and urine specimen when you 
come to the hospital to have your kidney biopsy; the blood sample will consist of around 10 
mls of blood, which is equivalent to two teaspoonfuls. The urine specimen will consist of a 
spot urine specimen like to one you give every time you attend the outpatient clinic which is 
equivalent to 200 mls (20 teaspoonfuls or half a cup in size). No additional biopsy will be taken 
as the one being taken for clinical purposes is suitable.  We will request access to the pathology 
report of your biopsy, and where possible acquire an image of the biopsy slide that we can use 
for computer based analysis.  The socio-economic data will also be gathered at the start of the 
study; this refers to some information relating to where you live, your education, employment 
as well as income. This information is optional as you do not have to provide it to be involved 
in this educational research project.  With your permission, your GP (General Practitioner) 
will be informed of your participation in this study if you consent to take part.  All blood and 
urine samples taken from you in relation to this research project will be analysed and stored 
for up to 8 years after which the study will be completed and all samples taken from you 
destroyed.  However the urine and blood samples we collect are extremely valuable to us and 
would be extremely useful both in the extension of this current study as well as in future 
biomarker and pathology studies on kidney disease.  On the consent form you will be given 
the option to donate the samples we take for future research projects. 
 
7. What are the alternatives for diagnosis or treatment? 
The current way of define the severity of kidney damage is by taking a piece of the kidney 
(biopsy) and examining it under the microscope. It is hoped that by identifying blood or urine 
markers that can accurately reflect the severity of kidney damage we may, in the long term, be 
able to replace many kidney biopsies with urine measurements. 
 
8. What are the side effects of any treatment received when taking part? 
No side effects are expected from donating an additional blood and urine specimens when 
you attend the outpatient clinic. No additional biopsy will be taken and thus there is no 
additional discomfort or risk. 
 
9. What are the possible disadvantages and risks of taking part? 
The minor disadvantage of having to give one more blood and urine specimen when you attend 
the Sheffield Kidney Institute to have your kidney biopsy.  
 
10. What are the possible benefits of taking part? 
If we can manage to find proteins/markers in the blood or urine of kidney patients that 
accurately reflect the severity of their kidney damage; this may one day reduce the need to 
bring patients into hospital for biopsies. 
 
11. What if new information becomes available? 
Any additional research-derived information that becomes available will help us in our focus 
on proteins that may be of relevance to your own kidney condition or stage of progression. 
We will also keep you personally informed of any new discoveries and findings. 
 
12. What happens when the research study stops? 
After we take your blood and urine sample we will undergo a lengthy analysis and examine 
our results in the light of your own clinical data derived from the routine tests we undertake 
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After we take your blood and urine sample we will undergo a lengthy analysis and examine 
our results in the light of your own clinical data derived from the routine tests we undertake 
every time you come to the clinic. When the research is completed we hope to identify new 
markers for kidney disease and their outcome and disseminate this knowledge through 
scientific publications. 
 
 
13. What if something goes wrong? 
It is extremely unlikely that anything can go wrong in providing an additional blood or urine 
sample along with all those you provide routinely during your hospitalisation. 
 
 14. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  Any information about you which leaves the hospital/surgery will have 
your name and address removed so that you cannot be recognised from it.  
 
15. What will happen to the results of the research study? 
Once the study is completed and the data analysed, we intend to disseminate the results 
obtained through scientific publications, seminars and conferences. The study will also form 
the basis for the award of a higher degree by the University of Sheffield. However; under no 
circumstances will you be identified in any way in the process. We will also provide all our 
participants with a summary of our key findings for their own records. 
 
16. Who is organising and funding the research? 
The research is organised by the Sheffield Kidney Institute and funding is provided by the 
Sheffield Kidney institute and the research fees (bench fees) provided by postgraduate 
students undertaking this research. 
 
17. Who has reviewed the study? 
This study has been reviewed by the relevant experts in the field through the Sheffield Teaching 
Hospitals Trust’ Research Department and The Bradford Research Ethics Committee. 
 
18. Contact for Further Information 
For any more information concerning this study please contact: 
Professor Tim Johnson, Academic Nephrology Unit, The Medical School, University of 
Sheffield, Beech hill Road, Sheffield S10 2RZ.  T.johnson@sheffield.ac.uk, 0114 2712842 
 
Thank you very much for taking time to read this information sheet. 
 
If you choose to participate in this study, you will be given a copy of the patient information 
sheet and a signed consent form to take home with you and keep for future reference. 
 
 
 
 
 
(Form to be on headed paper) 
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T S Johnson BSc PhD         University of Sheffield 
Professor of Kidney Science        Medical School 
Sheffield Kidney Institute       Sheffield, S10 2RZ, UK 
 
Direct line: 0114 2712842         
Direct fax: 0114 2431575 
Email: t.johnson@sheffield.ac.uk 
 
 
Version 3, 10th July 2013 
  
1. Study title: Study of the natural history of diabetic & non-diabetic chronic kidney 
disease). 
 
2. Invitation paragraph 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
Thank you for reading this. 
 
3. What is the purpose of the study? 
This is an educational research study aimed to collect blood and urine samples from patients 
who have chronic kidney disease (CKD) and are followed up at the Sheffield Kidney institute 
(SKI). This will involve patients whose own kidneys are affected. The blood and urine collected 
will allow us to study proteins patterns that may predict the progression of the kidney disease 
and its fate. Proteins identified in such a way will be studied in relation to patient’s kidney 
function and its progression. This may in turn identify predictors of the future course of the 
kidney function and thus allow better tretment. We will continue to follow you up at the 
outpatient clinic and monitor your kidney function and compare it with the proteins we have 
found in the urine or blood.  
 
4. Why have I been chosen? 
We intend to study a sample of patients with various types kidney disease and are followed 
up at the Sheffield Kidney Institute outpatients’ clinics, who have either stable or declining 
kidney function. This will allow us to compare the protein patterns in blood and urine and match 
them against the patient’s kidney function and rate of progression of their kidney condition.  
 
5. Do I have to take part? 
No, it is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. You can take the 
necessary time (up to 4 weeks) to read this information sheet, discuss it with friends and 
relatives if you deem appropriate before you make your mind up about your involvement in this 
study. However, if after thorough explanation of the study and adequate time (up to 30 minutes) 
for you to read the patient information sheet (PIS), you are happy to participate, you will be 
asked to sign the consent form. If you decide to take part you are still free to withdraw at any 
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at any time and without giving a reason.  A decision to withdraw at any time, or a decision not 
to take part, will not affect the standard of care you receive. 
 
6. What will happen to me if I take part? 
If you decide to take part, we will ask when you attend the outpatient clinic for your routine 
visits to donate a blood and urine specimen once a year for 5 years (the duration of the study; 
a total of 6 samples, one at the beginning of the study, the second after 1 year, the third after 
2 years etc). This will ensure that the levels of these markers in individuals with diabetes are 
not variable with time.  The blood sample will be equivalent to 10 mls (two teaspoonfuls in 
size); whereas urine sample will be equivalent to 200 mls (20 teaspoonfuls or half a cup in 
size).  The socio-economic data will also be gathered at the start of the study; this refers to 
some information relating to where you live, your education, employment as well as income. 
This information is optional as you do not have to provide it to be involved in this educational 
research project.  With your permission, your GP (General Practitioner) will be informed of your 
participation in this study if you consent to take part.  All blood and urine samples taken from 
you in relation to this research project will be analysed and stored for up to 8 years after which 
the study will be completed and all samples taken from you destroyed.  However the urine and 
blood samples we collect are extremely valuable to us and would be extremely useful both in 
the extension of this current study as well as in future biomarker and pathology studies on 
kidney disease.  On the consent form you will be given the option to donate the samples we 
take for future research projects. 
 
7. What are the alternatives for diagnosis or treatment? 
The Current alternative predictors of the outcome of your condition (involvement of kidneys by 
diabetes) include the quality of your diabetes (blood sugar) control if you are diabetic, your 
blood pressure control as well as the degree/level of protein in your urine. However, these are 
not fully predictive of the outcome of kidney disease in people with kidney disease and we are 
seeking better and novel alternatives. 
  
8. What are the side effects of any treatment received when taking part? 
No side effects are expected from donating an additional blood and urine specimens when you 
attend the outpatient clinic. 
 
9. What are the possible disadvantages and risks of taking part? 
The minor disadvantage of having to give one more blood and urine specimen when you attend 
your routine outpatient appointments. 
 
10. What are the possible benefits of taking part? 
Indirect benefits in the long term if we manage to identify markers in your blood or urine that 
will predict the outcome of kidney function and the natural history of kidney conditions such as 
yours. 
 
11. What if new information becomes available? 
Any additional research-derived information that becomes available will help us in our focus 
on proteins that may be of relevance in your own kidney condition or stage of progression. We 
will also keep you personally informed of any new discoveries and findings. 
 
12. What happens when the research study stops? 
After we take your blood and urine sample we will undergo a lengthy analysis and examine 
our results in the light of your own clinical data derived from the routine tests we undertake  
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every time you come to the clinic. When the research is completed we hope to identify new 
markers for kidney disease and their outcome and disseminate this knowledge through 
scientific publications. 
 
13. What if something goes wrong? 
It is extremely unlikely that anything can go wrong in providing an additional blood or urine 
sample along with all those you provide routinely at every outpatient visit  
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms should 
be available to you.  
 
If you have any complaints or concerns relating to the above study please contact:  
Dr Mike Richmond, Medical Director, Sheffield Teaching Hospitals NHS Foundation Trust,  
8 Beech Hill Road, Sheffield S10 2SB (Tel: 0114 271 2923). 
 
14. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  Any information about you which leaves the hospital/surgery will have your 
name and address removed so that you cannot be recognised from it.  
 
15. What will happen to the results of the research study? 
Once the study is completed and the data analysed, we intend to disseminate the results 
obtained through scientific publications, seminars and conferences. The study will also form 
the basis for the award of a higher degree by the University of Sheffield. However; under no 
circumstances will you be identified in any way in the process. We will also provide all our 
participants with a summary of our key findings for their own records. 
 
16. Who is organising and funding the research? 
The research is organised by the Sheffield Kidney Institute and funding is provided by the 
Sheffield Kidney institute and the research fees (bench fees) provided by postgraduate 
research students who will undertake this research. 
 
17. Who has reviewed the study? 
This study has been reviewed by the relevant experts in the field through the Sheffield 
Teaching Hospitals Trust’ Research Department and Bradford Research Ethics Committee. 
 
18. Contact for Further Information 
For any more information concerning this study please contact: 
For any more information concerning this study please contact: 
Professor Tim Johnson, Academic Nephrology Unit, The Medical School, University of 
Sheffield, Beech hill Road, Sheffield S10 2RZ.  T.johnson@sheffield.ac.uk, 0114 2712842 
 
Thank you very much for taking time to read this information sheet.   
If you choose to participate in this study, you will be given a copy of the patient information 
sheet and a signed consent form to take home with you and keep for future reference. 
 
 
(Form to be on headed paper) 
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T S Johnson BSc PhD         University of Sheffield 
Professor of Kidney Science        Medical School 
Sheffield Kidney Institute       Sheffield, S10 2RZ, UK 
 
Direct line: 0114 2712842         
Direct fax: 0114 2431575 
Email: t.johnson@sheffield.ac.uk 
 
 
Version 3, 10th July 2013 
  
1. Study title: Study of the natural history of diabetic & non-diabetic chronic kidney 
disease). 
 
2. Invitation paragraph 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
Thank you for reading this. 
 
3. What is the purpose of the study? 
This is an educational research study aimed to collect blood and urine samples from patients 
who have chronic kidney disease (CKD) and are followed up at the Sheffield Kidney institute 
(SKI). This will involve patients whose own kidneys are affected. We would like to be able to 
better understand why kidney disease develops and develop new tests to monitor its 
development.  To do this we intend to follow a group of patients with chronic kidney disease 
for 5 years.  We also need to be able to compare their course with that of a small group of 
healthy individuals like you who don’t have diabetes or suffering from any form of 
kidney disease. 
 
4. Why have I been chosen? 
Basically, we would like to measure some blood and urine substances that may explain why 
some patients do well in the long term without any damage while others have ongoing 
problems with their kidneys. We also need to know what the level of these substances is in 
normal healthy individuals. For that, we would require a blood and urine sample from you 
once a year.  This will allow us to compare the protein patterns in blood and urine and match 
them against the patient’s kidney function and rate of progression. 
 
5. Do I have to take part? 
No, it is up to you to decide whether or not to take part.  You can take the necessary time (up 
to 4 weeks) to read this information sheet, discuss it with friends and relatives if you deem 
appropriate before you make your mind up about your involvement in this study.  However, if 
after thorough explanation of the study and adequate time (up to 30 minutes) for you to read 
the patient information sheet (PIS), you are happy to participate, you will be asked to sign the 
consent form. If you do decide to take part you will be given this information sheet to keep  
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and be asked to sign a consent form.  If you decide to take part you are still free to withdraw 
at any time and without giving a reason  
 
6. What will happen to me if I take part? 
If you decide to take part, we will ask you to donate a blood and urine specimen once a year 
for 5 years (the duration of the study; a total of 5 samples, one at the beginning of the study, 
the second after 1 year, the third after 2 years etc..).   This will ensure that the levels of these 
markers in normal healthy volunteers are not variable with time.  The blood sample will consist 
of around 10 mls of blood, which is equivalent to two teaspoons; whereas urine sample will be 
equivalent to 200 mls (40 teaspoonfuls or half a cup in size). 
All blood and urine samples taken from you in relation to this research project will be analysed 
and stored for up to 8 years after which the study will be completed and all samples destroyed.  
However the urine and blood samples we collect are extremely valuable to us and would be 
extremely useful both in the extension of this current study as well as in future biomarker and 
pathology studies on kidney disease.  On the consent form you will be given the option to 
donate the samples we take for future research projects. 
 
7. What are the side effects of any treatment received when taking part? 
No side effects are expected from donating blood and urine specimens once a year. 
 
8. What are the possible disadvantages and risks of taking part? 
The minor disadvantage of having to give one blood sample and urine specimen once a year. 
 
9. What are the possible benefits of taking part? 
There will be no benefit to you personally, but we hope to identify markers in blood and urine 
that will predict the outcome of kidney function. 
 
10. What if new information becomes available? 
We will keep you personally informed of any new discoveries and findings. 
 
11. What happens when the research study stops? 
After we take your blood and urine sample we will undergo a lengthy analysis and examine 
our results in the light of your own clinical data. When the research is completed we hope to 
identify new markers for kidney disease and their outcome and disseminate this knowledge 
through scientific publications. 
 
12. What if something goes wrong? 
It is extremely unlikely that anything can go wrong in providing blood or urine sample. If you 
are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms should 
be available to you.   
If you have any concerns or complaints relating to the above study please contact:  
Dr Mike Richmond, Medical Director, Sheffield Teaching Hospitals NHS Foundation Trust, 8 
Beech Hill Road, Sheffield S10 2SB (Tel: 0114 271 2923). 
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13. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  Any information about you which leaves the hospital/surgery will have your 
name and address removed so that you cannot be recognised from it.  
 
14. What will happen to the results of the research study? 
Once the study is completed and the data analysed, we intend to disseminate the results 
obtained through scientific publications, seminars and conferences. The study will also form 
the basis for the award of a higher degree by the University of Sheffield. However; under no 
circumstances will you be identified in any way in the process. We will also provide all our 
participants with a key summary of our findings for their own records. We hold regular open 
meetings where all those involved in a given research projects are invited to share with them 
the outcome of the research.  
 
15. Who is organising and funding the research? 
The research is organised by the Sheffield Kidney Institute and Academic nephrology Unit and 
the University of Sheffield.  Funding is provided by the Sheffield Kidney Institute and the 
research fees (bench fees) provided by postgraduate students who will undertake this 
research. 
 
16. Who has reviewed the study? 
This study has been reviewed by the relevant experts in the field through the Sheffield 
Teaching Hospitals Trust’ Research Department and Bradford Research Ethics Committee. 
 
19. Contact for Further Information 
For any more information concerning this study please contact: 
Professor Tim Johnson, Academic Nephrology Unit, The Medical School, University of 
Sheffield, Beech hill Road, Sheffield S10 2RZ.  T.johnson@sheffield.ac.uk, 0114 2712842 
 
Thank you very much for taking time to read this information sheet. 
 
If you choose to participate in this study, you will be given a copy of the patient information 
sheet and a signed consent form to take home with you and keep for future reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Form to be on headed paper) 
